Cardiac resynchronization therapy : advances in optimal patient selection by Bleeker, G.B.
Cardiac resynchronization therapy: 
Advances in optimal patient selection
Gabe B. Bleeker
The studies described in this thesis were performed at the department of Cardiology of the 
Leiden University Medical Center, Leiden, The Netherlands
Cover: After a painting by Floor de Bruijn Kops, Bloemendaal
Lay out: Optima Graﬁsche Communicatie, Rotterdam
Printed by: Optima Graﬁsche Communicatie, Rotterdam
ISBN: 978-90-855926-7-9
Copyright © 2006 Gabe B. Bleeker, Leiden, The Netherlands. All rights reserved. No part of this 
book may be reproduced or transmitted, in any form or by any means,  without prior permis-
sion of the author.
Financial support to the costs associated with the publication of this thesis from Guidant BV, 
Medtronic BV, Biotronik BV, de Jacques H. De Jong Stichting, Astellas Pharma BV, Siemens BV, 
St Jude Medical, Stichting EMEX, Eli Lilly BV, GE Medical Systems Ultrasound, Pﬁzer BV, Bristol-
Myers Squibb BV, Servier Farma BV, de J.E. Jurriaanse stichting, Toshiba Medical Systems BV, 
Sanoﬁ-Aventis BV, AstraZeneca BV, GE Healthcare Medical Diagnostics, Merck Sharp & Dohme 
BV, Boehringer Ingelheim BV, Terumo Europe BV is gratefully acknowledged.
 
 
Cardiac resynchronization therapy:  
 
 
Advances in optimal patient selection
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit van Leiden,
op gezag van de Rector Magniﬁcus prof.mr. P.F. van der Heijden, 
volgens besluit van van het College voor Promoties
te verdedigen op woensdag 14 maart 2007
klokke 13.45 uur
door
Gabe Berend Bleeker
geboren te Groningen
in 1978
PROMOTIECOMMISSIE:
Promotores:  Prof.Dr. J.J. Bax 
  Prof.Dr. M.J. Schalij
Referent:  Prof. P. Nihoyannopoulos (Imperial College, London, UK)
Overige leden: Prof.Dr. H. Wellens (Universiteit van Maastricht)
  Prof.Dr. E.E. van der Wall
  Prof.Dr. R.A.E. Dion
  Dr. E.R. Holman
The study described in this thesis was supported by a grant of the Netherlands Heart Founda-
tion (grant nr NHF-2002B109) and the Interuniversity Cardiology Institute of the Netherlands 
(ICIN, project nr 51). 
Financial support by the Netherlands Heart Foundation and the Interuniversity Cardiology 
Institute of the Netherlands to the costs associated with the publication of this thesis is grate-
fully acknowledged.
TABLE OF CONTENTS
Chapter 1 General introduction and outline of the thesis 7
Part I: Beneﬁcial eﬀects of CRT
Chapter 2 Comparison of eﬀectiveness of cardiac resynchronization therapy in 
patients <70 versus ≥70 years of age. 
Am J Cardiol 2005;96:420-422. 
27
Chapter 3 Does a gender diﬀerence in response to cardiac resynchronization 
therapy exist? 
PACE 2005;28:1271-5. 
37
Chapter 4 Clinical versus echocardiographic parameters to assess response to 
cardiac resynchronization therapy. 
Am J Cardiol 2006;97:260-263. 
49
Part II: Mechanism of beneﬁt from CRT
Chapter 5 Left ventricular dyssynchrony predicts right ventricular remodeling 
after cardiac resynchronization therapy. 
J Am Coll Cardiol 2005;46:2264-9. 
61
Chapter 6 Left ventricular reverse remodeling but not clinical improvement 
predicts long-term survival after cardiac resynchronization therapy. 
Circulation 2005;112:1580-1586. 
75
Chapter 7 Hemodynamic eﬀects of long-term cardiac resynchronization therapy 
– Analysis by pressure-volume loops. 
Circulation 2006;113:1295-304. 
89
Chapter 8 Left ventricular resynchronization is mandatory for response to 
cardiac resynchronization therapy. 
submitted
107
Part III: Prediction of response to CRT
Chapter 9 Relationship between QRS duration and left ventricular dyssynchrony 
in patients with end-stage heart failure. 
J Cardiovasc Electrophysiol 2004;15:544-549. 
123
Chapter 10 Frequency of left ventricular dyssynchrony in patients with heart 
failure and a narrow QRS complex. 
Am J Cardiol 2005;95:140-2. 
135
Chapter 11 Relative merits of M-mode echocardiography and tissue Doppler im-
aging for prediction of response to cardiac resynchronization therapy. 
Am J Cardiol in press
145
Chapter 12 Left ventricular dyssynchrony predicts response and prognosis after 
cardiac resynchronization therapy. 
J Am Coll Cardiol 2004 ;44:1834-1840. 
161
Chapter 13 Eﬀect of postero-lateral scar tissue on clinical and echocardiographic 
improvement following cardiac resynchronization therapy. 
Circulation 2006;113:969-76. 
177
Part IV: Emerging indications
Chapter 14 Cardiac resynchronization therapy in patients with a narrow QRS 
complex. 
J Am Coll Cardiol 2006;48:2243-2250
197
Chapter 15 Cardiac resynchronization therapy in patients with systolic left 
ventricular dysfunction and mild symptoms of heart failure.
 Am J Cardiol 2006;48:464-70.
211
Part V: Optimal use of echocardiography in CRT 
Chapter 16 Optimal use of echocardiography in cardiac resynchronization 
therapy. 
Heart in press. 
225
Summary, Conclusions and Future Perspectives 251
Samenvatting, Conclusies en Toekomstperspectief 263
List of publications 277
Acknowledgements 285
Curriculum Vitae 287
Chapter 1
General introduction and 
outline of the thesis

General introduction and outline of the thesis 9
Chronic heart failure 
Chronic (systolic) heart failure is a clinical syndrome which evolves from damage of the myo-
cardium resulting in the inability of the heart to eject blood in line with the needs of the 
body. As a result of this relative shortage in cardiac output (in particular during exercise) 
the syndrome of heart failure mainly manifests itself as dyspnea and fatigue, ﬂuid retention 
and exercise intolerance [1,2]. The severity of heart failure symptoms generally progresses 
over time and is classiﬁed according to the classiﬁcation of the New York Heart Association 
(NYHA). 
In the majority of heart failure patients the damage to the myocardium is the result of isch-
emic heart disease, due to a previous myocardial infarction or chronic ischemia. Other rea-
sons for the damage to the myocardium are a persistent overload, such as in hypertension or 
valvular disease or from loss of functional myocardium as a result of (usually viral) myocar-
ditis or the prolonged presence of tachycardia [1,3] (Table 1). After the initial damage to the 
myocardium (e.g. after an acute myocardial infarction), the clinical syndrome of heart failure 
usually takes several years to arise. During these years the heart attempts to restore and/or 
maintain cardiac output through several adaptational mechanisms. Initially, the main adap-
tational mechanism is hypertrophy of the (surviving) myocardium, but this mechanism is 
only able to maintain cardiac function for a limited period of time. If myocardial hypertrophy 
alone is inadequate the left ventricle starts to dilate in order to maintain stroke volume (this 
process is referred to as LV remodeling). However, the wall stress induced by LV dilatation and 
the increased load of the left ventricle results in (further) myocyte death and a consequent 
stretch of the mitral annulus leading to an increasing mitral regurgitation. This process can be 
Table 1: Causes of heart failure
• Myocardial disease
 o Coronary artery disease
  - Post myocardial infarction
  - Chronic ischemia
 o Hypertension
 o Infectious
 o Auto-immune
 o Metabolic/inﬁltrative
 o Endocrine
 o Toxic
 o Idiopathic
• Valvular disease 
• Pericardial disease
• Congenital heart disease
• Arrhythmias (brady-or tachycardia)
• High output states
• Volume overload
Adapted from reference #3 
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considered as a vicious circle leading to continuing LV dilatation which will eventually lead to 
progressive heart failure symptoms and ﬁnally end-stage heart failure [1,3].
Prevalence and Prognosis
Over the past decades chronic heart failure has emerged as a growing health-care problem 
in the Western World with an almost “epidemic” increase in the number of patients who de-
velops end-stage heart failure, which makes it one of the major challenges in clinical cardiol-
ogy today [4-6]. This increase is caused largely by the aging of the population in developed 
countries, and the improved survival following acute cardiac events such as myocardial in-
farction. 
According to a report by the American Heart Association nearly 5 million people suﬀer from 
heart failure in the US alone, with an incidence of 10 per 1000 among persons older than 65 
years of age [1,4,5]. These numbers are in line with recent European data that reported an 
incidence of 14.4 per 1000 among persons aged over 55 [6]. The prevalence of heart failure 
is somewhat higher in men than in women and shows a strong relationship with increasing 
age ranging from 0.9% in subjects aged 55-64 years to 17.4% in those aged ≥85 years. At the 
age of 55 the life-time risk for the development of heart failure is 33% in men and 29% for 
women [6]. 
Among patients with heart failure, the rates of related morbidity and mortality are alarm-
ingly high and the prognostic importance of heart failure is often underestimated. Despite 
the introduction of new pharmacologic therapies, such as ACE inhibitors, beta-blockers and 
spironolactone, mortality is similar or worse than most cancers; after ﬁrst admission for heart 
failure, 1-year survival is 63% and the 5-year survival is only approximately 30% [6,7]. Heart 
failure mortality is closely related to the severity of heart failure symptoms (Figure 1), the 
severity of LV dysfunction and the extent of LV remodeling (Figure 2) [7-10]. The predominant 
modes of death in heart failure patients are either death from progressive heart failure or 
sudden cardiac death due to ventricular arrhythmias [11]. 
In addition to the high mortality, patients with heart failure suﬀer from a considerable mor-
bidity. The quality-of-life of heart failure patients (in particular NYHA class III and IV patients) 
is usually poor, which is mainly caused by a (severely) reduced exercise capacity resulting in 
severe limitations of patient activities in daily life. Moreover, heart failure patients frequently 
suﬀer from episodes of acute heart failure resulting in hospitalizations. Heart failure is the 
single most important cause for hospitalizations in patients over 65 and the rate of hospi-
talizations for acute decompensated heart failure has increased by 159 percent over the last 
decade which makes heart failure a costly disorder. [1]. 
Therapeutic options for heart failure
The cornerstone of the treatment of every patient with chronic heart failure is an optimal 
pharmacological regimen [8,9,12-14]. In the last decade several improvements have been 
General introduction and outline of the thesis 11
�
��
��
��
��
��
��
��
� �� ��� ��
NYHA class
Mortality (%)
Figure 1: Mortality of heart failure patients according to New York Heart Association (NYHA) functional class after a mean follow-up period of 
41.4 months. Data from 2569 heart failure patients included in the SOLVD-trial [8]. 
Figure 2: Patient survival according to LV end-systolic volume (ESV) and LV ejection fraction (EF). Survival curves of 605 male patients after 
myocardial infarction divided into three groups according to their ESVs (top) and EFs (bottom) (reprinted with permission from reference #10) 
12
C
ha
pt
er
 1
made in the pharmacological treatment of heart failure with the introduction of ACE inhibi-
tors [8,9,12], beta-blockers [13] and spironolactone [14]. However, despite aggressive medi-
cal treatment of heart failure many patients show a progression of heart failure symptoms 
and their prognosis remains poor. 
The presence of patients with drug refractory heart failure has increased great interest in 
a variety of non-pharmacological treatments for patients with drug-refractory heart failure. 
Heart transplant probably remains the best solution with a good quality-of-life and a 1-and 
5-year survival of 90% and 70%, respectively [15]. However, at present cardiac transplantation 
is limited to a small minority of patients due to the shortage of donor hearts. In addition, 
coronary revascularization in the presence of myocardial ischemia is a good option if heart 
failure is the result of coronary artery disease, however bypass surgery in patients with im-
paired LV function is associated with a considerable mortality of 10-15% and LV dysfunction 
frequently persists [16,17]. Other surgical options that are increasingly being used in patients 
with heart failure include surgical ventricular restoration (Dor plasty) [18,19] or mitral valve 
surgery [20]. Still, despite these continuous advances, many patients remain in advanced 
heart failure and/or have a contra-indication for these treatment options. 
Thus, the search for other therapies to improve symptoms and survival in patients with chronic 
heart failure has continued. Now more than a decade ago atrial synchronized biventricular 
pacing or cardiac resynchronization therapy (CRT) has been introduced for the treatment of 
heart failure patients [21,22]. CRT has been developed as a novel pacemaker technology that 
aims at resynchronizing cardiac contractions in order to improve cardiac pumping eﬃciency. 
In recent large trials CRT resulted in dramatic improvements in both patient morbidity and 
mortality and is therefore considered a major revolution in the treatment of patients with 
drug-refractory heart failure. 
CARDIAC RESYNCHRONIZATION THERAPY 
CRT has been developed as a novel pacemaker technology that aims at resynchronizing 
cardiac contractions in patients with drug-refractory heart failure, but without any classic 
indication for permanent cardiac pacing. The ﬁrst clinical cases of CRT were described in 1994 
by Bakker et al. in the Netherlands [21] and Cazeau et al. in France [22]. After these ﬁrst prom-
ising cases the use of CRT has developed dramatically and is now considered a Class I (level of 
evidence A) indication in patients with drug refractory heart failure [23,24].
Rationale for CRT 
Since many years it has been recognized that in failing hearts, LV function is aﬀected not only 
by a depressed contractile status of the myocardium, abnormal loading conditions or both, 
but frequently also by a dyssynchronous activation of the heart, resulting in an ineﬃcient 
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cardiac pumping function and poor hemodynamics [25-28]. The rationale for CRT is to cor-
rect the dyssynchronous activation (and subsequent contraction) of the heart through atrial 
synchronized biventricular pacemaker stimulation in order to improve LV hemodynamics 
and cardiac eﬃciency. 
A dyssynchronous activation of the heart is a relatively common problem in heart failure 
patients and can be divided into three types: 
1] atrio-ventricular dyssynchrony, 
2] inter-ventricular dyssynchrony (dyssynchrony between the left and the right ventricle) 
3] (intra-) LV dyssynchrony (dyssynchrony within the left ventricle). 
Atrio-ventricular dyssynchrony
Atrio-ventricular dyssynchrony results from a prolonged atrio-ventricular conduction time. 
As a consequence the diastolic ﬁlling period, in particular the early passive diastolic ﬁlling 
time, is reduced leading to suboptimal ventricular ﬁlling. This negatively aﬀects ventricular 
performance, particularly in patients with already impaired LV function. In addition, a late 
diastolic mitral regurgitation may occur. 
By deﬁnition, CRT reduces the AV conduction interval (in patients with intact atrio-ventricu-
lar conduction), since the ventricles have to be pre-excited in order to achieve biventricular 
stimulation. The reduction of the AV-interval by CRT improves diastolic ﬁlling time, which has 
proved to be beneﬁcial in patients undergoing CRT [29]. 
Inter-ventricular dyssynchrony
In normal hearts, left-and right ventricular contractions occur almost simultaneously. How-
ever, heart failure patients frequently exhibit inter-ventricular dyssynchrony (dyssynchrony 
between the right and the left ventricle), which is usually the result of the delayed activa-
tion of the left ventricle. Early activation of the right ventricle may push the inter-ventricular 
septum into the left ventricle resulting in a dyssynchrony within the left ventricle (LV dys-
synchrony) [30]. 
Left ventricular dyssynchrony
A notable proportion of patients with heart failure has a substantial dyssynchrony within the 
left ventricle, referred to as LV dyssynchrony [31]. Recent studies have indicated that LV dys-
synchrony can heavily aﬀect LV hemodynamics and pumping eﬃciency [27,32]. The abnor-
mal activation of the left ventricle in the presence of LV dyssynchrony results in a prestretch 
of the LV region of latest activation (generally the (postero-)lateral wall) during contraction 
of the early activated segments (usually the inter-ventricular septum). Next, the contraction 
of the late activated LV region results in a higher stress and systolic stretch of the early ac-
tivated segments. The LV dyssynchrony reﬂects a balance of forces, with the early activated 
region being unable to withstand the stress generated by the late activated LV segments 
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[25-28,33,34]. The regional wall contractions are not eﬀectively converted to pressure build 
up in the left ventricle, but rather cause substantial blood volume shifts within the LV cav-
ity. The overall result is a decrease in LV pumping eﬃciency because LV ejection fraction is 
reduced despite maintained or even increased energy demand. Other detrimental eﬀects of 
LV dyssynchrony include mitral valve dysfunction due to a lack of co-ordination of the papil-
lary muscles and an impairment of LV diastolic function related to the late systolic stretch 
and consequent delayed muscle relaxation [25-28,33,34]. The presence of LV dyssynchrony 
in patients with heart failure also has clear prognostic implications. Bader et al. [32] studied 
104 patients with heart failure and noted that patients with severe LV dyssynchrony were at 
higher risk of cardiac events than patients without LV dyssynchrony, irrespective of LV ejec-
tion fraction [32]. 
Although still incompletely understood the correction of the LV dyssynchrony is currently 
believed to be the key beneﬁcial mechanism of CRT. For example Bax et al. evaluated 25 
patients undergoing CRT and reported an acute improvement in LV ejection fraction, as-
sociated with an immediate reduction in LV dyssynchrony (from 97±35 ms to 28±21 ms, 
P<0.05) [35]. Subsequent studies demonstrated that patients with extensive baseline LV 
dyssynchrony had a high likelihood of improvement following CRT, whereas patients with-
out LV dyssynchrony did not improve [36-39]. Moreover, all other parameters, including the 
presence of inter-ventricular dyssynchrony, were unable to predict improvement following 
CRT [30,36,38]. 
Technical aspects 
To achieve cardiac resynchronization typically three diﬀerent pacing leads are implanted: one 
lead will be inserted in the right atrium, one in the right ventricle (usually in the apex) and 
the other one will be placed on the LV (postero-) lateral wall through the coronary sinus (or in 
some cases by a minimally invasive surgical technique inserted directly on the LV epicardial 
region of interest) (Figure 3). These three leads will be connected to a biventricular device 
and cardiac dyssynchrony is corrected through atrial synchronized biventricular stimulation. 
The dyssynchrony within the left ventricle is restored by simultaneously stimulating the RV 
apex (RV pacing lead activates the inter-ventricular septum) and the LV lateral wall (LV pacing 
lead) [40] (Figure 4). The hemodynamic beneﬁt of CRT can be further enhanced by optimizing 
the AV pacing interval and (in the latest generation of CRT devices) by adjusting the pacing 
interval between the right and the LV pacing lead (the VV interval) [41,42]. 
In addition, ventricular arrhythmias are a frequent observation in patients with impaired LV 
function. In order to prevent sudden cardiac death in patients undergoing CRT implantation 
the majority of CRT devices is now combined with a deﬁbrillator backup (ICD) in the same 
device [40,43,44]. 
General introduction and outline of the thesis 15
RA lead
RV lead
LV lead
Figure 3: Position of the pacemaker leads in cardiac resynchronization therapy. One lead is positioned in the right atrium (RA lead). One lead is 
placed in the right ventricle (usually in the apex, RV lead) and the other one will be placed on the LV (postero-) lateral wall through the coronary 
sinus (LV lead) (or in some cases by a minimally invasive surgical technique inserted directly on the LV epicardial region of interest).
Biventricular stimulation
LV
RV sept
lat
Figure 4: Schematic display of atrial synchronized biventricular stimulation in CRT. After atrial sensing (right atrial lead) both ventricles 
are stimulated using the right (RV) and left ventricular (LV) pacing leads. LV dyssynchrony generally occurs between the early activated inter-
ventricular septum (sept) and the late activated (postero-) lateral LV wall (lat) and is restored through the simultaneous activation of the inter-
ventricular septum by the RV pacing lead and the LV (postero-)lateral wall by the LV pacing lead. 
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Clinical results
After the ﬁrst cases of CRT reported by Bakker et al. and Cazeau et al. [21,22] the beneﬁcial 
eﬀects of CRT in patients with drug-refractory heart failure have been widely studied. Several 
studies have demonstrated the immediate beneﬁt of CRT on hemodynamics and systolic per-
formance of the left ventricle [29,45,46]. Moreover, the immediate beneﬁts of CRT were ac-
companied by an improvement in heart failure symptoms, exercise capacity, and LV ejection 
fraction at mid-term follow-up [47-49]. In addition, CRT resulted in a signiﬁcant LV reverse 
remodeling and a dramatic reduction in heart failure related hospitalizations. The startling 
beneﬁts of CRT observed in many smaller studies have now been clearly conﬁrmed in larger 
randomized controlled multi-center trials which have now included more than 4000 patients 
[50-61] (Table 2).
The Multicenter InSync Randomized Clinical Evaluation (MIRACLE)-trial [57] was the ﬁrst pro-
spective double-blind randomized controlled trial evaluating CRT. In this trial 453 patients 
(inclusion criteria NYHA class III-IV, QRS duration ≥130 ms and LV ejection fraction ≤35%) un-
derwent successful CRT device implantation. After implantation, patients were randomized 
to a CRT group (n=228) or a control group (Pacemaker OFF, n=225) for 6 months, while opti-
mal medical therapy for heart failure was maintained. Neither the patients nor the physicians 
were aware of the treatment assignment. The rate of implantation related complications was 
very low (1.3%) with 4 patients suﬀering from refractory hypotension, bradycardia or asystole 
(2 of whom died) and by perforation of the coronary sinus requiring pericardiocentesis in two 
others. 
Improvements in clinical parameters (NYHA class, quality of life and the distance walked in 6 
minutes) at 6 months follow-up were the primary end-points of the MIRACLE-trial. Compared 
to the control group CRT patients experienced an improvement in the 6 minute walking dis-
tance (+39 m versus +10 m, P<0.005), NYHA functional class (Figure 5), quality-of-life (-18.0 
Table 2: Major clinical trials on cardiac resynchronization therapy and their main inclusion criteria   
No of patients  NYHA class QRS duration (ms) Rhythm
PATH-CHF [50,51] 41 III-IV ≥120  SR
PATH CHF II [52] 86 II-IV ≥120 SR
CONTAK-CD [53] 490 III-IV ≥120  SR
MUSTIC-SR [54,55] 58 III >150 SR 
MUSTIC-AF [55,56] 43 III >200* AF
MIRACLE [57] 453 III,IV ≥130 SR
MIRACLE ICD [58] 362 III,IV ≥130 SR
COMPANION [59] 1520 III,IV ≥120 SR
CARE HF [60] 813 III,IV ≥120** SR
All trials required the presence of an LV ejection fraction ≤35%. * = during right ventricular pacing , ** = when QRS duration was 120-149 
patients were required to have echocardiographic evidence of left ventricular dyssynchrony. (NYHA= New York Heart Asssociation, SR = sinus 
rhythm, AF = atrial ﬁbrillation). 
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Figure 5: Changes in New York Heart Association functional (NYHA) functional class after 6 months follow-up in the MIRACLE trial [57] for 
patients in the cardiac resynchronization (CRT) group (n=228) and the control group (n=225). Note that although the level of clinical improvement 
is higher in the patients undergoing CRT, still 32% of the patients in the CRT group do not improve in NYHA functional class (referred to as clinical 
non-responders).
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* = P<0.001
Figure 6 : Changes in left ventricular (LV) end-systolic volume after 3 and 6 months follow-up in the MIRACLE trial [57,61] for patients in the 
cardiac resynchronization (CRT) group versus the control group (n=225). 
versus -9.0 points, P=0.001), time on the treadmill during exercise testing (+81 sec versus +19 
sec, P=0.001) and LV ejection fraction (+4.6 % versus -0.2 %). In addition, CRT patients had 
fewer heart failure hospitalizations than the controls (P=0.02) [57]. 
In addition, St John Sutton et al. studied the Doppler echocardiograms of the patients in the 
MIRACLE-trial and revealed the favourable eﬀects of CRT on LV volumes (LV reverse remodel-
ing) (Figure 6) and on the severity of mitral regurgitation. In contrast, the patients in the 
control group did not experience LV reverse remodeling or improvement in mitral regurgita-
tion [61,62]. 
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Thus, the MIRACLE-trial clearly demonstrated the beneﬁcial eﬀects of CRT on heart failure 
symptoms, exercise capacity and LV function [57]. 
The Comparison of Medical Therapy, Pacing and Deﬁbrillation in Heart Failure (COMPANION) 
trial [59] was the largest prospective multi-center randomized controlled clinical trial to date 
and was designed to evaluate the eﬀects of CRT on a composite end-point of all-cause mor-
tality and all-cause hospitalization. A total of 1520 patients (inclusion criteria: NYHA class 
III-IV, LVEF ≤35% and QRS duration ≥120 ms) were randomized in a 1:2:2 ratio to receive opti-
mal pharmacological therapy alone or in combination with a CRT-pacemaker or a combined 
CRT-deﬁbrillator. This trial conﬁrmed previous ﬁndings demonstrating that CRT results in 
improved clinical symptoms, greater functional capacity and reduced morbidity. 
In addition, the risk of death from any cause or hospitalization for heart failure was reduced 
by 34 % in the CRT-pacemaker group (P<0.002) and by 40% in the CRT-deﬁbrillator group 
(P<0.001). Also, the CRT-deﬁbrillator reduced the risk of all cause mortality (secondary end-
point) by 36% (P=0.003). Implantation of a CRT-pacemaker however, did not result in a sig-
niﬁcant decrease in the all-cause mortality of (24% P=0.06). These ﬁndings support the use of 
an ICD backup in patients undergoing CRT implantation [59].
The recently published Cardiac Resynchronization-Heart Failure (CARE-HF)-trial [60] was the 
ﬁrst CRT-trial to demonstrate an improvement in all-cause mortality of CRT without an ICD 
backup compared to patients on optimal medical therapy alone. A total of 813 patients were 
enrolled (inclusion criteria: NYHA class III-IV, QRS duration ≥120 ms and LV ejection fraction 
≤35%). In addition, patients with a QRS duration between 120 of 149 ms were required to 
meet some (simple) echocardiographic criteria of cardiac dyssynchrony. Patients were ran-
domized in an unblinded fashion to evaluate the eﬀects of CRT without a deﬁbrillator in 
advanced heart failure. There were 82 deaths in the CRT group, as compared with 120 in the 
medical-therapy group (20% versus 30%, P<0.002) (Figure 7). Heart failure hospitalizations 
were reduced by 52% and the positive eﬀects of CRT on LV ejection fraction, mitral regurgita-
tion and LV end-systolic volume were conﬁrmed. 
Thus, the CARE-HF trial demonstrated for the ﬁrst time the beneﬁcial eﬀects of CRT (without 
an ICD) on survival in patients with drug-refractory heart failure [60]. 
The vast majority of the randomized CRT-trials trials only included patients in sinus rhythm. 
At present, the evidence for the use of CRT in patients with atrial ﬁbrillation is less strong. 
The Multisite Stimulation In Cardiomyopathies and Atrial Fibrillation (MUSTIC-AF) [56] is the 
only randomized CRT trial addressing the issue of CRT in patients with atrial ﬁbrillation. In 
this trial 43 patients were randomized in a crossover study of three months for biventricular 
pacing versus three months of RV pacing, both in VVIR-mode (ventricular inhibited pacing). 
In the patients with eﬀective CRT the mean walked distance increased by 9.3% (P=0.05) and 
peak oxygen uptake increased by 13% (P=0.04). In addition, the number of hospitalizations 
decreased by 70% and 85% of patients preferred the biventricular pacing period (P<0.001) 
[56]. 
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Based on the results from these large trials (Table 2) CRT is now considered a Class I (level of 
evidence A) indication in patients drug refractory moderate-to-severe heart failure (NYHA 
class III/IV), QRS duration ≥120 ms, sinus rhythm and LV ejection fraction ≤35% (Figure 8). 
The issue of non-responders to CRT
Despite the impressive results of CRT in recent large randomized trials a consistent number 
of patients fails to improve following CRT implantation when the established CRT selection 
criteria (NYHA class III-IV heart failure, LV ejection fraction ≤35% and QRS duration >120 ms) 
Figure 7 : Kaplan-Meier curves of the time to all-cause mortality (optimal medical therapy versus cardiac resynchronization without ICD) in 
the CARE-HF trial. (reprinted with permission from reference #60). 
• NYHA class III-IV
• LV ejection fraction �35%
• QRS duration �120 ms
• Sinus rhythm
• Optimal medical therapy
CRT selection criteria
������������ ���������� �����
Figure 8 : Current implantation criteria for a cardiac resynchronization (CRT) device according to the 2005 HRS/AHA/ACC guidelines (level of 
evidence IA, HRS = Heart Rhythm Society, AHA = American Heart Association, ACC = American College of Cardiology) [23]. 
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were applied. For example, close analysis of the data from the MIRACLE trial revealed that 
32% of patients did not improve or even worsened in NYHA class after 6 months of CRT [57] 
(Figure 5). The presence of clinical non-responders to CRT has now been conﬁrmed in several 
other studies and is usually around 30% [47,59] . In addition, if response to CRT is deﬁned 
using more objective parameters such absence of LV reverse remodeling or lack of improve-
ment in LV ejection fraction on echocardiography at mid-term follow-up the number of non-
responders is usually between 40-50% [39]. 
In view of the unnecessary procedure risks and health care expenses in patients without re-
sponse to CRT the percentage of non-responders among patients selected according to the 
current selection criteria (Figure 8) is unacceptably high and should be reduced. 
AIM AND OUTLINE OF THE THESIS 
The relatively high number of patients without beneﬁt from CRT (referred to as non-respond-
ers) indicates the need for reﬁnement of the current selection criteria in order to 1] better 
identify those patients with the highest likelihood of response to CRT and 2] avoid device 
implantations in patients that are unlikely to respond to CRT. 
The aim of the current thesis was to improve and reﬁne the current CRT selection criteria 
through the evaluation of the mechanisms underlying (non-) response to CRT. 
In part I the clinical and echocardiographic response rates to CRT were studied and com-
pared between diﬀerent patient subgroups. The eﬀects of age and gender on response to 
CRT were studied in Chapter 2 and Chapter 3. The precise relationship between clinical and 
echocardiographic response following CRT was evaluated in Chapter 4 in order to better un-
derstand and deﬁne response to CRT 
In part II the pathophysiological mechanisms underlying clinical and echocardiographic 
beneﬁt to CRT were studied on a ventricular level. The positive eﬀects of CRT on both left 
and right ventricular size and function were evaluated in Chapters 5 and 6. The mid-term 
hemodynamic eﬀects of CRT were studied using pressure-volume loop in Chapter 7. Finally, 
the beneﬁcial eﬀects of CRT were related to the eﬀects of CRT on LV dyssynchrony (Chapter 
8). 
Next, the information about the mechanisms of (non-)response to CRT derived from parts I 
and II was used in part III to develop improved selection criteria for CRT. The ability of QRS 
duration to detect LV dyssynchrony was tested in Chapter 9 and in chapter 10 the occurrence 
of LV dyssynchrony was evaluated in a group of heart failure patients with a narrow QRS 
complex. The ability of M-mode echocardiography to detect LV dyssynchrony and to predict 
response to CRT was evaluated in Chapter 11. Next, a novel echocardiographic technique 
called color-coded tissue Doppler imaging (TDI) was used to quantify LV dyssynchrony and 
to predict response to CRT (Chapter 12). The relationship between scar tissue in the postero-
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lateral LV segments (which is usually the area of the LV pacing tip) and response to CRT was 
evaluated in chapter 13 using contrast enhanced MRI. 
The better understanding of the mechanisms of beneﬁt from CRT in parts I and II and the 
development of additional selection criteria in part III led to the observation that several 
patients groups outside the current selection criteria may potentially beneﬁt from CRT. These 
novel indications for CRT are evaluated in part IV. In chapter 14 the eﬀects of CRT are tested 
in patients with a narrow QRS complex (<120 ms) and LV dyssynchrony and in chapter 15 
the eﬀects of CRT were investigated in patients with a mild symptoms of heart failure (NYHA 
class II). 
Part V (Chapter 16) contains an integration of the information described in chapters 2-15 and 
gives an overview of the optimal use of diﬀerent non-invasive imaging modalities, in particu-
lar echocardiography, in patients undergoing CRT implantation, both before implantation (to 
optimize patient selection), as well as during follow-up (evaluation of therapy success and 
optimization of pacemaker settings). 
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ABSTRACT 
In the present study, the eﬀects of cardiac resynchronization therapy (CRT) in elderly patients 
were evaluated. The study included 170 consecutive patients whose clinical and echocardio-
graphic improvements were evaluated at 6 months follow-up. Survival was evaluated up to 2 
years. The eﬀects of CRT in elderly patients (≥70 years) were compared to results in younger 
(<70 years) patients. 
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INTRODUCTION
Cardiac resynchronization therapy (CRT) has been demonstrated to be beneﬁcial in patients 
with end-stage heart failure despite optimized medical therapy. Various studies have shown 
improvement in heart failure symptoms, exercise capacity and left ventricular (LV) systolic 
function [1-4]. However, patient responses to CRT vary signiﬁcantly. Whether patient age 
would negatively aﬀect response to CRT is currently unknown; this is an important issue, 
since the majority of patients with heart failure are of older age. Accordingly the beneﬁcial 
eﬀects of CRT were evaluated in patients ≥70 years and compared to results obtained in pa-
tients <70 years.
METHODS
Patients and study protocol
A total of 170 consecutive patients with heart failure, scheduled for the implantation of a 
CRT device, were included. The following selection criteria for CRT were applied: moderate-
to-severe heart failure (New York Heart Association (NYHA) class III or IV), LV ejection fraction 
≤35% and QRS duration >120 ms with left bundle branch block conﬁguration). Patients with 
a recent myocardial infarction (<3 months) or decompensated heart failure were excluded.
Before pacemaker implantation, clinical status was assessed and two-dimensional echocar-
diography was performed to assess LV volumes and LV ejection fraction. Next, tissue Doppler 
imaging was performed to evaluate LV dyssynchrony; tissue Doppler imaging was also used 
to assess resynchronization immediately after implantation. The clinical status and changes 
in LV ejection fraction and LV volumes were re-assessed at 6 months follow-up.
Clinical evaluation
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota living with Heart Failure questionnaire) and evaluation of exercise 
capacity using the 6-minute hall-walk test. Patients with an improvement of at least 1 NYHA 
functional class at 6 months follow-up were classiﬁed as responders. Data on long-term sur-
vival were collected by chart review and telephone contact. Follow-up data were acquired 
up to 2 years.
Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system FiVe/Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). 
Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and 
apical views (standard long-axis and 2- and 4-chamber images). The LV volumes (end-systolic, 
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end-diastolic) and LV ejection fraction were calculated from the conventional apical 2- and 
4-chamber images, using the biplane Simpson’s technique [5]. 
For tissue Doppler imaging, color Doppler frame rates varied between 80 and 115 frames/s 
depending on the sector width of the range of interest; pulse repetition frequencies were 
between 500 Hz and 1 KHz, resulting in aliasing velocities between 16 and 32 cm/s. Data were 
analyzed using commercial software (Echopac 6.1, General Electric - Vingmed). To determine 
LV dyssynchrony, the sample volume was placed in the basal portions of the septum and the 
LV lateral wall; peak systolic velocities and time-to-peak systolic velocities were obtained and 
the septal-to-lateral delay in peak velocity was calculated as an indicator of LV dyssynchrony. 
Based on previous observations a septal-to-lateral delay >60 ms was considered to repre-
sent substantial LV dyssynchrony [6]. Inter- and intra-observer agreement for assessment 
of septal-to-lateral delay were 90% and 96%, respectively [7]. Echocardiographic data were 
analyzed by 2 independent observers, blinded to clinical outcome. 
Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained using a balloon catheter. Next the LV pacing lead was inserted 
through the coronary sinus with the help of an 8Fr-guiding catheter, and positioned as far 
as possible in the venous system, preferably in a (postero-) lateral vein. When a conventional 
indication for an internal deﬁbrillator existed, a combined device was implanted. In all pa-
tients the implantation of the CRT device (Contak TR or CD, Guidant, Minneapolis, Minnesota, 
and Insync III or CD, Medtronic Inc., Minneapolis, Minnesota) was successful without major 
complications. Two types of LV leads were used (Easytrak 4512 to 80, Guidant, or Attain-SD 
4189, Medtronic Inc.). 
Statistical analysis
Data are presented as mean ±SD, and compared using (un-)paired Student’s t-test when ap-
propriate. Univariate analysis for categorical variables was performed using the chi-square 
test with Yates' correction. Simultaneous comparison of >2 values was performed by using 
one-way ANOVA with Bonferroni correction. Survival was evaluated by the method of Ka-
plan-Meier. For all tests, a P-value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
A total of 170 consecutive patients were included, the study population comprised 137 
men/33 women with a mean age of 66±11 years (range 18-85 years); 102 patients were aged 
<70 years and 68 patients were ≥70 years. Mean NYHA class was 3.2±0.4, with most patients 
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in NYHA class III (83%). Severe dilatation of the LV was observed in most patients (LV end-
diastolic volume 254±86 ml and LV end-systolic volume 201±79 ml), accompanied by an LV 
ejection fraction of 21±9%. Tissue Doppler imaging demonstrated severe LV dyssynchrony in 
this patient group (98±60 ms).
The baseline characteristics of the patients <70 years and the patients ≥70 years are sum-
marized in Table 1. Patients ≥70 years were more likely to have an ischemic origin of the 
cardiomyopathy (48% vs. 66%, P<0.05). No other diﬀerences in baseline characteristics were 
observed between these patient groups.
Post-implantation
Following CRT implantation, QRS duration decreased from 173±27 ms to 153±24 ms (P<0.001). 
Tissue Doppler imaging demonstrated a reduction in LV dyssynchrony immediately after im-
plantation from 98±60 ms to 36±33 ms (P<0.001), indicating LV resynchronization. Within 6 
months after CRT, 10 patients (6%) died, (6 patients due to refractory heart failure, 3 patients 
due to sudden cardiac death; in 1 patient the cause of death was unknown). Another 2 pa-
tients (1%) underwent cardiac transplantation within 6 months following CRT implantation, 
both because of ongoing heart failure. Because these patients did not have the 6-month 
follow-up assessment, they could not be included in the comparison of response to CRT, but 
they were included in the comparison of survival following CRT. In addition, no diﬀerences 
were observed between the baseline characteristics of patients with (n=158) and without 
(n=12) 6-month follow-up assessment.
Table 1. Baseline characteristics of patients <70 years (n=102) versus patients ≥70 years (n=68).
<70 years ≥70 years 
Age (years) 59±9 76±4 
Male/Female 80/22 57/11
NYHA class  
 III 83 58
 IV 19 10
Etiology
 Ischemic 49 (48%)* 45 (66%)*
 Idiopathic 53 (52%) 23 (44%) 
QRS duration (ms) 175±28 171±24
6-minute walking distance (m) 290±142 250±125
Quality-of-life score 42±16 41±14 
LV ejection fraction (%) 22±8 21±7 
LV end-diastolic volume (ml) 261±84 239±79
LV end-systolic volume (ml) 207±79 191±71
LV dyssynchrony (ms) 100±60 95±59
* = P<0.05
32
C
ha
pt
er
 2
Clinical and echocardiographic improvement following CRT
At 6 months follow-up the clinical status of the patients was re-assessed. NYHA class im-
proved from 3.2±0.4 to 2.2±0.7 (P<0.001). In addition, the Minnesota score decreased from 
42±16 to 27±17 (P<0.001) and the 6-minute walking distance increased from 273±138 to 
385±148 (P<0.001). Based on lack of improvement in NYHA class at 6 months, 38 patients 
(24%) were classiﬁed as non-responders.
LV ejection fraction improved from 21±8% to 28±9% (P<0.05), associated with a signiﬁcant 
reduction in LV volumes (end-systolic volume from 200±76 ml to 163±74 ml and end-diastolic 
volume from 252±82 ml to 220±79 ml, both P<0.05).
Patients <70 years versus patients ≥70years
The extent of immediate resynchronization was similar between the patients <70 years and 
≥70 years (from 100±60 ms to 36±32 ms (P<0.001) vs. from 95±59 ms to 35±34 ms (P<0.001), 
respectively, ns). In addition, both patient groups showed a signiﬁcant improvement in clini-
cal symptoms at 6 months follow-up. Improvements in NYHA class, Minnesota- score and 6-
minute walking distance were similar in both groups (Table 2). The number of non-responders 
was equal in the patients <70 years and ≥70 years (response rate 75% vs. 78%, respectively, 
ns). Furthermore, improvement in LV ejection fraction and the extent of LV remodeling were 
Table 2. Six months follow-up results in patients <70 years (n=102) versus patients ≥70 years (n=68). 
<70 years (n=102) ≥70 years (n=68)
NYHA class 
 Baseline 3.2±0.4 3.1±0.4
 Follow-up  2.2±0.7* 2.2±0.6*
6- minute walking distance (m) 
 Baseline 290±142 250±125
 Follow-up 399±154* 363±139*
Quality-of-life score 
 Baseline 42±16 41±14 
 Follow-up 28±17* 27±16*
LV end-systolic volume (ml) 
 Baseline 207±79 191±71
 Follow-up 173±78* 150±65*
LV end-diastolic volume (ml)
 Baseline 261±84 239±79
 Follow-up 230±83* 206±72*
LV ejection fraction (%)
 Baseline 22±8 21±7 
 Follow-up 28±10* 28±9* 
Died within 6 months 5 (5%) 5 (7%)
Heart transplantation within 6 months 2 (2%) 0 
*:P<0.05 follow-up vs. baseline value. 
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not statistically diﬀerent between the two groups (Table 2). Survival at 1 year after implanta-
tion was comparable in the patients <70 years (90%;95% conﬁdence interval 84-96%) and 
patients ≥70 years (83%;95% conﬁdence interval 73-93%, ns, Figure 1). 
DISCUSSION
Despite the encouraging results from CRT in recent trials, the individual responses to CRT 
vary signiﬁcantly. It is currently unclear whether elderly patients respond less favorably to 
CRT as compared to younger patients. If age would have an inﬂuence on clinical outcome, 
this may be an argument to restrict the use of CRT according to age. Therefore, in the pres-
ent study, the beneﬁcial eﬀects of CRT were compared between patients <70 years versus 
patients ≥70years. Elderly patients were more likely to have an ischemic etiology of cardio-
myopathy as compared to patients <70 years. Other baseline clinical and echocardiographic 
characteristics were similar; in particular, the extent of LV dyssynchrony (assessed by tissue 
Doppler imaging) was comparable. Immediately after implantation of the CRT device, tissue 
Doppler imaging showed a substantial decrease in LV dyssynchrony, which was similar in 
patients <70 years and patients ≥70 years; this observation indicates that resynchronization 
following CRT occurs also in elderly patients.
At 6 months follow-up, CRT proved beneﬁcial in both groups, as reﬂected by an improvement 
in clinical and echocardiographic parameters. Moreover, the magnitude of improvement was 
comparable between the two groups, both in clinical (NYHA class, quality-of-life score and 
6-minute walking distance), as well as in echocardiographic parameters (improvement in LV 
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Figure 1: One-year survival was similar in patients <70 years (n=102) and patients ≥70 years (n=68), (90% vs. 83%, ns). 
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ejection fraction and the extent of LV reverse remodeling). In addition, the number of non-re-
sponders was comparable between the patients <70 years (25%) and the patients ≥70 years 
(22%). Although the deﬁnition of a clinical responder by an improvement of ≥1 NYHA class is 
widely used, this remains a somewhat subjective parameter, which may be considered as a 
limitation. Finally, patient survival was not diﬀerent between the patients groups. 
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ABSTRACT
Background 
Cardiac resynchronization therapy (CRT) has a beneﬁcial eﬀect on clinical symptoms, exercise 
capacity and systolic left ventricular (LV) performance in patients with heart failure. The aim 
of the current study was to evaluate whether a gender diﬀerence exists in the response to 
CRT.
Methods 
Consecutive patients with end-stage heart failure (NYHA class III-IV), LV ejection fraction 
≤35%, QRS duration >120 ms, and left bundle branch block conﬁguration underwent CRT. At 
baseline and 6 months post-CRT, clinical and echocardiographic parameters were evaluated; 
follow-up was obtained up to 5 years. The eﬀects of CRT were compared between women 
and men. 
Results 
The study population comprised 137 men and 36 women (mean age 66±11 years). No diﬀer-
ences in baseline characteristics were observed except that non-ischemic cardiomyopathy 
was more frequent in women than men (67% vs. 38%, P<0.05).
In all patients, clinical and echocardiographic parameters improved signiﬁcantly at 6 months 
follow-up. The magnitude of improvement in diﬀerent parameters was similar between 
women and men; e.g. the improvement in NYHA class was 0.9±0.6 in women and 1.0±0.7 in 
men (NS) and the increase in LV ejection fraction was 8±8% in women as compared to 7±9% 
in men (NS). The percentage of individual responders was not diﬀerent between women and 
men (76% vs. 80%, NS) and 2-year survival was comparable for women and men (84% vs. 
80%, NS). 
Conclusion 
No gender diﬀerences were observed in response to CRT and long-term survival after CRT.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is currently considered a major breakthrough in 
the treatment of patients with drug-refractory heart failure. In recent years, several major 
randomized trials have shown the beneﬁcial eﬀects of CRT on clinical symptoms, exercise 
capacity and left ventricular (LV) systolic function [1-4]. More recently, it was demonstrated in 
the CARE-HF trial that CRT also increased survival as compared to optimized medical therapy, 
and this was associated with a signiﬁcant reduction in the number of re-hospitalizations for 
heart failure [4]. 
Despite these impressive results, it is known that individual response to CRT varies signiﬁ-
cantly. Whether a gender-related diﬀerence in response to CRT exists is unknown. This is an 
important issue, since various studies pointed out the gender diﬀerences in presentation of 
coronary artery disease and diﬀerences in response to therapy [5-7]. Accordingly, the objec-
tive of the present study was to evaluate whether a gender diﬀerence exists in response to 
CRT. To address this issue, the eﬀects of CRT on clinical symptoms, LV function and survival 
were evaluated in a consecutive cohort of patients undergoing CRT and the responses be-
tween women and men were compared.
METHODS
Study Population
A total of 173 consecutive patients with heart failure, scheduled for the implantation of a CRT 
device, were included. The following selection criteria for CRT were applied: moderate-to-se-
vere heart failure (New York Heart Association (NYHA) class III or IV), LV ejection fraction (EF) 
≤35% and QRS duration >120 ms with left bundle branch block conﬁguration. Patients with a 
recent myocardial infarction (<3 months) or decompensated heart failure were excluded.
Before pacemaker implantation, clinical status was assessed and 2D echocardiography was 
performed to assess LV volumes and LVEF. Next, tissue Doppler imaging (TDI) was performed 
to evaluate LV dyssynchrony. LV dyssynchrony was re-assessed immediately after implanta-
tion. Clinical status, LVEF and LV volumes were re-assessed at 6 months follow-up.
Clinical Evaluation 
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota living with Heart Failure questionnaire) and evaluation of exercise 
capacity using the 6-minute hall-walk test. Patients with an improvement of at least 1 NYHA 
functional class at 6 months follow-up were classiﬁed as responders. 
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In addition, long-term follow-up was performed by chart review, telephone contact and out-
patient clinical visits. Events were classiﬁed as death or heart transplantation. Follow-up data 
were acquired up to 5 years. 
Echocardiography and Tissue Doppler Imaging
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). Im-
ages were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and 
apical views (standard long-axis and 2- and 4-chamber images). Standard 2D and color Dop-
pler data, triggered to the QRS complex, were saved in cine-loop format. The LV volumes 
(end-systolic, end-diastolic) and LVEF were calculated from the conventional apical 2- and 
4-chamber images, using the biplane Simpson’s technique [8]. 
For TDI, color Doppler frame rates varied between 80 and 115 frames/s depending on the 
sector width of the range of interest; pulse repetition frequencies were between 500 Hz and 
1 KHz, resulting in aliasing velocities between 16 and 32 cm/s. TDI parameters were measured 
from color images of 3 consecutive heart beats by oﬄine analysis. Data were analyzed using 
commercial software (Echopac 6.1, General Electric - Vingmed). 
To determine LV dyssynchrony, the sample volume was placed in the basal portions of the 
septum and the LV lateral wall; peak systolic velocities and time-to-peak systolic velocities 
were obtained and the septal-to-lateral delay in peak velocity was calculated as an indicator 
of LV dyssynchrony [9,10]. Based on previous observations a septal-to-lateral ≥65 ms was 
considered to represent substantial LV dyssynchrony [9]. Inter- and intra-observer agreement 
for assessment of septal-to-lateral delay were 90% and 96%, respectively [11]. Echocardio-
graphic data were analyzed by 2 independent observers, blinded to clinical outcome. 
Pacemaker Implantation
The LV pacing lead was inserted transvenously via the subclavian route. First a coronary si-
nus venogram was obtained using a balloon catheter. Next the LV pacing lead was inserted 
through the coronary sinus with the help of an 8Fr-guiding catheter, and positioned as far 
as possible in the venous system, preferably in a (postero-) lateral vein. The right atrial and 
right ventricular leads were positioned conventionally. When a conventional indication for 
an internal deﬁbrillator existed, a combined device was implanted. In all patients the im-
plantation of the CRT-device (Contak TR or CD, Guidant, Minneapolis, Minnesota, USA and 
Insync III or CD, Medtronic Inc., Minneapolis, Minnesota, USA) was successful without major 
complications. Two types of LV leads were used (Easytrak 4512 to 80, Guidant, or Attain-SD 
4189, Medtronic Inc.).
Gender diﬀ erences in response to CRT 41
Statistical Analysis
Data are presented as mean ±SD, and compared using (un-)paired Student’s t-test when ap-
propriate. Univariate analysis for categorical variables was performed using the chi-square 
test with Yates' correction. Survival was evaluated by the method of Kaplan-Meier. For all 
tests a P-value <0.05 was considered statistically signiﬁcant.
RESULTS
Study Population 
The study population comprised 173 patients (137 men, mean age 66±11 years) with a wide 
QRS complex (mean QRS duration 173±27 ms) and left bundle branch block conﬁguration. 
Most patients were in NYHA class III (87%). The majority of the patients (88%) were in sinus 
rhythm. Severe dilatation of the LV was present in most patients (LV end-diastolic volume 
254±81 ml and LV end-systolic volume 202±75 ml), with a mean LV ejection fraction of 21±9%. 
TDI showed the presence of severe baseline LV dyssynchrony (98±59 ms).
In Table 1, the baseline characteristics of men and women are compared. Male patients more 
frequently had ischemic cardiomyopathy (62% vs. 33%, P<0.05), whereas female patients 
more frequently had non-ischemic cardiomyopathy. No other diﬀerences in baseline charac-
teristics were observed between the groups. 
Table 1. Baseline characteristics of the study population (n=173).
Men (n=137) Women (n=36) P-value
Age (yrs) 66±11 65±11 NS
NYHA class 
 III 117 (85%) 33 (92%) NS
 IV 20 (15%) 3 (8%)
Etiology
 Ischemic 85 (62%) 12 (33%) P<0.05
 Idiopathic 52 (38%) 24 (67%)
QRS (ms) 173±28 168±35 NS
6-MWT (m) 248±113 225±135 NS
LVEF (%) 21±8 21±7 NS
LVEDV (ml) 257±82 242±78 NS
LVESV (ml) 204±76 193±72 NS 
LV dyssynchrony (ms) 101±61 86±47 NS
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; 6-MWT: 6-minute 
walk test; NYHA: New York Heart Association; QoL: quality of life score.
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Following CRT implantation, QRS duration decreased from 173±27 ms to 153±23 ms 
(P<0.001). TDI demonstrated a reduction in LV dyssynchrony immediately after implantation 
from 98±59 ms to 36±33 ms (P<0.001), indicating LV resynchronization. Within 6 months after 
CRT, 8 patients (5%) died, (5 patients due to worsening heart failure, 2 patients due to sudden 
cardiac death and in 1 patient the cause of death was unknown). Another 2 patients (1%) 
underwent cardiac transplantation within 6 months following CRT implantation because of 
worsening heart failure. These patients did not have the 6-month clinical and echocardio-
graphic follow-up assessment; they were included in the comparison of survival following 
CRT, but could not be included in the comparison of 6-months response to CRT. Of note, no 
diﬀerences were observed between the baseline characteristics of patients with (n=163) and 
without (n=10) the 6-month follow-up assessment. 
Clinical and Echocardiographic Changes After 6-months of CRT
At 6 months follow-up, the clinical status of the patients was re-assessed. NYHA class im-
proved from 3.1±0.3 to 2.1±0.7 (P<0.001). In addition, the Minnesota score decreased from 
41±15 to 26±16 (P<0.001) and the 6-minute walking distance increased from 243±110 m to 
358±136 m (P<0.001). Based on lack of improvement in NYHA class at 6-month follow-up, 35 
patients (20%) were classiﬁed as non-responders.
Long-term Follow-up
The mean follow-up was 21±14 months (range 1-60 months). During follow-up, 33 (19%) pa-
tients died: 4 patients died of sudden cardiac death, 21 due to end-stage heart failure, 1 due 
to acute myocardial infarction, 3 of non-cardiac origin (1 septic shock, 1 prostate cancer and 
1 cerebral hemorrhage) and in 4 patients the cause of death was unknown. Three patients 
(2%) underwent cardiac transplantation for progressive heart failure. The event-free survival 
at 1- and 2-year follow-up was 87% and 81% respectively.
Gender versus Response to CRT 
The eﬀects of CRT in men versus women are shown in Table 2. The mean reduction in QRS du-
ration was not diﬀerent in men and women (19±29 ms vs. 25±21 ms, NS). Also, the extent of 
immediate LV resynchronization was similar between men and women (64±61 ms vs. 54±45 
ms, NS). 
Both men and women showed a signiﬁcant improvement in clinical criteria at 6-months follow-
up. The reduction in NYHA class was comparable between men and women: 1.0±0.7 in men vs. 
0.9±0.6 in women (NS). Also, the improvement in symptoms was not diﬀerent: the reduction in 
Minnesota quality-of-life score was 15±14 in men as compared to 16±13 in women (NS). More-
over, the improvement in exercise capacity was similar: the 6-minute walking distance improved 
on average 114±98 m in men and 121±111 m in women (NS). The absolute number of clinical 
responders was also not diﬀerent between men and women (80% vs. 76%, see Figure 1). The 
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increase in LV ejection fraction was comparable (on average 7±9% in men and 8±8% in women, 
NS) and the extent of LV reverse remodeling was similar between men and women (see Table 2). 
Finally, no diﬀerences were observed in long-term survival between men and women. The 
1-year survival was 86% in men vs. 93% in women (NS), whereas the 2-year survival was 80% 
in men and 84% in women (NS, see Figure 2).
DISCUSSION
Over the past few years, the beneﬁcial eﬀect of CRT in patients with end-stage heart failure has 
been demonstrated in various studies. These studies have reported improvements in heart 
failure symptoms, quality of life, exercise capacity and systolic LV function, associated with 
a reduction in LV volumes (reverse LV remodeling) following CRT [1-4,12]. These beneﬁcial 
eﬀects were also observed in the current study. More recently, a superior long-term survival 
after CRT as compared to optimized medical therapy was shown [4]. The 2-year survival in the 
current study was comparable to that in the previously reported studies [3,4].
Table 2. Men versus women, clinical variables at 6 months follow-up.
Men (n=137) Women (n=36) P-value
NYHA class 
 baseline 3.1±0.4 3.1±0.3 NS
 follow-up 2.1±0.7* 2.2±0.6* NS
6-MWT (m)  
 baseline 248±113 225±135 NS
 follow-up 362±142* 345±142* NS
QoL score 
 baseline 40±15 45±14 NS 
  follow-up 25±16* 29±16* NS
LVESV (ml)
 baseline 204±76 193±72 NS 
 follow-up 167±71* 156±90* NS
LVEDV (ml)
 baseline 257±82 242±78 NS 
 follow-up 226±77* 206±93* NS
LVEF (%)
 baseline 21±8 21±7 NS
 follow-up 28±9* 29±11* NS
Died within 6 months  8 (6%) 0 NS
HTX within 6 months 1 (1%) 1 (3%) NS 
EDV: End-systolic volume; ESV: End-systolic volume; HTX: heart transplantation; LVEF: Left ventricular ejection fraction; 6-MWT: 6-minute walk 
test; NYHA: New York Heart Association; QoL: quality of life score. 
*: P<0.05 follow-up vs. baseline value. 
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However, despite the impressive results from CRT in major trials, individual response to CRT 
still varies substantially. Careful analysis of the data from the MIRACLE trial revealed that 
20-30% of patients did beneﬁt from CRT [1]. Similar percentages of non-responders were 
reported in other studies [9,10,13,14]. In the current study, 20% of patients did not respond 
to CRT.
At present, only limited data are available regarding diﬀerences in beneﬁt from CRT among 
diﬀerent patient subgroups. For example, it is unknown whether gender inﬂuences response 
Men Women
Non-responder
20%
Non-responder
24%
Responder
80%
Responder
76%
Figure 1. No signiﬁcant diﬀerence was observed in the percentage of responders and non-responders to CRT in men (n=137) and women 
(n=36), (80% vs. 76%, NS). 
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Figure 2. Kaplan-Meier curves of the event rates (death or heart transplantation) in men (n=137) and women (n=36) over a 2-year follow-up 
period, demonstrating no signiﬁcant diﬀerence in event-free survival between men and women.
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to CRT. This is a relevant issue, since previous studies concerning women and heart disease 
have reported epidemiologic, diagnostic and prognostic diﬀerences between women and 
men [5-7, 15-17]. This may be of particular importance in heart failure. For example, data 
from the SOLVD trial revealed that women experienced a lesser reduction in mortality and 
re-hospitalizations after treatment with enalapril as compared to men [18,19]. 
In the present study the potential eﬀect of gender on response to CRT was evaluated in a 
large cohort of consecutive patients with heart failure referred for CRT according to estab-
lished selection criteria [20]. The percentage of women included in the current study was 
21%, which is comparable to the percentage of women included in the large, randomized 
CRT trials (ranging from 27% to 32%) [1-4]. Moreover, the percentage of women included in 
large, randomized drug trials in heart failure usually varies between 15% to 30% [18,21,22], 
although it has been suggested that the percentage of women with moderate-to-severe 
heart failure in the general population may be higher [15,23,24]. Thus, the relatively low per-
centage of women included in CRT trials may indicate a referral bias, as already suggested 
in previous studies reporting a lower referral rate in women for diagnostic and therapeutic 
procedures [16,25]. 
In the current study, no diﬀerences were observed in baseline characteristics between men 
and women, except for the signiﬁcantly higher percentage of women with non-ischemic car-
diomyopathy (67% vs. 38%, P<0.05). Immediately after implantation of the CRT device, TDI 
showed a substantial decrease in LV dyssynchrony in men and women, indicating no gender 
diﬀerence in resynchronization after onset of CRT. 
The immediate LV resynchronization was followed by a signiﬁcant improvement in clinical 
and echocardiographic parameters at mid-term follow-up in both groups. Moreover, the 
magnitude of improvement in clinical parameters (NYHA class, quality-of-life score and 6-
minute walking distance), as well echocardiographic parameters (LV ejection fraction, LV 
volumes) was comparable between men and women. Importantly, the percentage of non-re-
sponders to CRT was also not diﬀerent between men (20%) and women (24%). Finally, patient 
survival at 1-year (86% for men and 93% for women) and 2-year follow-up (80% and 84%, 
respectively) were not diﬀerent.
Conclusion
The percentage of women referred for CRT is lower than man. However, no gender diﬀer-
ences were observed in individual response rate to CRT. Men and women experienced a 
comparable beneﬁt from CRT in terms of improvement in clinical and echocardiographic 
parameters. Also, 2-year survival after CRT was not diﬀerent between men and women.
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ABSTRACT
Currently, a clear deﬁnition of response to cardiac resynchronization therapy (CRT) is still 
lacking and both clinical and echocardiographic end-points are used. It is also unclear wheth-
er patients with clinical response also improve in echocardiographic end-points (and vice 
versa). To better understand and deﬁne response to CRT, the relation between improvement 
in clinical and echocardiographic parameters was evaluated in 144 patients. 
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INTRODUCTION
Cardiac resynchronization therapy (CRT) has been demonstrated beneﬁcial in patients with 
end-stage heart failure [1]. However, patient responses to CRT vary signiﬁcantly [2,3]. It is cur-
rently unclear what the precise relation is between response (or non-response) following CRT 
deﬁned by clinical parameters as compared to echocardiographic parameters. It is unknown 
whether patients with a clinical response to CRT also improve in echocardiographic param-
eters (and vice versa). Accordingly, the correlation between clinical and echocardiographic 
response to CRT was evaluated in 144 consecutive patients. 
METHODS
Patients and study protocol
Consecutive patients with severe heart failure, scheduled for implantation of a CRT device 
were prospectively included in the study. Patients were selected according to established 
selection criteria for CRT: 1) severe heart failure (New York Heart Association (NYHA) class III 
or IV); 2) left ventricular (LV) ejection fraction (EF) ≤35% and 3) QRS duration ≥120 ms with left 
bundle branch block conﬁguration. 
Patients with a recent myocardial infarction (<3 months) or decompensated heart failure were 
excluded. The study protocol was as follows: before CRT implantation, clinical status was as-
sessed. Two-dimensional echocardiography at rest was performed to determine LV volumes 
and LVEF. Next, tissue Doppler imaging (TDI) was performed to evaluate LV dyssynchrony. 
The day after CRT implantation, LV dyssynchrony was re-assessed to evaluate resynchroniza-
tion. Clinical status, LV volumes and LVEF were re-assessed at 3-6 months follow-up. 
Clinical evaluation
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota quality-of-life questionnaire) and 6-minute hall-walk test. In all 
patients, QRS duration was measured from the surface electrocardiogram using the widest 
QRS complex from the leads II, V1 and V6. The electrocardiograms were recorded at a speed 
of 25 mm/sec and were evaluated by two independent observers without knowledge of the 
clinical status of the patient. Patients with an improvement of at least 1 NYHA functional class 
at 6 months follow-up were classiﬁed as clinical responders.
Echocardiographic evaluation
Resting echocardiography and TDI were performed at baseline, the day after CRT implanta-
tion and at 3-6 months follow-up. Patients were imaged in the left lateral decubitus position 
using a commercially available system (Vingmed system Seven, General Electric-Vingmed, 
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Milwaukee, Wisconsin, USA). Images were obtained using a 3.5 MHz transducer, at a depth 
of 16 cm in the parasternal and apical views (standard long-axis and 2- and 4-chamber im-
ages). Standard two-dimensional and color Doppler data, triggered to the QRS complex were 
saved in cine-loop format. LV volumes (end-systolic, end-diastolic) were derived from the 
conventional apical two- and four-chamber images, and LVEF was calculated using the bi-
plane Simpson’s technique [4].
Based on previous studies, patients with a decrease >15% in LV end-systolic volume at 6 
months follow-up were classiﬁed as echocardiographic responders [2,5,6]. Similarly, a de-
crease >15% in LV end-diastolic volume at 6 months follow-up was considered signiﬁcant. In 
addition, an (absolute) improvement in LVEF >5% was considered signiﬁcant [7,8].
Tissue Doppler imaging to assess LV dyssynchrony In addition to the conventional echo-
cardiographic examination, TDI was performed to assess LV dyssynchrony. For TDI, color Dop-
pler frame rates varied between 80 and 115 frames/s depending on the sector width of the 
region of interest; pulse repetition frequencies were between 500 Hz and 1 KHz, resulting in 
aliasing velocities between 16 and 32 cm/s. TDI parameters were measured from color-coded 
images from 3 consecutive heart beats by oﬄine analysis. Data were analyzed using com-
mercially available software (Echopac 6.1, General Electric - Vingmed). 
To determine LV dyssynchrony, the sample volume was placed in the basal portions of the 
septum and the LV lateral wall; peak systolic velocities and time-to-peak systolic velocities 
were obtained and the delay in peak velocity between the septum and the LV lateral wall was 
calculated as an indicator of LV dyssynchrony (referred to as the septal-to-lateral delay) [2,9]. 
Inter- and intra-observer agreement for assessment of the septal-to-lateral delay were 90% 
and 96%, respectively [10]. 
Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained during occlusion of the coronary sinus using a balloon catheter. 
Next, the LV pacing lead was inserted in the coronary sinus with the help of an 8Fr-guiding 
catheter, and positioned as far as possible in the venous system, preferably in the (postero-) 
lateral vein. The right atrial and right ventricular leads were positioned conventionally. When 
a conventional indication for an internal deﬁbrillator existed, a combined device was im-
planted. For each patient the atrio-ventricular interval was adjusted to maximize the mitral 
inﬂow duration using pulsed-wave Doppler echocardiography.
CRT-device (Contak TR or CD, Guidant, Minneapolis, Minnesota, USA and Insync III or CD, 
Medtronic Inc., Minneapolis, Minnesota, USA) and lead implantation was successful in all 
patients without major complications. Two types of LV leads were used (Easytrack 4512 to 80, 
Guidant, or Attain-SD 4189, Medtronic Inc.).
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Statistical analysis
Data are presented as mean ± SD, and compared using the (un-)paired Student’s t-test when 
appropriate. Univariate analysis for categorical variables was performed using the chi-square 
test with Yates' correction. For all tests, a P-value <0.05 was considered statistically signiﬁ-
cant.
RESULTS 
A total of 144 consecutive patients were included in the study (108 men, mean age 66±11 
years). Baseline characteristics of the study population are summarized in Table 1.
Outcome Post-implantation
Following CRT implantation, QRS duration decreased from 165±26 ms to 149±23 ms 
(P<0.001). TDI demonstrated a reduction in LV dyssynchrony immediately after implantation 
from 76±58 ms to 37±34 ms (P<0.001), indicating LV resynchronization.
Table 1. Patient characteristics (n=144).
Age (years) 66±11 
Male/female 108/36
NYHA class
 III 126 (87%)
 IV 18 (13%)
QRS duration (ms) 165±26
Sinus rhythm 128 (89%)
Atrial ﬁbrillation 16 (11%)
Etiology
 Ischemic 77 (53%)
 Non-ischemic 67 (47%)
Medication
 Diuretics 130 (90%)
 ACE inhibitors 123 (85%)
 Beta-blockers 83 (58%)
LV ejection fraction (%) 21±8
LV end-diastolic volume (ml) 227±84
LV end-systolic volume (ml) 180±77 
LV dyssynchrony (ms) 76±58
LV: left ventricular; NYHA: New York Heart Association.
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Outcome after 3-6 Months of CRT 
At 3-6 months follow-up a signiﬁcant improvement in clinical status was observed. NYHA 
class improved signiﬁcantly from 3.1±0.4 to 2.3±0.6 (P<0.001), the Minnesota quality-of-life 
score decreased from 39±20 to 24±18 (P<0.001) and the 6-minute walking distance improved 
from 285±135 m to 365±141 m (P<0.001).
Signiﬁcant LV reverse remodeling was observed at 3-6 months follow-up. LV end-diastolic 
volume decreased from 227±84 ml to 196±84 ml (P<0.001), whereas LV end-systolic volume 
decreased from 180±77 ml to 144±74 ml (P<0.001). This resulted in an increase of the LVEF 
from 21±8% to 28±10% (P<0.001).
Agreement between Clinical and Echocardiographic Response
An improvement of at least 1 NYHA class at 3-6 months follow-up was observed in 101 (70%) 
patients, indicating clinical response to CRT. These patients also showed a signiﬁcant im-
provement in 6-minute walking distance (from 289±132 m to 404±116 m, P<0.001) and qual-
ity-of-life score (from 39±19 to 20±15, P<0.001). In contrast, the 43 patients (30%) without 
an improvement in NYHA class (clinical non-responders) also failed to improve in 6-minute 
walking distance (from 278±143 m to 278±153 m, ns) and quality-of-life score (from 39±20 
to 36±19, ns). 
Echocardiographic response (deﬁned as >15% reduction in LV end-systolic volume) was ob-
served in 81 (56%) patients. A reduction >15% in LV end-diastolic volume occurred in 66 (46%) 
patients and an (absolute) improvement in LVEF >5% was detected in 77 (54%) patients. 
The agreement between clinical response (reduction in ≥1 NYHA class) after 3-6 months of 
CRT and echocardiographic response (deﬁned as a decrease >15% in LV end-systolic vol-
ume) is shown in Figure 1. The agreement between clinical and echocardiographic response 
was 76% (74 patients (51%) exhibited both a reduction in NYHA class and a reduction in LV 
end-systolic volume, and 36 patients (25%) had no reduction in either NYHA class or LV end-
systolic volume). Clinical improvement without >15% reduction in LV end-systolic volume 
was observed in 27 (19%) patients, whereas 7 (5%) patients failed to show clinical response 
although a reduction in LV end-systolic volume >15% was observed. Thus, in 34 (24%) pa-
tients disagreement between clinical and echocardiographic response was noted; the dis-
agreement was mainly due to patients with clinical response without echocardiographic 
response. Of note, in the presence of more extensive LV reverse remodeling, the percentage 
of clinical responders increased gradually (Figure 2). When a cut-oﬀ value of >15% reduction 
in LV end-diastolic volume was applied, disagreement was present in 47 (32%) patients. The 
disagreement was mainly caused by patients with clinical response and without improve-
ment in LV end-diastolic volume (n=41, 28%). Finally, in 36 (25%) patients, there was a dis-
agreement between clinical response and an (absolute) improvement >5% in LVEF. Again, 
the disagreement was mainly caused by patients who showed a clinical response without an 
echocardiographic response (Figure 3). 
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Figure 1. Percentage of echocardiographic responders (deﬁned as a reduction >15% in LV end-systolic volume) in the patients with (n=101) 
and without (n=43) clinical response (deﬁned as an improvement in NYHA class).
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Figure 2. Number of clinical responders (deﬁned as an improvement ≥1 NYHA class) according to the extent of reduction in LV end-systolic 
volume.
37 (26%)30 (21%)
6 (4%)71 (49%)
Clinical response Clinical non-response
LVEF
increase
>5%
LVEF
increase
�5%
Figure 3. Agreement between clinical (non-) response and an (absolute) increase in LV ejection fraction (LVEF) >5%.
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DISCUSSION
In the present study, potential end-points of CRT were evaluated and it was particularly stud-
ied to which extent patients respond both clinically and echocardiographically. The deﬁnition 
for clinical response in the current study was improvement in NYHA class by 1 grade or more. 
Using this deﬁnition, the percentage of clinical responders was 70%, which is in line with 
previous studies. For example, in the MIRACLE-trial 32% of patients did not improve in NYHA 
class [1]. Also, in other studies the number of clinical non-responders is 20-30% [2,11,12]. 
Moreover, in the present study, the patients with a reduction in NYHA class demonstrated a 
signiﬁcant improvement in other clinical end-points including the quality-of-life score and 
the 6-minute walking distance. Conversely, the patients without an improvement in NYHA 
class did not show an improvement in quality-of-life score or 6-minute walking distance.
Besides clinical end-points, echocardiographic end-points have been used in heart failure 
trials [13]. In particular, a reduction in LV end-systolic volume has been used in CRT trials as an 
end-point. Yu et al. [14] studied 56 patients undergoing CRT and demonstrated a reduction 
>15% in LV end-systolic volume in 54% of patients after 3 months of CRT. Moreover, Stellbrink 
et al. found 64% of patients with reduction >15% in LV end-systolic volume at mid-term fol-
low-up [15].
In the current study, 56% of patients demonstrated a reduction >15% in LV end-systolic vol-
ume after 3-6 months of CRT, which is well in line with these previous studies. 
Next, the agreement between the clinical response and echocardiographic response was 
evaluated on an individual basis. The agreement between the 2 parameters was good; in 76% 
of patients there was an agreement between clinical and echocardiographic (non-) response. 
Disagreement existed in 34 patients (24% of the entire group), with 27 (19%) showing an im-
provement in NYHA class without a reduction in LV end-systolic volume, and 7 (5%) showing 
a reduction in LV end-systolic volume without an improvement in NYHA class. Accordingly, 
the disagreement between the 2 end-points was mainly related to patients who responded 
clinically without showing LV reverse remodeling. This observation may be explained by the 
presence of a placebo eﬀect with respect to improvement in clinical symptoms following 
CRT, as already reported in double-blind randomized trials [1]. In a previous study by Yu et al. 
[3], 30 patients underwent CRT and 80% improved in NYHA class whereas only 57% showed 
LV reverse remodeling. The precise relation between the 2 end-points however was not 
evaluated in that study.
It is of interest though that the likelihood of improvement in NYHA class increased in parallel 
to the extent of LV reverse remodeling (Figure 2), indicating some relation between the 2 
parameters.
When other echocardiographic end-points were used in the current study, i.e. a reduction in 
LV end-diastolic volume or an increase in LVEF, a similar discrepancy was observed between 
clinical response and echocardiographic response. Only 59% of patients with an improve-
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ment in NYHA class showed a reduction >15% in LV end-diastolic volume, whereas 70% 
showed an improvement in LVEF. Again, the disagreement was mainly related to patients 
with a clinical response not showing an echocardiographic response.
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ABSTRACT
Objective To evaluate right ventricular (RV) remodeling after 6 months of cardiac resynchro-
nization therapy (CRT).
Background CRT is beneﬁcial in patients with end-stage heart failure. The eﬀect of CRT on 
RV size is currently unknown. Accordingly, the eﬀects of CRT on RV size, severity of tricuspid 
regurgitation and pulmonary artery pressure were evaluated. 
Methods Fifty-six consecutive patients with end-stage heart failure (52% ischemic cardio-
myopathy), left ventricular (LV) ejection fraction (EF) ≤35%, QRS duration >120 ms and left 
bundle branch block were included. Clinical parameters, LV volumes, LVEF, LV dyssynchrony 
and RV chamber size were assessed at baseline and after 6 months of CRT. LV dyssynchrony 
was assessed using tissue Doppler imaging.
Results Clinical parameters improved signiﬁcantly. LV dyssynchrony was acutely reduced 
after CRT and remained unchanged at 6 months follow-up. LVEF improved signiﬁcantly from 
19±6% to 26±8% (P<0.001) and LV end-diastolic volume decreased from 257±98 ml to 227±86 
ml (P<0.001). RV annulus decreased signiﬁcantly from 37±9 mm to 32±10 mm, RV short-axis 
from 29±11 mm to 26±7 mm, and RV long-axis from 89±11 mm to 82±10 mm (all P<0.001). 
LV and RV reverse remodeling were only observed in patients with substantial LV dyssyn-
chrony at baseline. Finally, signiﬁcant reductions in severity of tricuspid regurgitation and 
pulmonary artery pressure were observed.
Conclusion CRT results in signiﬁcant reverse LV and RV remodeling after 6 months of CRT in 
patients with LV dyssynchrony. Moreover, CRT leads to a reduction of the severity of tricuspid 
regurgitation and a decrease in pulmonary artery pressure. 
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INTRODUCTION 
Congestive heart failure is one of the leading causes of morbidity and mortality in the Western 
world [1,2]. A relatively new treatment modality in patients with end-stage heart failure and 
a wide QRS complex is cardiac resynchronization therapy (CRT). Several large randomized 
trials have shown sustained clinical beneﬁt from CRT [3-7]. Patients experienced an improve-
ment in heart failure symptoms, quality-of-life and exercise capacity. Moreover CRT results 
in a signiﬁcant reduction of the number of hospitalisations for decompensated heart failure 
and recent trials indicate a positive eﬀect of CRT on mortality [3-8]. 
Echocardiographic evaluation of patients undergoing CRT indicated that clinical improve-
ment is caused by resynchronization of dyssynchronous left ventricular (LV) contraction [9-
12]. CRT induced LV resynchronization results in improved LV systolic function, a decrease in 
mitral regurgitation and reverse LV remodeling [9-13]. Currently, no data are available regard-
ing the eﬀects of CRT on right ventricular (RV) chamber size and the severity of tricuspid 
regurgitation. Beneﬁcial eﬀects of CRT on the size of the RV and on the severity of tricuspid 
regurgitation may further explain the mechanism of symptomatic beneﬁt from CRT [14,15]. 
Accordingly, the objective of this study was to evaluate RV remodeling after 6 months of CRT 
using echocardiography. The eﬀects of CRT on the severity of tricuspid regurgitation and pul-
monary artery pressure were also evaluated. Finally, the relation between LV dyssynchrony 
and the eﬀects of CRT on the RV was explored.
METHODS
Patients and Study Protocol
Fifty-six consecutive patients with severe heart failure, scheduled for implantation of a biven-
tricular pacemaker were prospectively included in this study. Patients were selected accord-
ing to traditional selection criteria for CRT: LV ejection fraction (EF) ≤35%, severe heart failure 
(New York Heart Association (NYHA) class III or IV) and a QRS duration >120 ms with left 
bundle branch block conﬁguration. Patients with a recent myocardial infarction (<3 months) 
or decompensated heart failure were excluded. 
Before pacemaker implantation, clinical status and QRS duration were assessed. 
Two-dimensional echocardiography at rest was performed to calculate LV volumes and LVEF, 
and to assess RV chamber size. Next, tissue Doppler imaging (TDI) was performed to evalu-
ate LV dyssynchrony. LV dyssynchrony and QRS duration were re-assessed on the day after 
implantation and at 6 months follow-up. Clinical status, LV volumes, LVEF, and RV chamber 
size were also re-assessed at 6 months follow-up. 
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Clinical Evaluation 
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota quality-of-life questionnaire) and 6-minute hall-walk test. In all 
patients, QRS duration was measured from the surface ECG using the widest QRS complex 
from the leads II, V1 and V6. The ECGs were recorded at a speed of 25 mm/sec and were evalu-
ated by two independent observers without knowledge of the clinical status of the patient.
Echocardiography
Resting echocardiography and TDI were performed at baseline, the day after implantation 
and at 6 months follow-up. Patients were imaged in the left lateral decubitus position using 
a commercially available system (Vingmed system Seven, General Electric-Vingmed, Milwau-
kee, Wisconsin, USA). Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm 
in the parasternal and apical views (standard long-axis and two- and four-chamber images). 
Standard two-dimensional and colour Doppler data, triggered to the QRS complex were 
saved in cine loop format. LV volumes (end-systolic, end-diastolic) and LVEF were calculated 
from the conventional apical two- and four-chamber images, using the biplane Simpson’s 
technique [16]. 
Assessment of RV chamber size. RV end-diastolic chamber size was assessed using three 
parameters which were described previously by Foale et al. [17,18]. These parameters were 
assessed from the apical four-chamber view, as schematically displayed in Figure 1. The ﬁrst 
parameter is the diameter of the annulus of the tricuspid valve (TV ANN), deﬁned as the point 
of attachment of the septal and posterior leaﬂets to the atrioventricular junction. The second 
measurement is the maximum dimension of the middle third of the RV, parallel to the tricus-
pid annulus (RV SAX). The last measurement included the major axis of the RV (RV LAX) and is 
deﬁned as the distance between the RV apex to the mid-point of the tricuspid annulus. 
Inter- and intra-observer agreement for assessment of RV chamber size were 98% and 96% 
for TV ANN, 90 and 92% for RV SAX, and 94% and 95% for RV LAX respectively.
Tissue Doppler imaging to assess LV dyssynchrony. In addition to the conventional echo-
cardiographic examination, TDI was performed to assess LV dyssynchrony. For TDI, color Dop-
pler frame rates varied between 80 and 115 frames/s depending on the sector width of the 
range of interest; pulse repetition frequencies were between 500 Hz and 1 KHz, resulting 
in aliasing velocities between 16 and 32 cm/s. TDI parameters were measured from color 
images of three consecutive heart beats by oﬄine analysis. Data were analyzed using com-
mercial software (Echopac 6.1, General Electric - Vingmed). 
To determine LV dyssynchrony, the sample volume was placed in the basal portions of the 
septum and the LV lateral wall; peak systolic velocities and time-to-peak systolic velocities 
were obtained and the delay in peak velocity between the septum and the LV lateral wall 
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was calculated as an indicator of LV dyssynchrony (referred to as the septal-to-lateral delay) 
[9,19,20]. Interventricular dyssynchrony was assessed by comparing the delay between peak 
systolic velocity of the RV free wall and the LV lateral wall [11].
Based on previous observations, a septal-to-lateral delay >60 ms was considered to represent 
severe LV dyssynchrony [9]. Inter- and intra-observer agreement for assessment of the septal-
to-lateral delay were 90% and 96%, respectively [21]. 
Assessment of mitral and tricuspid regurgitation. The severity of mitral and tricuspid re-
gurgitation was graded semi-quantitatively from color-ﬂow Doppler images. For quantiﬁca-
tion of mitral and tricuspid regurgitation, the apical 4-chamber images were used. Mitral and 
tricuspid regurgitation were classiﬁed as: mild=1+ (jet area/atrial area <10%), moderate=2+ 
(jet area/atrial area 10-20%), moderately severe =3+ (jet area/atrial area 20-45%), and se-
vere=4+ (jet area/atrial area >45%) [22,23]. 
Continuous-wave Doppler examination was also performed to estimate pulmonary artery 
systolic pressure from the trans-tricuspid maximal regurgitant ﬂow velocity. 
All echocardiographic measurements were obtained by two independent observers without 
knowledge of the clinical status of the patient. 
Pacemaker Implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained during occlusion of the coronary sinus using a balloon catheter. 
Next, the LV pacing lead was inserted in the coronary sinus with the help of an 8Fr-guiding 
catheter, and positioned as far as possible in the venous system, preferably in the (postero-) 
lateral vein. The right atrial and RV leads were positioned conventionally. When a conven-
tional indication for an internal deﬁbrillator existed, a combined device was implanted. For 
each patient the atrio-ventricular interval was adjusted to maximize the mitral inﬂow dura-
tion using pulsed-wave Doppler echocardiography. No adjustments were made to the V-V 
interval during the ﬁrst 6 months of CRT. 
CRT-device and lead implantation was successful in all patients without major complications 
(Contak TR or CD, Guidant, Minneapolis, Minnesota, USA and Insync III or CD, Medtronic 
Inc., Minneapolis, Minnesota, USA). Two types of LV leads were used (Easytrack 4512 to 80, 
Guidant, or Attain-SD 4189, Medtronic Inc.).
Statistical Analysis
Continuous data were expressed as mean ± SD and compared with the 2-tailed Student's t 
test for paired and unpaired data when appropriate. Univariate analysis for categorical vari-
ables was performed using the chi-square test with Yates' correction. For all tests a P-value 
<0.05 was considered statistically signiﬁcant.
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RESULTS
Fifty-six consecutive patients were included in this study (44 male, age 64±11 years). Baseline 
patient characteristics are summarized in Table 1.
Follow-up after CRT
Clinical parameters and left ventricular remodeling. QRS duration at baseline was 176±30 
ms (range 122-240 ms) and shortened to 149±23 ms (P<0.001, range 92-198 ms) immediately 
post-implantation, which remained unchanged (153±22 ms, range 86-202 ms) at 6 months 
after CRT. 
At 6 months follow-up a signiﬁcant improvement in clinical status was observed, in combina-
tion with an improvement in LVEF and a signiﬁcant LV reverse remodeling (Table 2). 
Left ventricular dyssynchrony. The day after implantation of the pacemaker, TDI demon-
strated a signiﬁcant reduction in septal-to-lateral delay from 114±57 ms to 37±32 ms (P<0.001), 
indicating LV resynchronization. Resynchronization was maintained after 6 months of CRT, as 
evidenced by a septal-to-lateral delay of 40±36 ms (P<0.001 vs baseline, ns vs immediately 
Table 1. Baseline characteristics
Patient characteristics
(n=56)
Age (yrs, range) 64±11 (18-81)
Gender (M/F) 44/12
NYHA 
 class III 50 (89%)
 class IV 6 (11%)
Etiology
 ischemic 29 (52%)
 nonischemic 27 (48%)
QRS duration (ms) 176±30
Rhythm
 sinus rhythm 49 (87%)
 atrial ﬁbrillation 7 (13%)
LVEF (%) 19±6
LVEDV (ml) 258±98
LVESV (ml) 213±91
Medication:
 diuretics 46 (82%)
 ACE-inhibitors 52 (93%)
 beta-blockers 28 (50%)
 anticoagulants/aspirin 52 (93%)
LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; NYHA: New York 
Heart Association
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after implantation). Mean inter-ventricular (RV-LV) dyssynchrony at baseline was 51±36 ms, 
which decreased signiﬁcantly after 6 months of CRT to 37±27 ms (P<0.05).
Right ventricular remodeling. In line with the reverse remodeling of the LV, CRT also re-
sulted in a signiﬁcant reverse remodeling of the RV at 6 months follow-up (Table 2). All three 
parameters reﬂecting RV chamber size showed a signiﬁcant decrease after 6 months of CRT. 
The TV ANN showed a signiﬁcant decrease from 37±9 mm to 32±10 mm (P<0.01), RV SAX de-
creased from 29±11 mm to 26±7 mm (P<0.001) and RV LAX showed a reduction from 89±11 
mm to 82±10 mm (P<0.001). Of note, RV reverse remodeling did not occur immediately after 
CRT (e.g. the RV SAX was 29±11 mm before CRT and 30±10 mm immediately after CRT, NS).
Patients were subsequently divided into quartiles according to the baseline values for each 
RV size parameter. RV reverse remodeling was most outspoken in patients with the largest RV 
dilatation at baseline (Figures 2A-C). A signiﬁcant reduction in TV ANN was demonstrated in 
the third and fourth quartiles, whereas the patients with smaller TV ANN at baseline (ﬁrst and 
second quartiles) showed no signiﬁcant reduction in size (Figure 2A). Similarly, RV SAX and RV 
LAX showed a signiﬁcant reduction after 6 months CRT in patients with larger baseline values 
(Figure 2B and 2C). Of note, 6 of 14 patients in the fourth quartile had signs of right-sided 
heart failure. 
RV reverse remodeling was associated with a signiﬁcant reduction in tricuspid regurgitation 
from 1.8±0.8 to 1.3±1.0 (P<0.001, Table 2). Moreover, CRT also resulted in a signiﬁcant reduc-
tion of pulmonary artery pressure from 40±12 mmHg to 30±11 mmHg (P<0.001).
Table 2. Clinical and echocardiographic variables before and after 6 months of CRT.
Baseline data 
(n=56)
6 months follow-up
(n=56)
P-value
NYHA class 3.1±0.3 1.9±0.5 <0.001
QOL-score 41±15 24±13 <0.001
6-MWT (m) 277±143 409±140 <0.001
LVEF (%) 19±6 26±8 <0.001
LVEDV (ml) 257±98 227±86 <0.001
LVESV (ml) 213±91 172±80 <0.001
RV chamber size:
 TV ANN (mm) 37±9 32±10 <0.001
 RV SAX (mm) 29±11 26±7 <0.001
 RV LAX (mm) 89±11 82±10 <0.001
Mitral Regurgitation
(grade)
2.1±0.9 1.3±0.9 <0.001
Tricuspid regurgitation
(grade)
1.8±0.8 1.3±1.0 <0.001
Pulmonary artery pressure (mmHg) 40±12 30±11 <0.001
6-MWT: 6 minute walk test; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-
systolic volume; NYHA:  New York Heart Association; QOL: Quality-of-life; RV: right ventricle; RV SAX: right  ventricular short axis; RV LAX: right 
ventricular long axis; TV ANN: tricuspid valve annulus
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    TV ANN      RV  SAX       RV LAX
Figure 1. Apical four-chamber two-dimensional echocardiogram. Schematic display of parameters reﬂecting RV end-diastolic chamber size. (RV 
LAX = right ventricular long-axis, RV SAX = right ventricular short-axis, TV ANN = tricuspid valve annulus).
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Figure 2a. TV ANN at baseline and after 6 months of CRT. Patients are divided into quartiles according to baseline TV ANN. (* = P<0.05)
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Figure 2b. RV SAX at baseline and after 6 months of CRT. Patients are divided into quartiles according to baseline RV SAX. (* = P<0.05)
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Reverse Remodeling versus LV Dyssynchrony
Patients with severe baseline LV dyssynchrony were deﬁned as having a septal-to-lateral 
delay >60 ms on TDI before implantation of the pacemaker. Accordingly, 44 (79%) patients 
had signiﬁcant LV dyssynchrony (mean septal-to-lateral delay 137±41 ms, with an immediate 
decrease to 40±40 ms after CRT, P<0.001), and 12 (19%) patients did not have substantial 
dyssynchrony on TDI (mean septal-to-lateral delay 41±27 ms, which remained unchanged 
following CRT, 38±25 ms, NS). Baseline characteristics were not statistically diﬀerent between 
the two groups (Table 3). 
The changes in LV volumes, LVEF and RV diameters in patients with and without LV dyssy-
chrony are summarized in Table 4. Patients with severe LV dyssynchrony before implantation 
showed reverse LV remodeling, whereas LV volumes did not decrease signiﬁcantly after 6 
months of CRT in patients without LV dyssynchrony at baseline. Moreover, LVEF increased 
signiﬁcantly after 6 months of CRT in the patients with LV dyssynchrony only. Similarly, a sig-
niﬁcant reduction in RV dimensions was only observed in the patients with LV dyssynchrony 
at baseline.
Of note, in the patients with signiﬁcant LV dyssynchrony at baseline, 86% showed an im-
provement of at least 1 NYHA class after 6 months of CRT. 
DISCUSSION
The main ﬁndings can be summarized as follows. In patients with LV dyssynchrony, CRT in-
duces not only LV reverse remodeling, but also a signiﬁcant reverse remodeling of the RV. 
This eﬀect was most outspoken in patients with severe RV dilatation at baseline. 
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Figure 2c. RV LAX at baseline and after 6 months of CRT. Patients are divided into quartiles according to baseline RV LAX. (* = P<0.05)
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At present, CRT is considered a major breakthrough in the treatment of patients with moder-
ate-to-severe heart failure and has been demonstrated to result in a sustained improvement 
in symptoms and LV systolic function [5,13]. Similar beneﬁts were demonstrated in the cur-
rent study. Despite the reproducible positive clinical results, the exact mechanism underlying 
the beneﬁt of CRT is still not entirely clear but may be related to 1). an improvement of LV 
systolic function, 2). reduction of mitral regurgitation, and 3). reverse remodeling of the LV. 
The presence of LV dyssynchrony appears mandatory for these eﬀects to occur as demon-
strated in previous studies [9-11,13]. In the present study, LV dyssynchrony (assessed by TDI 
prior to CRT) was signiﬁcant with a septal-to-lateral delay of 114±57 ms. In particular, 79 % of 
patients exhibited signiﬁcant LV dyssynchrony (deﬁned as a septal-to-lateral delay >60 ms) 
and 21% of patients did not show LV dyssynchrony. In the patients with LV dyssynchrony, 
resynchronization was obtained immediately after CRT, which persisted during 6 months 
follow-up. A signiﬁcant improvement in LVEF was observed in the dyssynchronous patients 
with signiﬁcant reverse LV remodeling, in line with previous studies [9,11,12]. However, these 
beneﬁcial eﬀects were not observed in the absence of dyssynchrony at baseline (Table 4), 
conﬁrming previous observations [9,11].
No data were yet available regarding the eﬀects of CRT on RV function. Since CRT causes 
an improvement in LV function, reduces mitral regurgitation and normalizes neurohormonal 
status, it seems plausible that CRT may also have beneﬁcial eﬀects on pulmonary artery pres-
sure, RV function and RV dilatation. In the current study, the eﬀects of CRT on RV size, tricus-
pid regurgitation and pulmonary artery pressure were evaluated. RV chamber size was evalu-
ated using 3 echocardiographic measurements that were introduced previously by Foale et al 
[17,18]. This standardized echocardiographic approach for the assessment of RV dimensions 
Table 3. baseline characteristics in patients with (n=44) and without LV dyssynchrony (n=12) at baseline.
LV dyssynchrony 
(n=44)
No LV dyssynchrony 
( n=12)
P-value
Age (yrs) 64±12 65±8 NS
Gender (M/F) 34/10 10/2 NS
NYHA 
 class III 38 12 NS
 class IV 6 0
Etiology
 ischemic 23 6 NS
 non-ischemic 21 6
QRS duration (ms) 178±31 169±27 NS
6-MWT (m) 270±126 303±139 NS
QOL-score 42±15 37±16 NS
Septal-to-lateral delay (ms) 137±41 41±27 -
6-MWT: 6 minute walk test; NYHA: New York Heart Association; QOL: Quality-of-life
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has been demonstrated to adequately reﬂect RV size. The current results illustrate that CRT 
not only induced LV reverse remodeling, but also resulted in a signiﬁcant reverse remodeling 
of the RV. Of interest, the eﬀect was most outspoken in patients with more severe RV dilata-
tion at baseline. Moreover, RV reverse remodeling was associated with a reduction in the 
severity of tricuspid regurgitation and a signiﬁcant decrease in pulmonary artery pressure. 
The precise mechanism underlying the beneﬁcial eﬀects on the right ventricle is unclear. 
Similar to LV reverse remodeling, RV reverse remodeling was related to the presence of LV 
dyssynchrony at baseline. Patients without baseline LV dyssynchrony did not exhibit RV 
reverse remodeling after 6 months of CRT (Table 4). Still, the reduction in RV dimensions 
appears not related by an acute recovery in LV dyssynchrony. An acute reduction in septal-to-
lateral delay occurred after initiation of CRT (from 114±57 ms at baseline to 37±32 ms imme-
diately after CRT, P<0.01), but this reduction was not accompanied by an acute reduction in 
RV dimensions (the baseline RV-SAX was 29±11 mm as compared to 30±10 mm immediately 
after CRT). It thus appears that a more coordinated motion of the interventricular septum 
following CRT was not responsible for the reduction in RV dimensions. Possibly, sustained 
improved LV performance has led to a reduction in pulmonary artery pressure (observed in 
the current study), resulting in an improved RV function (as evidenced also by a reduction in 
tricuspid regurgitation). Although improvement in RV size and function following CRT have 
Table 4. LV volumes, LV ejection fraction and RV dimensions at baseline and after 6 months of CRT in patients with (n=44) and without LV 
dyssynchrony (n=12) at baseline.
Baseline 6 months 
follow-up
P-value
LVESV (ml)
 LV dyssynchrony present 220±93 170±83 P<0.05
 LV dyssynchrony absent 189±82 176±77 NS
LVEDV (ml)
 LV dyssynchrony present 265±100 229±88 P<0.05
 LV dyssynchrony absent 232±90 223±82 NS
LVEF (%)
 LV dyssynchrony present 18±6 27±8 P<0.05
 LV dyssynchrony absent 20±7 22±8 NS
TV ANN (mm)
 LV dyssynchrony present 37±8 32±6 P<0.05
 LV dyssynchrony absent 38±9 34±8 NS
RV SAX (mm)
 LV dyssynchrony present 30±11 25±7 P<0.05
 LV dyssynchrony absent 29±10 29±8 NS
RV LAX (mm)
 LV dyssynchrony present 90±10 82±9 P<0.05
 LV dyssynchrony absent 86±9 82±6 NS
LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume; RV LAX: right 
ventricular long axis. RV SAX: right ventricular short axis; TV ANN: tricuspid valve annulus
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been demonstrated in the current study, the inclusion of a control group could potentially 
have contributed to a better understanding of the mechanism involved. Future studies are 
needed to further resolve these issues. 
Conclusion
The clinical beneﬁt of CRT on improvement in LV function was conﬁrmed in the current study. 
The beneﬁt from CRT was related to the presence of LV dyssynchrony before CRT. In addition, 
this is the ﬁrst study to demonstrate reverse RV remodeling following CRT, which was associ-
ated with a reduction in tricuspid regurgitation and a decrease in pulmonary artery pressure; 
reverse RV remodeling was most outspoken in severely dilated RVs and only observed when 
LV dyssynchrony was present at baseline. These ﬁndings may lead to a better understand-
ing of the beneﬁcial eﬀects of CRT on cardiac function as RV reverse remodeling, decreased 
tricuspid regurgitation and reduced pulmonary artery pressure are likely to contribute to the 
symptomatic beneﬁt from CRT in patients with drug-refractory heart failure. 
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ABSTRACT
Background In patients with severe heart failure and dilated cardiomyopathy, cardiac resyn-
chronization therapy (CRT) improves left ventricular (LV) systolic function associated with LV 
reverse remodeling and favorable 1-year survival. However, it is unknown whether LV reverse 
remodeling translates into a better long-term prognosis, and what extent of reverse remodel-
ing is clinically relevant, which will be addressed by the present study.
Methods and Results 141 patients with advanced heart failure (mean age 64±11 years, 73% 
men) who received CRT were followed-up for a mean period of 695±491 days. The extent of 
reduction in LV end-systolic volume (LVESV) at 3-6 months relative to baseline was examined 
for its predictive value on long-term clinical outcome. The cut-oﬀ value of LV reverse remod-
eling in predicting mortality was derived from the ROC curve. Then the relationship between 
the potential predictors of mortality and heart failure hospitalizations were compared by 
Kaplan-Meier survival analysis, and followed by Cox regression analysis. 
There were 22 (15.6%) deaths, mostly due to heart failure or sudden cardiac death. The 
ROC curve derived that a reduction of LVESV ≥9.5% has a sensitivity of 70% and speciﬁcity 
of 70% in predicting all-cause mortality, and 87% and 69% respectively for cardiovascular 
mortality. With this cut-oﬀ value, there were 87 (61.7%) responders of reverse remodeling. In 
Kaplan-Meier survival analysis, responders has signiﬁcantly lower all-cause mortality (6.9% 
Vs 30.6%, Log-rank χ2=13.26, p=0.0003), cardiovascular mortality (2.3% Vs 24.1%, Log-rank 
χ2=17.1, p<0.0001), and heart failure events (11.5% Vs 33.3%, Log-rank χ2=8.71, p=0.0032) 
than non-responders. In the Cox-regression analysis model, the change in LVESV is the single 
most important predictor of all-cause (β=1.048, CI=1.019-1.078, p=0.001) and cardiovascular 
mortality (β=1.072, CI=1.033-1.112, p<0.001). Clinical parameters were unable to predict any 
outcome event. 
Conclusions A reduction in LVESV of 10% signiﬁes clinically relevant reverse remodeling, 
which is a strong predictor of lower long-term mortality and heart failure events. This study 
suggests that assessing volumetric changes following an intervention in patients with heart 
failure provides information predictive of natural history outcomes. 
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is an established treatment for patients with ad-
vanced chronic heart failure with electromechanical delay.1-4 Apart from the beneﬁcial eﬀects 
of CRT on symptoms and exercise capacity, left ventricular (LV) reverse remodeling5,6 and 
improvement of clinical outcome were also observed in large, multicenter clinical trials.2,4 
Whether the observed LV reverse remodeling is clinically relevant is unclear. 
However, large heart failure trials demonstrated that drug therapy limiting or reversing LV 
remodeling resulted in improved long-term survival.7 In these studies, LV end-systolic vol-
ume (LVESV) was the strongest predictor of survival among clinical and echocardiographic 
parameters.8 For example, in the multicenter trials of angiotensin converting enzyme inhibi-
tors (e.g. the SAVE study), LV volumes were strong predictors of long-term mortality and car-
diovascular events, independent of the eﬀect of the ACE inhibitor captopril.9 The extent of LV 
reverse remodeling after CRT was reported to be larger than 20% reduction in LVESV, which 
is much larger than that observed in medical therapy for heart failure.10-12 This phenomenon 
was observed in the ﬁrst 3 to 6 months after CRT. Since the mechanism of beneﬁt of device 
therapy is somewhat diﬀerent from medical therapy, it is currently unclear whether the LV 
reverse remodeling observed in patients undergoing CRT is predictive for improved long-
term clinical outcome. Moreover, what extent of LV reverse remodeling is needed to result 
in an improved survival is also not clear. Therefore, the aims of the current study were: 1. to 
examine whether the LV reverse remodeling observed at 3-6 months is associated with better 
long-term clinical outcome in heart failure patients who received CRT, and 2. to determine 
what extent of LV reverse remodeling predicts improved outcome in this population.
METHODS
Patients 
This is a prospective, follow-up study which involved 2 University Hospitals. The study popu-
lation included 141 heart failure patients (mean age 64±11 years, 73% men) who underwent 
CRT and had a baseline and 3-6 months follow-up echocardiographic study to assess poten-
tial LV reverse remodeling. The inclusion criteria included severe symptomatic heart failure 
despite optimized medical therapy, LV systolic dysfunction with a LV ejection fraction <40%, 
and QRS duration >120 ms. Serial echocardiographic studies with tissue Doppler imaging 
(TDI) were performed before and 3-6 months after CRT to assess LV reverse remodeling. 
These patients have been put on optimal medical therapy before considering for CRT. Medi-
cation was unchanged within the ﬁrst 6 months of CRT, and any changes afterwards were 
avoided unless clinically mandatory. Clinical assessment were also performed at the same 
time points including New York Heart Association (NYHA) class, Minnesota Living With Heart 
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Failure quality of life questionnaire and 6-minute hall walk distance. Two patients died (one 
refractory heart failure, one sudden cardiac death) before the 3-6 months echocardiographic 
follow up and. Since these patients did not have follow-up echocardiographic evaluation to 
assess LV reverse remodeling, they were excluded from the study. The study was approved 
and conducted in compliance with the regulations of the local Ethics Committees of both 
institutions and informed consent was obtained in all patients. 
Pacemaker implantation
CRT devices were implanted as previously described.10,13 The LV pacing lead was inserted by 
a transvenous approach through the coronary sinus into either the lateral or postero-lateral 
cardiac vein whenever possible. All patients received CRT devices had biventricular stimula-
tion of the heart with implantation of right ventricular leads. 
Echocardiography
Standard echocardiography, including TDI studies, was performed using commercially avail-
able equipment (Vivid 7, GE Vingmed Ultrasound, Horten, Norway). The LV end-diastolic vol-
ume (LVEDV), LVESV and LV ejection fraction were assessed by biplane Simpson’s equation 
using the apical 4-chamber and 2-chamber views. The intra- and interobserver variability for 
volumetric assessment were 4% and 5%, respectively.12 The severity of mitral regurgitation 
was assessed by the percentage jet area relative to the left atrial size in the apical 4-chamber 
view. At least 3 consecutive beats of sinus rhythm were measured and the average value was 
taken.
TDI was performed using the apical 4-chamber view for the long-axis motion of the ventricle 
as previously described.5,10,14,15 Two-dimensional echocardiography with TDI-color imaging 
views were optimized for pulse repetition frequency, color saturation, sector size and depth, 
allowing the highest possible frame-rate. At least 3 consecutive beats were stored and the 
images were analyzed oﬀ-line by a customized software package (EchoPac 6.1 for PC, GE 
Vingmed Ultrasound, Horten, Norway). The myocardial velocity curves were constructed 
oﬀ-line, and the septal-to-lateral delay at the basal segments was measured as an index of 
systolic dyssynchrony using the beginning of the QRS complex as the reference point.14,15
Long-term follow-up and assessment of cardiovascular events 
All the patients were followed-up regularly (typically every 2-3 months) in the heart failure 
clinic, with regular clinical assessment, ECG and device interrogation to ensure biventricular 
pacing was maintained. Only outcomes occurring after the 3-6 months follow-up echocar-
diogram were related to echocardiographic changes of LV volume. The occurrence of cardio-
vascular events was adjudicated by cardiologists blinded to the echocardiographic ﬁndings. 
The cause of death was ascertained by reviewing the clinical record and investigation results, 
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report of the close relatives and post-mortem ﬁndings. For cardiovascular hospitalization, 
the diagnosis of heart failure was based on clinical symptoms (limitation of activity, fatigue, 
and dyspnea or orthopnea), physical signs (edema, elevated jugular venous pressure, rales, 
or third heart sound with gallop), or radiological evidence of pulmonary congestion.16 Acute 
coronary syndrome was deﬁned according the current guidelines based on the presence of 
typical chest pain or discomfort, and elevation of cardiac enzymes such as CK-MB, tropo-
nin I or troponin T. ECG changes were not employed as a criterion since these patients had 
baseline LBBB, and subsequent ventricular pacing which hampers assessment of myocardial 
ischemia or infarction. 
Statistical analysis 
Results are presented as mean values ±SD. Data were compared using the paired and un-
paired Student t-test when appropriate. Comparison of proportions was performed using 
Chi-square analysis with Yates’ correction. Receiver operating characteristic (ROC) curves were 
analyzed to assess the best cut-oﬀ value of LVESV to predict mortality. Life table estimated 
actuarial survival was calculated by Kaplan-Meier curves where the Log-rank χ2 values were 
presented. Cox-regression multivariable survival analysis was used to evaluate the predictive 
value of multiple factors on mortality. The data from patients in this dataset have not been 
published. A P-value <0.05 was considered statistically signiﬁcant. 
RESULTS
Among 141 patients, 12 were in NYHA class II, 106 in class III and 23 in class IV. The etiology 
of heart failure was ischemic in 68 (48%) and non-ischemic in 73 (52%) patients. Medications 
included diuretics in nearly all patients, angiotensin converting enzyme inhibitors or angio-
tensin receptor blockers in 91%, β-blockers in 75%, spironolactone in 49% and digoxin in 
16% of patients. The echocardiographic studies demonstrated LV reverse remodeling after 3-
6 months of CRT. The LVESV decreased signiﬁcantly by 17.6±18.4% (P<0.001) whereas LVEDV 
decreased by 11.0±14.3% (P<0.001). LV ejection fraction increased by 6.3±6.9% (P<0.001). 
Clinical outcome of patients during long-term follow-up
The mean duration of follow-up was 695±491 days (range 90 to 1992 days). There were 22 
(15.6%) deaths. The causes of death included heart failure in 9 patients, sudden cardiac death 
in 6, myocardial infarction in 1, cerebrovascular accident in 1 and non-cardiac related deaths 
in 5 patients. Accordingly, 17 patients had cardiovascular mortality. Table 1 compares the 
clinical and echocardiographic parameters between the survivors and the patients who died 
during follow-up. All baseline characteristics were comparable, except for a slightly higher 
mean NYHA class in the patients who died during follow-up. Also, the extent of LV dyssyn-
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chrony at baseline was larger in the survivors. The reduction in clinical parameters (NYHA 
class, quality of life score, 6-minute walking distance) tended to improve more in survivors, 
although the diﬀerences were not statistically diﬀerent. The extent of LV reverse remodel-
ing and the improvement in LV ejection fraction were signiﬁcantly larger in survivors. The 
mean reduction in LVESV in survivors was 19.8±17.7% as compared to 5.9±18.0% (P=0.001) 
in the patients who died during follow-up; the mean reduction of LVEDV in survivors was 
12.4±14.2% versus 3.0±12.6% (P=0.004) in the patients who died during follow-up. Nineteen 
patients were hospitalized for decompensated heart failure. Twenty-one patients were hospi-
talized for other cardiovascular causes, including acute coronary syndrome in 7, arrhythmias 
in 11, stroke in 2, and percutaneous coronary intervention in 1 patient. 
What extent of LV reverse remodeling predicts survival? 
This study attempted to determine a clinically useful cut-oﬀ value of change in LVESV to 
assess whether LV reverse remodeling after CRT may predict a favorable long-term clinical 
outcome. Based on ROC curve analysis, a reduction in LVESV of 9.5% was identiﬁed as the 
optimal cut-oﬀ value to predict long-term survival (AUC 0.711, P=0.002, see Figure 1A). Using 
this cut-oﬀ value, a sensitivity and speciﬁcity of 70% were obtained to predict all-cause mor-
Table 1. Comparison of baseline clinical and echocardiographic parameters between survivors and patients who died after cardiac 
resynchronization therapy. 
Survivors
(N = 119)
Deaths
(N = 22)
P value
Age, years 64±11 65±12 NS
Male / female, % 74 / 26 68 / 32 χ2=0.39, p=NS
Ischemic vs Non-ischemic 57 vs 62 11 vs 11 NS
QRS duration, ms 157±38 151±34 NS
NYHA class 3.0±0.5 3.3±0.5 0.038
6-min hall walk, m 302±124 278±142 NS
Quality of life score 37±21 39±20 NS
LVESV, cm3 165±67 181±77 NS
LVEDV, cm3 217±76 232±80 NS
LV ejection fraction, % 24.9±7.3 24.0±11.2 NS
LV dyssynchrony, ms 62.9±47.3 28.3±23.5 <0.001
Medications, % 
 Diuretics 98 100 χ2=0.02, P=NS
 ACE inhibitor or angiotensin receptor  
 blocker
90 95 χ2=0.34, P=NS
 β-Blocker 75 77 χ2=0.03, P=NS
 Spironolactone 48 55 χ2=0.58, P=NS
 Digoxin 16 18 χ2=0.08, P=NS
ACE, angiotensin converting enzyme; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; NYHA, New York 
Heart Association. 
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Figure 1. The ROC curve of predicting all cause (A) and cardiovascular (B) mortality by left ventricular reverse r emodeling as reﬂected by the 
reduction of LVESV (dark line) and LVEDV (light line) volumes. 
Figure 2. Kaplan Meier curves for all-cause mortality (A), fatal and non-fatal heart failure hospitalizations (B) and mortality or heart failure 
hospitalizations (C) dichotomized by the status of left ventricular reverse remodeling. Responders are deﬁned as a reduction of LV end-systolic 
volume (LVESV) for ≥10% while non-responders has a <10% reduction of LV end-systolic volume (LVESV)
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tality. Similarly, a reduction in LVESV of 9.5% had a sensitivity and speciﬁcity of 87% and 69% 
respectively, to predict cardiovascular mortality (AUC 0.774, P=0.001, see Figure 1B). Further-
more, the change in LVESV was consistently better than the change in LVEDV in predicting 
all-cause and cardiovascular mortality (Figures 1A and 1B). The AUC for LVEDV to predict all-
cause and cardiovascular mortality were 0.688 (P=0.005) and 0.720 (P=0.005), respectively. 
LV reverse remodeling after CRT and prediction of long-term prognosis 
Based on the aforementioned ﬁndings, a reduction of LVESV ≥10% was used as the cut-oﬀ 
value to deﬁne patients with clinically relevant LV reverse remodeling. There were 87 (61.7%) 
patients with a reduction of LVESV ≥10% (called “responders”) and 54 (38.3%) patients with 
<10% reduction in LVESV (called “non-responders”). During long-term follow-up, 81 of 87 
(93.1%) responders of LV reverse remodeling survived, as compared to only 38 of 54 (70.4%) 
non-responders (χ2=13.1, P<0.001). By Kaplan-Meier life-table survival analysis demonstrated 
that responders of LV reverse remodeling (reduction in LVESV ≥10%) were associated with 
signiﬁcantly lower all-cause (N=22 who had the censored event) (6.9% Vs 30.6%, Log-rank 
χ2=13.26, P=0.0003) (Figure 2A) and cardiovascular (N=17) mortality (2.3% Vs 24.1%, Log-
rank χ2=17.1, P<0.0001) as compared to non-responders. Furthermore, patients with reverse 
remodeling had a lower rate of heart failure events (both fatal and non-fatal, N=28) (11.5% 
Vs 33.3%, Log-rank χ2=8.71, P=0.0032) (Figure 2B), all-cause mortality or heart failure hospi-
talization (N=33 who had the censored event) (13.8% Vs 38.9%, Log-rank χ2=9.92, P=0.0016) 
(Figure 2C) and the composite end-point of all-cause mortality or cardiovascular hospitaliza-
tion (N=54 who had the censored event) (29.1% Vs 55.8%, Log-rank χ2=9.18, P=0.0025).
The baseline assessment of LV dyssynchrony was also compared with long-term survival. It 
was observed that survivors were associated with signiﬁcantly more severe dyssynchrony 
than those who died (P<0.001) (Table 1). Patients who had baseline dyssynchrony >60 ms 
predicted a lower all-cause mortality (6.6% Vs 21.8%, Log-rank χ2=4.46, P=0.03). 
Table 2. Comparison of changes in clinical and echocardiographic parameters between survivors and patients who died after cardiac 
resynchronization therapy. 
Survivors
(N = 119)
Deaths
(N = 22)
P value
ΔNYHA class -0.87±0.66 -0.75±0.79 NS
Δ6-min hall walk, m 85±104 56±103 NS
ΔQuality of life score -13.7±17.5 -12.0±20.0 NS
ΔLVESV, % -19.8±17.7 -5.9±18.0 0.001
ΔLVEDV, % -12.4±14.2 -3.0±12.6 0.004
ΔLV ejection fraction, % 7.0±6.7 2.8±7.4 0.008
Δ indicated change
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Clinical parameters were evaluated for their predictive values on mortality. However, only 
the NYHA class at baseline was signiﬁcantly higher (P=0.038) in those who died. There was 
no diﬀerence in 6-minute hall walk distance or Minnesota Living-With-Heart-Failure quality 
of life score between the two groups, or the changes in these parameters after CRT for 3-6 
months (Table 2). Therefore, clinical parameters for heart failure assessment were unable to 
predict the long-term outcome in these patients. 
The predictive values of clinical / echocardiographic parameters on all-cause mortality were 
compared by the Cox-regression multivariable analysis model. It was found that the reduc-
tion of LVESV is the only independent predictor of all-cause mortality (β=1.048, CI=1.019-
1.078, P=0.001) and cardiovascular mortality (β=1.072, CI=1.033-1.112, P<0.001), while the 
LV dyssynchrony at baseline, etiology (ischemic Vs non-ischemic) and other clinical or echo-
cardiographic parameters listed in Table 1 became insigniﬁcant. 
DISCUSSION 
This study examined the relationship between LV reverse remodeling and long-term clini-
cal outcome. Patients who died during follow-up exhibited less LV reverse remodeling as 
compared to survivors. Based on the ROC curve, a cut-oﬀ value of <10% reduction of LVESV 
yielded the best prediction of all-cause and cardiovascular mortality. Besides the LV reverse 
remodeling, baseline LV dyssynchrony was also predictive of survival. On multivariable analy-
sis however, LV reverse remodeling was the best predictor of long-term survival. Of note, 
improvement of clinical status after 3-6 months of CRT was not predictive of long-term clini-
cal outcome. 
Deﬁnition of LV reverse remodeling after CRT and its prognostic signiﬁcance 
Previous studies observed that CRT not only improves clinical status (NYHA class, quality of 
life and exercise capacity),1,2,4 but also reverses LV remodeling and improves systolic func-
tion.6,10,11 However, lack of a favorable response to CRT was observed in about one-third of 
patients in clinical studies; the deﬁnition of non-responders is diﬃcult, but has been deﬁned 
as the lack of clinical response or absence of LV reverse remodeling.2,10,11,17 Initial studies ar-
bitrarily deﬁned responders of LV reverse remodeling by a reduction of LVESV>15% after 3 
to 6 months of CRT.10,11 However, there is no study that examined the potential link between 
LV reverse remodeling and long-term clinical outcome; and it is not known if such arbitrarily 
deﬁned cut-oﬀ value of 15% is clinically relevant. Since improvement in LVESV represents 
favorable structural and functional changes of the LV after CRT, this may potentially predict 
a favorable long-term clinical outcome. In pharmacological trials, LV reverse remodeling (in 
particular reduction of LVESV) was associated with a better prognosis, in particular in clinical 
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trials with angiotensin converting enzyme inhibitors and β-blockers.9,18,19 Since CRT beneﬁts 
cardiac function by a diﬀerent mechanism that involves primarily the coordination of the 
regional contraction rather than direct tackling of neurohormonal pathways,10,14 it has not 
been explored if reduction of LV volume in patients received CRT will also predict a better 
long-term clinical outcome. 
The present study is the largest study directly examining the relation of LV reverse remodel-
ing to outcomes among patients with heart failure in the contemporary treatment era. A new 
cut-oﬀ value derived from the ROC curves of mortality prediction concluded that a reduc-
tion of LVESV≥10% was clinically relevant since this cut-oﬀ value has a high sensitivity and 
speciﬁcity for prediction of long-term all-cause and cardiovascular mortality. Furthermore, 
this cut-oﬀ value of LV reverse remodeling also predicts heart failure events and composite 
end-points of cardiovascular hospitalization or mortality. Therefore, volumetric assessment 
by echocardiography is not only a surrogate marker of favorable cardiac response to CRT, but 
also an objective measure that predicts the long-term clinical outcome. 
Lack of predictive value of clinical parameters on long-term outcome 
Another important observation in the current study is the lack of predictive value of baseline 
clinical status or change in clinical status after CRT on long-term clinical outcome. The clinical 
parameters in the current study included NYHA class, 6-minute hall walk distance and heart 
failure quality of life score. These parameters are frequently used as standard soft clinical end-
points for assessment of treatment eﬃcacy in heart failure trials including CRT,1-4 and have 
been employed as criteria to assess “clinical” response to CRT.20 However, in the present study, 
clinical improvement of quality of life and walking distance were not signiﬁcantly diﬀerent 
between those who survived and died during long-term follow-up, whereas the diﬀerence 
in NYHA class was only marginal. Therefore, the evaluation of volumetric response provides 
complementary information to clinical assessment, especially in predicting the long-term 
clinical outcome after CRT. Since the measurement of LV volume was performed oﬄine in a 
blinded fashion, the inﬂuence of a placebo eﬀect was minimized. 
Clinical implications and conclusion 
The present study established the missing link between LV reverse remodeling response and 
long-term clinical outcome in CRT. Therefore, reduction of LV volume consistently translated 
into a better clinical outcome disregarding the modality of therapy (medical or device). The 
results indicated that LV reverse remodeling after 3-6 months of CRT does not only explain the 
structural and functional beneﬁts of the ventricle as result of resynchronization, but also im-
plied the translation of cardiac structural beneﬁt into a lower clinical hard event rate. Of note, 
improvement in clinical parameters was not predictive for long-term survival. The baseline 
LV dyssynchrony was predictive of long-term survival, but multivariable analysis identiﬁed 
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reverse LV remodeling as the best predictor for long-term survival. Accordingly, LV reverse 
remodeling response is a useful criterion that also determines long-term clinical outcome, 
and provides complementary information to clinical parameters such as NYHA class, 6-min-
ute walking distance or quality of life score. Moreover, ROC curve analysis demonstrated that 
10% improvement in LVESV had the best predictive accuracy for long-term survival, and may 
be considered as an objective measure to assess a clinically useful response to CRT in future 
clinical trials. 
Limitations of the study
In this study, the number of events is relatively small. This probably reﬂects the beneﬁt of CRT 
in the improvement of clinical outcome, which is recently proven by the CARE-HF study.21 
However, with the relatively large sample size of patients undergoing CRT, we were able to 
achieve the objective of examining and conﬁrming that LV reverse remodeling is an indepen-
dent predictor of long-term clinical outcome. Large, multicenter trials are needed to conﬁrm 
our ﬁndings and validate whether a 10% reduction in LVESV is the best volumetric parameter 
to predict a favorable clinical outcome. 
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ABSTRACT
Background Acute hemodynamic eﬀects of cardiac resynchronization therapy (CRT) were 
reported previously, but detailed invasive studies showing hemodynamic consequences of 
long-term CRT are not available.
Methods and Results We studied 22 patients scheduled for implantation of a CRT device 
based on conventional criteria (NYHA class III-IV, left ventricular (LV) ejection fraction <35%, 
left bundle-branch block, QRS duration >120ms). During diagnostic catheterization prior to 
CRT we acquired pressure-volume loops using conductance catheters during atrial pacing 
at 80, 100, 120 and 140 beats/min. Studies were repeated during biventricular pacing at the 
same heart rates after 6 months of CRT. Our data show signiﬁcant clinical beneﬁt of CRT (NYHA 
class: 3.1±0.5 to 2.1±0.8; Quality-of-Life score: 44±12 to 31±16; 6-min hall-walk: 260±149 to 
396±129m; all p<0.001), improved LV ejection fraction (29±10 to 40±13%, p<0.01), decreased 
end-diastolic pressure (18±8 to 13±6mmHg, p<0.05), and reverse remodeling (end-diastolic 
volume: 257±67 to 205±54mL, p<0.01). Previously reported acute improvements in LV func-
tion remained present at 6 months: dP/dtMAX (+18%, p<0.01), -dP/dtMIN (+13%, p<0.01), stroke 
work (+34%, p<0.01). Eﬀects of increased heart rate were improved towards more physi-
ological responses for LV ejection fraction, cardiac output and dP/dtMAX. Moreover, our study 
showed improved ventricular-arterial coupling (+69%, p<0.01) and improved mechanical 
eﬃciency (+44%, p<0.01).
Conclusions Hemodynamic improvements with CRT, previously shown in acute invasive 
studies, are maintained long-term. In addition, ventricular-arterial coupling, mechanical ef-
ﬁciency, and chronotropic responses are improved after 6 months of CRT. These ﬁndings may 
help to explain the improved functional status and exercise tolerance in patients treated with 
CRT.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) improves quality of life, symptoms, and exercise 
capacity in patients with heart failure and intraventricular conduction delay.1 A recent study 
conﬁrmed these favorable eﬀects and also demonstrated that CRT signiﬁcantly reduced the 
risk of death.2 Whereas previous randomized controlled trials have clearly demonstrated 
beneﬁcial clinical eﬀects over a period of up to 6 months, small-scaled studies suggest that 
these clinical improvements are maintained long-term.3-5 The primary working mechanism 
of CRT is the optimization of the mechanical activation pattern of the left ventricle (LV), 
which is achieved by pre-excitation of the region which is otherwise activated late due to 
delayed intrinsic conduction.6 In addition to this intraventricular resynchronization, ad-
ditional beneﬁt may be obtained by optimizing the delay between atrial and ventricular 
systole, and the timing of LV and right ventricular (RV) stimulation. Acute improvements in 
mechanical dyssynchrony resulting in enhanced systolic function have been demonstrated 
by various studies.7-10 Invasive studies have shown increased LV ejection fraction and stroke 
volume, accompanied by increased systolic pressure, dP/dtMAX, and stroke work, and reduced 
diastolic pressure.9;11 Interestingly, these improvements in cardiac function are obtained at 
diminished energy cost.12 In the long-term, CRT is associated with LV reversed remodeling13 
and improved myocardial eﬃciency.14 However, currently no invasive studies are available 
regarding the eﬀects of long-term CRT on systolic and diastolic hemodynamic parameters. 
In this study we assessed the long-term hemodynamic eﬀects of CRT, and investigated the 
underlying mechanisms. To this end, we acquired pressure-volume loops prior to CRT during 
right atrial pacing at 80, 100, 120 and 140 beats/min, and these studies were repeated during 
biventricular pacing at the same heart rates after 6 months of CRT.
METHODS
Patients
Twenty-two patients (mean age, 66±11 years; 17 men) with NYHA class III or IV heart failure 
despite optimized medical treatment, echocardiographic LV ejection fraction <35% and 
QRS duration >120ms scheduled for implantation of a CRT device were included. The pro-
tocol was approved by our institutional review committee and all patients gave informed 
consent. The etiology of heart failure was ischemic in 14 and non-ischemic in 8 patients. 
All patients received stable medical therapy for chronic heart failure, including diuretics 
(n=19), spironolactone (n=8), β-blockers (n=10), ACE inhibitors (n=20), and amiodarone 
(n=6). Medication was unchanged and no new therapies were installed during the 6-
months follow-up period. In addition to the invasive studies described in detail below, we 
performed echocardiography, 6-minute hall-walk tests, and quality of life assessments by 
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the Minnesota Living with Heart Failure Questionnaire at baseline and after 6 months of 
CRT. 
Protocol
Baseline (i.e. pre-CRT) hemodynamic data were obtained during routine diagnostic right and 
left heart catheterization, including thermodilution cardiac output, left ventriculography 
and coronary angiography. To acquire pressure-volume loops at incremental heart rates, a 7F 
combined pressure-conductance catheter (CD Leycom, Zoetermeer, The Netherlands) was 
placed in the LV via the femoral artery, and a temporary pacing lead was placed in the right 
atrium. Pressure-volume signals were displayed on-line and digitized at a sample frequency 
of 250Hz (Leycom CFL, CD Leycom). LV volume was calibrated using thermodilution and 
hypertonic saline dilution as previously described.15;16 Right atrial pacing was performed at 
80, 100, 120 and 140 beats/min. Data were acquired consecutively approximately 60s after 
changing to a higher rate, and periods of at least 20s were selected for oﬀ-line analysis. All 
measurements were repeated during recatheterization after at least 6 months of chronic CRT. 
During this session biventricular pacing was performed at 80, 100, 120 and 140 beats/min by 
reprogramming the CRT device. The atrioventricular (AV) delay was kept ﬁxed at the optimal 
clinical setting based on Doppler mitral ﬂow velocity recordings obtained previously at the 
outpatient clinic.
Data analysis
Analysis of the steady state pressure-volume loops was performed using custom software as 
previously described.17 Brieﬂy, for each patient and each pacing rate hemodynamic indexes 
were calculated as the mean of all beats during a steady state period of approximately 20s. 
LV function was quantiﬁed by cardiac output and stroke volume, end-diastolic and end-
systolic volume, LV ejection fraction, end-systolic and end-diastolic pressure, maximal and 
minimal rate of LV pressure change (dP/dtMAX, dP/dtMIN). The time constant of relaxation (τ) 
was determined using phase-plot analysis.18 Stroke work was calculated as the area of the 
pressure-volume loop. LV end-systolic elastance (EES) was estimated by end-systolic pressure 
divided by end-systolic volume, and end-diastolic stiﬀness (EED) by end-diastolic pressure 
divided by end-diastolic volume. Eﬀective arterial elastance (EA) was calculated as end-sys-
tolic pressure divided by stroke volume.19 Ventricular-arterial coupling was quantiﬁed as 
EES/EA,
20 and mechanical eﬃciency was calculated as the ratio of external stroke work and 
pressure-volume area (a measure of total mechanical work).21 Nonuniform LV performance 
was determined from the segmental LV conductance signals and quantiﬁed by calculating 
the percentage of time within the cardiac cycle that a speciﬁc segment is dyssynchronous 
(i.e. opposite in phase with the global LV volume signal). Overall LV mechanical dyssynchrony 
was determined as the mean of the segmental dyssynchronies. In addition, we calculated the 
internal ﬂow fraction, which quantiﬁes the ineﬀective shifting of blood volume within the 
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LV due to nonuniform contraction and ﬁlling. This approach was described and validated in 
a previous study.17 Time-varying wall stress, WS(t), was calculated from the instantaneous LV 
pressure and volume signals (P(t) and V(t), respectively) as described by Arts et al.22: WS(t) = 
P(t)·(1+3·V(t) / LVM). LV mass (LVM) was calculated from M-mode echocardiography accord-
ing to the conventions proposed by the American Society of Echocardiography.23 Atrioven-
tricular delay was determined as the time between the right atrial pacing and the start of left 
ventricular contraction.24
Statistical analysis
We used a linear mixed-eﬀects model to account for repeated measurements on each patient. 
In this model, patients were included as random eﬀects and conditions (baseline, CRT), pac-
ing (80, 100, 120, and 140 beats/min), and their interaction as ﬁxed eﬀects.25 To assess statisti-
cal signiﬁcances between pacing levels and conditions, appropriate contrasts were selected. 
Data are presented as mean±SD. A p-value <0.05 was considered statistically signiﬁcant. The 
authors had full access to the data and take full responsibility for its integrity. All authors have 
read and agree to the manuscript as written.
RESULTS
Clinical assessment and atrioventricular delay
All patients were successfully implanted with a CRT device (Contak Renewal, Guidant 
(n=21), or InSync III, Medtronic (n=1)). All patients received CRT for at least 6 months 
(7.2±1.6 months). Table 1 shows the clinical parameters which all improved significantly, 
consistent with previous reports1. AV delay was optimized based on Doppler mitral flow 
velocity recordings at our outpatient clinic shortly after pacemaker implantation: The AV 
delay was set to achieve the longest left ventricular filling time without premature trunca-
tion of the A-wave by mitral valve closure26. Baseline AV delay (during right atrial pacing at 
80 beats/min) was 184±96 ms and tended to decrease at higher pacing rates. Mean opti-
mized AV delay with biventricular pacing was 97±15 ms and was unchanged at the higher 
pacing rates (Table 2). 
Table 1: Clinical parameters at baseline (pre-CRT) and after 6 months of CRT
Baseline 6-mo CRT
NYHA class 3.05±0.49 2.05±0.79 *
Quality of life score 44±12 31±16 *
6-min hall-walk, m 260±149 396±129 *
* p<0.001 vs. baseline by paired t-tests.
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Table 2: Left ventricular function indexes at baseline (pre-CRT) and at 6 months of CRT
Changes vs. p80 P-values of Eﬀects
p80 p100 p120 p140 Condition Pacing Interaction
HR (beats/min) BL 78.6±4.4 21.6±0.7** 43.8±0.8** 62.7±0.8** 0.308 <0.001 0.093
CRT 80.1±2.2 20.6±0.7** 41.1±0.7** 61.8±0.8**
AVD (ms) BL 184±96 -12±16 -20±16 -28±17 <0.001 0.832 0.472
CRT 97±15## 0.4±12 2±12 3±13
CO (L/min) BL 4.36±0.70 0.09±0.17 -0.25±0.19 -1.14±0.20** <0.001 <0.001 0.026
CRT 4.98±0.86## 0.45±0.17** 0.08±0.17 -0.32±0.19
ESV (mL) BL 195±72 4.1±13.6 -5.3±14.7 -15.0±15.9 <0.001 0.615 0.947
CRT 137±52## -2.6±12.4 -5.6±12.4 -9.5±14.1
EDV (mL) BL 257±67 0.6±15.2 -25.7±16.5* -44.9±17.8** <0.001 0.005 0.814
CRT 205±54## -4.3±14.0 -14.2±14.0 -21.9±15.8*
EF (%) BL 29.1±10.4 -3.5±2.4 -8.9±2.6** -12.6±2.8** <0.001 <0.001 0.235
CRT 39.5±12.8## -0.2±2.2 -2.3±2.2 -7.4±2.5**
SW (mmHg·L) BL 4.37±2.07 -0.82±0.39* -1.91±0.42** -2.62±0.49** <0.001 <0.001 0.468
CRT 5.87±2.26## -0.43±0.35 -1.06±0.35** -2.24±0.39**
ESP (mmHg) BL 105±29 -1.2±3.5 -7.0±3.8 -17.6±4.1** <0.001 <0.001 0.701
CRT 108±22 -1.8±3.3 -5.7±3.3 -12.1±3.7**
EDP (mmHg) BL 17.9±8.2 0.9±1.9 1.7±2.0 3.0±2.2 <0.001 0.013 0.614
CRT 13.2±6.4# -0.4±1.8 2.1±1.8 5.7±2.1**
dP/dtMAX (mmHg/s) BL 807±264 51±42 39±45 -42±48 <0.001 0.045 0.296
CRT 953±287## 79±39* 98±39* 77±44
-dP/dtMIN 
(mmHg/s)
BL 829±237 5±34 -36±37 -84±40 <0.001 0.105 0.650
CRT 936±281## 17±32 6±32 -25±37
τ (ms) BL 83.1±12.6 -7.0±2.9* -7.5±3.1* -13.2±3.3** 0.637 <0.001 0.653
CRT 81.4±12.7 -3.2±2.7 -8.0±2.7** -10.7±3.0**
PWS (mmHg) BL 342±89 -2.5±20 -22±21 -54±23* 0.149 0.012 0.940
CRT 331±99 -9.5±18 -19±18 -43±21*
WSED (mmHg) BL 61±26 1.4±8.0 -3.1±8.6 -3.5±9.3 0.142 0.323 0.105
CRT 47±31 -2.5±7.3 8.5±7.3 19.7±8.2
DYS (%) BL 31.4±3.2 -0.2±1.1 -0.5±1.2 -1.4±1.3 <0.001 0.960 0.346
CRT 27.4±4.5## -0.5±1.0 -0.1±1.0 1.2±1.2
IFF (%) BL 71±23 -0.7±6.4 -1.0±6.8 -3.2±7.3 <0.001 0.979 0.959
CRT 42±23## -0.8±6.0 -2.5±6.0 0.6±6.7
EA (mmHg/mL) BL 1.94±0.33 0.43±0.11** 1.03±0.12** 2.06±0.12** <0.001 <0.001 <0.001
CRT 1.78±0.41 0.25±0.10* 0.74±0.10** 1.29±0.11**
EES (mmHg/mL) BL 0.67±0.43 -0.03±0.10 -0.04±0.11 -0.11±0.12 <0.001 0.902 0.936
CRT 1.00±0.67## -0.02±0.09 -0.03±0.09 -0.02±0.10
EED (mmHg/mL) BL 0.074±0.038 0.002±0.011 0.014±0.012 0.035±0.014* 0.777 <0.001 0.810
CRT 0.067±0.029 0.001±0.010 0.020±0.010 0.050±0.012**
PVA (mmHg·L) BL 14.5±4.4 -1.50±0.79 -2.90±0.85** -5.20±1.06** 0.056 <0.001 0.505
CRT 13.1±3.2 -0.62±0.71 -1.64±0.71* -3.44±0.78**
ME BL 0.31±0.14 -0.03±0.03 -0.09±0.03** -0.09±0.04* <0.001 <0.001 0.470
CRT 0.45±0.15## -0.02±0.02 -0.03±0.02 -0.08±0.03**
EES/EA BL 0.34±0.21 -0.08±0.04 -0.14±0.04** -0.22±0.05** <0.001 <0.001 0.841
CRT 0.57±0.39## -0.09±0.04* -0.19±0.04** -0.23±0.04**
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Left ventricular function
Figure 1 shows typical examples of pressure-volume loops at 80 beats/min at baseline and 
after 6 months of CRT from two patients. Full hemodynamic data including the eﬀects of 
increased pacing rate from all patients are summarized in Table 2. Comparison of 6 months of 
CRT vs. baseline at the lowest pacing rate (80 beats/min, p80) shows that cardiac output and 
LV ejection fraction improved signiﬁcantly, whereas end-diastolic volume and end-systolic 
volume were signiﬁcantly reduced. The latter indicates substantial reversed remodeling con-
sistent with previous reports.13 Improved systolic function was evidenced by a signiﬁcantly 
increased dP/dtMAX, EES and stroke work. In addition, end-diastolic pressure was signiﬁcantly 
reduced. Diastolic stiﬀness EED and τ showed a non-signiﬁcant tendency to reduce. dP/dtMIN 
was signiﬁcantly improved indicating improved active relaxation. The increase in EES com-
bined with a modest decrease in EA resulted in a signiﬁcantly improved ventricular-arterial 
coupling ratio (EES/EA). The signiﬁcant increase in external stroke work with unchanged total 
mechanical work resulted in a signiﬁcantly improved mechanical eﬃciency. Mechanical dys-
synchrony and internal ﬂow fraction were signiﬁcantly reduced. Mechanical dyssynchrony 
was improved at all segmental levels except for the apical segment (Figure 2). Despite the 
Table 2: Left ventricular function indexes at baseline (pre-CRT) and at 6 months of CRT
Changes vs. p80 P-values of Eﬀects
p80 p100 p120 p140 Condition Pacing Interaction
HR (beats/min) BL 78.6±4.4 21.6±0.7** 43.8±0.8** 62.7±0.8** 0.308 <0.001 0.093
CRT 80.1±2.2 20.6±0.7** 41.1±0.7** 61.8±0.8**
AVD (ms) BL 184±96 -12±16 -20±16 -28±17 <0.001 0.832 0.472
CRT 97±15## 0.4±12 2±12 3±13
CO (L/min) BL 4.36±0.70 0.09±0.17 -0.25±0.19 -1.14±0.20** <0.001 <0.001 0.026
CRT 4.98±0.86## 0.45±0.17** 0.08±0.17 -0.32±0.19
ESV (mL) BL 195±72 4.1±13.6 -5.3±14.7 -15.0±15.9 <0.001 0.615 0.947
CRT 137±52## -2.6±12.4 -5.6±12.4 -9.5±14.1
EDV (mL) BL 257±67 0.6±15.2 -25.7±16.5* -44.9±17.8** <0.001 0.005 0.814
CRT 205±54## -4.3±14.0 -14.2±14.0 -21.9±15.8*
EF (%) BL 29.1±10.4 -3.5±2.4 -8.9±2.6** -12.6±2.8** <0.001 <0.001 0.235
CRT 39.5±12.8## -0.2±2.2 -2.3±2.2 -7.4±2.5**
SW (mmHg·L) BL 4.37±2.07 -0.82±0.39* -1.91±0.42** -2.62±0.49** <0.001 <0.001 0.468
CRT 5.87±2.26## -0.43±0.35 -1.06±0.35** -2.24±0.39**
ESP (mmHg) BL 105±29 -1.2±3.5 -7.0±3.8 -17.6±4.1** <0.001 <0.001 0.701
CRT 108±22 -1.8±3.3 -5.7±3.3 -12.1±3.7**
EDP (mmHg) BL 17.9±8.2 0.9±1.9 1.7±2.0 3.0±2.2 <0.001 0.013 0.614
CRT 13.2±6.4# -0.4±1.8 2.1±1.8 5.7±2.1**
dP/dtMAX (mmHg/s) BL 807±264 51±42 39±45 -42±48 <0.001 0.045 0.296
CRT 953±287## 79±39* 98±39* 77±44
-dP/dtMIN 
(mmHg/s)
BL 829±237 5±34 -36±37 -84±40 <0.001 0.105 0.650
CRT 936±281## 17±32 6±32 -25±37
τ (ms) BL 83.1±12.6 -7.0±2.9* -7.5±3.1* -13.2±3.3** 0.637 <0.001 0.653
CRT 81.4±12.7 -3.2±2.7 -8.0±2.7** -10.7±3.0**
PWS (mmHg) BL 342±89 -2.5±20 -22±21 -54±23* 0.149 0.012 0.940
CRT 331±99 -9.5±18 -19±18 -43±21*
WSED (mmHg) BL 61±26 1.4±8.0 -3.1±8.6 -3.5±9.3 0.142 0.323 0.105
CRT 47±31 -2.5±7.3 8.5±7.3 19.7±8.2
DYS (%) BL 31.4±3.2 -0.2±1.1 -0.5±1.2 -1.4±1.3 <0.001 0.960 0.346
CRT 27.4±4.5## -0.5±1.0 -0.1±1.0 1.2±1.2
IFF (%) BL 71±23 -0.7±6.4 -1.0±6.8 -3.2±7.3 <0.001 0.979 0.959
CRT 42±23## -0.8±6.0 -2.5±6.0 0.6±6.7
EA (mmHg/mL) BL 1.94±0.33 0.43±0.11** 1.03±0.12** 2.06±0.12** <0.001 <0.001 <0.001
CRT 1.78±0.41 0.25±0.10* 0.74±0.10** 1.29±0.11**
EES (mmHg/mL) BL 0.67±0.43 -0.03±0.10 -0.04±0.11 -0.11±0.12 <0.001 0.902 0.936
CRT 1.00±0.67## -0.02±0.09 -0.03±0.09 -0.02±0.10
EED (mmHg/mL) BL 0.074±0.038 0.002±0.011 0.014±0.012 0.035±0.014* 0.777 <0.001 0.810
CRT 0.067±0.029 0.001±0.010 0.020±0.010 0.050±0.012**
PVA (mmHg·L) BL 14.5±4.4 -1.50±0.79 -2.90±0.85** -5.20±1.06** 0.056 <0.001 0.505
CRT 13.1±3.2 -0.62±0.71 -1.64±0.71* -3.44±0.78**
ME BL 0.31±0.14 -0.03±0.03 -0.09±0.03** -0.09±0.04* <0.001 <0.001 0.470
CRT 0.45±0.15## -0.02±0.02 -0.03±0.02 -0.08±0.03**
EES/EA BL 0.34±0.21 -0.08±0.04 -0.14±0.04** -0.22±0.05** <0.001 <0.001 0.841
CRT 0.57±0.39## -0.09±0.04* -0.19±0.04** -0.23±0.04**
Table 2 Legends: p80..p140 indicates paced at 80..140 beats/min; BL, baseline (i.e. pre-CRT) ; CRT, 6-months cardiac resynchronization 
therapy; Condition eﬀect, BL vs. CRT; Pacing eﬀect, eﬀect of incremental paced heart rate; Interaction eﬀect, condition-pacing interaction; HR, 
heart rate; AVD, atrioventricular delay; CO, cardiac output; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; SW, stroke 
work; ESP, end-systolic pressure; EDP, end-diastolic pressure; τ, relaxation time constant; PWS, peak wall stress; WSED, end-diastolic wall stress; 
DYS, mechanical dyssynchrony; IFF, internal ﬂow fraction; EA, eﬀective arterial elastance; EES, end-systolic elastance; EED, end-diastolic stiﬀness; 
PVA, pressure-volume area; ME = SW/PVA, mechanical eﬃciency; and EES/EA, ventricular-arterial coupling. Statistical signiﬁcances and contrasts 
(changes vs. p80) were determined by using a linear mixed-eﬀects model (see text for details). CRT-p80 vs. BL-p80: # p<0.05, ## p<0.01. Changes 
vs. p80 at same condition (BL or CRT): * p<0.05, ** p<0.01. 
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Figure 1: Eﬀects of chronic CRT in two patients. Typical pressure-volume loops at baseline (grey) and after 6 months of chronic CRT (black) 
are shown (in all cases at a heart rate of 80 beats/min). Note the left ward shift of the pressure-volume loops indicating substantial reversed 
remodeling
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signiﬁcant reduction in LV volumes, LV wall stress was not signiﬁcantly reduced. This was due 
to a concomitant signiﬁcant reduction in LV mass from 324±92g at baseline to 290±107g 
(p<0.001) after 6 months of CRT.
Responses to increased heart rate
Table 2 shows mean values at baseline and 6-months CRT for all hemodynamic indexes at 80 
beats/min, and the related changes during pacing at 100, 120 and 140 beats/min. The mean 
values of the main indexes are also graphically displayed in Figure 3. At baseline, cardiac 
output did not increase with incremental pacing, but rather cardiac output was signiﬁcantly 
reduced at 140 beats/min, indicating an exhausted chronotropic reserve in these heart 
failure patients. In contrast, at 6 months follow-up, cardiac output, which was signiﬁcantly 
higher at 80 beats/min compared to the same heart rate at baseline, increased further at 
100 beats/min and remained stable at higher rates (Figure 3A). Similarly, at follow-up, LV 
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Figure 2: Mechanical dyssynchrony (DYS) and internal ﬂow fraction (IFF) at baseline and after 6 months of CRT (at 80 beats/min). DYS is also 
shown per segment. Signiﬁcances vs. baseline: # p<0.05, ### p<0.005.
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ejection fraction was signiﬁcantly higher at 80 beats/min, and the reduction in LV ejection 
fraction at incremental pacing was substantially less pronounced than at baseline (Figure 
3B). The negative chronotropic responses at baseline mainly resulted from a rapid decrease 
in end-diastolic volume with incremental pacing, with a less pronounced drop in end-systolic 
volume. After 6 months of CRT, the reduction in end-diastolic volume was more limited (only 
signiﬁcant at 140 beats/min) whereas end-systolic volume remained unchanged (Figure 3C). 
At the same time systolic pressure dropped signiﬁcantly at 140 beats/min both at baseline 
and at 6 months of CRT, and diastolic pressure tended to increase with pacing rate at both 
time-points. These eﬀects are clearly shown by the average (i.e. based on mean end-systolic 
and end-diastolic pressures and volumes) pressure-volume loops in Figure 4. Note the sub-
stantial reverse remodeling evidenced by the leftward shift of all pressure-volume loops at 
Figure 3: Main hemodynamic indexes at baseline and after 6 months of CRT. CO indicates cardiac output; EDP, end-diastolic pressure; EF, LV 
ejection fraction; EES, end-systolic elastance; EA, arterial elastance; EDV, end-diastolic volume; ESV, end-systolic volume; ME, mechanical eﬃciency. 
The Figures show mean±SD at 80, 100, 120 and 140 beats/min (p80, p100, p120 and p140). Signiﬁcances vs. p80 at the same condition (baseline 
or CRT): * p<0.05, ** p<0.01. Signiﬁcances at p80 for CRT vs. baseline: # p<0.05, ## p<0.01.
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Figure 4: Mean pressure-volume loops at baseline and after 6 months of CRT. Mean pressure-volume loops are based on mean end-systolic 
and end-diastolic pressures and volumes and are shown at heart rates 80, 100, 120 and 140 beats/min. At baseline we used right atrial pacing via 
a temporary pacing lead; at follow-up biventricular pacing was performed by reprogramming the CRT device.
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Figure 5: Typical examples of LV pressure and LV dP/dt during incremental pacing rate at baseline and after 6 months of CRT. Note that dP/dtMAX 
was unchanged with increasing heart rate at baseline, whereas dP/dtMAX substantially increased after CRT (See the bottom panels which extent 
the ﬁrst 100ms of the dP/dt tracings).
Hemodynamic eﬀ ects of long-term CRT 99
6 months of CRT, and the fact that stroke volume (the width of the pressure-volume loops) 
was better maintained during increased heart rate after 6 months of CRT. Interestingly, after 
6 months of CRT, dP/dtMAX showed a signiﬁcant increase at higher pacing levels as compared 
to the value at 80 beats/min, whereas at baseline no signiﬁcant increases were found during 
incremental pacing. This indicates a more physiological response after 6 months of CRT. This 
is illustrated in Figure 5, which shows LV pressure and LV dP/dt for the diﬀerent heart rates 
at baseline and after 6 months of CRT in a typical patient. Note the higher dP/dtMAX after 6 
months of CRT and the gradual increase in dP/dtMAX with increased pacing rate, which was ab-
sent at baseline. This change towards normalization of chronotropic response was not found 
for dP/dtMIN. Ventricular-arterial coupling, quantiﬁed by the ratio of ventricular and arterial 
elastance, was highly abnormal in the heart failure patients, but improved signiﬁcantly after 6 
months of CRT. The drop in EES/EA with increased heart rate was still present after CRT (Figure 
3E). Likewise, mechanical eﬃciency was improved at follow-up, but dropped signiﬁcantly at 
140 beats/min both at baseline and after 6 months of CRT (Figure 3F).
DISCUSSION
CRT is a highly eﬀective new therapy in patients with left bundle-branch block and severe 
heart failure. Large-scale studies have reported long-term clinical beneﬁt with improved LV 
function and reverse LV remodeling.1;6;13;27 In these studies, follow-up is generally performed 
with echocardiography, and improvements in LV function are reported mainly in terms of 
increased ejection fraction. Detailed invasive hemodynamic studies of the acute eﬀects of 
CRT, including analyses with pressure-volume loops12;28, have been published previously, but 
to our best knowledge no such data are available for chronic CRT. In the present study we 
obtained invasive hemodynamics by pressure-volume loops at baseline and after 6 months 
of CRT. Our data conﬁrm previous ﬁndings regarding clinical beneﬁt, improved LV ejection 
fraction and reverse remodeling. In addition, it shows that hemodynamic improvements in 
terms of increased dP/dtMAX, dP/dtMIN and stroke work, and reduced end-diastolic pressure, 
previously found in acute studies6;11;28;29, are still present at 6 months follow-up.
Moreover, our study shows improved ventricular-arterial coupling and improved mechanical 
eﬃciency. These hemodynamic ﬁndings are consistent with the observed improvements in 
clinical and functional status. The altered responses to increased heart rate may partly ex-
plain the improved exercise capacity of patients treated with CRT. At baseline, cardiac output 
was unchanged when heart rate was increased illustrating the exhausted LV function reserve 
of these patients. At follow-up this is converted to a more physiological response although 
the capacity to increase cardiac output is still limited. The latter presumably is partly due to 
an abnormal relaxation reﬂected by a relatively long isovolumic relaxation time (τ), which 
did not improve after CRT. In the normal heart, τ substantially shortens at higher heart rate, 
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which enables adequate ﬁlling despite a shortened diastolic period. This response is largely 
lost in heart failure, and did not normalize after 6 months of CRT in our patients. Consistent 
with our ﬁndings, previous studies failed to show improvements in isovolumic relaxation 
neither with acute biventricular pacing29;30 nor at long-term.13 A theoretical model by Hay et 
al.31 shows a close correlation between increased τ and increased diastolic pressure, which 
is most evident at high heart rates. Our data are consistent with this prediction and show 
that the phenomenon is still present after 6 months of CRT. The improved mechanical ef-
ﬁciency found in our study is in line with previous studies on acute eﬀects of CRT by Nelson 
et al.12 and is consistent with studies by, e.g., Sundell et al.14 in patients treated long-term. 
Most likely, the improved mechanical intraventricular synchrony underlies the more eﬃcient 
conversion of total mechanical energy to external stroke work. This is most evident from a 
highly signiﬁcant reduction in internal ﬂow fraction from 71 to 42%, which indicates that 
segmental volume changes are more eﬃciently used for eﬀective ejection rather than for en-
ergy-wasting shifting of blood volumes between segments within the ventricle. In addition, 
ventricular-arterial coupling was signiﬁcantly improved which further optimizes production 
of external work32;33. However, whereas in the normal heart optimal ventricular-arterial cou-
pling is maintained with increased heart rate34, EES/EA signiﬁcantly dropped in our patients 
and this abnormal response was still present after long-term CRT. The baseline values for 
mechanical eﬃciency and ventricular-arterial coupling found in our study (0.31 and 0.34, 
respectively) were in the same range but somewhat lower than values reported by Kim et 
al.35: 0.38 and 0.42, respectively. However, the patients in their study had less severe heart 
failure evidenced by an average NYHA classiﬁcation of 1.8±0.7 and an LV ejection fraction of 
37±13%. Asanoi et al.36 reported that in the failing heart homeostatic mechanisms maintain 
arterial blood pressure within the normal range, but that this blood pressure level causes a 
deviation from energetically optimal conditions in hearts with a severely reduced contractile 
state. This discrepancy results from worsening of ventricular-arterial coupling and decreased 
mechanical eﬃciency. Conversely, the improved ventricular-arterial coupling and mechanical 
eﬃciency after 6 months of CRT, as found in our study, constitutes a more optimal energetic 
condition. Interestingly, despite the substantial reverse remodeling in our study, wall stress 
was not signiﬁcantly reduced after 6 months of CRT. This was due to a concomitant reduc-
tion in LV mass. We would hypothesize that the regression in LV volumes initially leads to a 
reduction in wall stress, which then in turn may cause a reduction in LV hypertrophy. Note 
however that, although not statistically signiﬁcant, diastolic wall stress was reduced by 23% 
at 80 beats/min and by 30% at 100 beats/min. At higher heart rates, wall stress was virtually 
unchanged or even increased compared to baseline (-5% at 120 beat/min, and +24% at 140 
beats/min). This ﬁnding is explained by the fact that at baseline end-diastolic volume drops 
substantially at the high heart rates (which also limits the increase in end-diastolic pressure), 
whereas end-diastolic volume is better maintained at 6-months follow-up. Furthermore, the 
global model to calculate wall stress does not take into account spatial dyssynchrony, and 
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conversion to a more uniform contraction pattern at 6-months follow-up may lead to reduc-
tions in wall stress at a regional level.
In our study we used simultaneous biventricular pacing in all patients. Sequential biventricu-
lar pacing has been proposed to optimize CRT, and either right ventricular or left ventricular 
pre-excitation may optimize hemodynamics in individual patients.8;37 However, Hay et al.28 
demonstrated that sequential biventricular stimulation oﬀered minimal beneﬁt and that, on 
the average, most systolic and diastolic function parameters reached a maximum with si-
multaneous pacing. In addition to improvement of intra- and interventricular dyssynchrony, 
the patients may also have beneﬁted from optimization of the AV delay. In our study the AV 
delay was reduced from a baseline value of 184±96 ms to a mean value of 97±15 ms during 
CRT. Studies by Auricchio et al.24 showed that the maximal increases in pulse pressure and 
dP/dtMAX were obtained at 45% of the intrinsic AV interval. Consistently, most studies report 
optimal AV delays of 100-120 ms, but small diﬀerences in delay have far less inﬂuence than 
pacing site.29
Because our baseline studies were performed prior to implantation of the CRT device we 
could not assess the acute hemodynamic eﬀects of CRT. However, these eﬀects were docu-
mented in previous studies. Acute improvements in CO or SV, in most studies assessed by 
changes in aortic pulse pressure, were reported to be in the range of 7 to 15% 3;11;24;28;29;38;39, 
which is comparable to the 14% increase found at 6-months in our study. Previous studies 
show an acute reduction of 10 to 18% in end-systolic volume, and a relatively smaller reduc-
tion in end-diastolic volume of 5 to 9% 8;30;39 , which lead to 15 to 33% relative improvement 
in EF. The reductions in end-systolic and end-diastolic volume at 6 months in our study were 
30 and 20%, respectively. Apparently, the acute improvement in cardiac output is maintained 
long-term, but both end-systolic and end-diastolic volume show a gradual, more or less par-
allel, further reversed remodeling, as previously documented over a 3-months period by Yu 
et al.27 With regard to dP/dtMAX, previous studies fairly consistently showed an acute increase 
of 13 to 21% 3;7;11;24;28;29;38, which is close to the 18% increase found in our study at 6-months 
follow-up. Yu’s study revealed that more than 60% of the gain in dP/dtMAX obtained after 3 
months CRT is lost immediately after turning oﬀ the pacemaker, whereas 4 weeks after ces-
sation of CRT dP/dtMAX had completely returned to pre-CRT values. Their study also showed 
that left ventricular volumes increased and other echocardiographic beneﬁts were gradually 
lost over the 4-week period. We did not systematically investigate the eﬀects of turning oﬀ 
the pacemaker, but in a few patients we registered pressure-volume loops during temporary 
cessation of pacing in the follow-up study. Figure 6 shows two typical examples: The pres-
sure-volume loops show an immediate reduction in stroke volume, whereas dP/dtMAX was 
decreased by 20 and 7%, respectively. These immediate on-oﬀ responses are very similar to 
those registered previously in acute studies.29
102
C
ha
pt
er
 7
Study limitations
The number of patients included in this study was relatively small in comparison to the num-
ber of outcome variables. Thus, some diﬀerences that reached statistical signiﬁcance might 
be spurious due to the relatively large number of statistical tests. Moreover, the sample size 
was too small to justify a meaningful responder/non-responder analysis. Only 4 patients did 
not show an improved clinical status: 3 patients with NYHA class III remained in class III, one 
class III patient deteriorated to class IV. All other patients improved by 1 or 2 NYHA classes. 
In the ‘non-responder’ group the baseline end-diastolic volume and end-systolic volume 
(282±73 and 228±70 mL, respectively) appeared to be somewhat higher than in the group as 
a whole, and ejection fraction somewhat lower (21±6%).
In conclusion, our study shows that hemodynamic improvements that were previously shown 
in acute studies are maintained with long-term CRT. In addition, ventricular-arterial coupling, 
mechanical eﬃciency, and chronotropic responses are improved after 6 months of CRT. These 
ﬁndings may help to explain the improved functional status and exercise tolerance in heart 
failure patients treated with cardiac resynchronization.
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Figure 6: Immediate eﬀects of cessation of biventricular pacing after 6-months CRT in two patients. Typical pressure-volume loops during pacing ON (black) and OFF (grey). 
Note the immediate reduction in stroke volume.
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ABSTRACT 
Background Recent studies have demonstrated that a positive response to cardiac resyn-
chronization therapy (CRT) is related to the presence of pre-implantation left ventricular (LV) 
dyssynchrony. However, the time course and the extent of LV resynchronization following 
CRT implantation and their relationship to response are currently unknown.
Methods One hundred consecutive patients scheduled for the implantation of a CRT de-
vice were prospectively included, using the following criteria: NYHA class III-IV, LV ejection 
fraction ≤35%, QRS duration >120 ms and LV dyssynchrony (≥65 ms) on color-coded tissue 
Doppler imaging (TDI). 
Results Immediately after CRT implantation, LV dyssynchrony was reduced from 114±36 ms 
to 40±33 ms (P<0.001) which persisted at 6 months follow-up (35±31 ms, P<0.001 vs base-
line, P=NS vs immediately post-implantation). At 6 months follow-up, 85% of patients were 
classiﬁed as responders to CRT (deﬁned as >10% reduction in LV end-systolic volume). Imme-
diately post-implantation, the responders to CRT demonstrated a signiﬁcant reduction in LV 
dyssynchrony from 115±37 ms to 32±23 ms (P<0.001). The non-responders however, did not 
show a signiﬁcant reduction in LV dyssynchrony (106±29 ms vs 79±44 ms, P=NS). If the extent 
of acute LV resynchronization was <20%, response to CRT at 6 months follow-up was never 
observed. Conversely, 93% of patients with LV resynchronization ≥20% responded to CRT. 
Conclusion LV resynchronization following CRT is an acute phenomenon, and predicts re-
sponse to CRT at 6 months follow-up. 
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is considered an important breakthrough in the 
treatment of selected patients with drug-refractory heart failure. Recent large randomized 
trials have clearly demonstrated the beneﬁcial eﬀects of CRT on heart failure symptoms and 
left ventricular (LV) systolic function. In addition, CRT resulted in a reduction in heart failure 
hospitalizations and an improvement in survival [1-4]. Despite these impressive results, CRT 
was not successful in 20-30% of patients [1,5-7]. Detailed analysis revealed that none of the 
established CRT selection criteria (NYHA class III-IV, LV ejection fraction ≤35% and QRS du-
ration >120 ms) were able to predict a positive response to CRT [5,7]. Recent studies have 
indicated that the beneﬁt from CRT is related to the presence of LV dyssynchrony before im-
plantation [5-10]. It is currently unclear however, whether a reduction in LV dyssynchrony (LV 
resynchronization) after implantation of the CRT device is mandatory for a positive response. 
Moreover, whether LV resynchronization appears acutely after CRT implantation or occurs 
gradually over time is also unknown. Accordingly, a prospective analysis in patients with pre-
implantation LV dyssynchrony on color-coded tissue Doppler imaging (TDI) was performed, 
aiming to answer the following questions:
1]  What is the time course of LV resynchronization after CRT: does LV resynchronization occur 
acutely or develop gradually over time? 
2] What extent of LV resynchronization is obtained following CRT?
3] Is LV resynchronization necessary for response to CRT?
METHODS
Study population and protocol
Consecutive heart failure patients, scheduled for implantation of a CRT device, were included 
in the study. The selection criteria for CRT included moderate-to-severe heart failure (NYHA 
class III or IV), LV ejection fraction ≤35% and QRS duration >120 ms. In addition, patients 
had to show substantial LV dyssynchrony (≥65 ms) on TDI. Patients with a recent myocardial 
infarction (<3 months) or decompensated heart failure were excluded. Before CRT implan-
tation, clinical status was assessed and 2-dimensional echocardiography was performed to 
determine LV volumes and LV ejection fraction. Assessment of LV dyssynchrony using TDI was 
repeated immediately post-CRT implantation and at 6 months follow-up. The clinical status 
and changes in LV ejection fraction and LV volumes were re-assessed at 6 months follow-up.
Clinical evaluation
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota living with Heart Failure questionnaire) and evaluation of exer-
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cise capacity using the 6-minute hall-walk test. All parameters were re-assessed at 6 months 
follow-up.
Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available sys-
tem (Vingmed system Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). Images 
were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and api-
cal views (standard long-axis, 2- and 4-chamber images). Standard 2-dimensional and color 
Doppler data, triggered to the QRS complex, were saved in cine-loop format. The LV volumes 
(end-systolic, end-diastolic) and LV ejection fraction were calculated from the conventional 
apical 2- and 4-chamber images, using the biplane Simpson’s technique [11].
Patients with a reduction of >10% in LV end-systolic volume at 6 months follow-up were con-
sidered responders to CRT [12]. In addition, patients who died from progressive heart failure 
before the 6 months follow-up assessment were classiﬁed as non-responders.
LV dyssynchrony assessment using color-coded TDI
In addition to the conventional echocardiographic examination, TDI was performed to as-
sess LV dyssynchrony. For TDI, color Doppler frame rates were > 80 frames/s; pulse repetition 
frequencies were between 500 Hz and 1 KHz, resulting in aliasing velocities between 16 and 
32 cm/s. TDI parameters were measured from color-coded images of 3 consecutive heart 
beats by oﬄine analysis. To determine LV dyssynchrony, the sample volume (6 mm x 6 mm) 
was placed in the LV basal parts of the anterior, inferior, septal and lateral walls (using the 2-
and 4-chamber apical views) and per region, the time interval between the onset of the QRS 
complex and the peak systolic velocity was derived (i.e. the electro-systolic delays). LV dys-
synchrony was deﬁned as the maximum delay between peak systolic velocities among the 
four walls within the left ventricle (most frequently observed between the inter-ventricular 
septum and the lateral wall) [7]. The analysis of peak systolic velocities was limited to the LV 
ejection period and post-systolic peaks were excluded. To ensure highly interpretable and 
reproducible TDI curves (and minimize artefacts) high frame rates are crucial. The highest 
possible frame-rates were achieved by narrowing the 2- and 4-chamber apical TDI views 
down to the left ventricle (i.e. excluding the right ventricle and atria). Previously reported 
inter- and intra-observer agreement for assessment of LV dyssynchrony were 90% and 96%, 
respectively [13]. Based on previous data, a cut-oﬀ value of 65 ms was used as a marker of LV 
dyssynchrony [7].
Data were analyzed using commercial software (Echopac version 5.0.1, General Electric 
– Vingmed). Echocardiographic data were analyzed by 2 independent observers, blinded to 
all other patient data.
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Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. A coronary sinus 
venogram was obtained using a balloon catheter. Next the LV pacing lead was inserted 
through the coronary sinus with the help of an 8Fr-guiding catheter, and positioned as far 
as possible in the venous system, preferably in a (postero-) lateral vein. The right atrial and 
right ventricular leads were positioned conventionally. CRT-device and lead implantation 
were successful in all patients without major complications (Contak TR or Contak Renewal 
TR2/1/2/4, Guidant, Minneapolis, Minnesota, USA and Insync (Marquis) III or Sentry, Medtron-
ic Inc., Minneapolis, Minnesota, USA). Two types of LV leads were used (Easytrak, Guidant, or 
Attain, Medtronic Inc.). No adjustments were made to the V-V interval before the 6 months of 
follow-up assessment.
Statistical analysis
Continuous data were expressed as mean ± SD and compared with the 2-tailed Student's t 
test for paired and unpaired data when appropriate. Categorical variables were compared 
using the chi-square test with Yates' correction. Linear regression analysis was performed 
to determine the relationship between immediate LV resynchronization and LV reverse re-
modeling at 6 months follow-up. For all tests, a P-value <0.05 was considered statistically 
signiﬁcant.
RESULTS 
A total of 100 consecutive patients were prospectively included, the study population com-
prised 86 men and 14 women, with a mean age of 67±11 years. By deﬁnition, all patients had 
pre-implantation LV dyssynchrony ≥65 ms (mean 114±36 ms). The baseline characteristics of 
the patients are summarized in Table 1.
Immediately after CRT implantation, QRS duration was reduced from 168±27 ms to 151±25 
ms (P<0.001). One patient died at 3 months after CRT implantation as a result of worsening 
heart failure. Accordingly, this patient did not have the follow-up assessment at 6 months 
and was classiﬁed as a non-responder to CRT. In the remaining patients a signiﬁcant improve-
ment in NYHA class was observed (from 3.0±0.2 to 2.0±0.5, P<0.001) at 6 months follow-up. In 
addition, the quality-of-life score decreased from 38±16 to 19±15 (P<0.001) and the 6-minute 
walking distance increased from 292±108 m to 407±100 m (P<0.001). Echocardiography at 6 
months follow-up revealed a signiﬁcant improvement in LV ejection fraction from 23±7% to 
33±10% (P<0.001) and signiﬁcant LV reverse remodeling with a decrease in LV end-diastolic 
volume from 243±76 ml to 204±73 ml (P<0.001) and a decrease in LV end-systolic volume 
from 188±71 ml to 136±63 ml (P<0.001).
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Eighty-ﬁve patients (85%) showed a reduction >10% in LV end-systolic volume at 6 months 
follow-up and were therefore classiﬁed as responders to CRT. 
LV resynchronization after CRT
Immediately after CRT implantation TDI demonstrated a reduction in LV dyssynchrony from 
114±36 ms to 40±33 ms (P<0.001). At 6 months follow-up the reduction in LV dyssynchrony 
by CRT was sustained with a LV dyssynchrony of 35±31 ms (P<0.001 versus baseline and 
P=NS versus immediate post-implantation) (Figure 1).
Although the reduction in LV dyssynchrony following CRT was highly signiﬁcant with an im-
mediate reduction in LV dyssynchrony of 65% and a 69% reduction at 6 months follow-up, 
not all patients experienced a similar extent of LV resynchronization. The distribution of the 
extent of immediate LV resynchronization after CRT is displayed in Figure 2. In the majority of 
patients, CRT induced a ≥60% reduction in LV dyssynchrony both immediately post-implan-
tation (n=61, 61%) and at 6 months follow-up (n=67, 67%). In other patients however, CRT 
resulted in only a minimal reduction or even an increase in LV dyssynchrony (Figure 2).
Table 1. Baseline characteristics (n=100)
Age (yrs) 67±11
Gender
 male 
 female  
86 (86%)
14 (14%)
Etiology
 ischemic 
 non-ischemic 
59 (57%)
41 (43%)
QRS duration (ms) 168±27
Rhythm
 Sinus rhythm 
 Atrial ﬁbrillation
89 (89%)
11 (11%)
NYHA functional class
  III 
 IV
95 (95%)
5 (5%)
Medication
 Diuretics 
 ACE inhibitors 
 Beta-blockers 
88 (88%)
92 (92%)
77 (77%)
Qol-score 38±16
6-MWT 292±108
LVEF (%) 23±7
LVEDV (ml) 243±76
LVESV (ml) 188±71
LV dyssynchrony (ms) 114±36
6-MWT: 6-minute walking distance; LV: left ventricular; LVEF: left ventricular ejection fraction; LVEDV left ventricular end-diastolic volume; LVESV 
left ventricular end-systolic volumes; NYHA: New York Heart Association; Qol: quality-of-life score. 
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LV resynchronization versus response to CRT 
As indicated above, 85 patients (85%) showed a reduction >10% in LV end-systolic volume 
at 6 months follow-up and were therefore classiﬁed as responders to CRT. Fourteen patients 
(14%) had a reduction ≤10% in LV end-systolic volume and 1 patient died from progressive 
heart failure before 6 months follow-up; these patients were classiﬁed as non-responders to 
CRT (15%).
At baseline, no signiﬁcant diﬀerences were observed between responders and non-respond-
ers (Table 2). In particular, baseline LV dyssynchrony was similar between responders and 
non-responders (115±37 ms versus 106±29 ms, NS). The prevalence of ischemic cardiomy-
opathy was higher in the non-responders, although this diﬀerence was not statistically sig-
niﬁcant (80% versus 55%, P=NS). 
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Figure 1. Time course of LV resynchronization following CRT implantation in all patients (n=100). 
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Figure 2. Extent of the decrease in LV dyssynchrony immediately following CRT implantation. 
114
C
ha
pt
er
 8
By deﬁnition, LV end-systolic volume did not decrease in the non-responders at 6 months 
follow-up (170±79 ml at baseline versus 177±73 ml at follow-up, P=NS). In contrast, the 
responders showed a signiﬁcant reduction in LV end-systolic volume from 190±69 ml to 
130±59 ml (P<0.001). In addition, the non-responders showed no improvement in LV ejec-
tion fraction (from 24±7% to 25±7%, P=NS), whereas the responders improved from 23±7% 
to 34±9% (P<0.001) (Table 2). 
An interesting observation was the diﬀerence in immediate LV resynchronization between 
the responders and the non-responders. The patients without response showed no signiﬁ-
cant reduction in LV dyssynchrony (from 106±29 ms to 79±44 ms, P=NS), whereas the re-
Table 2. Patients with LV reverse remodeling at 6 months follow-up (deﬁned as a reduction in LV end-systolic volume >10% (n=85) versus 
patients without LV reverse remodeling (reduction of LV end-systolic volume ≤10%). Clinical and echocardiographic variables at baseline and at 
6 months follow-up.
LV reverse remodeling Present LV reverse remodeling 
Absent #
P-Value
Age (yrs) 67±10 66±15 NS
Gender (M/F) 73/12 13/2 NS
Etiology
(isch/non-isch)
47/38 12/3 NS
QRS duration (ms) 169±28 158±18 NS
LV dyssynchrony (ms)  
 Baseline 115±37 106±29 NS
 follow-up (acute) 32±23* 79±44 <0.05
NYHA class  
 baseline 3.0±0.2 3.1±0.3 NS
 follow-up 2.0±0.5* 2.6±0.5* <0.05
6-MWT (m)  
 baseline 295±110 264±89 NS
 follow-up 419±85* 337±151* <0.05
QoL score 
 Baseline 37±17 42±13 NS
 follow-up 18±14* 28±16* <0.05
LVESV (ml)   
 Baseline 190±69 170±79 NS
 follow-up 130±59* 177±73 <0.05
LVEDV (ml)  
 Baseline 245±75 220±84 NS
 follow-up 200±72* 231±80 NS
LVEF (%)
 Baseline 23±7 24±7 NS
 follow-up 34±9* 25±7 <0.05
6-MWT: 6-minute walking distance; LV: left ventricular; LVEF: left ventricular ejection fraction; LVEDV left ventricular end-diastolic volume; LVESV 
left ventricular end-systolic volumes; NYHA: New York Heart Association; Qol: quality-of-life score. *: P<0.05 follow-up vs. baseline value, # 1 
patient died before 6 months follow-up. 
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sponders demonstrated a signiﬁcant reduction in LV dyssynchrony from 115±37 ms to 32±23 
ms (P<0.001) (Figure 3).
Linear regression demonstrated a modest but signiﬁcant relationship between the immedi-
ate reduction in LV dyssynchrony and the reduction in LV end-systolic volume at 6 months 
follow-up (y=0.29x+8, r=0.41, n=99, P<0.001) (Figure 4). 
Of interest, when patients showed less than 20% LV resynchronization (n=9) immediately 
after CRT, response to CRT never occurred. Conversely, 85 of 91 patients with ≥20% LV resyn-
chronization immediately after CRT implantation, responded to CRT at 6 months follow-up. 
Applying this cut-oﬀ value of 20% immediate LV resynchronization, resulted in a positive and 
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LV dyssynchrony (ms)
Figure 3. Immediate decrease in LV dyssynchrony in the patients with response to CRT (n=85, 85%, deﬁned as >10% reduction in LV end-
systolic volume) versus the patients without response (n=15, 15%).
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Figure 4. Relationship between immediate LV resynchronization and reduction in LV end-systolic volume at 6 months follow-up (y=0.29x+8, 
n=99, r=0.41, P<0.001). 
116
C
ha
pt
er
 8
negative predictive value of 100% and 93% respectively, for prediction of response to CRT 
at 6 months follow-up. Importantly, no diﬀerences were observed in baseline characteristics 
between the patients with and without immediate LV resynchronization (Table 3).
 
DISCUSSION
The main ﬁndings of the current study can be summarized as follows:
LV resynchronization following CRT occurs acutely and is sustained at 6 months follow-up, 
without further resynchronization over time however; 2. large inter-individual variation in the 
extent of LV resynchronization was observed, but the vast majority revealed more than 60% 
reduction in LV dyssynchrony acutely after CRT implantation; 3. less than 20% resynchroniza-
tion never resulted in response to CRT, whereas 93% of patients with ≥20% resynchronization 
responded to CRT at 6 months follow-up. 
Mechanism of response to CRT
Recent studies have clearly demonstrated that the presence of substantial LV dyssynchrony 
before implantation is an important predictor of a response to CRT [5-9], which may be su-
perior over the traditional selection criteria (severe heart failure, depressed LV function and 
wide QRS complex). For example Dohi et al. demonstrated that the extent of LV dyssynchrony 
was the only pre-implantation parameter that was diﬀerent between responders and non-
responders to CRT; responders had signiﬁcantly larger septal to posterior peak wall strain as 
compared to non-responders (249±94 ms versus 137±136 ms, P<0.05) [14]. 
Table 3. Baseline characteristics in patients with LV resynchronization (≥20% reduction in LV dyssynchrony, n=91) versus patients without 
LV resynchronization (n=9).
Resynchronization Present Resynchronization Absent# P-Value
Age (yrs) 67±10 65±17 NS
Gender (M/F) 79/12 7/2 NS
Etiology (isch/non-isch) 53/38 6/3 NS
QRS duration (ms) 169±28 157±17 NS
LV dyssynchrony (ms) 114±37 112±24 NS
NYHA class  3.0±0.2 3.1±0.3 NS
LVESV (ml) 187±70 197±79 NS
LVEDV (ml) 241±76 255±84 NS
LVEF (%)  23±7 23±7 NS
LV: left ventricular; LVEF: left ventricular ejection fraction; LVEDV left ventricular end-diastolic volume; LVESV left ventricular end-systolic volumes; 
NYHA: New York Heart Association
# 1 patient died before 6 months follow-up
Left ventricular resynchronization following CRT 117
In the current study, all patients had echocardiographic evidence of LV dyssynchrony and 
the echocardiographic response rate (deﬁned as a decrease >10% in LV end-systolic volume 
at 6 months follow-up) was indeed much higher (85%) as compared to previous studies that 
included patients selected according to the traditional CRT selection criteria; these stud-
ies reported echocardiographic response rates in the range of 50-55% [5,6,15]. The current 
ﬁndings strongly support the use of echocardiographic selection of potential candidates for 
CRT.
The parameter for LV dyssynchrony used in the current study was derived previously from 
85 heart failure patients undergoing CRT, who were evaluated with color-coded TDI [7]. ROC 
curve analysis revealed that LV dyssynchrony ≥65 ms (as determined from 4 basal LV seg-
ments) yielded a sensitivity and speciﬁcity of 92% to predict LV reverse remodeling after CRT 
implantation [7]. Based on this pre-deﬁned cut-oﬀ value, only patients with evidence of LV 
dyssynchrony ≥65 ms on TDI were included in the current study. 
The deﬁnition of response used in the current study (reduction >10% in LV end-systolic vol-
ume at 6 months follow-up was derived from a study by Yu et al. who studied 141 patients 
undergoing CRT and observed that a reduction in LV end-systolic volume after 3-6 months 
of CRT was the most important predictor of all-cause and cardiovascular mortality, whereas 
clinical parameters were unable to predict response to CRT. ROC curve analysis revealed that 
a cut-oﬀ value of 10% reduction in LV end-systolic volume was the optimal cut-oﬀ value for 
prediction of response to CRT [12]. 
Time course and extent of LV resynchronization following CRT
Various studies have reported on LV resynchronization after CRT [6,7,16,17]. The majority of 
studies showed immediate resynchronization after CRT. For example Breithardt et al. studied 
the acute eﬀects of CRT on the extent of LV dyssynchrony in 34 patients using echocardio-
graphic phase analysis [17]. Immediately after implantation, a 37% decrease in LV dyssyn-
chrony was observed (from 104±41° to 66±42°, P<0.001).
The time course however, of LV resynchronization during follow-up is currently unknown and 
the question whether initial LV resynchronization is followed by a further reduction in LV dys-
synchrony is unanswered. The present ﬁndings clearly demonstrate that LV resynchroniza-
tion is an acute phenomenon, which occurs immediately after CRT implantation. At mid-term 
follow-up, the extent of immediate LV resynchronization is sustained, but a further reduction 
in LV dyssynchrony could not be demonstrated (Figure 1). An interesting observation is the 
high inter-individual variation in the extent of immediate LV resynchronization following CRT 
implantation. Although the majority of patients demonstrated ≥60% reduction in LV dys-
synchrony, some patients only demonstrated a minimal amount of LV resynchronization or 
even experienced an increase in LV dyssynchrony. 
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Lack of LV resynchronization 
In search for optimal prediction of response to CRT, previous studies have shown that patients 
with LV dyssynchrony have a relatively high likelihood to respond to CRT whereas patients 
without LV dyssynchrony do not respond, although not all patients with LV dyssynchrony 
responded to CRT [7,14-16]. In the current study, patients were selected based on the pres-
ence of LV dyssynchrony before CRT implantation, resulting in a high response rate (85%), 
but 15% of patients still did not respond. Comparison of responders and non-responders 
revealed no diﬀerences in baseline clinical and echocardiographic characteristics (Table 2). 
Interestingly, further analysis of the individual patient data revealed that the extent of imme-
diate LV resynchronization can be used to optimize prediction of response. Patients with less 
than 20% reduction in LV dyssynchrony never responded to CRT. In contrast, patients with LV 
resynchronization ≥20% had an excellent response rate of 93%. 
The explanation for absence of resynchronization may be related to LV lead positioning: a 
mismatch between the site of latest activation and position of the LV pacing may prohibit 
resynchronization. This issue needs further study.
In conclusion, LV resynchronization following CRT is an acute phenomenon, without further 
reduction in LV dyssynchrony during follow-up. Despite the presence of substantial LV dys-
synchrony before implantation, patients with a <20% immediate reduction in LV dyssynchro-
ny never showed response to CRT at 6 months follow-up, indicating that resynchronization is 
mandatory for response to CRT.
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ABSTRACT 
Introduction Patients with end-stage heart failure and a wide QRS complex are  considered 
candidates for cardiac resynchronization therapy (CRT). However, 20-30% of patients do not 
respond to CRT. Lack of left ventricular dyssynchrony may explain non-response. Accordingly, 
we have evaluated the presence of left ventricular dyssynchrony using tissue Doppler imag-
ing (TDI) in 90 consecutive patients with heart failure. 
Methods Ninety patients with severe heart failure (left ventricular ejection fraction<35%, 
NYHA class III-IV) were prospectively evaluated. Based on the QRS duration, 30 consecutive 
patients with a narrow QRS complex were included (QRS duration ≤120 ms), 30 patients 
with an intermediate QRS duration (120-150 ms), and 30 patients with a wide QRS complex 
(>150 ms). All patients underwent TDI to assess left ventricular dyssynchrony. Extensive left 
ventricular dyssynchrony was deﬁned as an electro-mechanical delay on TDI between the 
septum and lateral wall, the so-called septal-to-lateral delay, of more than 60 ms.
Results Severe dyssynchrony was observed in 27% of patients with narrow QRS complex, 
in 60% of patients with intermediate QRS duration and in 70% of patients with wide QRS 
complex. No relation existed between QRS duration and septal-to-lateral delay. 
Conclusions 30-40% of heart failure patients with QRS duration >120 ms do not exhibit left 
ventricular dyssynchrony, which may explain non-response to CRT. Alternatively, 27% of 
patients with heart failure and a narrow QRS complex show signiﬁcant left ventricular dys-
synchrony and may be candidates for CRT.
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INTRODUCTION
Over the past decades end-stage heart failure has emerged as a growing health-care prob-
lem in the Western World with an almost “epidemic” increase in the number of patients with 
end-stage heart failure [1-3].
A relatively new option of therapy for patients with end-stage heart failure and a wide QRS 
complex, is atrial synchronized biventricular pacing or cardiac resynchronization therapy 
(CRT). Promising results were demonstrated in recent large randomized controlled trials [4-
7]. In these trials the clinical beneﬁt of CRT has been shown, as evidenced by improvement 
in heart failure symptoms and functional class, quality of life, exercise capacity and left ven-
tricular systolic performance.
In these trials however, approximately 20-30% of the patients fails to improve during CRT 
(referred to as non-responders), although they are selected according to traditional patient 
selection criteria (QRS >120 ms, left bundle branch block, NYHA class III-IV and left ventricular 
ejection fraction <35%) [6-8].
In order to avoid unnecessary medical expenses and procedure risks, the number of non-
responders should be reduced. To achieve this goal, traditional selection criteria must be 
reﬁned. It has recently been suggested that dyssynchrony within the left ventricle may be 
the most important predictor of response to CRT [8-11]. However, a wide QRS complex may 
not be synonymous with substantial left ventricular dyssynchrony. This consideration is sup-
ported by the fact that recent studies demonstrated poor prediction of success when the QRS 
duration was used. In contrast, preliminary studies that used tissue Doppler imaging (TDI) to 
assess left ventricular dyssynchrony demonstrated that identiﬁcation of responders was pos-
sible before implantation of a CRT system [8,11-14]. Thus, QRS duration may not adequately 
reﬂect left ventricular dyssynchrony and some patients with a wide QRS complex may not 
have substantial left ventricular dyssynchrony. In addition, it is also unclear whether patients 
with a narrow QRS complex may have left ventricular dyssynchrony.
Therefore, we have evaluated the relationship between the QRS duration on the surface ECG 
and left ventricular dyssynchrony in a large group of patients with end-stage heart failure 
using tissue Doppler echocardiography; a subset of patients with a narrow QRS complex was 
also studied.
METHODS
Study Population
A total of 90 consecutive patients with severe heart failure were prospectively included. The 
inclusion criteria were: 
-severe heart failure (NYHA class III or IV) 
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-left ventricular ejection fraction ≤35%. 
Patients with a paced rhythm were excluded. 
Based on the QRS duration, 30 consecutive patients with a narrow QRS complex were in-
cluded (QRS duration ≤120 ms), 30 patients with an intermediate QRS duration (between 120 
and 150 ms) and 30 patients with a wide QRS complex (>150 ms).
Electrocardiographic analysis
In all patients, QRS duration was measured from the surface ECG using the widest QRS 
complex from the leads II, V1 and V6. The electrocardiograms were recorded at a speed of 
25mm/sec. The ECGs were evaluated by two independent observers without knowledge of 
the clinical status of the patient.
Echocardiography and tissue Doppler imaging
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system FiVe/Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). 
Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal 
and apical views (standard long-axis and 2- and 4-chamber images). Standard 2-dimensional 
and colour Doppler data, triggered to the QRS complex were saved in cine loop format. The 
left ventricular volumes (end-systolic, end-diastolic) and left ventricular ejection fraction 
were calculated from the conventional apical 2- and 4-chamber images, using the biplane 
Simpson’s technique [15]. 
For TDI, color Doppler frame rates varied between 80 and 115 frames/s depending on the 
sector width of the range of interest; pulse repetition frequencies were between 500 Hz and 
1 KHz, resulting in aliasing velocities between 16 and 32 cm/s. Tissue Doppler parameters 
were measured from color images of 3 consecutive heart beats by oﬄine analysis. Data were 
analyzed using commercial software (Echopac 6.1, General Electric - Vingmed). To determine 
left ventricular dyssynchrony, the sample volume was placed in the basal portions of the 
septum and the lateral wall; peak systolic velocities and time-to-peak systolic velocities were 
obtained and the septal-to-lateral delay in peak velocity was calculated as an indicator of left 
ventricular dyssynchrony. Based on previous observations, a cut-oﬀ point of 60 ms delay be-
tween peak systolic velocity of the septum and lateral wall was used to identify patients with 
severe left ventricular dyssynchrony [8]. Inter- and intra-observer agreement for assessment 
of septal-to-lateral delay were 90% and 96%, respectively.
All echocardiographic measurements were obtained by two independent observers without 
knowledge of the clinical status of the patient. 
Statistical analysis
Data are presented as mean ± SD, and compared using (un-)paired Student’s t-test when 
appropriate. Univariate analysis for categorical variables was performed using the chi-square 
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test with Yates' correction. Simultaneous comparison of >2 mean values was performed by 
using 1-way ANOVA with Bonferoni correction. Linear regression analysis was performed to 
determine the relationship between QRS duration and septal-to-lateral delay. For all tests a 
P-value <0.05 was considered statistically signiﬁcant.
RESULTS
Study population
A total of 90 patients were included (69 men, mean age 62.1 ± 12 years); the underlying 
etiology of heart failure was idiopathic dilated cardiomyopathy in 31 % and ischemic car-
diomyopathy in 69 %. Mean QRS duration was 144 ms and varied from 78 to 238 ms; 93 % of 
patients with a QRS of more than 120 ms had left bundle branch block. The majority (84%) 
of patients were in sinus rhythm. All patients were in NYHA class III (94%) or IV (6%). The left 
ventricular ejection fraction was 22 ± 7% (range 11-35 %) with a left ventricular end-systolic 
volume of 190 ± 76 ml and a left ventricular end-diastolic volume of 240 ± 86 ml.
The characteristics of the 3 groups (divided according to QRS duration) are summarized in 
Table 1. By deﬁnition, the mean QRS duration was longest in group 3, and shortest in group 
1 (187±9 ms vs 106±12 ms). Among those patients with QRS width > 120ms, over 90% had 
left bundle branch block. 
Patients with a narrow QRS complex had less severe heart failure symptoms.
Left ventricular volumes increased in parallel to the QRS duration; since both left ventricular 
end-systolic and end-diastolic volume increased, left ventricular ejection fraction was com-
parable between the diﬀerent between the 3 groups (Table 2).
QRS duration versus left ventricular dyssynchrony
The septal-to-lateral delays for the 3 diﬀerent groups are shown in Figure 1. A stepwise in-
crease in septal-to-lateral delay was noted over the 3 groups, with a mean septal-to-lateral 
delay of 43ms in the patients with narrow QRS complex and 97ms with a wide QRS complex 
(P<0.05). 
Signiﬁcant left ventricular dyssynchrony was observed in the vast majority (70%) of patients 
with wide QRS complex. Also, 60% of the patients with an intermediate QRS duration exhib-
ited signiﬁcant left ventricular dyssynchrony. Of interest, 27% of patients with a narrow QRS 
complex also demonstrated left ventricular dyssynchrony. The precise distribution of dys-
synchrony in relation to the 3 groups is displayed in Figure 2. Linear regression failed to show 
a signiﬁcant relation between the QRS duration and the septal-to-lateral delay (Figure 3).
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Etiology versus dyssynchrony
To evaluate the eﬀect of underlying etiology on left ventricular dyssynchrony, the patients 
with ischemic and non-ischemic cardiomyopathy were analyzed separately.
The 2 subsets of patients showed similar ﬁndings. A gradual increase in septal-to-lateral delay 
paralleled the increase in QRS duration (Figure 4). The shortest septal-to-lateral delays were 
observed in the patients with a narrow QRS complex (44 and 40ms for patients with ischemic 
Table 1: Baseline patient characteristics
 QRS ≤ 120
(n= 30)
QRS 120 –150
(n=30 )
QRS > 150
(n=30 )
M/F 26/4 21/9 22/8 NS
Age (years) 59.0 ± 14.3
(20-77)
61.2 ± 11.9
(31-80)
65.9 ± 8.6
(46-81)
<0.05
Ischemic 22 (73%) 20 (67%) 20 (67%) NS
Nonischemic 8 (27%) 10 (33%) 10 (33%)
QRS duration (ms) 106.2 ± 12.3
(78-120)
139.5 ± 9.2
(122-150)
186.7 ± 8.6
(158-238)
_
QRS conﬁguration:
 LBBB 0 27 (90%) 29 (97%) NS
 RBBB 0 3 (10%) 1 (3%) NS
Rhythm:
 Sinus rhythm 24 (80%) 26 (87%) 26 (87%) NS
 Atrial ﬁbrillation 6 (20) 4 (13%) 4 (13%) NS
NYHA class III 29 28 28 NS
NYHA class IV 1 2 2 NS
Medication:
 Diuretics 20 (67%) 24 (80%) 26 (87%) NS
 ACE-inhibitors 24 (80%) 26 (87%) 27 (90%) NS
 Beta-blockers 17 (57%) 18 (60%) 19 (63%) NS
 Anticoagulants/Aspirin 27 (90%) 28 (93%) 27 (90%) NS
LBBB: left bundle branch block ,RBBB: right bundle branch block M/F: male/female 
Table 2: Left ventricular ejection fraction and left ventricular volumes
QRS < 120
(n= 30)
QRS 120 –150
(n=30 )
QRS > 150
(n=30 )
LVEF (%) 22 ± 6
(13-35)
22 ± 7
(11-34)
21 ± 7
(11-34)
NS
ESV 164 ± 63
(84-305)
188 ± 67
(86-320)
218 ± 88
(94-487)
<0.05
EDV 210 ± 71
(105-350)
236 ± 73
(130-387)
273 ± 101
(140-559)
<0.05
EDV: end-diastolic volume
ESV: end-systolic volume 
LVEF: left ventricular ejection fraction
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Figure 1. Mean septal-to-lateral delay in the diﬀerent patient groups according to QRS duration. (P < 0.05 by ANOVA).
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Figure 2. Distribution of septal-to-lateral delay (as marker of left ventricular dyssynchrony) and QRS duration. 
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Figure 3. Relationship between septal-to-lateral delay and QRS duration. No signiﬁcant relation existed between QRS duration and 
septal-to-lateral delay. (y = 0.44 x + 9.1, n=90, r=0.26, ns)
130
C
ha
pt
er
 9
and non-ischemic cardiomyopathy respectively).The largest delays were observed in the pa-
tients with wide QRS complex: 87ms for patients with ischemic cardiomyopathy and 118ms 
for non-ischemic cardiomyopathy.
In both groups, the majority of patients (60% and 90% respectively) with a wide QRS complex 
had substantial dyssynchrony. In the narrow QRS group, 27% and 25% (ischemic and non-
ischemic cardiomyopathy respectively) had substantial left ventricular dyssynchrony.
Linear regression demonstrated no relation between QRS duration and septal-to-lateral delay 
in the patients with ischemic cardiomyopathy (y = 0.30 x + 28.0, n=62, r=0.18, ns), whereas a 
weak relation between these 2 parameters existed in the patients with non-ischemic cardio-
myopathy (y = 0.79 x -40.0, n=28 r=0.48, P<0.05). 
Inﬂuence of NYHA class and left ventricular ejection fraction
Patients with NYHA class IV (n=5) had a wider QRS complex (although not signiﬁcant) as com-
pared to the patients in NYHA class III (154 vs. 144ms, ns). Also, patients in NYHA class IV had 
more extensive dyssynchrony as compared to the NYHA class III patients (85 vs. 71ms, ns). 
Linear regression demonstrated no relation between left ventricular ejection fraction and 
septal-to-lateral delay (y = 1.79 x + 33.4, n=90, r=0.19, ns). 
DISCUSSION
Currently, CRT is considered a major breakthrough in treatment of patients with dilated car-
diomyopathy and end-stage heart failure. Various studies have demonstrated the immediate 
beneﬁt of CRT on hemodynamics [16-18] and systolic performance of the left ventricle [19]. 
Moreover, the immediate beneﬁts were accompanied by an improvement in symptoms, ex-
ercise capacity, and left ventricular ejection fraction at mid-term follow-up [7,20]. Multicenter 
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Figure 4. Distribution of septal-to-lateral delay and QRS duration. Ischemic versus non-ischemic cardiomyopathy. 
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large trials have clearly conﬁrmed the ﬁndings from smaller studies [4-6]. In addition, dura-
tion and number of hospitalisations for decompensated heart failure is reduced after CRT 
[21]. Finally, meta-analysis of the available studies demonstrated an improved survival (over 
6 months) after CRT as compared to optimal medical therapy [22].
The indications for use of CRT include, severe heart failure (NYHA class III or IV), dilated car-
diomyopathy with depressed left ventricular ejection fraction (<35%), and wide QRS complex 
on the ECG with left bundle branch block conﬁguration [4-6]. Some patients do not improve 
during CRT, these patients are referred to as non-responders. Careful analysis of data from the 
MIRACLE Trial revealed that 20-30% of patients (selected according to these criteria) did not 
improve in symptoms [6]. This percentage of non–responders has also been reported in other 
studies [7,8]. The deﬁnition of a non-responder is diﬃcult: some patients do not improve in 
symptoms, but do also not deteriorate in symptoms. Despite the absence of improvement, 
these patients may still be considered as responders since without CRT these patients may 
have worsened in symptoms. Still, additional selection criteria for CRT are needed to enhance 
the likelihood of response to CRT.
Recently, it has been proposed that the most important predictor of response to CRT may 
be the presence of dyssynchrony within the left ventricle [8,11,23]. Patients with extensive 
dyssynchrony within the left ventricle appeared to respond well to CRT, whereas patients 
without dyssynchrony did not respond to CRT [8,11]. Assessment of dyssynchrony is possible 
with a variety of techniques including magnetic resonance imaging [24], scintigraphy [25], 
and various echocardiographic techniques [12-14,26-30]. Among the echocardiographic 
approaches, most experience has been obtained with TDI [8,10,12-14,26,27]. Yu et al dem-
onstrated the feasibility of TDI to assess left ventricular dyssynchrony in patients eligible for 
CRT [10,11]. Moreover, these authors showed a signiﬁcant reduction in left ventricular dys-
synchrony after CRT [8,10-14]. Besides TDI, strain and strain rate analyses have also been used 
to assess left ventricular dyssynchrony. In particular, Sogaard et al. have shown the value of 
these approaches for predicting response to CRT [26,27].
Potentially, the combination of the traditional selection criteria for CRT combined with the 
assessment of left ventricular dyssynchrony may be ideal to select the best candidates for 
CRT. In the current study, we have evaluated patients meeting the traditional selection crite-
ria for CRT, and we have assessed the presence or absence of left ventricular dyssynchrony 
with TDI. The parameter to assess dyssynchrony used in the present study, the septal-to-lat-
eral delay, has been used in previous studies. It represents the delay in long-axis function 
between the septum and the lateral wall. In patients with non-ischemic cardiomyopathy, 
it was demonstrated that CRT resulted in a substantial reduction in septal-to-lateral delay, 
indicating resynchronization after CRT [8,10-14]. In a subsequent study, it was shown that a 
septal-to-lateral delay >60 ms was highly predictive of response to CRT [8].
Using this cut-oﬀ of 60 ms, the data in the present study showed that 70% of patients with 
a wide QRS complex (>150 ms) had substantial left ventricular dyssynchrony. However, 30% 
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of patients with a wide QRS complex did not have substantial dyssynchrony; this percentage 
of patients without dyssynchrony is very similar to the percentage non-responders in the 
various CRT trials[6-8]. Similarly, in the patients with an intermediate QRS duration (120-150 
ms), 40% did not show substantial left ventricular dyssynchrony. Additional evaluation of 
patients with and without dyssynchrony after CRT to further determine the relation between 
dyssynchrony and outcome after CRT is needed.
The majority (73%) of patients with a narrow QRS complex (≤120 ms) did not exhibit dys-
synchrony, but interestingly, 27% of patients had signiﬁcant dyssynchrony. Whether these 
patients also beneﬁt from CRT needs further testing. 
In addition, other factors may inﬂuence response to CRT, including LV lead positioning, and 
optimisation of the AV and V-V delay.
Conclusion
TDI allows assessment of left ventricular dyssynchrony. Patients with a wide QRS complex 
frequently have substantial left ventricular dyssynchrony, although 30%-40% did not exhibit 
dyssynchrony. The combination of the traditional selection criteria, complemented by dem-
onstration of left ventricular dyssynchrony, may allow more accurate prediction of response 
to CRT.
In addition, 27% of patients with heart failure, dilated cardiomyopathy and a narrow QRS 
complex had dyssynchrony, suggesting that a subset of these patients may also beneﬁt from 
CRT.
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ABSTRACT
Cardiac resynchronization therapy (CRT) is considered a major advance in the treatment of 
patients with heart failure. The presence of left ventricular (LV) dyssynchrony seems manda-
tory for a positive response to CRT. Currently only patients with a wide QRS complex are 
considered for CRT, although patients with a narrow QRS complex may also have LV dyssyn-
chrony. In the present study we prospectively evaluated the incidence of LV dyssynchrony in 
64 patients with heart failure and a narrow QRS complex using tissue Doppler imaging.
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INTRODUCTION
It is unclear how many patients with a narrow QRS complex have substantial dyssynchrony 
and may thus be considered for cardiac resynchronization therapy (CRT). Accordingly, the 
incidence of left ventricular (LV) dyssynchrony in patients with heart failure and a narrow QRS 
complex was evaluated using tissue Doppler imaging (TDI).
METHODS
Patients and study protocol
A total of 64 consecutive patients with known heart failure, severe impairment of LV systolic 
function (LV ejection fraction ≤ 35%) and a narrow QRS complex (≤ 120 ms) on the surface 
electrocardiogram were prospectively included in the study. Patients with a recent myocardi-
al infarction (< 3 months) or decompensated heart failure, and a permanent pacemaker were 
excluded. In the patients, the clinical status was assessed and QRS duration was measured 
from the surface electrocardiogram. Two-dimensional echocardiography was conducted to 
assess LV volumes and LV ejection fraction. LV dyssynchrony was determined by TDI, calculat-
ing the delay between peak systolic velocities of the septum and the lateral wall (referred to 
as the septal-to-lateral delay). The level of inter-ventricular dyssynchrony was derived from 
conventional pulsed-wave Doppler echocardiography. 
Electrocardiographic analysis
The QRS duration was measured from the surface ECG using the widest QRS complex in 
the leads II, V1 and V6. The electrocardiograms were recorded at a speed of 25 mm/sec. The 
electrocardiograms were evaluated by 2 independent observers without knowledge of the 
clinical status of the patient.
Echocardiography and tissue Doppler imaging
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system FiVe/Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). 
Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and 
apical views (standard long-axis and 2- and 4-chamber images). Standard 2-dimensional im-
ages and color Doppler data, triggered to the QRS complex were saved in cine-loop format. 
The LV volumes (end-systolic, end-diastolic) and LV ejection fraction were calculated from the 
conventional apical 2- and 4-chamber images, using the biplane Simpson’s technique [1]. 
The severity of mitral regurgitation was graded semi-quantitatively from color-ﬂow Doppler 
in the conventional parasternal long-axis and apical 4-chamber images. Mitral regurgitation 
was characterized as: mild=1+ (jet area/left atrial area<10%), moderate=2+ (jet area/left 
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atrial area 10-20%), moderately severe =3+ (jet area/left atrial area 20-45%), and severe=4+ 
(jet area/left atrial area >45%) [2]. 
For TDI, color Doppler frame rates varied between 80 and 115 frames/s depending on the 
sector width of the range of interest; pulse repetition frequencies were between 500 Hz and 
1 KHz, resulting in aliasing velocities between 16 and 32 cm/s. TDI parameters were measured 
from color images of 3 consecutive heart beats by oﬄine analysis. Data were analyzed using 
commercial software (Echopac 6.1, General Electric - Vingmed). 
To assess LV dyssynchrony, the sample volume was placed in the basal portions of the sep-
tum and the lateral wall; peak systolic velocities and time-to-peak systolic velocities were 
obtained and the septal-to-lateral delay in peak velocity was calculated as an indicator of LV 
dyssynchrony. Based on previous observations, a cut-oﬀ point of 60 ms delay between peak 
systolic velocity of the septum and lateral wall was used to identify patients with severe LV 
dyssynchrony; the 60 ms cut-oﬀ value was not derived from a normal population [3]. Inter- 
and intra-observer agreement for assessment of septal-to-lateral delay were 90% and 96%, 
respectively.
The delay between the systolic contraction of the left and the right ventricle (inter-ventricular 
dyssynchrony) was calculated using Doppler ﬂow signals. The aortic and pulmonary ejec-
tion ﬂows were measured respectively in the apical four-chamber and parasternal views. The 
aortic pre-ejection time interval was deﬁned as the time interval between the onset of the 
QRS complex on surface electrocardiogram and the onset of the aortic ejection ﬂow, whereas 
the pulmonary pre-ejection time interval was deﬁned as the time duration between the on-
set of the QRS complex on surface electrocardiogram and the onset of pulmonary ejection 
ﬂow. The diﬀerence between the aortic and the pulmonary pre-ejection times represents the 
delay between left and right ventricular systolic contraction (inter-ventricular dyssynchrony). 
Based on recent data, a delay of >50ms between left and right ventricular contraction was 
considered to represent substantial inter-ventricular dyssynchrony [4,5]. The echocardio-
graphic data were analyzed by two independent observers without knowledge of  the clinical 
status of the patient. 
Statistical analysis
Data are presented as mean ± SD, and compared using the (un-)paired Student’s t-test when 
appropriate. Univariate analysis for categorical variables was performed using the chi-square 
test with Yates' correction. Linear regression analysis was performed to determine the rela-
tionship between QRS duration and the septal-to-lateral delay and the relationship between 
QRS duration and inter-ventricular dyssynchrony. For all tests, a p-value <0.05 was considered 
statistically signiﬁcant.
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RESULTS
A total of 64 patients were included in this study (50 male, mean age 61 ± 14 years). Baseline 
characteristics are summarized in Table 1.
Left ventricular dyssynchrony 
The mean LV dyssynchrony was 45 ± 38 ms (range 0-140 ms) Of these patients, 21 (33%) 
showed a septal-to-lateral delay of ≥ 60 ms, representing severe LV dyssynchrony, and 43 
patients (67%) showed minor (< 60 ms) LV dyssynchrony.
An example of a patient with a narrow QRS complex and severe LV dyssynchrony is shown in 
Figure 1. There was no relation between the QRS duration and the extent of LV dyssynchrony 
Table 1: Patient characteristics and echocardiographic data (n=64)
Variable Value
Male/Female 50/14
Age (years) 61 ± 14 
Etiology
 Ischemic 44 (69%)
 Nonischemic 20 (31%)
QRS duration (ms), (range) 105 ± 12   (78-120) 
Rhythm 
 Sinus rhythm 56 (88%)
 Atrial ﬁbrillation 6 (9%)
 Atrial ﬂutter 2 (3%)
New York Heart Association class
 II 20 (31%)
 III 39 (61%)
 IV 5 (8%)
Medication:
 Diuretics 53 (83%)
 ACE-inhibitors 56 (88%)
 Beta-blockers 44 (69%)
 Anticoagulants/aspirin 58 (91%)
Left ventricular ejection fraction (%) (range) 24 ± 6    (12-34)
End-diastolic volume (ml), (range) 209 ± 67   (105-37
End-systolic volume (ml), (range) 160 ± 59   (82-323)
Mitral regurgitation 1.6 ±1.0
Septal-to-lateral delay (ms), (range) 45 ± 38   (0-140)
Septal-to-lateral delay > 60ms 21 (33%)
Interventricular delay (ms), (range) 17 ± 15   (0-65)
Interventricular delay > 50ms 3 (5%)
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(Figure 2, y=0.4x + 3.2, n=64, r=0.12, ns). In Table 2, the characteristics of patients with and 
without substantial LV dyssynchrony are compared. All characteristics were comparable, only 
the LV ejection fraction was slightly but signiﬁcantly higher in the patients with LV dyssyn-
chrony (22% vs 26%, p<0.05). 
Figure 1. An example of a patient with a narrow QRS duration (112 ms) and extensive LV dyssynchrony. The septal-to-lateral delay was 120 ms. 
The tracing shows peak systolic velocities (1: basal septum, 2: basal lateral wall) and diastolic parameters (E’ and A’). 
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Figure 2. No signiﬁcant relationship existed between QRS duration and septal-to-lateral delay. (y=0.4x + 3.2, n=64, r=0.12, ns)
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Inter-ventricular dyssynchrony
Mean inter-ventricular delay was 17 ± 15 ms (range 0-65 ms) for the patients in this group. 
Only 3 patients (5%) showed severe inter-ventricular dyssynchrony (>50 ms). There was no 
relationship between the QRS duration and the extent of inter-ventricular dyssynchrony 
(y=0.2x – 8.6, n=64, r=0.20, ns). 
DISCUSSION
In the present study, the incidence of LV dyssynchrony in patients with a narrow QRS complex 
was speciﬁcally addressed. Sixty-four consecutive patients with heart failure and a narrow 
QRS complex were prospectively evaluated for the presence of LV dyssynchrony using TDI. 
Severe LV dyssynchrony was observed in one third of the patients. This percentage is in line 
Table 2: Patient characteristics: left ventricular dyssynchrony (n=43) versus no left ventricular dyssynchrony (n=21)
Variable group 1: s-l delay ≤ 60 ms group 2: s-l delay > 60 ms
Male/Female 32/11 18/3
Age (years) 60 ± 15 64 ± 13
Etiology 
 Ischemic 28 (64%) 16 (76%)
 Nonischemic 15 (36%) 5 (24%)
QRS duration (ms) 105 ± 13 106 ± 9
Rhythm: 
 Sinus rhythm 36 (84%) 18 (86%)
 Atrial ﬁbrillation 5 (12%) 3 (14%)
 Atrial ﬂutter 2 (4%) 0
New York Heart Association class
 II 11 (26%) 9 (43%)
 III 28 (65%) 11 (52%)
 IV 4 (9%) 1 (5%)
Medication:
 Diuretics 37 (86%) 16 (76%)
 ACE-inhibitors 39 (91%) 17 (81%)
 Beta-blockers 31 (73%) 13 (62%)
 Anticoagulants/Aspirin 39 (91%) 19 (90%)
LV ejection fraction (%) (range) 22 ± 6 *  (12-34) 26 ± 6 * (13-33)
End-diastolic volume (ml), (range) 209 ± 70 (105-372) 209 ± 50 (114-322)
End-systolic volume (ml), (range) 162 ± 63 (85-323) 155 ± 62 (82-252)
Mitral regurgitation grade 1.6 ± 0.9 1.4 ± 1.1
Septal-to-lateral delay (ms), (range) 22 ± 17 (0-55) 93 ± 22 (60-140) 
Interventricular delay (ms), (range) 18 ± 14 (0-65) 15 ± 16 (0-57)
* = P <0.05
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with previous studies, reporting an incidence varying between 27% and 56%, although these 
studies did not speciﬁcally focus on patients with a narrow QRS complex. The diﬀerences in 
incidence of LV dyssynchrony in the various studies may be related to diﬀerences in study 
population, but also in methodology and analysis of echo data; in particular, the deﬁnition 
of substantial LV dyssynchrony varied among the studies [6,7,8]. In particular, in the current 
study, only dyssynchrony between the septum and lateral wall was evaluated, whereas in 
some patients dyssynchrony may involve other regions. The issue of dyssynchrony in the 
patients with narrow QRS complex is intriguing, and could be due to electrical delay but also 
reﬂect scar tissue; this information cannot be derived from the current study, and further 
studies are needed. 
Also in the present study, the relation between the QRS duration and LV dyssynchrony was 
evaluated, and no signiﬁcant correlation was observed. Moreover, no baseline clinical pa-
rameters were able to predict the presence of LV dyssynchrony in these patients, except that 
the LV ejection fraction was slightly but signiﬁcantly higher in the patients with LV dyssyn-
chrony. 
In conclusion, substantial dyssynchrony is present in one third of the patients with heart 
failure and a narrow QRS complex, implying that CRT should be considered in these patients. 
Initial data by Achilli et al. [8] indeed suggest that patients with narrow QRS may also beneﬁt 
from CRT. 
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ABSTRACT
Both M-mode echocardiography (using the septal-to-posterior wall motion delay, SPWMD) 
and color-coded tissue Doppler imaging (TDI, using the septal-to-lateral delay in peak sys-
tolic velocity) have been proposed for assessment of left ventricular (LV) dyssynchrony and 
prediction of response to cardiac resynchronization therapy (CRT). In this study, a head-to-
head comparison between M-mode echocardiography and color-coded TDI was performed 
for assessment of LV dyssynchrony and prediction of response to CRT. Consecutive (n=98) 
patients with severe heart failure (NYHA class III-IV), LV ejection fraction ≤35% and QRS du-
ration >120 ms underwent CRT. Before pacemaker implantation, LV dyssynchrony was as-
sessed by M-mode echocardiography (SPWMD) and color-coded TDI (septal-to-lateral delay). 
At baseline and 6 months after implantation, clinical and echocardiographic parameters 
were evaluated. SPWMD measurement was not feasible in 41% of patients due to akinesia of 
the septal and/or posterior walls or poor acoustic windows. Conversely, the septal-to-lateral 
delay could be assessed in 96% of patients. At 6 months follow-up, 75 patients (77%) were 
classiﬁed as responders to CRT (improvement ≥1 NYHA class). The sensitivity and speciﬁc-
ity of SPWMD were lower as compared to the septal-to-lateral delay (66% vs. 90%, P<0.05 
and 50% vs. 82%, P= NS respectively). LV dyssynchrony assessment was feasible in 59% of 
patients with M-mode echocardiography as compared to 96% (P< 0.05) when color-coded 
TDI was used. Color-coded TDI was superior over M-mode echocardiography for prediction 
of response to CRT.
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INTRODUCTION
In the search for more optimal selection criteria for cardiac resynchronization therapy (CRT), 
left ventricular (LV) dyssynchrony has been deﬁned as a promising parameter to predict a 
positive response [1,2]. Various echocardiographic techniques have been developed to 
identify LV dyssynchrony, ranging from simple measurements obtained with routine echo-
cardiography to more sophisticated techniques using tissue Doppler imaging (TDI) [1-3]. Re-
cently, M-mode echocardiography has been proposed to quantify LV dyssynchrony, which is 
a simple and practical approach [3-5]. Pitzalis et al. reported promising results on the predic-
tion of response to CRT with M-mode echocardiography [3,4], whereas Marcus et al. recently 
reported less optimistic data [5]. The current study was designed to evaluate feasibility and 
value of M-mode echocardiography for the prediction of response to CRT; moreover in the 
same patients TDI was performed, allowing for a head-to-head comparison between the 2 
techniques for the prediction of response to CRT.
METHODS
Study population and protocol
Consecutive heart failure patients, scheduled for implantation of a CRT device, were included 
in the study. The selection criteria for CRT included severe heart failure (NYHA class III or 
IV), LV ejection fraction ≤35% and QRS duration >120 ms. Patients with a recent myocardial 
infarction (<3 months) or decompensated heart failure were excluded. Before CRT implan-
tation, clinical status was assessed and 2-dimensional echocardiography was performed to 
determine LV volumes and LV ejection fraction. LV dyssynchrony was assessed using both 
M-mode echocardiography [3,4] and color-coded tissue TDI [2,6]. Assessment of LV dyssyn-
chrony was repeated at 1 day post-CRT implantation. The clinical status and changes in LV 
ejection fraction and LV volumes were re-assessed at 6 months follow-up.
Clinical evaluation
Evaluation of clinical status included assessment of NYHA class, quality-of-life score (using 
the Minnesota living with Heart Failure questionnaire) and evaluation of exercise capacity 
using the 6-minute hall-walk test. QRS duration was measured from the surface ECG using 
the widest QRS complex from the leads II, V1 and V6. Patients with an improvement of at least 
1 grade in NYHA class were considered responders to CRT. 
Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available sys-
tem (Vingmed system Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). Images 
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were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and api-
cal views (standard long-axis, 2- and 4-chamber images). Standard 2-dimensional and color 
Doppler data, triggered to the QRS complex, were saved in cine-loop format. The LV volumes 
(end-systolic, end-diastolic) and LV ejection fraction were calculated from the conventional 
apical 2- and 4-chamber images, using the biplane Simpson’s technique [7]. 
All echocardiographic data were analyzed oﬄine using commercial software (Echopac 4.0.3, 
General Electric ). Echocardiographic data were analyzed by 2 independent observers, blind-
ed to all other patient data. 
LV dyssynchrony assessment using M-mode echocardiography
Assessment of LV dyssynchrony from M-mode echocardiography was performed according 
to the method described by Pitzalis et al. [3,4]. Brieﬂy, a parasternal short-axis view was se-
lected at the level of the papillary muscles. In this view, an M-mode recording was obtained 
through the septum and posterior LV wall. LV dyssynchrony was calculated by measuring the 
shortest interval between the maximal posterior displacement of the septum and the maxi-
mum displacement of the LV posterior wall. According to Pitzalis et al., a septal-to-posterior 
wall motion delay (SPWMD) >130 ms was considered to indicate substantial LV dyssynchrony 
[3]. Inter- and intra-observer agreement for assessment of SPWMD were 86% and 92% in the 
current study.
LV dyssynchrony assessment using color-coded TDI Assessment of LV dyssynchrony from 
color-coded TDI was performed according to methods described previously [2,6]. Brieﬂy, 
4-chamber color-coded TDI images were selected and sample volumes were placed in the 
basal portions of the septum and the LV lateral wall. The time-to-peak systolic velocities were 
obtained from both samples and the septal-to-lateral delay in peak systolic velocities was 
calculated as a marker of LV dyssynchrony. The analysis of peak systolic velocities was limited 
to the LV ejection period and post-systolic peaks were excluded. The opening and closure of 
the aortic valve were measured from the pulsed-wave Doppler signals in the LV outﬂow tract 
and subsequently superimposed on the TDI curves to mark the LV ejection period (using the 
“event-timing” function on the Echopac analysis software). Based on previous observations, 
a septal-to-lateral delay ≥65 ms was considered to indicate substantial LV dyssynchrony [6]. 
Inter- and intra-observer agreement for assessment of septal-to-lateral delay were 90% and 
96%, respectively [8].
For color-coded TDI, frame rates were > 80 frames/s depending on the sector width of the 
range of interest; pulse repetition frequencies were between 500 Hz and 1 KHz, resulting in 
aliasing velocities between 16 and 32 cm/s. TDI parameters were measured from images of 
three consecutive heart beats by oﬄine analysis. 
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Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. A coronary sinus 
venogram was obtained using a balloon catheter. Next the LV pacing lead was inserted 
through the coronary sinus with the help of an 8Fr-guiding catheter, and positioned as far as 
possible in the venous system, preferably in a (postero-) lateral vein. The right atrial and right 
ventricular leads were positioned conventionally. CRT-device and lead implantation was suc-
cessful in all patients without major complications (Contak TR or Contak Renewal TR2/1/2/4, 
Guidant, Minneapolis, Minnesota, USA and Insync (Marquis) III or Sentry, Medtronic Inc., Min-
neapolis, Minnesota, USA). Two types of LV leads were used (Easytrak, Guidant, or Attain, 
Medtronic Inc.). 
Statistical analysis
Continuous data were expressed as mean ± SD and compared with the 2-tailed Student's t 
test for paired and unpaired data when appropriate. Categorical variables were compared 
using the chi-square test with Yates' correction. 
The agreement between the presence/absence of substantial dyssynchrony on TDI (cut-oﬀ 
value 65 ms) and M-mode echocardiography (cut-oﬀ value 130 ms) was expressed as percent-
age with corresponding κ-value. In addition, sensitivity and speciﬁcity to assess response to 
CRT were calculated for both TDI and M-mode echocardiography; the 95% conﬁdence in-
tervals (95% CI) were calculated according to standard deﬁnitions. The optimal cut-oﬀ value 
for SPWMD to predict response to CRT was determined by receiver-operating characteristic 
(ROC) curve analysis. The output is an area-under-the (AUC) value ranging between 0 and 1. 
The performance can be classiﬁed using the AUC value with 0.90-1 = excellent, 0.80-0.90 = 
good, 0.70-0.80 = fair, 0.60-0.70 = poor, 0.50-0.60 test without value. The optimal cut-oﬀ value 
was deﬁned as the optimal balance between sensitivity and speciﬁcity. For all tests a P-value 
<0.05 was considered statistically signiﬁcant. 
RESULTS
Study population
The study population comprised 98 patients (78 men, 20 women) with a mean age of 66±11 
years. Mean NYHA class was 3.1±0.3, with 92% of patients in NYHA class III. Patients showed 
severe LV dilatation (LV end-diastolic volume 236±71 ml and LV end-systolic volume 184±64 
ml), with a depressed LV ejection fraction of 23±8%. 
Post-CRT implantation
Within 6 months after CRT, 2 patients (2%) died, (both due to refractory heart failure) and 
did not have the clinical and echocardiographic follow-up assessment at 6 months, but were 
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classiﬁed as non-responders to CRT. Following CRT implantation, QRS duration decreased 
from 168±30 ms to 151±24 ms (P<0.001). At 6 months follow-up, NYHA class improved 
from 3.1±0.3 to 2.2±0.7 (P<0.001). The quality of life score decreased from 39±18 to 25±18 
(P<0.001) and the 6-minute walking distance increased from 290±136 m to 387±135 m 
(P<0.001). LV ejection fraction improved from 23±8% to 30±10% (P<0.001), associated with a 
signiﬁcant reduction in LV volumes; the LV end-systolic volume decreased from 184±64 ml to 
151±69 ml (P<0.001) and the LV end-diastolic volume decreased from 236±71 ml to 208±76 
ml (P<0.001).
Feasibility of LV dyssynchrony assessment: M-mode echocardiography versus 
color-coded TDI
The feasibility to assess LV dyssynchrony before CRT implantation was evaluated for both 
M-mode echocardiography using the SPWMD and for TDI using the septal-to-lateral delay. 
Assessment of the SPWMD was not feasible in a relatively high proportion of patients (n=40, 
41%, Figure 1). The reasons for lack of interpretability of the SPWMD were: absence of systolic 
motion of the myocardium on M-mode echocardiography due to akinesia of the inter-ven-
tricular septum (n=21, 53%), the posterior wall (n=5, 12%), or both walls (n=1, 3%) or a poor 
acoustic window of the parasternal view (n=13, 32%).
98 patients
������������������������������������
58 patients
(100%)
58 patients (59%)
���������������������������������
40 patients (41%)
���������������������������������
Interpretable?
0 patients
(0%)
Interpretable? Interpretable?
36 patients
(90%)
4 patients
(10%)
���
��� ����� ��
��
Figure 1. Feasibility of left ventricular (LV) dyssynchrony assessment using M-mode echocardiography and color-coded tissue Doppler 
imaging (TDI).
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In contrast, assessment of septal-to-lateral delay using TDI was feasible in the majority of 
patients (n=94, 96%, P<0.05 versus M-mode echocardiography, Figure 1). The reasons for lack 
of interpretablity of the TDI curves were: akinesia of the inter-ventricular septum (n=3, 75%) 
or poor acoustic window of the apical view (n=1, 25%).
Assessment of the septal-to-lateral delay on TDI was feasible in all patients with an interpre-
table SPWMD (n=58, Figure 1). Importantly, assessment of the septal-to-lateral delay using 
TDI was also feasible in 36 of 40 (90%) patients without an interpretable SPWMD (Figure 1). 
An example of a patient in whom interpretation of the SPWMD was not feasible is shown in 
Figure 2. The SPWMD could not be measured due to absence of a clear systolic excursion 
of both the inter-ventricular septum and the posterior wall on M-mode echocardiography. 
Measurement of the septal-to-lateral delay using TDI however was possible (Figure 3). The 
baseline characteristics of the patients with (n=58) and without (n=40) an interpretable SP-
WMD are summarized in Table 1. No diﬀerences in clinical or echocardiographic parameters 
were present between both patient groups. In particular, the incidence of ischemic cardiomy-
opathy was not higher in the patients without an interpretable SPWMD.
Prediction of response to CRT: M-mode echocardiography versus TDI
A total of 23 patients (23%) were classiﬁed as clinical non-responder at 6 months follow-up 
(n=21 patients without improvement in NYHA class and 2 patients who died from progres-
sive heart failure before 6 months follow-up). Besides a lack of improvement in NYHA class, 
the non-responders also failed to improve in 6-minute walking distance (from 290±158 m 
Figure 2. Example of a patient in whom assessment of left ventricular dyssynchrony using M-mode echocardiography was not feasible due to 
akinesia of both the inter-ventricular septum and the posterior wall. 
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to 277±155 m, NS), quality-of-life score (from 45±22 to 45±21, NS) and LV function (LV end-
systolic volume from 173±58 ml to 182±75 ml and LV ejection fraction from 25±9% to 24±8%, 
both NS).
The baseline clinical and echocardiographic characteristics of the clinical responders and 
non-responders are compared in Table 2. Baseline LV dyssynchrony assessment using TDI 
showed that responders had a signiﬁcantly larger septal-to-lateral delay as compared to pa-
tients without response to CRT (103±42 ms vs. 41±37 ms). The SPWMD was slightly larger in 
the responders, but the diﬀerence was not statistically signiﬁcant (188±123 ms vs. 155±103 
ms, NS). Other diﬀerences in baseline characteristics between responders and non-respond-
ers included the patient’s age and gender (Table 2). Figure 4 shows the agreement between 
TDI (using the septal-to-lateral delay, cut-oﬀ value 65 ms) and M-mode echocardiography 
(using the SPWMD, cut-oﬀ value 130 ms) for assessment of LV dyssynchrony. In 50% of 
patients both methods detected substantial LV dyssynchrony, and in 17% of patients both 
methods indicated the absence of LV dyssynchrony. Accordingly, the agreement between 
the 2 techniques was 67% (κ= 0.27, Figure 4). 
The predictive accuracy of TDI (using the septal-to-lateral delay) for response to CRT was ex-
cellent; using the previously validated cut-oﬀ value of 65 ms, a sensitivity of 90% (95% CI 83% 
- 97%) and speciﬁcity of 82% (95% CI 66% - 98%) were obtained. The sensitivity and speci-
ﬁcity of M-mode echocardiography (using the SPWMD) were substantially lower; using the 
previously published cut-oﬀ value of 130 ms, a sensitivity of 66% (95% CI 53% - 79%, P<0.05 
vs. TDI) and speciﬁcity of 50% (95% CI 24% - 76%, P = NS vs. TDI) were obtained (Table 3). 
��
Figure 3. Left ventricular dyssynchrony assessment using color-coded tissue Doppler imaging. The sample volumes are placed in the basal 
part of the septum and lateral wall, and tracings are derived. The arrows indicate the peak systolic velocity (ﬁrst peak = septum and second peak 
= lateral wall (AVO = aortic valve opening, AVC = aortic valve closure). The septal-to-lateral delay is 40 ms, indicating the absence of substantial 
left ventricular dyssynchrony (same patient as in Figure 2).
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Next, ROC-curve analysis was performed to deﬁne the optimal cut-oﬀ value for the SPWMD 
in the current patient group. The optimal cut-oﬀ value for SPWMD was 148 ms and the area 
under the curve was 0.57. The cut-oﬀ value of 148 ms yielded a sensitivity and a speciﬁcity 
of 55% (Figure 5).
When a decrease in LV end-systolic volume >10% at 6 months follow-up was applied as a 
measurement of response to CRT, 35 patients (36%) were classiﬁed as non-responders (in-
Table 1. Baseline characteristics of patients with interpretable septal-to-posterior wall motion delay (n=58) vs. patients with non-interpretable 
septal-to-posterior wall motion delay (n=40)
 Variable  
 
Septal to posterior wall motion delay 
Interpretable 
Septal to posterior wall motion delay 
Non-interpretable
Age (years) 65±10 67±12 
Male/female 46/12 32/8
NYHA class 3.0±0.3 3.1±0.3
 Etiology
 Ischemic 33 (56%) 24 (60%)
Idiopathic 25 (44%) 16 (40%)
QRS-duration (ms) 165±30 174±29 
6-minute walking distance (m) 292±144 280±130 
LV ejection fraction (%) 24±8 22±7 
LV end-diastolic volume (ml) 225±67 252±74
LV end-systolic volume (ml) 175±60 198±68 
Table 2. Baseline characteristics of responders (n=75) vs. non-responders (n=23) 
Variable 
 
Responders  Non-responders P-value
Age (years) 68±11 60±11 <0.05
Male/female 65/10 13/10 <0.05
NYHA class 3.1±0.3 3.1±0.3 NS
Etiology
 Ischemic 45 (60%) 11 (48%) NS 
 Idiopathic 30 (40%) 12 (52%)
QRS duration (ms) 170±30 162±28 NS
6-minute walking distance (m) 240±28 273±160 NS
LV ejection fraction (%) 23±8 24±9 NS
LV end-diastolic volume (ml) 238±73 231±64 NS
Left ventricular end-systolic volume (ml) 186±66 177±58 NS 
TDI:
  Septal-to-lateral delay (ms) 103±42 41±37 <0.05
 non-interpretable patients 3 (4%) 1 (4%) NS
Mmode:
 Septal-to-posterior wall   
 motion delay (ms)
188±123 155±103 NS
 non-interpretable patients 31 (41%) 9 (39%) NS
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10 (17%)7 (12%)
12 (21%)29 (50%)
SPWMD >130 ms SPWMD �130ms
S-L Delay
�65ms
S-L Delay
<65ms
Figure 4. Agreement between left ventricular dyssynchrony using the septal-to-lateral delay (S-L delay, derived from color-coded tissue 
Doppler imaging, cut-oﬀ value 65 ms) and the septal-to-posterior-wall-motion delay (SPWMD, derived from M-mode echocardiography, cut-oﬀ 
value 130 ms). 
Table 3: Sensitivity, speciﬁcity, positive and negative predictive values of septal-to-lateral delay ≥65 ms and septal-to-posterior wall motion 
delay >130 ms for prediction of response to cardiac resynchronization therapy.
Septal-to-lateral delay ≥65 ms Septal-to-posterior wall motion delay 
>130 ms
Sensitivity 90% 66%
Speciﬁcity 82% 50%
Positive predictive value 94% 81%
Negative predictive value 72% 32%
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Figure 5. Receiver-operating characteristic (ROC) curve analysis demonstrated a sensitivity and speciﬁcity of 55% to predict response to CRT 
at a cut-oﬀ value of 148 ms for septal-to-posterior-wall-motion-delay (SPWMD). The AUC is 0.57. 
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cluding the 2 patients who died before 6 months follow-up). 
The predictive accuracy of TDI for echocardiographic response to CRT was excellent with a 
sensitivity of 92% (95% CI 81%-97%) and a speciﬁcity of 74% (95% CI 55%-87%). The predic-
tive accuracy of M-mode echocardiography was lower with a sensitivity of 65% (95% CI 47% 
- 79%, P<0.05 vs. TDI) and a speciﬁcity of 48% (95% CI 26%-70%, P=NS vs. TDI). 
DISCUSSION
The main results of the present study are: 1) analysis of LV dyssynchrony using M-mode echo-
cardiography was not feasible in 41% of patients; conversely, LV dyssynchrony was feasible in 
96% of patients when color-coded TDI was used. 2) the accuracy of color-coded TDI to predict 
response to CRT was superior over M-mode echocardiography.
In recent large CRT trials including patients based on established CRT selection criteria (NYHA 
class III-IV, LV ejection fraction ≤35% and QRS duration >120 ms), 20-30% of patients did 
not respond to CRT [9,10]. Recent studies revealed that the likelihood of response to CRT 
is related to the presence of substantial LV dyssynchrony and various (echocardiographic) 
techniques have been developed to detect LV dyssynchrony [3,4,6,11-13]. 
A relatively simple and elegant echocardiographic approach is M-mode echocardiography 
where an M-mode recording is used to measure the delay between the systolic excursion of 
the inter-ventricular septum and the posterior wall (SPWMD) [3,4]. Another frequently used 
echocardiographic technique is color-coded TDI. With color-coded TDI diﬀerent segments 
can be evaluated simultaneously and the segment with the latest mechanical activity can be 
identiﬁed. Studies have indicated that most patients demonstrate LV dyssynchrony between 
the septum and lateral or posterior wall [6,11,14]. 
The ideal technique for assessment of LV dyssynchrony to screen heart failure patients for eli-
gibility for CRT should be non-time consuming, technically feasible with interpretable results 
in a high number of patients and have a high predictive value for response to CRT. 
Recent studies from Pitzalis et al. [3,4] have demonstrated the use of SPWMD for assessment 
of LV dyssynchrony. In 20 patients with severe heart failure (20% ischemic cardiomyopathy), 
assessment of SPWMD was feasible in all patients [3]. In a subsequent study [4], the same 
authors evaluated another 60 patients (22% ischemic cardiomyopathy) and indicated that in 
2 (3%) patients an akinetic septum prevented assessment of the SPWMD. 
The feasibility of assessing the SPWMD was recently evaluated retrospectively in a large 
cohort (n=79 patients, 72% ischemic cardiomyopathy) of heart failure patients who were 
included in the CONTAK-CD trial [5]. The authors reported diﬃculties in interpretation of M-
mode recordings in more than 50% of patients due to the absence of a clear deﬁnition of the 
systolic deﬂection of the septal and/or posterior walls. Similarly, de Sutter et al. [15] evaluated 
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138 patients with heart failure (with 77% ischemic cardiomyopathy) and were unable to as-
sess the SPWMD in 56% of patients.
In the current study (with 58% of patients having ischemic cardiomyopathy), the SPWMD 
could not be assessed in 41% of patients. The lack of interpretability was due to the absence 
of a clear systolic excursion of the inter-ventricular septum, the posterior wall or both in 
53%, 12% and 3% of patients respectively and a poor acoustic window in 32% of patients. 
Accordingly, these data in larger groups of patients consistently report a high number of 
non-interpretable M-mode recordings; this may in part be related to the inclusion of a larger 
proportion of patients with ischemic cardiomyopathy who frequently have large areas of scar 
tissue. Still, in the current study, 40% of the patients with non-interpretable SPWMD had non-
ischemic cardiomyopathy. Moreover, in the clinical setting, a large percentage of patients 
with heart failure have ischemic heart disease underlying the cardiomyopathy [16]. 
In contrast, LV dyssynchrony assessment using TDI was feasible in 96% of patients. The non-
interpretability was due to septal akinesia in 3 patients and a poor acoustic window in 1 
patient. Importantly, in many patients with a non-interpretable SPWMD, assessment of LV 
dyssynchrony with color-coded TDI is possible. In addition, a poor acoustic window is more 
frequently encountered in the parasternal view as compared to the apical view in heart fail-
ure patients (13% vs. 1%, P<0.05, in the current patient population). 
Besides a high percentage of interpretable results, the ideal technique for screening of CRT 
patients should have a high predictive accuracy to predict response to CRT. Pitzalis et al. [3,4] 
demonstrated that responders to CRT had a signiﬁcantly larger SPWMD as compared to non-
responders. Using a cut-oﬀ value of 130 ms, SPWMD yielded an accuracy of 85% (sensitivity 
100%, speciﬁcity 63%) to predict response after CRT. Recent data however, revealed less fa-
vourable results of SPWMD to predict response to CRT. Retrospective analysis of the CONTAK-
CD data, yielded a sensitivity of 24% with a speciﬁcity of 66% [5], and results from the current 
study showed a sensitivity of 66% with a speciﬁcity of 50% to predict clinical response to 
CRT. In contrast, color-coded TDI using the septal-to-lateral delay yielded signiﬁcantly higher 
values: a sensitivity of 90% and speciﬁcity of 82% were obtained, which is in line with other 
studies using TDI for prediction of response to CRT [6,12,17]. 
Several factors can be considered to explain this substantial diﬀerence between M-mode 
echocardiography and color-coded TDI. First, the 2 techniques use diﬀerent myocardial seg-
ments to quantify LV dyssynchrony. The SPWMD measures the delay between the antero-
septum and the posterior wall, whereas color-coded TDI measures the delay between the 
basal septum and lateral wall, and recent studies have suggested that the beneﬁt of CRT 
may be predominantly related to correction of LV dyssynchrony in the septal-lateral direc-
tion, rather than the antero-posterior direction [6,17,18]. Moreover, color-coded TDI permits 
interrogation of many diﬀerent segments (although only 2 were used in the current study) 
whereas the SPWMD is derived from 2 regions. Alternatively, M-mode echocardiography and 
color-coded TDI measure diﬀerent dyssynchronies: SPWMD provides information on delay 
M-mode echocardiography versus tissue Doppler imaging 157
in systolic motion, whereas color-coded TDI provides information on delay in peak systolic 
velocities. The fact that both techniques measure a diﬀerent “type” of LV dyssynchrony is also 
reﬂected by the relatively poor agreement (67%, κ=0.27, Figure 4) between both techniques 
for identiﬁcation of LV dyssynchrony. 
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ABSTRACT
Objectives To predict the response and prognosis after cardiac resynchronization therapy 
(CRT) in patients with end-stage heart failure.
Background CRT improves heart failure symptoms, exercise capacity and left ventricular 
(LV) function. Since not all patients respond, pre-implantation identiﬁcation of responders 
is needed. In the present study, response to CRT was predicted by the presence of LV dys-
synchrony assessed by tissue Doppler imaging (TDI). Moreover, the prognostic value of LV 
dyssynchrony in patients undergoing CRT was assessed.
Methods Eighty-ﬁve patients with end-stage heart failure, QRS duration >120 ms and LBBB 
were evaluated by TDI before CRT. At baseline and 6 months follow-up, NYHA class, quality 
of life and 6-minute walking distance, LV volumes and LV ejection fraction (EF) were deter-
mined. Events (death, hospitalization for decompensated heart failure) were obtained during 
1-year follow-up.
Results Responders (74%) and non-responders (26%) had comparable baseline character-
istics, except for a larger dyssynchrony in responders (87±49 ms versus 35±20 ms, P<0.01). 
ROC curve analysis demonstrated that an optimal cutoﬀ value of 65 ms for LV dyssynchrony 
yielded a sensitivity and speciﬁcity of 80% to predict clinical improvement and of 92% to pre-
dict LV reverse remodeling. Patients with dyssynchrony ≥65 ms had an excellent prognosis 
(6% event-rate) after CRT, as compared to a 50% event-rate in patients with dyssynchrony 
<65 ms (P<0.001).
Conclusion Patients with LV dyssynchrony ≥65 ms respond to CRT and have an excellent 
prognosis after CRT.
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INTRODUCTION
Cardiac resynchronization therapy (CRT) has been proposed as an alternative treatment in 
patients with drug-refractory heart failure [1-3]. Initial studies demonstrated acute improve-
ment in hemodynamics immediately after CRT [4]. Other studies have demonstrated the 
sustained clinical beneﬁt of CRT at longer follow-up, evidenced by improvement in heart 
failure symptoms, quality-of-life, exercise capacity and left ventricular (LV) systolic perfor-
mance [1-3,5-7]. However, it has also become clear that 20-30% of patients do not respond 
to CRT [1-3]. Therefore, interest has shifted towards identiﬁcation of potential responders to 
CRT before implantation of the pacemaker [8-14]. It is hypothesized that LV dyssynchrony is 
the most important determinant of response to CRT and various techniques to detect and 
quantify LV dyssynchrony are currently under investigation [8-14]. However, no large studies 
have focused on the prediction of beneﬁt from CRT based on the degree of LV dyssynchrony. 
More important, it is unclear whether patients with LV dyssynchrony who respond to CRT 
have a better prognosis as compared to patients without dyssynchrony.
Accordingly, we have related the extent of LV dyssynchrony prior to implantation of the CRT 
device (assessed by tissue Doppler imaging, TDI) to clinical outcome and LV reverse remodel-
ing after CRT, in 85 consecutive patients. The accuracy of this approach (and the cutoﬀ value 
for LV dysynchrony) to predict outcome was determined using receiver operator characteris-
tic (ROC) curve analysis. Finally, the most important issue was addressed: would identiﬁcation 
of responders prior to pacemaker implantation translate in a favourable prognosis during 
follow-up?
METHODS
Patients and study protocol
Eighty-ﬁve consecutive patients with end-stage heart failure, scheduled for implantation of 
a biventricular pacemaker, were included in the current study. The patients were selected 
according to the established selection criteria for CRT: 1. severe heart failure (New York Heart 
Association (NYHA) class III or IV), 2. severely depressed LV ejection fraction (LVEF ≤35%), QRS 
exhibiting left bundle branch block conﬁguration with a duration ≥120 ms [1-3].
Patients with atrial ﬁbrillation or with a previously implanted pacemaker were excluded. 
The study protocol was as follows: before pacemaker implantation, resting two-dimensional 
(2D) and color Doppler transthoracic echocardiography were performed to measure LVEF 
and LV volumes, and analyze the severity of mitral regurgitation. Next, myocardial TDI was 
performed to assess inter- and intraventricular dyssynchrony.
Clinical status was assessed at baseline and 6 months follow-up, including assessment of 
NYHA class, quality of life (using the Minnesota Living with Heart Failure questionnaire) [15], 
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and evaluation of exercise capacity using the 6-minute walking test [16]. At 6 months follow-
up, LVEF and LV volumes and severity of mitral regurgitation were re-assessed by echocar-
diography; LV dyssynchrony was also re-assessed.
Hospitalization for heart failure and survival were assessed during 1 year follow-up after 
pacemaker implantation.
Echocardiography and data acquisition/analysis
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vivid Seven, General Electric – Vingmed, Milwaukee, WI, USA). Images were obtained 
using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal and apical views (standard 
long-axis, 2-chamber and 4-chamber images). Standard 2-dimensional and color Doppler 
data (3 consecutive beats), triggered to the QRS complex, were saved in cineloop format. For 
TDI, color Doppler frame rates varied between 100 and 120 frames/sec depending on the 
sector width of the range of interest, and pulse repetition frequencies between 500 Hz to 1 
KHz, resulting in aliasing velocities between 16 and 32 cm/sec. Tissue Doppler parameters 
were measured from color images by oﬀ-line analysis. 
The LV volumes and the LVEF were calculated from the apical 2- and 4-chamber images, using 
the biplane Simpson’s rule [17]. The severity of mitral regurgitation was graded semi-quanti-
tatively from color-ﬂow Doppler in the conventional parasternal long-axis and apical 4-cham-
ber images. Mitral regurgitation was characterized as: mild=1+ (jet area/left atrial area<10%), 
moderate=2+ (jet area/left atrial area 10-20%), moderately severe =3+ (jet area/left atrial 
area 20-45%), and severe=4+ (jet area/left atrial area >45%) [18]. 
For TDI analysis, the digital cineloops were analyzed using commercial software (Echopac 
6.1, General Electric – Vingmed, Milwaukee, WI, USA) by 2 independent observers, blinded to 
the clinical outcome. The sample volume was placed in the LV basal portions of the anterior, 
inferior, septal and lateral walls (using the 2- and 4-chamber images), and per region, the time 
interval between the onset of the QRS complex and the peak systolic velocity was derived. 
LV dyssynchrony was deﬁned as the maximum delay between peak systolic velocities among 
the 4 walls within the LV (most frequently observed between the interventricular septum 
and the lateral wall) [19]. Interventricular dyssynchrony was assessed by comparing the delay 
between peak systolic velocity of the right ventricular free wall and the LV lateral wall [8]. The 
time required to analyze the tissue Doppler data was 10-15 min.
Pacemaker Implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary sinus 
venogram was obtained using the balloon catheter. Next, the LV pacing lead was inserted 
via the coronary sinus using an 8F guiding catheter and positioned preferably in a (postero-
)lateral vein. 
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The right atrial and ventricular leads (with separate connectors) were positioned convention-
ally. The atrioventricular delay was optimized by 2D echocardiography so that it provided the 
longest ﬁlling time for completion of the end-diastolic ﬁlling ﬂow before LV contraction [20]. 
A dedicated resynchronization device was used in all patients. When a conventional indica-
tion for an ICD existed, a combined device was implanted.
Statistical Analysis
Results are presented as mean ± SD. Data were compared using paired or unpaired Student’s 
t-test when appropriate. Proportions were compared using Chi-square analysis with Yates’ 
correction. Optimal cutoﬀ values of parameters to predict response to CRT were determined 
by ROC curve analysis. The optimal cutoﬀ value was deﬁned as that providing the maximal 
accuracy to distinguish between responders/non-responders. 
Diﬀerences in cardiac event-rates (death and hospitalization for heart failure) over time were 
analyzed by the method of Kaplan-Meier, and log-rank test. For all tests, a P-value <0.05 was 
considered signiﬁcant.
RESULTS
Study Population
Eighty-ﬁve patients were included. The patient characteristics are summarized in Table 1. Pa-
tients had severe LV dysfunction (mean LVEF 23±7%, range 9-34%), with extensive dilatation 
(LV end-diastolic volume 258±56 ml). Approximately equal numbers of patients had heart 
failure of ischemic and non-ischemic etiology. The QRS duration was prolonged, ranging 
from 120 to 240 ms. 
The mean LV dyssynchrony was 73±49 ms (range 0 - 221 ms) before CRT. The site of latest 
activation was the lateral wall in 89% of patients; in the remaining 11%, the site of latest 
activation was the septum (n=4, although this may also be due to passive motion rather 
than true late activation), anterior wall (n=2) or the inferior wall (n=3). The mean RV-LV dys-
synchrony was 47±38 ms.
Thirty-seven patients received a resynchronization pacemaker (Contak TR (n=27), Guidant, 
MN, USA or InSync III (n=10), Medtronic Inc., MN, USA) and 48 a combined CRT-ICD device 
(Contak CD (n=15) or Contak Renewal (n=30), Guidant, MN, USA and InSync III CD (n=3), 
Medtronic Inc., MN, USA). Two types of LV leads were used (Easytrack 4512-80 (n=73), Guidant, 
MN, USA or Attain-SD 4189 (n=12), Medtronic Inc., MN, USA). The procedure was successful in 
all patients and no procedure related complications were observed. 
Following CRT, the QRS-duration was reduced from 178±36 ms to 155±22 ms (P<0.01).
The optimized atrioventricular delay was 115±32 ms. 
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Within 6 months after CRT, 5 patients died of worsening heart failure. Since these patients did 
not have the 6 month follow-up assessment, they were could not be included in the predic-
tion of response to CRT, but they were included in the prognostic evaluation.
Clinical Improvement Following CRT
At baseline and 6 months follow-up, the clinical status of the patients was assessed. 
NYHA class improved from 3.2±0.4 to 2.1±0.7 (P<0.01). In addition, the Minnesota score de-
creased from 42±16 to 29±16 (P<0.01), and the 6-minute walking distance increased from 
278±132 m to 399±149 m (P<0.01). The LVEF demonstrated a modest improvement (from 
23±7% to 28±8%, P<0.05), with a reduction in LV end-diastolic volume (259±57 ml to 237±58 
ml, P<0.05) and end-systolic volume (201±54 ml to 173±53 ml, P<0.05). Mitral regurgitation 
improved by at least 1 grade in 12 of 19 (63%) patients with severe regurgitation (2 patients 
of the 21 patients with severe mitral regurgitation at baseline died before echocardiographic 
follow-up).
Responders and Non-responders
The patients were subsequently divided into responders and non-responders, based on an 
improvement in NYHA class by ≥1 score and an improvement by ≥25% in 6-minute walking 
Table 1. Patient characteristics (n=85).
Age (yrs) 66±12 
Gender (M/F) 64/21
Previous MI 39 (46%)
NYHA class
 III n=68
 IV n=17
Etiology
Ischemic 47 (55%)
Idiopathic 38 (45%)
QRS (ms) 178±36
LVEF (%) 23±7
LVEDV (ml) 258±56
LVESV (ml) 200±53
Severe MR 21 (25%)
Medication
 Diuretics 83 (98%)
 ACE inhibitors 81 (95%)
 Spironolactone 46 (54%)
 B-blockers 71 (84%)
 Amiodarone 35 (41%)
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; MI: myocardial 
infarction; MR: mitral regurgitation; NYHA: New York Heart Association.
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distance (Tables 2 and 3). In the responders, the mean NYHA class improved from 3.2±0.4 to 
1.7±0.5, whereas it remained unchanged in the non-responders (by deﬁnition). The 6-minute 
walking distance improved from 291±122 m to 438±116 m and remained unchanged in the 
non-responders (279±155 m vs 254±175 m) (by deﬁnition).
At baseline, no signiﬁcant diﬀerences were observed between responders and non-respond-
ers, except that the non-responders tended to have larger LV end-diastolic and end-systolic 
volumes, although these diﬀerences were not signiﬁcant (Table 2). The only variable that was 
signiﬁcantly diﬀerent between the 2 groups was the LV dyssynchrony, which was extensive 
in the responders and minimal in the non-responders (Table 2). Of note, RV-LV dyssynchrony 
was not diﬀerent between responders and non-responders.
The responders showed a signiﬁcant improvement in clinical parameters after CRT (Table 3), 
whereas none of the clinical parameters improved in the non-responders after CRT. Further-
more, the LVEF improved in the responders, and reverse remodeling was observed after CRT. 
In the non-responders, the LVEF did not improve and the LV volumes did not decrease after 
CRT.
In the responders, 12 patients had severe mitral regurgitation and 11 (92%) patients im-
proved in mitral regurgitation by at least 1 grade after CRT. In the non-responders, 7 patients 
had severe mitral regurgitation, and only 1 (14%, P<0.05 vs responders) improved at least 1 
grade after CRT.
Table 2. Responders (n=59) vs non-responders (n=21), baseline characteristics.
Responders (n=59) Non-responders (n=21) P-value
Age (yrs) 64±9 66±12 ns
Gender (M/F) 46/13 14/7 ns
Previous MI  27 (46%) 9 (43%) ns
NYHA class (III/IV) 81%/29% 90%/10% ns
Etiology
 Ischemic 33 (56%) 11 (52%) ns
 Idiopathic 26 (44%) 10 (48%) ns
QRS (ms) 174±29 171±26 ns
6-MWT 291±122 279±155 ns
QoL score 40±15 43±16 ns
LVEF (%) 23±6 22±8 ns
LVEDV (ml) 254±57 272±55 ns
LVESV (ml) 197±55 214±55 ns
Severe MR 12 (20%) 7 (33%) ns
RV-LV dyssynchrony (ms) 47±34 49±29 ns
LV dyssynchrony (ms) 87±49 35±20 <0.01
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; MI: myocardial 
infarction; MR: mitral regurgitation; 6-MWT: 6-minute walk test; NYHA: New York Heart Association; QoL: quality of life score.
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In responders, the LV dyssynchrony had decreased from 87±49 ms to 21±28 ms (P<0.01), 
whereas in the non-responders, the LV dyssynchrony tended to increase, although the diﬀer-
ence was not signiﬁcant (35±20 ms vs 42±23 ms, ns).
Prediction of Response
The only variable at baseline that was signiﬁcantly diﬀerent between responders and non-
responders was the LV dyssynchrony. To deﬁne the optimal cutoﬀ value to predict clinical 
response, ROC curve analysis was performed. When responders were deﬁned as patients 
exhibiting an improvement in NYHA class ≥1 score and an improvement ≥25% in 6-minute 
walking distance, an optimal sensitivity and speciﬁcity of 80% were obtained at a cutoﬀ level 
of 65 ms for LV dyssynchrony (Figure 1).
ROC curve analysis was also performed to deﬁne the optimal cutoﬀ value for LV dyssynchrony 
to predict reverse LV remodeling. At a cutoﬀ value of 65 ms for LV dyssynchrony a sensitivity 
Table 3. Responders (n=59) vs non-responders (n=21), clinical and echocardiographic variables before and after 6 months CRT.
Responders  (n=59) Non-responders (n=21) P-value
NYHA class
 baseline 3.2±0.4 3.3±0.2 ns
 follow-up 1.7±0.5* 3.1±0.3 <0.01
6-MWT (m)
 baseline 291±122 279±155 ns
 follow-up 438±116* 254±175 <0.01
QoL score
 Baseline 40±15 43±16 ns
 follow-up 24±12* 44±17 <0.01
QRS (ms)
 baseline 174±29 171±26 ns
 follow-up 142±27* 165±31 <0.01
LVEF (%) 
 baseline 23±6 22±8 ns
 follow-up 29±8* 23±9 <0.05
LVEDV (ml)
 baseline 254±57 272±55 ns
 follow-up 225±53* 271±60 <0.01 
LVESV (ml)
 baseline 197±55 214±55 ns 
 follow-up 160±46* 211±56 <0.01
Severe MR 
 Baseline 12 (20%) 7 (33%) ns
 follow-up 1 (2%)* 6 (29%) <0.05
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; MR: mitral 
regurgitation; 6-MWT: 6-minute walk test; QoL: quality of life score. *:P<0.05 follow-up vs baseline value. 
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and speciﬁcity of 92% were obtained to predict a reduction of ≥15% LV end-systolic volume 
(Figure 2).
The continuous relation between the LV dyssynchrony and the reduction in LV end-systolic 
volume is displayed in Figure 3. A linear relation existed between the LV dyssynchrony and 
the reduction in LV end-systolic volume until the LV dyssynchrony reached 100 ms. After this 
point, even if LV dyssynchrony increased further, no further reduction in LV end-systolic vol-
ume occurred (as evidenced by the horizontal line, y=55, Figure 3).
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Figure 1. ROC curve analysis demonstrated a sensitivity and speciﬁcity of 80% to predict response to CRT (deﬁned as an improvement in NYHA 
class ≥1 score and an improvement ≥25% in 6-minute walking distance) at a cutoﬀ level of 65 ms for LV dyssynchrony.
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Figure 2. ROC curve analysis demonstrated a sensitivity and speciﬁcity of 92% to predict reverse LV remodeling after CRT (deﬁned as an 
improvement in LV end-systolic volume ≥15%) at a cutoﬀ level of 65 ms for LV dyssynchrony.
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Prediction of Prognosis
Follow-up was performed during 1 year after implantation. A total of 16 events occurred in 
the 80 patients, including 7 deaths (1 non-cardiac death, 6 worsening heart failure), and 9 
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Figure 3. A linear relation existed between the extent of LV dyssynchrony and the change in LV end-systolic volume after CRT. However, LV 
dyssynchrony over 100 ms did not result in further reduction in LV end-systolic volume.
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Figure 4. Cardiac events (cardiac death, hospitalization for decompensated heart failure) during 1-year follow-up after cardiac resynchronization 
therapy. Patients with left ventricular dyssynchrony ≥65 ms had a signiﬁcantly lower event-rate after cardiac resynchronization therapy as 
compared to patients with dyssynchrony <65 ms (6% vs 50%, P<0.001).
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hospitalizations for decompensated heart failure. The event-rate in responders was signiﬁ-
cantly lower than in non-responders (8% vs 52%, <0.01).
Moreover, when patients were divided according to the presence/absence of LV dyssynchrony 
(using a 65 ms cutoﬀ value), only 3 (6%) events occurred in the 49 patients with dyssynchrony 
as compared to 13 (33%) in the 31 patients without dyssynchrony. None of the 5 patients 
who died before the 6 months follow-up assessment had LV dyssynchrony; inclusion of these 
patients resulted in a 50% event-rate during the 1-year follow-up in the patients without 
dyssynchrony (Figure 4).
Moreover, 6 of 48 (13%) patients with a combined CRT-ICD device experienced adequate 
shocks (for ventricular arrhythmias) during the 1-year follow-up; all of these patients were 
non-responders.
DISCUSSION 
The ﬁndings in the current study can be summarized as follows:
1. all baseline characteristics are comparable in responders and non-responders to CRT, ex-
cept for the LV dyssynchrony, which was larger in responders; 2. baseline LV dyssynchrony of 
65 ms or more has a sensitivity and speciﬁcity of 80% to predict clinical response and 92% 
to predict reverse LV remodeling; 4. patients with extensive dyssynchrony who undergo CRT 
have an excellent prognosis (6% event-rate) whereas patients who do not have dyssynchrony 
and undergo CRT have a poor prognosis (event-rate 50%).
Beneﬁt of CRT
In the entire study population, an improvement in all clinical parameters was observed, in line 
with previous studies concerning CRT [5-7]. Comparable to recent randomized clinical trials 
(MIRACLE, MUSTIC, PATH-CHF), a reduction in NYHA class and quality of life score were noted 
and an increase in 6-minute walking distance was observed [5-7]. Moreover, in the present 
study, a modest improvement in LVEF was shown, comparable to results of the MIRACLE trial 
[6]. In addition, signiﬁcant reverse remodeling was demonstrated, also in line with data from 
the MIRACLE trial [21]. 
However, not all patients responded equally to CRT, and when patients were divided in re-
sponders and non-responders, based on improvement in NYHA class, it became evident that 
an improvement in clinical parameters was only observed in the responders. Moreover, im-
provement in LVEF and reverse remodeling were also observed only in the responders. When 
individual results were analyzed, it became clear that 21 (26%) patients did not respond to 
CRT. When the 5 patients who died before the 6-month follow-up were also included, the per-
centage of non-responders was 31%. This observation is in agreement with previous studies 
[8,14]. For example, in the MIRACLE trial, 20% of patients did not experience an improvement 
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in symptoms and 32% did not improve in NYHA class [6]. Similarly, Reuter and coworkers 
[22] demonstrated that 18% of 102 consecutive patients undergoing CRT did not improve in 
NYHA class and quality of life score.
In the current study and in most of the large clinical trials, the selection criteria included 
severe heart failure (NYHA class III or IV) with severely depressed LVEF (≤35%), and wide QRS 
complex (≥120 ms). Thus, additional selection criteria are needed to reduce the high number 
of non-responders. 
Left ventricular dyssynchrony to select candidates for CRT
When baseline characteristics were compared between responders and non-responders 
(Table 2), the only variable that was diﬀerent among the 2 groups was the LV dyssynchrony 
(whereas the RV-LV dyssynchrony was also not diﬀerent). This ﬁnding was not unexpected, 
since various studies have recently emphasized the importance of LV dyssynchrony for the 
response to CRT [8-14]. Pitzalis et al [23] have used M-mode echocardiography to assess LV 
dyssynchrony by measuring the septal-to-posterior wall motion delay. Although this is an el-
egant and simple method to assess LV dyssynchrony, in patients with ischemic heart disease 
and previous anterior infarction, assessment of septal movement is frequently not possible. 
Recent studies have therefore focused on TDI applications to assess dyssynchrony. Sogaard 
and colleagues [10] have used tissue tracking in 25 patients to detect regions with delayed 
longitudinal contraction. The authors demonstrated that the extent of delayed longitudi-
nal contraction predicted response to CRT. Breithardt and coworkers [11] used strain rate 
imaging in 18 patients to assess dysynchrony. More recent studies have focused on timing 
of peak systolic velocities of diﬀerent myocardial regions to assess LV dyssynchrony. Yu and 
colleagues [12] have evaluated 30 patients before and after CRT with TDI and demonstrated 
that LV dyssynchrony allowed separation between patients with and without LV remodeling 
as expressed by a reduction in end-systolic volume by more than 15%. Assessment of dys-
synchrony was comparable to the present analysis, with the exception that 12 segments were 
used, instead of 4 segments in the present study. 
ROC curve analysis demonstrated a sensitivity and speciﬁcity of 80% for prediction of clinical sta-
tus and 92% for the prediction of reverse LV remodeling. ROC curve analysis identiﬁed the cutoﬀ 
value of 65 ms as optimal. Of interest, Gorcsan et al [13] have recently evaluated a small group of 
patients and also reported a similar value (65 ms) as optimal cutoﬀ value to predict response to 
CRT. This cutoﬀ level may now be used in further studies to prospectively select patients for CRT. 
Prognostic Value of CRT and Left Ventricular Dyssynchrony
The typical patients who are eligible for CRT (heart failure, depressed LVEF and wide QRS 
complex) have a poor prognosis when treated conservatively [1-3]. Moreover, Bader et al [19] 
have recently shown that in these patients the presence of LV dyssynchrony is an important 
predictor of poor outcome.
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Prognostic studies in patients undergoing CRT are still scarce. Various studies have evaluated 
patients after CRT; the initial studies have reported the acute beneﬁt [4], other studies have 
demonstrated response after 6 months to 1 year, and preliminary data have shown sustained 
beneﬁt over time [5-7]. A recent meta-analysis of the 11 published studies of 4 randomized 
trials (including 1634 patients) demonstrated a short-term (6-month) survival beneﬁt after 
CRT as compared to optimized medical therapy [24].
However, none of the studies have evaluated the relation between baseline dyssynchrony in 
patients undergoing CRT and prognosis. In the current study, 1-year follow-up was obtained 
and the results demonstrated a low event-rate (6%) after CRT in patients with LV dyssynchrony 
at baseline as compared to patients without dyssynchrony (50% event-rate). This observation 
further supports the hypothesis that the degree of LV dyssynchrony is not only predictive of 
response to CRT but is also related to favourable prognosis when treated by CRT. 
It is most likely that both patients with and without LV dyssynchrony have a poor prognosis 
if untreated, and possibly the patients with LV dyssynchrony have an even worse prognosis. 
If treated by CRT, the hemodynamic improvements observed after CRT in responders (i.e. 
the patients with LV dyssynchrony) may result in an improved prognosis as observed in the 
current study. The patients without LV dyssynchrony do not improve in hemodynamics, re-
sulting in poor long-term survival. 
Conclusion
Patients with extensive LV dyssynchrony responded well to CRT. Using a cutoﬀ level of 65 
ms, a sensitivity and speciﬁcity of 80% were obtained to predict clinical response and of 92% 
to predict reverse LV remodeling. Moreover, patients with LV dyssynchrony ≥65 ms had an 
excellent prognosis after CRT, in contrast to patients with <65 ms who had a high event-rate 
(50%) during 1-year follow-up.
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ABSTRACT
Background Currently, one third of patients treated with cardiac resynchronization therapy 
(CRT) do not respond. Non-response to CRT may be explained by the presence of scar tissue 
in the postero-lateral left ventricular (LV) segments, which may result in ineﬀective LV pacing 
and inadequate LV resynchronization. In the current study the relationship between trans-
mural postero-lateral scar tissue and response to CRT was evaluated.
Methods and Results Forty consecutive patients with end-stage heart failure (New York 
Heart Association (NYHA) class III/IV), LV ejection fraction (EF) ≤35%, QRS duration >120 ms, 
LBBB and chronic coronary artery disease were included. The localization and transmurality 
of scar tissue was evaluated with contrast-enhanced MRI. Next, LV dyssynchrony was assessed 
at baseline and immediately post-implantation using tissue Doppler imaging (TDI). Clinical 
parameters, LV volumes and LVEF were assessed at baseline and at 6 months follow-up. 
Fourteen patients (35%) had a transmural (>50% of LV wall thickness) postero-lateral scar. In 
contrast to patients without postero-lateral scar tissue, these patients showed a low response 
rate (14% vs. 81%, P<0.05) and did not improve in clinical or echocardiographic parameters. 
In addition, LV dyssynchrony remained unchanged after CRT implantation (84±46 ms vs. 
78±41 ms, ns). 
Patients without postero-lateral scar tissue and severe baseline dyssynchrony (≥65 ms) 
showed an excellent response rate of 95%, compared to patients with a postero-lateral scar 
and/or absent LV dyssynchrony (11%).
Conclusion CRT does not reduce LV dyssynchrony in patients with transmural scar tissue in 
the postero-lateral LV segments, resulting in clinical and echocardiographic non-response to 
CRT. 
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INTRODUCTION
Cardiac resynchronization therapy (CRT) is a rapidly evolving treatment option for patients 
with drug-refractory heart failure. Large clinical trials have reported the sustained beneﬁt of 
CRT in patients with severe heart failure (New York Heart Association (NYHA) class III or IV), 
impaired left ventricular (LV) ejection fraction (EF) (≤35%) and a wide QRS complex (>120 ms) 
[1-3]. Beneﬁcial eﬀects of CRT include improvement in heart failure symptoms, quality-of-life, 
exercise capacity and LV systolic performance [1-4]. Simultaneously however, it was noted 
that 20-30% of patients did not respond to CRT, emphasizing the need for better selection 
criteria [2,5,6]. In search for new selection criteria it was demonstrated that the predominant 
mechanism determining the response to CRT is the resynchronization of pre-existent LV dys-
synchrony [6-8]. 
Recently, new echocardiographic techniques, e.g. tissue Doppler imaging (TDI), have shown 
that QRS duration, which is traditionally considered as a marker of LV dyssynchrony, does not 
correlate well with LV dyssynchrony, thus explaining the low predictive value of the QRS dura-
tion for response to CRT [9,10]. Additional studies have indeed demonstrated that assessment 
of LV dyssynchrony using TDI was superior over electrocardiographically assessed QRS duration 
for prediction of response to CRT [7,8]. However, LV dyssynchrony may not be the only deter-
minant of response to CRT, since some patients with LV dyssynchrony do not respond to CRT. 
Another potential reason for non-response to CRT (in patients with ischemic cardiomyopathy) 
may be the presence of extensive scar tissue in the region of the tip of the LV pacing lead (usu-
ally the postero-lateral LV region). Pacing the left ventricle in non-viable or scarred myocardium 
may result in less eﬀective or even ineﬀective LV pacing, and as a consequence, failure of LV 
resynchronization and no response to CRT. Accordingly, the aim of the current study was to 
evaluate the response to CRT in relation to LV dyssynchrony on the one hand, and scar tissue 
in the postero-lateral wall on the other hand. To precisely determine the spatial and transmural 
extent of scar tissue, contrast-enhanced magnetic resonance imaging (MRI) was used.
METHODS
Patients and Study Protocol
Forty consecutive patients with severe heart failure and chronic coronary artery disease 
(ischemic cardiomyopathy), scheduled for the implantation of a CRT device were prospec-
tively included. Patients were selected according to the traditional selection criteria for CRT: 
1) severe heart failure (NYHA class III or IV), 2) severely depressed LV ejection fraction (LVEF) 
(≤35%), and 3) a QRS complex exhibiting left bundle branch block with a duration >120 ms. 
Chronic coronary artery disease was deﬁned as angiographically proven stenosis of more 
than 50% in ≥1 major epicardial coronary artery.
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Patients with a recent myocardial infarction (<3 months), decompensated heart failure, a 
previous cardiac pacemaker or intracranial aneurysm clips were excluded. 
The study protocol was as follows: before pacemaker implantation contrast-enhanced MRI 
was performed to determine the extent and transmurality of infarcted myocardial tissue. 
Next, clinical status was assessed and resting 2D transthoracic echocardiography was per-
formed to measure LV volumes and LVEF. Also, TDI was performed to assess the extent of LV 
dyssynchrony. 
LV dyssynchrony was re-assessed on the day after implantation, to assess the extent of resyn-
chronization. Clinical status, LV volumes, and LVEF were re-assessed at 6 months follow-up. 
The authors had full access to the data and take full responsibility for its integrity. All authors 
have read and agree to the manuscript as written. 
Magnetic Resonance Imaging 
Data acquisition. A clinical 1.5-T Gyroscan ACS-NT MRI scanner (Philips Medical Systems, 
Best, The Netherlands) equipped with Powertrack 6000 gradients, release 9.1 of the scanner 
software and a 5-element cardiac synergy coil was used. Patients were positioned in the su-
pine position. Images were acquired during breathholds of approximately 15 seconds using 
vector ECG gating. The heart was imaged from apex to base [11] with 20 to 24 imaging levels 
(dependent on the heart size) in short-axis views. Contrast-enhanced images were acquired 
approximately 15 minutes after bolus injection of gadopentetate dimeglumine 0.15 mmol/kg 
(gadolinium-diethylenetriamine pentaacetic acid, Magnevist, Schering AG/Berlex Laborato-
ries, Berlin, Germany) with an inversion-recovery gradient echocardiographic sequence; the 
inversion time was determined using a Look-Locker sequence [12,13]. Typical parameters were 
a ﬁeld of view of 400 × 400 mm2, a matrix size of 256 × 256, a slice thickness of 5 mm, a slice gap 
of -5 mm, a ﬂip angle of 15°, a time to echo of 1.36 ms and a time to repeat of 4.53 ms [14].
Data analysis. The contrast-enhanced images were scored visually by 2 experienced observ-
ers (blinded to other MRI, echocardiographic and clinical data) using a 17-segment model 
[15]. Each segment was graded on a ﬁve point scale (segmental scar score; 0 = absence of 
hyperenhancement, 1 = hyperenhancement of 1% to 25% of LV wall thickness, 2 = hyperen-
hancement extending to 26% to 50%, 3 = hyperenhancement extending to 51% to 75%, and 
4 = hyperenhancement extending to 76% to 100% of the LV wall thickness) [14]. 
A transmural scar in the postero-lateral region was deﬁned as a segmental scar score of 3 or 4 
(hyperenhancement extending to 51% to 100% of LV wall thickness) in ≥1 of the following LV 
segments: basal posterior, mid posterior, basal postero-lateral and mid postero-lateral.  
Clinical Evaluation 
Evaluation of clinical status included assessment of NYHA functional class, quality-of-life 
score (using the Minnesota quality-of-life questionnaire) and 6-minute hall-walk test. NYHA 
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functional class was scored by an independent physician, who was blinded to all other patient 
data. Patients with an improvement of ≥1 NYHA functional class and an improvement ≥25% 
in 6-min walking distance were classiﬁed as responders [8]. In addition, patients who died 
due to progressive heart failure before the 6-month follow-up assessment were classiﬁed as 
non-responders. In all patients, QRS duration was measured from the surface ECG using the 
widest QRS complex from the leads II, V1 and V6. Also, the QRS axis in the frontal plane was 
measured from the surface ECG immediately post-implantation. The ECGs were recorded at a 
speed of 25 mm/sec and were evaluated by two independent observers without knowledge 
of the clinical status of the patient. 
Echocardiography
Patients were imaged in the left lateral decubitus position using a commercially available 
system (Vingmed system Seven, General Electric-Vingmed, Milwaukee, Wisconsin, USA). 
Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in the parasternal 
and apical views (standard long-axis and two- and four-chamber images). Standard 2D and 
color Doppler data, triggered to the QRS complex were saved in cine loop format. LV volumes 
(end-systolic, end-diastolic) and LVEF were calculated from the conventional apical two- and 
four-chamber images, using the biplane Simpson’s technique [16]. 
Assessment of mitral regurgitation. The severity of mitral regurgitation was graded semi-
quantitatively from color-ﬂow Doppler images. For quantiﬁcation of mitral regurgitation, the 
apical 4-chamber images were used. Mitral regurgitation was classiﬁed as: mild=1+ (jet area/
left atrial area <10%), moderate=2+ (jet area/left atrial area 10-20%), moderately severe =3+ 
(jet area/left atrial area 20-45%), and severe=4+ (jet area/left atrial area >45%) [17]. 
Tissue Doppler imaging to assess LV dyssynchrony. In addition to the conventional echo-
cardiographic examination, TDI was performed to assess LV dyssynchrony. For TDI, color Dop-
pler frame rates varied between 80 and 115 frames/s depending on the sector width of the 
range of interest; pulse repetition frequencies were between 500 Hz and 1 KHz, resulting 
in aliasing velocities between 16 and 32 cm/s. TDI parameters were measured from color 
images of three consecutive heart beats by oﬄine analysis. Data were analyzed using com-
mercial software (Echopac 6.1, General Electric - Vingmed). To determine LV dyssynchrony, 
the sample volume was placed in the basal portions of the septum and the LV lateral wall; 
peak systolic velocities and time-to-peak systolic velocities were obtained and the delay in 
peak velocity between the septum and the LV lateral wall was calculated as an indicator of 
LV dyssynchrony (referred to as the septal-to-lateral delay) [6,8]. Based on previous observa-
tions, a septal-to-lateral delay ≥65 ms was considered to represent severe LV dyssynchrony 
[8]. Inter- and intra-observer agreement for assessment of the septal-to-lateral delay were 
90% and 96%, respectively [9]. 
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Pacemaker Implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained during occlusion of the coronary sinus using a balloon catheter. 
Next, the LV pacing lead was inserted in the coronary sinus with the help of an 8Fr-guiding 
catheter, and positioned as far as possible in the venous system, preferably in the (postero-) 
lateral vein. The right atrial and right ventricular leads were positioned conventionally. When 
a conventional indication for an internal deﬁbrillator existed, a combined device was im-
planted. At implant both sensing and pacing threshold (at pulse duration of 0.5 ms) of the 
LV pacing lead were measured. For each patient the atrio-ventricular interval was adjusted 
to maximize the mitral inﬂow duration using pulsed-wave Doppler echocardiography. No 
adjustments were made to the V-V interval during the ﬁrst 6 months of CRT. The ﬁnal position 
of the LV pacing lead was assessed using cine ﬂuoroscopy.
Statistical Analysis 
Continuous data are presented as mean ± SD, and dichotomous data are presented as 
numbers and percentages. Data within patient groups (to compare the eﬀect of CRT) are 
compared using paired Student’s t-tests (continuous variables) and Wilcoxon signed ranks 
tests (NYHA classiﬁcation). Diﬀerences in baseline characteristics and 6-months follow-up 
between independent patient groups are evaluated using unpaired Student’s t-tests (con-
tinuous variables) and Mann-Whitney tests (NYHA classiﬁcation). 
Multivariable linear regression analyses were applied to evaluate the relation between clinical 
and echocardiographical variables (quality-of-life score, 6-minute walking distance, LVEF, LV 
end-diastolic and end-systolic volumes) at 6 months follow-up and the presence of postero-
lateral scar tissue and/or LV dyssynchrony at baseline. We included a postero-lateral scar * LV 
dyssynchrony interaction term to study to what extent these variables modify each others 
relationship with improvement at 6-months follow-up.
Finally to compare response rate to CRT in diﬀerent patient groups the chi-square tests with 
Yates’ correction (dichotomous variables) are used. All tests are 2-sided, and a P-value <0.05 
was considered statistically signiﬁcant.
RESULTS
Forty consecutive patients were included in this study (35 men, mean age 67±10 years). Base-
line patient characteristics are summarized in Table 1.
Pacemaker implantation
CRT-device and lead implantation was successful in all patients without major complications 
(Contak TR or CD, Guidant, Minneapolis, Minnesota, USA and Insync III or CD, Medtronic 
Postero-lateral scar tissue and response to CRT 183
Inc., Minneapolis, Minnesota, USA). Two types of LV leads were used (Easytrack 4512 to 80, 
Guidant, or Attain-SD 4189, Medtronic Inc.).
The LV pacing lead was positioned in the mid lateral region in 20 patients (50%) and in the 
postero-lateral region in 20 patients (50%).
Post-implantation 
Following CRT implantation, QRS duration decreased from 160±29 ms to 149±24 ms (P<0.05). 
TDI demonstrated a reduction in LV dyssynchrony immediately after implantation of the CRT 
device from 90±43 ms to 47±39 ms (P<0.001).
Clinical and echocardiographic improvement following CRT
One patient died at 4 months after CRT implantation due to worsening heart failure. 
Accordingly, this patient did not have a clinical follow-up assessment at 6 months.
In the remaining 39 patients, a signiﬁcant improvement in NYHA class was observed, 5 pa-
tients showed an improvement of 2 NYHA classes, 18 patients improved by 1 NYHA class, 
14 patients did not improve and 2 patients showed a worsening in NYHA class. In addition, 
Table 1. Patient characteristics (n=40).
Age (yrs) 67±10 
Gender (M/F) 35/5
NYHA class
 III 36 (90%)
 IV 4 (10%)
QRS duration (ms) 160±29
 Rhythm 
 sinus rhythm 34 (85%)
 atrial ﬁbrillation 6 (15%)
Previous MI 27 (68%)
Multi-vessel disease  30 (75%)
Previous revascularization 23 (58%)
LVEF (%) 23±7
LVEDV (ml) 245±82
LVESV (ml) 191±77
Severe MR (grade 3-4+) 8 (20%)
LV dyssynchrony (ms) 90±43
Medication
 Diuretics 35 (88%)
 ACE inhibitors 38 (95%)
 Beta-blockers 33 (83%)
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; MI: myocardial 
infarction; MR: mitral regurgitation; NYHA: New York Heart Association.
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the quality-of-life score decreased from 39±15 to 23±20 (P<0.001) and the 6-minute walking 
distance increased from 290±99 m to 357±169 m (P<0.01). 
Based on a lack of improvement in NYHA class at 6 months or a lack of improvement ≥25% in 
6-minute walking distance, 16 patients (40%) were classiﬁed as non-responders. The patient 
who died before 6 months follow-up showed a gradual decline in his clinical situation follow-
ing CRT implantation and was therefore also classiﬁed as non-responder. 
A modest improvement in LVEF from 23±7% to 29±11 (P<0.01) was observed. Signiﬁcant 
reverse remodeling occurred after 6 months of CRT. The LV end-systolic volume decreased 
from 191±77 ml at baseline to 157±54 ml after 6 months of CRT (P<0.05). Similarly, LV end-
diastolic volume decreased from 245±82 ml at baseline to 226±77 ml at 6 months follow-up 
(P<0.05). 
Postero-lateral scar tissue 
Of the 680 segments that were evaluated, 314 segments (46%) revealed hyperenhancement 
on MRI. In particular, 102 (15%) showed minimal hyperenhancement (score 1), 86 (13%) had 
hyperenhancement score 2, 82 (12%) had score 3, and 44 (6%) score 4. 
Fourteen patients (35%) had a transmural scar (hyperenhancement score 3 or 4) in the pos-
tero-lateral region (basal posterior, mid posterior, basal postero-lateral and/or mid postero-
lateral segments). An example of a patient with a transmural scar in the postero-lateral region 
is shown in Figure 1.
Baseline characteristics between patients with (n=14) and without postero-lateral scar tissue 
(n=26) were comparable, in particular QRS duration was similar (158±42 ms vs. 164±26 ms 
respectively, ns). At implantation both LV sensing (14.3±8.6 mV vs. 13.6±9.9 mV respectively, 
ns) and the LV pacing threshold (1.1±1.1 V vs. 1.3±0.9 V, respectively, ns) were comparable 
between both groups. In addition, the direction of the QRS axis on surface ECG immediately 
following implantation was comparable between the patients with and without postero-lat-
eral scar tissue. 
Postero-lateral scar tissue and response following CRT (Table 2)
Baseline values of both clinical (NYHA class, 6-minute walking distance and quality-of-life 
score) and echocardiographic parameters (LVEF, LV end-systolic volume, LV end-diastolic 
volume) were comparable between patients with (n=14) and without postero-lateral scar 
tissue (n=26) (Table 2). In the patients without transmural postero-lateral scar tissue (n=26), 
21 patients (81%) were classiﬁed as responders. 
In these patients there was an immediate reduction in LV dyssynchrony following CRT implan-
tation (from 93±41 ms to 31±27 ms, P<0.05), indicating resynchronization of LV contraction. 
At 6 months follow-up there was a signiﬁcant improvement in NYHA class, 6-minute walking 
distance and quality-of-life score. In addition, LVEF improved signiﬁcantly (from 24±7% to 
32±10%, P<0.05), and signiﬁcant LV reverse remodeling was observed (Table 2).
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In the patients with a transmural scar in the postero-lateral region (n=14), only 2 patients 
(14%) were classiﬁed as a responder at 6 months follow-up (P<0.05 vs. patients without scar 
tissue).
Baseline LV dyssynchrony in these patients was not statistically diﬀerent compared to the 
patients without a transmural postero-lateral scar (84±46 ms vs. 93±41 ms respectively, ns). 
However, in the patients with a transmural postero-lateral scar, LV dyssynchrony remained 
unchanged following implantation of the CRT device (84±46 ms vs. 78±41 ms, ns), indicating 
absence of LV resynchronization. At 6 months follow-up no improvement was observed in 
NYHA class, 6-minute walking distance, and quality-of-life score. Also, LVEF failed to improve 
(from 22±7% to 23±10%, ns) and LV reverse remodeling was not observed.
LV dyssynchrony and response following CRT (Table 3)
Mean LV dyssynchrony in all patients was 90±43 ms (range 5-182 ms) before CRT. Thirty-three 
patients (83%) showed severe baseline LV dyssynchrony (≥65 ms). The site of latest activation 
was the postero-lateral region in all patients. No diﬀerences were observed in baseline clini-
cal and echocardiographic parameters between patients with (n=33) and patients without 
(n=7) severe baseline LV dyssynchrony (Table 3). 
In the patients with severe baseline LV dyssynchrony (≥65 ms, n=33), 23 patients (70%) were 
classiﬁed as responders at 6 months follow-up. In these patients, LV dyssynchrony decreased 
Figure 1. Contrast-enhanced MRI of a patient with transmural scar tissue in the postero-lateral wall. 
186
C
ha
pt
er
 1
3
from 103±32 ms to 50±41 ms after implantation (P<0.05). At 6 months follow-up, a signiﬁcant 
improvement in both clinical and echocardiographic parameters was observed. NYHA class 
improved signiﬁcantly, the 6-minute walking distance improved from 288±97 m to 383±164 
m (P<0.05) and the quality-of life score improved from 39±13 to 19±18 (P<0.05). LVEF showed 
an increase from 23±6% to 31±11% (P<0.05), with a signiﬁcant LV reverse remodeling (Table 
3). 
None of the 7 patients without severe baseline LV dyssynchrony (<65 ms), showed response 
to CRT at 6 months follow-up (P<0.05 vs. patients with LV dyssynchrony). No change was ob-
served in LV dyssynchrony immediately after implantation (from 24±17 ms to 32±27 ms, ns). 
Quality-of-life, LVEF and LV end-diastolic volume remained unchanged and a signiﬁcant de-
terioration was observed in the 6-minute walking distance (from 304±121 m to 239±147 m, 
P<0.05) and LV end-systolic volume at 6-months follow-up (from 171±95 ml to 197±70 ml, 
P<0.05). 
Table 2. Patients with (n=14) and without (n=26) postero-lateral scar tissue; clinical and echocardiographic variables before and after 6 
months CRT.
No Scar 
(n=26) 
Scar
(n=14)**
P-value
NYHA class (I/II/III/IV)  
 baseline 0/0/23/3 0/0/13/1 ns
 follow-up 3/18/4/1* 0/2/9/2* <0.05
6-MWT (m)
 baseline 276±99 320±99 ns
 follow-up 398±146* 275±187 <0.05
QoL score 
 baseline 40±14 37±18 ns
 follow-up 18±18* 33±20 <0.05
LVEF (%)  
 baseline 24±7 22±7 ns
 follow-up 32±10* 23±10 <0.05
LVEDV (ml)  
 baseline 239±82 257±87 ns
 follow-up 205±64* 270±86 <0.05
LVESV (ml) 
 baseline 184±76 205±82 ns
 follow-up 138±32* 204±62 <0.05
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; NYHA: New York 
Heart Association; 6-MWT: 6-minute walk test; QoL: quality-of-life score. * = P<0.05 follow-up vs. baseline; ** = 1 patient died before 6 months 
follow-up. 
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Postero-lateral scar tissue and LV dyssynchrony versus response to CRT (Table 4)
Figure 2 shows the percentage of responders to CRT for 4 diﬀerent patient categories based 
on the presence/absence of transmural postero-lateral scar tissue in combination with the 
presence/absence of severe baseline LV dyssynchrony (≥65 ms). 
Only the patients with severe baseline LV dyssynchrony and without a transmural postero-
lateral scar (n=22) showed an excellent response rate (95%). Of interest, the non-responding 
patient in this category had a non-transmural scar in the postero-lateral region (hyperen-
hancement score 2). In contrast, all other patients showed a low response rate following CRT. 
Patients with severe LV dyssynchrony and a transmural postero-lateral scar (n=11) had a re-
sponse rate of 18%. The patients without severe LV dyssynchrony at baseline had a response 
rate of 0%, irrespective of the presence (n=4) or absence (n=3) of postero-lateral scar tissue. 
The baseline clinical and echocardiographic parameters of the 22 patients with severe base-
line LV dyssynchrony and without postero-lateral scar tissue were comparable to the baseline 
parameters of the other patients (Table 4).
The patients with severe baseline LV dyssynchrony and without a transmural postero-lateral 
scar (n=22) showed a signiﬁcant reduction in LV dyssynchrony (from 105±31 ms to 30±28 ms, 
Table 3. Patients with (n=33) and without (n=7) baseline LV dyssynchrony; clinical and echocardiographic variables before and after 6 months 
CRT.
Dyssynchrony
(n=33)**
No Dyssynchrony (n=7) P-value
NYHA class (I/II/III/IV)
 baseline 0/0/29/4 0/0/7/0 ns
 follow-up 3/20/6/3* 0/0/7/0 <0.05
6-MWT (m)  
 baseline 288±97 304±121 ns
 follow-up 383±164* 239±147* <0.05
QoL score
 baseline 39±13 36±23 ns
 follow-up 19±18* 39±20 <0.05
LVEF (%)
 baseline 23±6 24±8 ns
 follow-up 31±11* 19±4 <0.05
LVEDV (ml)
 baseline 249±79 221±103 ns
 follow-up 222±71* 242±111 ns
LVESV (ml)
 baseline 194±74 171±95 ns
 follow-up 150±48* 197±70* <0.05
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; NYHA: New York 
Heart Association; 6-MWT: 6-minute walk test; QoL: quality-of-life score. * = P<0.05 follow-up vs. baseline; ** = 1 patient died before 6 months 
follow-up. 
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P<0.05) and an excellent improvement in both clinical and echocardiographic parameters at 
6 months follow-up.
The patients without baseline LV dyssynchrony and/or transmural postero-lateral scar tissue 
(n=18) failed to show a signiﬁcant reduction in LV dyssynchrony (from 71±48 ms to 68±42 ms, 
ns), and there was no improvement in clinical and echocardiographic parameters. 
Multivariable linear regression analysis (Table 5) 
Table 5 demonstrates that the presence of postero-lateral scar tissue and LV dyssynchrony at 
baseline are independently associated with an improvement in clinical (quality-of life score 
and 6-minute walking distance) and echocardiographic variables (LVEF, LV end-diastolic and 
end-systolic volumes) at 6-month follow-up. In addition, a signiﬁcant postero-lateral scar * LV 
dyssynchrony interaction was observed for improvement in quality-of-life, 6-minute walking 
distance and LVEF at 6 months follow-up. We found that in patients with postero-lateral scar 
tissue, LV dyssynchrony did not inﬂuence improvement in quality-of-life score (regression 
coeﬃcient -31.0 + 31.9; table 5), 6-minute walking distance (regression coeﬃcient 205 - 217) 
and LVEF (regression coeﬃcient 11.1 - 10.8) at 6 months follow-up. This supports the ﬁnding 
that patients with postero-lateral scar tissue are unlikely to improve following CRT, irrespec-
tive of baseline LV dyssynchrony. No interaction was observed for improvement in LV end-
diastolic and end-systolic volumes at 6 months follow-up.
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Figure 2. Percentages of responders to CRT for 4 diﬀerent patient categories based on the presence/absence of transmural postero-lateral scar 
tissue (Scar+/Scar-) in combination with the presence/absence of baseline LV dyssynchrony ≥65 ms (Dys+/Dys). 
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DISCUSSION
The ﬁndings in the current study demonstrate that patients with transmural scar tissue in 
the postero-lateral wall do not respond to CRT, even if extensive LV dyssynchrony exists. The 
combined assessment of scar tissue and LV dyssynchrony is needed to optimize prediction of 
response to CRT. Integration of these parameters resulted in a 95% response rate to CRT.
Cardiac resynchronization therapy was introduced in the early 1990s and is considered an 
important breakthrough in the treatment of patients with dilated cardiomyopathy and end-
stage heart failure. Traditional patient selection for CRT include severe heart failure (NYHA 
class III or IV), depressed LVEF (≤35%) and a widened QRS complex (>120 ms) with left bundle 
branch block conﬁguration [1-3,5]. Using these criteria, various studies have demonstrated 
the immediate beneﬁt of CRT on hemodynamics and systolic performance of the left ven-
tricle [18,19]. Moreover, large clinical trials have shown that these immediate eﬀects were 
accompanied by an improvement in heart failure symptoms, exercise capacity and LV ejec-
tion fraction at mid-term follow-up [1-4]. However, simultaneously it has also become clear 
Table 4. Patients with baseline LV dyssynchrony (≥65 ms) without postero-lateral scar tissue (n= 22) versus patients without baseline LV 
dyssynchrony and/or postero-lateral scar tissue (n=18); clinical and echocardiographic variables before and after 6 months CRT.
Dyssynchrony 
No Scar(n=22) 
Other
(n=18)** 
P-value
NYHA class (I/II/III/IV)
 baseline 0/0/19/3 0/0/17/1 ns
 follow-up 3/18/0/1* 0/2/13/2 <0.05
6-MWT (m)
 baseline 277±97 309±104 ns
 follow-up 432±118* 259±178 <0.05
QoL score 
 baseline 38±13 40±18 ns
 follow-up 12±10* 38±20 <0.05
LVEF (%)  
 baseline 24±7 23±7 ns
 follow-up 34±9* 22±9 <0.05
LVEDV (ml) 
 baseline 253±80 235±92 ns
 follow-up 211±67*  245±84 ns
LVESV (ml)
 baseline 197±75 183±82 ns
 follow-up 138±32* 191±59 <0.05
LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; NYHA: New York 
Heart Association; 6-MWT: 6-minute walk test; QoL: quality-of-life score. * = P<0.05 follow-up vs. baseline; ** = 1 patient died before 6 months 
follow-up. 
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that 20-30% of patients do not respond to CRT [2,5,6]. Therefore, better understanding of the 
mechanism underlying response (and failure to respond) is needed, to allow better selection 
of patients who will beneﬁt from CRT. Recent data have shown that baseline LV dyssynchrony 
is an important factor in the response to CRT. Indeed, patients with extensive LV dyssynchro-
ny showed good response to CRT, whereas patients without dyssynchrony did not respond 
[6-8]. For example, Yu et al. [20] have evaluated 30 patients undergoing CRT and showed a 
signiﬁcant improvement in clinical parameters (NYHA class, 6-minute walking distance) and 
echocardiographic variables (LV ejection fraction, LV reverse remodeling). The same authors 
have also demonstrated that TDI is the optimal approach to assess LV dyssynchrony [20,21].
Table 5. Multivariable linear regression models
Model without interaction 
term *
Model with interaction term
Independent 
variable
Dependent variables Coeﬃcient P-value Coeﬃcient P-value
Qol-post Intercept 7.4 24.7
Qol-pre 0.75 <0.001 0.57 <0.001
Postero-lateral scar tissue † 12.4 0.014 -13.5 0.2
LV dyssynchrony † -18.7 0.003 -31.0 <0.001
Interaction --- 31.9 0.014
6-MWT-post (m) Intercept -44.3 -109.7
6-MWT-pre (m) 1.2 <0.001 1.16 <0.001
Postero-lateral scar tissue † -142 <0.001 33.2 0.7
LV dyssynchrony † 117 0.014 205 <0.001
Interaction --- -217 0.016
LVEF- post (%) Intercept 12.2 6.2
LVEF-pre (%) 0.58 <0.001 0.67 <0.001
Postero-lateral scar tissue † -9.6 <0.001 -0.78 0.9
LV dyssynchrony † 6.6 0.009 11.1 <0.001
Interaction --- -10.8 0.031
LVEDV-post (ml) Intercept 66.8 65.3
LVEDV-pre (ml) 0.69 <0.001 0.68 <0.001
Postero-lateral scar tissue † 49.2 0.003 57.0 0.1
LV dyssynchrony † -32.1 0.093 -28.0 0.3
Interaction --- -9.6 0.8
LVESV-post (ml) Intercept 56.0 57.3
LVESV-pre (ml) 0.64 <0.001 0.65 <0.001
Postero-lateral scar tissue † 59.5 <0.001 54.1 0.1
LV dyssynchrony † -38.5 0.025 -41.3 0.077
Interaction --- 6.6 0.8
* Interaction between postero-lateral scar tissue and LV dyssynchrony
† Postero-lateral scar tissue and LV dyssynchrony are coded as 0 (no) or 1 (yes)
LV: left ventricular; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; 
6-MWT: 6-minute walk test; QoL: quality-of-life score.
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In the current study, a mechanical delay ≥65 ms between the septum and the lateral wall on 
TDI was used as a marker of LV dyssynchrony. This cutoﬀ value was recently demonstrated 
to be highly predictive for response to CRT [8]. Similar results were obtained in the current 
study; the patients with a delay ≥65 ms showed an immediate resynchronization after initia-
tion of CRT, accompanied by an improvement in NYHA class, 6-minute walking distance and 
quality-of-life score at 6 months of CRT. In addition, an improvement in LVEF and reduction in 
LV volumes was observed after 6 months of CRT. In contrast, these beneﬁcial eﬀects were not 
observed in patients with a delay <65 ms. Still, on an individual basis, only 71% of the patients 
with LV dyssynchrony responded to CRT, indicating that other factors are important.
In the present study, only patients with ischemic cardiomyopathy were included. These pa-
tients frequently have a history of myocardial infarction and may have large areas of scar 
tissue. It is currently unclear whether LV pacing in a scarred region will be beneﬁcial and 
was evaluated in the current study. The location and transmurality of scar tissue in the left 
ventricle was assessed using contrast-enhanced MRI, which currently has the highest spatial 
resolution and highest accuracy to assess scar tissue non-invasively [22]. It appeared that 
patients with transmural scar tissue in the postero-lateral wall, did not improve in clinical or 
echocardiographic parameters, not even in the patients with LV dyssynchrony at baseline. 
This observation suggests that transmural scar tissue in the target region (for LV pacing) pro-
hibits response to CRT, and this hypothesis is further supported by the fact that patients with 
LV dyssynchrony did not exhibit resynchronization after CRT.
The patients with the highest likelihood of improvement after CRT (95% response rate) were 
the patients without transmural scar tissue in the postero-lateral wall with severe baseline LV 
dyssynchrony. This observation underscores that assessment of LV dyssynchrony in patients 
with ischemic cardiomyopathy should be combined with pre-implantation evaluation of scar 
tissue in order to verify whether the region that will be targeted for LV pacing does not con-
tain transmural scar tissue.
Study limitations 
In the current study, all patients had ischemic cardiomyopathy. In these patients extensive 
scar tissue can be present and may interfere with response to CRT. In patients with idiopathic 
dilated cardiomyopathy, localized scar tissue may be a lesser issue. Still, recent observations 
with contrast-enhanced MRI in patients with idiopathic dilated cardiomyopathy have also 
demonstrated areas of ﬁbrosis. The eﬀect of ﬁbrosis in dilated cardiomyopathy on response 
to CRT needs further evaluation. 
The postero-lateral region was the site of latest activation in all patients with LV dyssynchrony 
in the present study. It is anticipated that the negative impact of scar tissue will also apply to 
other regions with late activation, but this needs further study.
The presence of contractile reserve (using provocative tests such as dobutamine stress echo-
cardiography or MRI) and its relation to response to CRT was not evaluated in the current 
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study and needs further study. Furthermore, the diﬀerentiation between passive myocardial 
movement or active contraction of scarred LV segments, as is possible with strain or strain 
rate imaging, needs further study. 
In the current study, no adjustments were made to the V-V interval of the CRT device. How-
ever, V-V optimization may be of additional beneﬁt in patients with postero-lateral scar 
tissue. By optimizing the V-V interval the negative eﬀects of a delayed activation of the LV 
lateral wall through the scarred LV myocardium may be corrected, and this issue remains to 
be evaluated.
Conclusion
In the current study, CRT does not reduce LV dyssynchrony in patients with transmural scar 
tissue in the postero-lateral LV segments, resulting in clinical and echocardiographic non-
response to CRT, irrespective of baseline LV dyssynchrony. Patients without transmural scar 
tissue in the postero-lateral LV segments and with severe baseline LV dyssynchrony (≥65 ms), 
on the other hand, have an excellent response rate of 95% following CRT implantation. 
Despite the observation that CRT has a low success rate in patients with postero-lateral scar 
tissue, the number of patients in the current study is relatively small, and the results of the 
present study need to be conﬁrmed in future larger studies. 
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ABSTRACT 
Objective To evaluate the eﬀects of cardiac resynchronization therapy (CRT) in heart failure 
patients with narrow QRS complex (<120 ms) and evidence of left ventricular (LV) dyssyn-
chrony on tissue Doppler imaging (TDI).
Background CRT is beneﬁcial in selected heart failure patients with wide QRS complex (≥120 
ms). Patients with narrow QRS complex (<120 ms) are currently not eligible for CRT and the 
potential eﬀects of CRT are not well studied.
Methods Thirty-three consecutive patients with narrow QRS complex and 33 consecutive 
patients with wide QRS complex (control group) were prospectively included. All patients 
needed to have LV dyssynchrony ≥65 ms on TDI, New York Heart Association (NYHA) class 
III/IV heart failure and LV ejection fraction ≤35%.
Results Baseline characteristics, particularly LV dyssynchrony, were comparable between 
patients with narrow and wide QRS complex (110±8 ms versus 175±22 ms, ns). No signiﬁcant 
relationship was observed between baseline QRS duration and LV dyssynchrony (r=0.21, ns). 
The improvement in clinical symptoms and LV reverse remodeling was comparable between 
patients with narrow and wide QRS complex (mean NYHA class reduction 0.9±0.6 versus 
1.1±0.6, ns and mean LV end-systolic volume reduction 39±34 ml versus 44±46 ml, ns).
Conclusion CRT appears to be beneﬁcial in patients with narrow QRS complex (<120 ms) and 
severe LV dyssynchrony on TDI, with similar improvement in symptoms and comparable LV 
reverse remodeling to patients with wide QRS complex. The current results need conﬁrma-
tion in larger patient cohorts.
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INTRODUCTION 
Cardiac resynchronization therapy (CRT) is a rapidly evolving treatment option for patients 
with drug-refractory heart failure. Large clinical trials have demonstrated the sustained bene-
ﬁt of CRT in patients with moderate-to-severe heart failure (New York Heart Association Class 
(NYHA) class III or IV), systolic dysfunction (left ventricular (LV) ejection fraction (EF) ≤35%) 
and a widened QRS complex (≥120 ms) [1-4]. Beneﬁcial eﬀects of CRT include the improve-
ment in heart failure symptoms, exercise capacity and LV systolic performance, associated 
with a reduction in re-hospitalization for heart failure and improved long-term survival as 
compared to optimized medical therapy [1-5].
Previous studies demonstrated that the predominant mechanism of beneﬁt from CRT ap-
pears related to the presence of LV dyssynchrony and subsequent resynchronization after 
CRT [6-10]. The presence of baseline LV dyssynchrony may thus be mandatory for response 
to CRT. Traditionally, the duration of the QRS complex on the surface ECG has been used 
as a marker of LV dyssynchrony [1-4,11,12]. However, recent studies demonstrated that QRS 
duration is only a weak marker of LV dyssynchrony [13-16]. It was observed that 20-30% of 
patients with QRS duration ≥120 ms did not have LV dyssynchrony, which may (partially) ex-
plain lack of response to CRT [13]. Conversely, it was demonstrated that 20% to 50% of heart 
failure patients with a narrow QRS complex (<120 ms) may also exhibit LV dyssynchrony, and 
these patients may beneﬁt from CRT [13-15]. At present, minimal data are available regard-
ing the eﬀects of CRT in heart failure patients with a narrow QRS complex. Accordingly, the 
objective of the current study was to evaluate the eﬀects of CRT in heart failure patients with 
a narrow QRS complex and LV dyssynchrony. In addition, these eﬀects were compared to 
results obtained in a control group of heart failure patients with wide QRS complex and LV 
dyssynchrony.
METHODS
Patients and study protocol
Consecutive heart failure patients with evidence of LV dyssynchrony (≥65 ms) on tissue Dop-
pler imaging (TDI) who were scheduled for implantation of a CRT device were prospectively 
screened for inclusion into 2 groups based on the baseline QRS duration. The target sample 
size for each group was 33 patients and enrollment was continued until the target sample for 
each group was met. 
The ﬁrst group consisted of 33 consecutive patients with a narrow QRS complex (<120 ms), 
LV dyssynchrony ≥65 ms, severe heart failure (NYHA class III-IV) and LVEF ≤35%. The number 
of consecutive heart failure patients with a narrow QRS complex who were screened with TDI 
for the presence of LV dyssynchrony ≥65 ms was 105. The second group served as a control 
200
C
ha
pt
er
 1
4
group and included 33 consecutive patients with a wide QRS complex (≥120 ms), LV dyssyn-
chrony ≥65 ms, severe heart failure (NYHA class III-IV) and LVEF ≤35%. 
Patients with a recent myocardial infarction (<3 months) or decompensated heart failure 
were excluded. Before CRT implantation, clinical status (including NYHA class, quality-of-life 
score and 6-minute walking distance) and QRS duration were assessed. Two-dimensional 
echocardiography at rest was performed to calculate LV volumes and LVEF. Next, TDI was 
performed to evaluate LV dyssynchrony. QRS duration was re-assessed on the day after im-
plantation. The extent of LV dyssynchrony was re-assessed both on the day after implanta-
tion and at 6 months follow-up. Clinical status, LV volumes and LVEF were re-assessed at 6 
months follow-up.
Clinical evaluation 
Evaluation of clinical status included assessment of NYHA class, quality-of-life score (using 
the Minnesota quality-of-life questionnaire) and exercise capacity using the 6-minute hall-
walk test. QRS duration was measured from the surface ECG using the widest QRS complex 
from the leads II, V1 and V6. QRS duration was scored by two independent observers who 
were blinded to all other patient data.
Echocardiography
Resting echocardiography was performed at baseline, on the day after implantation and at 
6 months follow-up. LV dyssynchrony assessment using TDI was performed at baseline and 
repeated on the day after implantation. Patients were imaged in the left lateral decubitus 
position using a commercially available system (Vingmed Vivid Seven, General Electric-Ving-
med, Milwaukee, Wisconsin, USA). Images were obtained using a 3.5 MHz transducer, at a 
depth of 16 cm in the parasternal and apical views (standard long- and short-axis and two- 
and four chamber images). Standard two-dimensional and color Doppler data, triggered to 
the QRS complex were saved in cine-loop format. LV volumes (end-systolic, end-diastolic) 
were derived and LVEF was calculated from the conventional apical two- and four-chamber 
images, using the biplane Simpson’s technique [17].
Tissue Doppler imaging to assess LV dyssynchrony. In addition to the conventional 
echocardiographic examination, TDI was performed to assess LV dyssynchrony. For TDI, 
color Doppler frame rates were > 80 frames/s; pulse repetition frequencies were between 
500 Hz and 1 KHz, resulting in aliasing velocities between 16 and 32 cm/s. TDI parameters 
were measured from color-coded images of 3 consecutive heart beats by offline analysis. 
Data were analyzed using commercial software (Echopac version 5.0.1, General Electric 
– Vingmed).
To determine LV dyssynchrony, the sample volume (6 mm x 6 mm) was placed in the LV basal 
parts of the anterior, inferior, septal, and lateral walls (using the four- and two chamber apical 
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views) and per region, the time interval between the onset of the QRS complex and the peak 
systolic velocity was derived (i.e. the electro-systolic delays). LV dyssynchrony was deﬁned 
as the maximum delay between peak systolic velocities among the four walls within the left 
ventricle (most frequently observed between the inter-ventricular septum and the lateral 
wall) [10]. The analysis of peak systolic velocities was limited to the LV ejection period and 
post-systolic peaks were excluded. The opening and closure of the aortic valve were mea-
sured from the pulsed-wave Doppler signals in the LV outﬂow tract and subsequently super-
imposed on the TDI curves to mark the LV ejection period (using the “event-timing” function 
on the Echopac echo analysis software). To ensure highly interpretable and reproducible TDI 
curves (and minimize artefacts) high frame rates are crucial. The highest possible frame-rates 
were achieved by narrowing the four-and two chamber apical TDI views down to the left 
ventricle (i.e. excluding the right ventricle and atria). Previously reported inter- and intra-
observer agreement for assessment of LV dyssynchrony were 90% and 96%, respectively [13]. 
Based on previous data, a cut-oﬀ value of 65 ms was used as a marker of LV dyssynchrony 
[10]. All echocardiographic measurements were obtained by two independent observers 
without knowledge of the clinical status of the patient. 
Pacemaker implantation
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained during occlusion of the coronary sinus using a balloon catheter. 
Next, the LV pacing lead was inserted in the coronary sinus with the help of an 8Fr-guiding 
catheter, and positioned as far as possible in the venous system, preferably in the (postero-) 
lateral vein. The right atrial and right ventricular leads were positioned conventionally. When 
a conventional indication for an internal deﬁbrillator existed, a combined device was im-
planted. 
CRT device and lead implantation were completed without major complications (Contak TR 
or Contak Renewal TR2/1/2/4, Guidant, Minneapolis, Minnesota, USA and Insync (Marquis) 
III or Sentry, Medtronic Inc., Minneapolis, Minnesota, USA). Two types of LV leads were used 
(Easytrak, Guidant, or Attain, Medtronic Inc.).
Statistical analysis
Continuous data were expressed as mean ± SD and compared with the 2-tailed Student's t 
test for paired and unpaired data when appropriate. Comparison of proportions was per-
formed using the Fisher’s exact test. Linear regression analysis was performed to determine 
the relationship between QRS duration and LV dyssynchrony and LV dyssynchrony and 
percentage change in LV end-systolic volumes . For all tests a P-value <0.05 was considered 
statistically signiﬁcant.
The data were analysed using the SPSS for Windows version 11.0.1 (SPSS Inc, Chicago, Il-
linois).
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RESULTS
Patients with narrow QRS complex
Thirty-three patients with a narrow QRS complex and LV dyssynchrony ≥65 ms were included 
(28 men, mean age 63±11 years). Baseline patient characteristics are summarized in Table 1.
Following CRT implantation, QRS duration showed a slight but signiﬁcant increase from 
110±8 ms to 129±21 ms (P<0.001). TDI demonstrated an immediate decrease in LV dyssyn-
chrony from 102±32 ms to 35±29 ms (P<0.001), indicating acute LV resynchronization (Figure 
1), which remained unchanged at 6 months follow-up (44±35 ms, P<0.001 vs. baseline and 
P=NS vs. immediate post-implant). Figure 2 shows an example of TDI recordings in a patient 
with a narrow (panel A) and a wide QRS complex (panel B). 
Table 1. Baseline characteristics of the patients with QRS duration <120 ms (n=33) compared to patients with QRS duration ≥120 ms (n=33).
QRS <120 ms QRS ≥120 ms P-value
Age (yrs) 63±11 67±9 ns
Gender 
 male 28 (85%) 25 (76%) ns
 female 5 (15%) 8 (24%)
Etiology
 ischemic 23 (70%) 21 (64%) ns
 non-ischemic 10 (30%) 12 (36%)
QRS duration (ms) 110±8 175±22 <0.001
Rhythm 
 sinus rhythm 27 (82%) 26 (79%) ns
 atrial ﬁbrillation 6 (18%) 7 (21%)
NYHA functional class
 III 29 (88%) 29 (88%) ns
 IV 4 (12%) 4 (12%) 
Medication
 Diuretics 27 (82%) 30 (91%) ns
 ACE inhibitors 29 (88%) 28 (85%) ns
 Beta-blockers 25 (76%) 26 (79%) ns
Qol-score 39±18 42±15 ns
6-MWT (m) 274±133 253±124 ns
LVEF (%) 22±6 21±6 ns
LVEDV (ml) 216±78 238±72 ns
LVESV (ml) 174±75 189±60 ns
LV dyssynchrony (ms) 102±32 113±30 ns
6-MWT: 6-minute walking distance; LVEF: left ventricular ejection fraction; LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular 
end-systolic volume; NYHA: New York Heart Association; Qol: quality-of-life score.
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Figure 1. LV dyssynchrony before and 1 day post-CRT implantation in patients with narrow QRS complex (<120 ms, n=33) and in patients 
with wide QRS complex (≥120 ms, n=33). 
� �
Figure 2. Panel A: Color-coded tissue Doppler recordings in a heart failure patient with narrow QRS complex (96 ms). The tissue Doppler 
tracings are obtained from samples placed in the basal part of the septum and the lateral wall, demonstrating a delay in peak systolic velocities of 
85 ms (ﬁrst arrow indicates peak systolic velocity of septum, second arrow indicates peak systolic velocity of the lateral wall). Panel B: Color-
coded tissue Doppler recordings in a patient with wide QRS complex (170 ms) illustrating a delay of 140 ms.
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Clinical and echocardiographic changes after 6 months of CRT. At 6 months follow-up, all 
clinical and echocardiographic parameters improved signiﬁcantly (Figure 3). Mean NYHA class 
improved from 3.1±0.3 to 2.2±0.6 (P<0.001). The Minnesota quality-of life score improved 
from 39±18 to 25±17 (P<0.001) with a signiﬁcant improvement in 6-minute walking distance 
(from 274±133 m to 370±119 m, P<0.001). Of note, on a patient basis, 88% of patients showed 
a clinical response to CRT (deﬁned as an improvement ≥1 NYHA class).
Echocardiography at 6 months follow-up revealed a signiﬁcant improvement in LVEF (from 
22±6% to 30±8%, P<0.001) and signiﬁcant LV reverse remodeling with a decrease in LV end-
diastolic volume from 216 ± 78 ml to 189 ± 81 ml and a decrease in LV end-systolic volume 
from 174 ± 75 ml to 134 ± 64 ml (both P<0.001, Figure 3). 
No correlation was observed between baseline LV dyssynchrony and percentage change in 
LV end-systolic volume at 6 months follow-up (y=-0,1x-9, n=33, r=0.22, ns).
Patients with wide QRS complex
Thirty-three consecutive patients with wide QRS complex and LV dyssynchrony ≥ 65 ms were 
also included in the current study and served as a control group (25 men, mean age 67±9 
years). Baseline characteristics are summarized in Table 1. Following CRT implantation, QRS 
duration decreased from 175±22 ms to 150±22 ms (P<0.001). The day after pacemaker im-
���������
�
������ �����
�
��������
�
����������
�
�
��
��
��
��
��
��
�������� � ������
�
���
���
���
���
���
�������� � ������
�
��
��
��
��
�������� � ������
�
��
��
���
���
���
���
���
�������� � ������
Figure 3. Improvements in clinical and echocardiographic parameters at 6 months follow-up in patients with a narrow QRS complex (<120 
ms). (Qol = Quality-of-life; 6-min WT = 6-minute walking distance; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic 
volume, *=P<0.05).
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plantation, TDI demonstrated a reduction in LV dyssynchrony from 113±30 ms to 34±24 ms 
(P<0.001, Figure 1), indicating immediate LV resynchronization, which remained unchanged 
at 6 months follow-up (32±32 ms P<0.001 vs. baseline and P=NS vs. immediate post-implant). 
At 6 months follow-up 91% of patients showed a clinical response to CRT. 
Clinical and echocardiographic changes after 6 months of CRT. At 6 months follow-up, clini-
cal parameters had improved signiﬁcantly. Mean NYHA class improved from 3.1±0.3 to 2.0±0.6 
(P<0.001). The quality-of-life score improved signiﬁcantly from 42±15 to 25±15 (P<0.001) and 
the 6-minute walking distance improved from 253±124 m to 385±119 m (P<0.001). 
Using echocardiography, a signiﬁcant improvement in LVEF (from 21±6% to 30±9%, P<0.001) 
and a signiﬁcant decrease in LV volumes (LV end-systolic volume from 189±60 ml to 144±58 
ml, and LV end-diastolic volume from 238±72 ml to 203±66 ml, both P<0.001) were observed. 
No correlation was observed between baseline LV dyssynchrony and percentage change in 
LV end-systolic volume at 6 months follow-up.(y=0,1x-35, n=33, r=0.14, ns). 
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y=0.2x + 82, n=66, r=0.21, ns
Figure 4. No signiﬁcant relationship existed between LV dyssynchrony and QRS duration in the entire patient group (n =66), both before 
implantation (Panel A) and at 1 day after implantation of the CRT device (Panel B). 
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Patients with narrow QRS versus wide QRS complex 
Baseline characteristics. In Table 1 the baseline characteristics of the patients with narrow 
versus wide QRS complex are compared. Apart from the diﬀerence in baseline QRS duration, 
no signiﬁcant diﬀerences were observed in baseline clinical and echocardiographic param-
eters. In particular, baseline LV dyssynchrony was similar between both groups (102±32 ms 
vs. 113±30 ms, ns).
No signiﬁcant correlation was observed between baseline LV dyssynchrony and baseline QRS 
duration, neither in patients with narrow baseline QRS complex (y=0.7x + 21, n=33, r=0.18, 
ns) nor in patients with wide QRS complex (y=0.2x + 86, n=33, r=0.11, ns) (pooled data pre-
sented in Figure 4A). 
Follow-up. In patients with narrow QRS complex at baseline, QRS duration showed a signiﬁ-
cant increase following CRT implantation, whereas QRS decreased in patients with baseline 
QRS duration ≥120 ms. The change in QRS duration was signiﬁcantly diﬀerent between both 
groups (Table 2). In contrast, the reduction in LV dyssynchrony (resynchronization) following 
CRT implantation was comparable between both patient groups (Table 2, Figure 1A/B).
Similar to the situation before CRT implantation, no signiﬁcant relation between the QRS 
duration and LV dyssynchrony could be assessed at 1 day post-implantation (Figure 4B). 
At 6 months follow-up, the magnitude of improvement in clinical parameters was not diﬀer-
ent between both patients groups. For example, NYHA class improved by 0.9±0.6 in patients 
with narrow QRS as compared to 1.1±0.6 in patients with wide QRS. Also, the magnitude of 
improvement in LVEF and the extent of LV reverse remodeling were comparable (Table 2). 
DISCUSSION
The eﬀects of CRT in this pilot study including heart failure patients with narrow QRS complex 
(<120 ms) and LV dyssynchrony can be summarized as follows. CRT resulted in an immediate 
reduction in LV dyssynchrony, which was followed at 6 months by an improvement in clinical 
symptoms and LVEF with LV reverse remodeling. Moreover, the extent of LV resynchroniza-
tion and the magnitude of clinical and echocardiographic improvement were comparable in 
a control group of patients with wide QRS complex and LV dyssynchrony.
QRS complex versus LV dyssynchrony
Recent studies have indicated that the key mechanism of beneﬁt from CRT is the resynchro-
nization of LV contraction. It was demonstrated that patients with extensive LV dyssynchrony 
at baseline improved in clinical symptoms and LV function following CRT, whereas patients 
without baseline LV dyssynchrony did not improve [6-10]. 
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Traditionally, the duration of the QRS complex on surface ECG has been used as a marker of 
LV dyssynchrony and consequently only patients with a wide QRS complex (>120-150 ms) 
were included in large trials [1-4,11,12]. However, recent data indicated that the QRS duration 
does not adequately reﬂect LV dyssynchrony [13-16, 18], as illustrated also in the current 
study (Figure 3). The lack of a relation between QRS duration and LV dyssynchrony has been 
reported not only in patients with wide QRS complex, but also in patients with narrow QRS 
complex. Moreover, various studies demonstrated that severe LV dyssynchrony may be pres-
ent in 20% to 50% of patients with narrow QRS complex [13-15,18], suggesting that CRT may 
also be beneﬁcial in heart failure patients with narrow QRS complex, provided the presence 
of severe LV dyssynchrony. This is an important issue, since the majority of heart failure pa-
tients may not show prolongation of the QRS complex and recent observations suggested 
that QRS widening >120 ms may only occur in 30% of heart failure patients [19-21]. Thus, 
the majority of the heart failure patients have a narrow QRS complex and are currently not 
eligible for CRT [19-21]. 
However, preliminary data from 2 small studies suggested that heart failure patients with 
narrow QRS complex may beneﬁt from CRT [22,23]. Turner et al. [22] studied only the acute 
eﬀects of CRT in a group of 20 heart failure patients with a QRS duration ≤120 ms. In these 
patients, CRT resulted in an acute hemodynamic improvement, in particular in patients with 
a pulmonary capillary wedge pressure >15 mmHg [22]. In addition, Achilli et al. studied the 
eﬀects of CRT in a group of 14 heart failure patients with a QRS duration ≤120 ms and com-
pared these eﬀects to a control group of 38 heart failure patients with a QRS duration >120 
ms [23]. All patients had evidence of LV dyssynchrony on M-mode echocardiography in com-
bination with inter-ventricular dyssynchrony. The authors demonstrated that the clinical and 
functional beneﬁt was similar in heart failure patients with wide and narrow QRS complex 
[23]. 
In the current study, both the immediate and mid-term eﬀects of CRT were evaluated in a 
group of 33 consecutive heart failure patients with a narrow QRS complex (≤120 ms), with LV 
dyssynchrony as detected by TDI. 
Eﬀects of CRT in patients with narrow QRS complex
Immediately following CRT implantation, a signiﬁcant reduction in LV dyssynchrony was ob-
served, indicating LV resynchronization. This reduction in LV dyssynchrony was comparable 
between patients with narrow and wide QRS complex, which is an important observation 
since recent studies indicated that resynchronization of LV dyssynchrony is the predominant 
mechanism underlying beneﬁt from CRT [6-10]. 
At 6 months follow-up, clinical status improved signiﬁcantly as evidenced by improvement in 
NYHA class, quality-of life score and 6-minute walking distance. Importantly, the magnitude 
of beneﬁt was comparable between patients with narrow and wide QRS complex. The clini-
cal improvement was associated with an improvement in LV systolic function and a reverse 
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LV remodeling. These ﬁndings clearly indicate the beneﬁcial eﬀects of CRT in patients with 
narrow QRS complex.
Of note, the magnitude of beneﬁcial eﬀects was not diﬀerent from patients with wide QRS 
complex.
Limitations
Various limitations need to be addressed. Patients with narrow QRS complex, but without LV 
dyssynchrony (<65 ms) on TDI were not included in the current study. However, recent studies 
in patients with QRS duration ≥120 ms have indicated that patients without LV dyssynchrony 
at baseline did not beneﬁt from CRT [6,10]. In addition, a control group of narrow QRS pa-
tients without CRT was not included, and needs to be evaluated in future studies. In addition, 
the current ﬁndings need conﬁrmation in larger studies. Moreover, whether CRT will improve 
survival in heart failure patients with narrow QRS complex remains to be determined.
In the present study, LV dyssynchrony was assessed from 4 basal LV segments [10], however 
evaluation of more segments may further improve accurate assessment of LV dyssynchrony.
Also, color-coded TDI measures the velocity of the myocardium, which may not always equal 
active myocardial contraction. Other echocardiographic techniques, e.g. strain and strain 
rate imaging, can discriminate between active and passive myocardial motion. Large, com-
parative studies are needed to deﬁne which technique is most accurate in assessment of LV 
dyssynchrony.
Finally, the importance of postero-lateral scar formation for response to CRT has recently 
been demonstrated [24]. The presence of postero-lateral scar tissue may be one of the expla-
nations for the lack of improvement in patients, despite the presence of baseline LV dyssyn-
chrony. In the current study, however, data on scar tissue were not systematically available. 
Conclusion
CRT has comparable eﬀects in heart failure patients with narrow QRS complex as compared 
to patients with wide QRS complex in terms of LV resynchronization, improvement in clinical 
symptoms, LVEF and LV reverse remodeling. These beneﬁcial eﬀects need conﬁrmation in 
studies with larger populations. 
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ABSTRACT
Cardiac resynchronization therapy (CRT) is beneﬁcial in selected patients with moderate-
to-severe heart failure (New York Heart Association (NYHA) class III-IV). Patients with mildly 
symptomatic heart failure (NYHA class II) are currently not eligible for CRT and potential ben-
eﬁcial eﬀects in these patients are not well studied. 
Fifty consecutive patients with NYHA class II heart failure and 50 consecutive NYHA class III-IV 
patients (control group) were prospectively included. All patients had left ventricular (LV) 
ejection fraction (EF) ≤35% and QRS duration >120 ms. The eﬀects of CRT in NYHA class II 
patients were compared to results obtained in the control group. 
The severity of baseline LV dyssynchrony (assessed with color-coded tissue Doppler imaging) 
was comparable between patients in NYHA class II vs NYHA class III-IV (83±49 ms vs 96±51 
ms, ns), and resynchronization was achieved in both groups. NYHA class II patients showed a 
signiﬁcant improvement in LVEF (from 25±7% to 33±10%, P<0.001) and reduction in LV end-
systolic volume (from 168±55 ml to 132±51 ml, P<0.001) following CRT, similar to patients in 
NYHA class III-IV. In addition, only 8% of NYHA class II patients showed progression in heart 
failure symptoms. 
In conclusion, CRT has comparable eﬀects in patients with NYHA class II and NYHA class III-IV 
heart failure in terms of LV resynchronization, improvement in LVEF and LV reverse remodel-
ing. 
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INTRODUCTION
Currently, patients presenting with mildly symptomatic heart failure (New York Heart Associa-
tion (NYHA) class II) are not eligible for cardiac resynchronization therapy (CRT) [1,2]. Nonethe-
less, patients with heart failure NYHA class II may also exhibit reduced left ventricular (LV) ejec-
tion fraction (EF) and LV dilatation in combination with a widened QRS complex. In view of 
the recent observations showing that CRT halts the progression of heart failure and resulted 
in improvement of LVEF and reversal of LV dilatation [3-5], it seems plausible that CRT may 
also improve LV function and reverse LV dilatation in patients with mildly symptomatic heart 
failure and severely impaired LV function. In addition, CRT may also prevent the progression of 
heart failure towards NYHA class III-IV. At present, the eﬀects of CRT in patients with NYHA class 
II and systolic LV dysfunction are not well studied and it is unknown whether the eﬀects are 
comparable to the results of CRT in patients with NYHA class III or IV. Accordingly, the objective 
of the current study was to evaluate the eﬀects of CRT in patients with mildly symptomatic 
heart failure (NYHA class II), LVEF ≤35% and a widened QRS complex (>120 ms) and to compare 
these eﬀects to the beneﬁts of CRT in a control group of patients in NYHA class III or IV with 
established selection criteria (LVEF ≤35%, and QRS duration >120 ms).
METHODS
Patients and study protocol
Patients who were scheduled for the implantation of a biventricular pacemaker were pro-
spectively included into 2 groups based on baseline NYHA functional class. 
The ﬁrst group consisted of 50 consecutive patients with mildly symptomatic heart failure 
(NYHA class II), LVEF ≤35% and QRS duration >120 ms. 
The second group served as a control group and included 50 consecutive patients in NYHA 
class III or IV with established selection criteria for CRT (LVEF ≤35% and QRS duration>120 ms). 
Patients with a recent myocardial infarction (<3 months) or decompensated heart failure were 
excluded. Before pacemaker implantation, clinical status (including NYHA class, quality-of-
life score and 6-minute walking distance) and QRS duration were assessed. Two-dimensional 
echocardiography at rest was performed to calculate LV volumes and LVEF. Next, color-coded 
tissue Doppler imaging (TDI) was performed to evaluate LV dyssynchrony. LV dyssynchrony 
and QRS duration were re-assessed on the day after implantation. Clinical status, LV volumes 
and LVEF were re-assessed at 6 months follow-up. 
Clinical Evaluation
Evaluation of clinical status included assessment of NYHA class, quality-of-life score (using 
the Minnesota quality-of-life questionnaire) and assessment of exercise capacity using the 
214
C
ha
pt
er
 1
5
6-minute hall-walk test. NYHA class II was deﬁned as shortness of breath during normal exer-
cise, NYHA class III was deﬁned as dyspnea during less minimal exercise (e.g. not able to climb 
1 ﬂight of stairs) and NYHA class IV was deﬁned as shortness of breath at rest. The assessment 
of NYHA class and other clinical parameters was performed by an independent physician, 
who was blinded to all other patient data. In all patients, QRS duration was measured from 
the surface ECG using the widest QRS complex from the leads II, V1 and V6. 
Echocardiography
Resting echocardiography and color-coded TDI were performed at baseline and on the day 
after implantation. Patients were imaged in the left lateral decubitus position using a com-
mercially available system (Vingmed Vivid Seven, General Electric-Vingmed, Milwaukee, 
Wisconsin, USA). Images were obtained using a 3.5 MHz transducer, at a depth of 16 cm in 
the parasternal and apical views (standard long- and short-axis and two- and four-chamber 
images). Standard two-dimensional and color Doppler data, triggered to the QRS complex 
were saved in cine loop format. LV volumes (end-systolic, end-diastolic) were derived and 
LVEF was calculated from the conventional apical two- and four-chamber images, using the 
biplane Simpson’s technique [6]. 
In addition to the conventional echocardiographic examination, color-coded TDI was per-
formed to assess LV dyssynchrony. For TDI, color Doppler frame rates varied between 80 and 
115 frames/s depending on the sector width of the range of interest; pulse repetition fre-
quencies were between 500 Hz and 1 KHz, resulting in aliasing velocities between 16 and 32 
cm/s. Color-coded TDI parameters were measured from color images of 3 consecutive heart 
beats by oﬄine analysis. Data were analyzed using commercial software (Echopac version 
4.0.3., General Electric – Vingmed).
To determine LV dyssynchrony, the color-coded TDI sample volume was placed in the basal 
portions of the septum and the LV lateral wall; peak systolic velocities and time-to-peak sys-
tolic velocities were obtained and the delay in peak velocity between the septum and the LV 
lateral wall was calculated as an indicator of LV dyssynchrony (referred to as the septal-to-
lateral delay) [7,8]. Inter- and intra-observer agreement for assessment of the septal-to-lateral 
delay were 90% and 96%, respectively [9]. 
The severity of mitral regurgitation was graded semi-quantitatively from color-ﬂow Doppler 
images. For quantiﬁcation of mitral regurgitation, the apical 4-chamber images were used. 
Mitral regurgitation was classiﬁed as: mild=1+ (jet area/ left atrial area <10%), moderate=2+ 
(jet area/ left atrial area 10-20%), moderately severe =3+ (jet area/left atrial area 20-45%), and 
severe=4+ (jet area/ left atrial area >45%) [10]. 
All echocardiographic measurements were obtained by 2 independent observers without 
knowledge of the clinical status of the patient. 
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Pacemaker Implantation 
The LV pacing lead was inserted transvenously via the subclavian route. First, a coronary si-
nus venogram was obtained during occlusion of the coronary sinus using a balloon catheter. 
Next, the LV pacing lead was inserted in the coronary sinus with the help of an 8Fr-guiding 
catheter, and positioned as far as possible in the venous system, preferably in the (postero-) 
lateral vein. The right atrial and right ventricular leads were positioned conventionally. When 
a conventional indication for an internal deﬁbrillator existed, a combined device was im-
planted. For each patient the atrio-ventricular interval was adjusted to maximize the mitral 
inﬂow duration using pulsed-wave Doppler echocardiography. No adjustments were made 
to the V-V interval during the ﬁrst 6 months of CRT. 
CRT-device and lead implantation was successful in all patients without major complications 
(Contak TR or Contak Renewal TR2/1/2/4, Guidant, Minneapolis, Minnesota, USA and Insync 
(Marquis) III or Sentry, Medtronic Inc., Minneapolis, Minnesota, USA). Two types of LV leads 
were used (Easytrak, Guidant, or Attain, Medtronic Inc.). 
Statistical Analysis
Continuous data were expressed as mean ± SD and compared with the 2-tailed Student's t 
test for paired and unpaired data when appropriate. Univariate analysis for categorical vari-
ables was performed using the chi-square test with Yates' correction. For all tests a P-value 
<0.05 was considered statistically signiﬁcant.
RESULTS
NYHA class II patients
Fifty patients with mildly symptomatic heart failure (NYHA functional class II) were included 
in this study (47 male, mean age 65±10 years). Baseline patient characteristics are summa-
rized in Table 1.
Following CRT implantation, QRS duration decreased from 160±30 ms to 148±20 ms (P<0.01). 
The day after pacemaker implantation, TDI demonstrated a reduction in LV dyssynchrony 
from 83±49 ms to 35±30 ms (P<0.001), indicating immediate LV resynchronization. 
At 6 months follow-up, all clinical parameters showed a small, but signiﬁcant improvement. 
Eighteen patients had improved to NYHA class I, whereas 28 patients remained in NYHA 
functional class II and only 4 patients had deteriorated to NYHA functional class III (Figure 
1). A modest, but signiﬁcant improvement in mean NYHA class was observed from 2±0 to 
1.7±0.6 (P<0.01). The quality-of life score improved from 22±14 to 13±13 (P<0.001) and a 
small but signiﬁcant improvement was observed in 6-minute walking distance (from 430±94 
m to 469±118 m, P<0.01, Figure 2).
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Echocardiography at 6 months follow-up revealed a signiﬁcant improvement in LVEF (from 
25±7% to 33±10%, P<0.001) and signiﬁcant LV reverse remodeling with a decrease in LV end-
diastolic volume from 219± 63 ml to 191± 51 ml (P<0.001) and a decrease in LV end-systolic 
volume from 168± 55 ml to 132± 51 ml (P<0.001, Figure 2). A reduction in mitral regurgitation 
was observed from grade 1.2±0.8 to 1.0±0.8 (P=0.01).
The patients who improved by 1 NYHA class at 6 months follow-up (n=18) and the patients 
who remained in NYHA class II (n=28) showed a signiﬁcant improvement in LVEF and LV 
volumes following CRT. The improvements in LVEF (7±11% versus 11±10%, respectively, ns) 
and reduction in LV end-systolic volume (48±42 ml versus 33±37 ml, respectively, ns) were 
slightly (but not signiﬁcant), higher in the patients who also improved in NYHA class (n=18, 
see Figure 3). 
Table 1. Baseline characteristics of the patients in New York Heart Association class II (n=50) compared to the patients in New York Heart 
Association class III-IV (n=50).
NYHA II NYHA III-IV P-value
Age (years) 65±10 66±11 ns
Gender 
 male 47 (94%) 41 (82%) ns
 female 3 (6%) 9 (18%)
Etiology
 ischemic 29 (58%) 28 (56%) ns
 non-ischemic 21 (42%) 22 (44%)
QRS duration (ms) 160±30 168±27 ns
QRS complex conﬁguration 
 Left bundle branch block 33 (66%) 32 (64%) ns
 Intra-ventricular conduction disorder 9 (18%) 8 (16%)
 Right bundle branch block 4 (8%) 3 (6%)
 Right ventricular paced 4 (8%) 7 (14%)
Rhythm 
 sinus rhythm 42 (84%) 44 (88%) ns
 atrial ﬁbrillation 8 (16%) 6 (12%)
Medication
 Diuretics 38 (76%) 43 (86%) ns
 ACE inhibitors 48 (96%) 44 (88%) ns
 Beta-blockers 35 (70%) 31 (62%) ns
Quality-of-life score 22±14 45±11 <0.05
6-minute walking distance (m) 430±94 243±103 <0.05
LV dyssynchrony ≥65 ms 32 (64%) 36 (72%) ns
LV ejection fraction (%) 25±7 20±7 <0.05
LV end-diastolic volume (ml) 219±63 243±90 ns
LV end-systolic volume (ml) 168±55 195±82 ns
Severe mitral regurgitation (grade 3-4+) 3 (6%) 12 (24%) <0.05
LV dyssynchrony (ms) 83±49 96±51 ns
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Figure 1. Change in NYHA functional class after 6 months of CRT in NYHA class II patients.
Figure 2. Improvements in clinical and echocardiographic parameters at 6 months follow-up in NYHA class II patients (Qol = Quality-of-life; 
6-min WT = 6-minute walking distance; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume, *=P<0.05).
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In contrast, the 4 patients who deteriorated to NYHA functional class III did not show im-
provement in LVEF or LV volumes (Figure 3). 
NYHA class III-IV patients (control group)
Fifty patients with moderate-to-severe heart failure (NYHA class III-IV) were included in the 
current study (41 male, mean age 66±11 years). At baseline 43 patients were in NYHA func-
tional class III and 7 patients were in NYHA class IV. Other baseline patient characteristics are 
summarized in Table 1.
Following CRT implantation, QRS duration decreased from 168±27 ms to 150±25 ms (P<0.001). 
The day after pacemaker implantation, TDI demonstrated a reduction in LV dyssynchrony 
from 96±51 ms to 31±27 ms (P<0.001), indicating immediate LV resynchronization. 
At 6 months follow-up, clinical parameters had improved signiﬁcantly. Mean NYHA class 
improved from 3.1±0.4 to 2.1±0.7 (P<0.001). The quality-of-life score improved signiﬁcantly 
from 45±11 to 29±15 (P<0.001) and the 6-minute walking distance improved from 243±103 
m to 370±150 m (P<0.001). 
Using echocardiography a signiﬁcant improvement in LVEF (from 20±7% to 27±10%, P<0.001) 
and a signiﬁcant decrease in LV volumes (LV end-systolic volume from 195±82 ml to 166±73 
ml, and LV end-diastolic volume from 243±90 ml to 221±78 ml, both P<0.001) were observed. 
Mitral regurgitation showed a reduction from grade 1.6±0.9 to 1.2±0.7 (P<0.001).
Figure 3. Magnitude of LV reverse remodeling at 6 months follow-up in NYHA class II patients with improvement in NYHA class (n=18) versus 
patients with unchanged NYHA class (n=28) or with deterioration in NYHA class (n=4, *=P<0.05).
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NYHA class II patients versus NYHA class III-IV patients
In Table 1 the baseline characteristics of the NYHA class II patients are compared to the 
baseline characteristics of the NYHA class III-IV patients. No diﬀerences were observed in 
age, gender and etiology of heart failure. The quality-of-life score and the 6-minute walk-
ing distance were signiﬁcantly lower in the NYHA class III-IV patients compared to the NYHA 
class II patients. The number of patients with LV dyssynchrony ≥65 ms was comparable in 
both groups (n=32 (64%) vs. n=36 (74%), P=ns). In addition, LVEF was signiﬁcantly higher in 
patients with NYHA class II (25±7% vs. 20±7%, P<0.05). Moreover, severe mitral regurgitation 
was less frequently observed in patients with NYHA class II. 
 The immediate reduction in LV dyssynchrony following CRT implantation was comparable 
between the NYHA class II patients and the NYHA class III-IV patients, indicating a similar level 
of LV resynchronization in both groups (Table 2). 
At 6 months follow-up, both the patients in NYHA class II (Figure 2) and the patients in NYHA 
class III-IV showed a signiﬁcant improvement in clinical and echocardiographic characteristics. 
However, the magnitude of improvement in clinical parameters was signiﬁcantly less in the 
NYHA class II patients. This diﬀerence was most outspoken for the reduction in NYHA class 
(0.3±0.6 versus 1.0±0.8, respectively, P<0.001) and the level of improvement in 6-minute 
walking distance (38±87 m versus 127±108 m, respectively, P<0.001).
Table 2. Magnitude of improvement in clinical and echocardiographic parameters following cardiac resynchronization therapy. Patients with 
baseline New York Heart Association class class II (n=50) are compared to patients with New York Heart Association class III-IV (n=50) 
NYHA II NYHA III-IV P-value
Immediate post-implant
Shortening in
QRS duration (ms)
11±26 18±30 ns
Reduction in
LV dyssynchrony (ms)
48±50 65±53 ns
6 months follow-up
Reduction in
NYHA class 
0.3±0.6 1.0±0.8 <0.001
Improvement in
6-minute walking distance 
(m)
38±87 127±108 <0.001
Reduction in
Quality-of-life score
8±11 16±14 <0.001
Improvement in
LV ejection fraction (%)
7±11 7±7 ns 
Reduction in
LV end-diastolic volume (ml)
28±38 22±43 ns
Reduction in
LV end-systolic volume (ml)
36±41 29±42 ns
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In contrast, the improvement in echocardiographic parameters was comparable between the 
NYHA class II patients and the patients in NYHA class III-IV. Both the increase in LVEF (7±11% 
versus 7±7%, respectively, ns) and the decrease in LV volumes were similar (Table 2).
In line with previous studies, only the patients with substantial LV dyssynchrony in both 
groups improved in LV function and showed a reduction in LV dyssynchrony (e.g. in the NYHA 
class II patients with LV dyssynchrony ≥65 ms (n=32) LVEF improved from 24±6% to 36±9% 
as compared to an improvement from 20±7% to 29± 9% in NYHA class III-IV patients, both 
P<0.001), whereas the patients without LV dyssynchrony at baseline showed no reduction in 
LV dyssynchrony and did not improve in LV function (e.g. in the NYHA class II patients with LV 
dyssynchrony < 65 ms (n=18) LVEF did not change (from 27±7% to 27±10%) and in the NYHA 
class III-IV patients with LV dyssynchrony <65 ms (n=14) LVEF changed from 21±8% to and 
22± 12%, both P=ns) 
DISCUSSION
The ﬁndings in the current study demonstrate that CRT induced signiﬁcant LV reverse remod-
eling with an improvement in LVEF in patients with systolic LV dysfunction and NYHA class II 
heart failure. The improvement in LV function was not restricted to patients who improved 
in NYHA class, but was also observed in patients without improvement in NYHA class at 6 
months follow-up. Only 4 patients (8%) showed a progression of heart failure towards NYHA 
class III and these patients failed to show an improvement in LVEF or LV reverse remodeling. 
The magnitude of improvement in LVEF and LV volumes in the NYHA class II patients was 
comparable to that observed in patients in NYHA class III or IV, whereas the improvement in 
clinical parameters was signiﬁcantly less compared to the patients in NYHA class III or IV. 
In the present study the eﬀects of CRT in patients with mildly symptomatic heart failure 
(NYHA class II) and systolic dysfunction were studied. These patients were less symptom-
atic as evidenced by a relatively low Minnesota score and long 6-minute walking distance. 
However, despite the presence of relatively mild symptoms of heart failure, all patients had 
severely impaired systolic LV function, severe LV dilatation and substantial LV dyssynchrony. 
Directly after CRT implantation, LV dyssynchrony decreased signiﬁcantly, indicating resyn-
chronization of LV contraction. This acute LV resynchronization was followed by a signiﬁcant 
improvement in both clinical and echocardiographic parameters at 6 months follow-up. The 
magnitude of improvement in clinical parameters was limited, as evidenced by the fact that 
only 36% of patients improved to NYHA class I, and NYHA class remained unchanged in 56% 
of patients. This ﬁnding is not surprising in view of the minimal symptoms at baseline. Impor-
tantly, the percentage of patients with a progression of heart failure symptoms to NYHA class 
III was low (8%), suggesting that CRT may prevent the progression of heart failure symptoms 
in NYHA class II patients. Similar observations have been reported by Abraham et al. in NYHA 
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class II patients undergoing CRT [11]. In addition, CRT may also prevent the progression/or 
prevention of heart failure in patients with an impaired LV function and an indication for a 
conventional pacemaker [12,13].
In contrast to the minimal improvements in clinical symptoms, the improvements in LV 
function after 6 months of CRT were substantial, as evidenced by considerable LV reverse 
remodeling and markedly improved LVEF. Of note, LV reverse remodeling and improvement 
in LVEF were not restricted to patients who improved in NYHA class, but were also present in 
patients without improvement in NYHA class. The patients with deterioration to NYHA class 
III however, did not improve in LV function. This is in line with the study by Higgins et al. who 
showed that the NYHA class I-II patients did not improve in clinical symptoms compared to a 
placebo group, however these patients did show a signiﬁcant reduction in LV volumes com-
pared to the placebo group [14]. In a cohort of patients in NYHA class III or IV, Yu et al. have 
recently demonstrated that the positive eﬀect of CRT on cardiac function, in particular the 
decrease in LV systolic volume, predicted improvement in survival following CRT whereas the 
improvement in clinical parameters did not predict long-term prognosis [15]. In view of these 
data, the substantial improvement in LV function (and particularly the LV reverse remodeling) 
observed in the NYHA class II patients is likely to be of clinical relevance [15]. Our results are 
in contrast to results reported by Kuhlkamp et al; these authors did not ﬁnd an improvement 
in clinical and echocardiographic parameters in NYHA class II [16]. 
The percentage of NYHA class II patients exhibiting progression of symptoms to NYHA class 
III following CRT is very low (8%), suggesting that CRT may prevent progression of heart fail-
ure in these patients. To ﬁrmly draw this conclusion, a control group of NYHA class II patients 
without CRT should have been included. This was indeed shown by Abraham recently, dem-
onstrating less progression of heart failure symptoms in NYHA class II patients undergoing 
CRT as compared to NYHA class II patients treated medically [11]. The strength however of 
the current study is the comparison with NYHA class III-IV patients showing comparable ef-
fect on improvement in LV function and LV reverse remodeling.
Follow-up after CRT was assessed at 6 months and sustained eﬀect at longer follow-up needs 
to be conﬁrmed in future studies.
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INTRODUCTION
At present, cardiac resynchronization therapy (CRT) is considered an important step forward 
in the treatment of patients with severe heart failure. To date, several large randomized trials 
have shown the sustained beneﬁcial eﬀects of CRT on heart failure symptoms and left ven-
tricular (LV) function [1-3]. However, in parallel to the impressive results of CRT in these large 
trials, a consistent percentage of patients did not respond to CRT (non-responders) when the 
traditional patient selection criteria (New York Heart Association (NYHA) class III-IV, LV ejec-
tion fraction <35% and QRS duration >120 ms) were applied [1,4,5].
When response to CRT is deﬁned using clinical parameters (e.g. improvement in NYHA class or 
quality-of life) the prevalence of non-responders is about 30% and when echocardiographic 
parameters (LV reverse remodeling, improvement in LV ejection fraction) are applied, the 
number of non-responders is usually around 40% [4,5]. 
The reduction of the number of non-responders is one of the main challenges in the ﬁeld 
of CRT today. Recent studies have indicated that selection of patients with a high likelihood 
of response is possible with several (novel) echocardiographic techniques [6] (Table 1). In 
addition to patient selection, echocardiography is also useful to assess acute and long-term 
beneﬁcial eﬀects of CRT. Moreover, echocardiography is needed for the optimization of pace-
maker settings [7-11]. These issues are discussed in the current review.
I. ECHOCARDIOGRAPHY TO PREDICT RESPONSE TO CRT
Recent studies, addressing the issue of non-response to CRT have indicated that none of the 
traditional selection criteria (NYHA class III-IV, LV ejection fraction ≤35% and QRS duration 
>120 ms) were able to predict a positive response to CRT, thereby highlighting the need for 
improvement of the selection criteria [5,12]. In search for better selection criteria, it has become 
clear that the key mechanism of beneﬁt from CRT is the presence and subsequent reduction 
of LV dyssynchrony [4,5]. Traditionally, QRS duration has been used as an (indirect) marker of 
LV dyssynchrony. The duration of the QRS complex, however proved to be a poor marker of LV 
Table 1: the most widely used techniques to assess LV dyssynchrony 
M-mode echocardiography
Pulsed-wave tissue Doppler imaging
Color-coded tissue Doppler imaging
Tissue synchronization imaging
Strain imaging 
Real time 3D echocardiography
228
C
ha
pt
er
 1
6
dyssynchrony, thereby explaining its low predictive value for response to CRT [13,14]; indeed, 
QRS duration merely reﬂects inter (right versus left) ventricular dyssynchrony [15].
Various studies have recently demonstrated that patients with extensive baseline LV dys-
synchrony had a high likelihood of response to CRT, whereas patients without baseline LV 
dyssynchrony did not respond to CRT. Of note, although inter-ventricular dyssynchrony (be-
tween the right and the left ventricle) tends to decrease after CRT, this parameter has limited 
value for the prediction of response to CRT [5,8].
Many diﬀerent techniques have been tested for their ability to detect and quantify LV dyssyn-
chrony in CRT patients. Since this observation, several cardiac imaging techniques have been 
tested for their ability to detect and quantify LV dyssynchrony. Among the diﬀerent tech-
niques, echocardiography proved particularly well suited for detection of LV dyssynchrony 
in the clinical setting.
The most important echocardiographic techniques to detect LV dyssynchrony in CRT pa-
tients will be discussed hereafter and are summarized in Table 1, ranging from simple M-
mode echocardiography to more sophisticated echocardiographic techniques, such as tissue 
Doppler imaging (TDI), strain (rate) imaging and 3D-echocardiography. 
A. M-mode echocardiography 
A relatively simple and elegant echocardiographic technique for the detection of LV dys-
synchrony has been developed by Pitzalis et al. who used M-mode echocardiography to 
measure the delay between the systolic excursion of the (antero-) septum and the posterior 
wall on the parasternal short-axis view, the so-called septal to posterior wall motion delay 
(SPWMD, Figure 1A) [16,17]. In an initial study, including 20 patients, responders to CRT had a 
signiﬁcantly larger SPWMD as compared to non-responders. Using a cut-oﬀ value of 130 ms, 
SPWMD yielded an accuracy of 85% (sensitivity 100%, speciﬁcity 63%) to predict response 
after CRT [16]. In a subsequent study the same authors evaluated another 60 patients and 
demonstrated that the cut-oﬀ value of 130 ms was a strong predictor of patient prognosis 
following CRT implantation [17]. 
In contrast however, Marcus et al. recently revealed less favourable results with this technique. 
The SPWMD measurement was applied retrospectively in a large cohort (n=79 patients, 72% 
ischemic cardiomyopathy) of heart failure patients who were included in the CONTAK-CD 
trial [18]. The authors reported a sensitivity of 24% with a speciﬁcity of 66% to predict re-
sponse to CRT, and the SPWMD could not be assessed in 50% of patients (Figure 1B). Recent 
data in 98 heart failure patients scheduled for CRT indicated that the poor interpretability of 
the SPWMD recordings was the result of the absence of a clear systolic motion on M-mode 
echocardiography due to akinesia of the inter-ventricular septum (53%), the posterior wall 
(12%) or both (3%) or a poor acoustic window in the parasternal view (32%). Of note, in the 
patients without an interpretable SPWMD, LV dyssynchrony assessment was still feasible in 
90% of patients when color-coded TDI was applied [19]. 
Optimal use of echocardiography in CRT 229
B. Tissue Doppler imaging 
One of the most widely studied techniques for the assessment of LV dyssynchrony in the 
selection of CRT patients is TDI. This technique allows the measurement of peak systolic ve-
locities in diﬀerent regions of the myocardium [4,5,20], and more importantly, the time-in-
tervals between electrical activity (QRS) and the mechanical activity (segmental peak systolic 
velocity) (Figure 2).
The myocardial velocity curves can either be constructed on-line using pulsed-wave TDI (Fig-
ure 3), or reconstructed oﬀ-line from the 2D color-coded TDI images (Figure 2). The advan-
tages of color-coded TDI over pulsed-wave TDI are the possibility for oﬀ-line analysis and the 
possibility to analyse multiple segments in one heart beat thereby avoiding potential errors 
�
�
Figure 1: Panel A: Measurement of the septal to posterior wall motion delay (SPWMD) using M-mode echocardiography. An M-mode 
recording through the (antero-) septum and posterior LV wall is obtained in the parasternal short-axis view. LV dyssynchrony is deﬁned as the 
shortest interval between the maximal systolic displacement of the septum and the maximum systolic displacement of the LV posterior wall. 
Arrows indicate maximal systolic displacement. Panel B: Patient example in which assessment of LV dyssynchrony was not feasible with M-
mode echocardiography due to akinesia of the antero-septal wall. 
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from diﬀerences in cardiac frequency. In addition, the peak systolic velocity is displayed more 
accurate when color-coded TDI is applied. 
In order to assess regional dyssynchrony, one commonly used method is to measure the 
time to peak systolic velocity of individual left ventricular (LV) segments with reference to 
the QRS complex [4,5]. Integration of this information allows accurate assessment of elec-
tromechanical coupling, estimation of severity of LV global delay, as well as evaluation of LV 
dyssynchrony (Figure 4).
PSV
E’
A’
Figure 2: Color-coded tissue Doppler imaging in the apical 4-chamber view in a normal individual. The sample is placed oﬀ-line in the basal 
part of the septum, demonstrating peak systolic velocity (PSV), and diastolic parameters (E’ and A’). (AVO en AVC indicate aortic valve opening 
and closure, respectively). 
PSV
E’
A’
Figure 3: Pulsed-wave tissue Doppler imaging in the apical 4-chamber view in a normal individual. The pulsed-wave sample is placed on-
line in the region of interest (basal part of the inter-ventricular septum) and the myocardial velocity curve is derived. (PSV = peak systolic 
velocity, E’ and A’ represent diastolic parameters).
Optimal use of echocardiography in CRT 231
The number of segments used for evaluation of LV dyssynchrony varied among the diﬀerent 
studies. Most frequently, 2 or 4 basal segments (septal, lateral, inferior, anterior) are evalu-
ated. Bax et al. [5] evaluated 85 heart failure patients with follow-up data obtained up to 1 
year. Receiver operating characteristic curve analysis was performed and revealed that LV 
dyssynchrony of 65 ms or more was highly predictive of both clinical response (sensitivity/
speciﬁcity 80%) and LV reverse remodeling (sensitivity/speciﬁcity 92%). 
Other studies have used a multiple segmental approach to create various models of LV dys-
synchrony in order to predict a favourable response to CRT. Examples of these models in-
clude 6 basal LV segments, or a combination of 6-basal and 6-mid LV segments. Notobartolo 
�
��
Figure 4: Panel A: 2-segment color-coded tissue Doppler imaging in the apical 4-chamber view in a normal individual without LV 
dyssynchrony. LV dyssynchrony is deﬁned as the time delay in peak systolic volume between the basal septum and lateral wall. The arrow indicates 
peak systolic velocity of both the basal septum and lateral wall illustrating perfect synchrony. 
Panel B: 2-segment color-coded tissue Doppler imaging in heart failure patient with LV dyssynchrony. The delay in peak systolic velocity 
between the basal septum and lateral wall is 130 ms indicating severe LV dyssynchrony. (Arrows indicate peak systolic velocities). 
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et al. used the 6-basal LV segmental model from the 3 apical views. The authors measured 
the time to the highest peak velocity in either ejection phase or post-systolic shortening, 
and calculated the maximal time diﬀerence to generate the “peak velocity diﬀerence” [20]. 
In 49 patients undergoing CRT, a peak velocity diﬀerence >110ms at baseline predicted LV 
reverse remodeling at 3 months follow-up with a sensitivity of 97% and a speciﬁcity of 55% 
[20]. Examination of ejection phase velocities appears to provide a better trade-oﬀ between 
sensitivity and speciﬁcity. Yu et al. proposed to measure the standard deviation of the time 
��
��
��
Figure 5: 12-segment color-coded tissue Doppler imaging in patient with LV dyssynchrony in multiple segments. Myocardial velocity curves 
were derived oﬀ-line at basal and mid levels of the left ventricle in the diﬀerent walls. The time to peak systolic velocities during the ejection 
phase in each view are compared. The ejection phase is deﬁned by the aortic valve opening (AVO) and aortic valve closure (AVC) markers. 
Panel A: Apical 4-chamber view showing delay in the lateral wall.  Panel B: Apical 2-chamber view showing delay in the anterior wall. 
Panel C: Apical long-axis view showing delay in the posterior wall. 
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to peak systolic velocity in ejection phase in the 6-basal/6-mid segmental model to compute 
the asynchrony index (or Ts-SD) (Figure 5). With a population-derived cut-oﬀ value of 32.6ms, 
the index was able to segregate responders from non-responders (deﬁned as presence/ab-
sence of LV reverse remodeling) [12,21].
Another method to assess systolic dyssynchrony is to measure the time to onset of mechani-
cal contraction in the ejection phase by pulsed-wave TDI (Figure 3). The work by Penicka et 
al. deﬁned LV dyssynchrony as the maximal electromechanical delay among the 3 basal LV 
segments (septal, lateral and posterior wall) [22]. The authors reported a cut-oﬀ value of 102 
ms, which yielded an accuracy of 88% to predict response to CRT (as deﬁned by a relative 
increase in LV ejection fraction >25%).
C. Tissue Synchronization imaging 
Another evolving technique to assess LV dyssynchrony is tissue synchronization imaging 
(TSI) (Vivid 7, General Electric-Vingmed, Milwaukee, Wisconsin, USA) [23]. This technique 
automatically calculates the peak systolic velocities from TDI and displays the timing of peak 
systolic velocities as a color-map, allowing for a quick visualization of the early activated seg-
ments (displayed in green) and identiﬁcation of the latest activated segments (displayed in 
red), without the need for TDI curve analysis. In addition, quantitative assessment of regional 
delay is still possible (through construction of myocardial velocity curves, similar to TDI). Yu 
et al. studied this qualitative approach in 56 heart failure patients and reported a sensitivity 
of 82% with a speciﬁcity of 87% to predict response to CRT [23] (Figure 6).
Recently, a novel 3-dimensional probe (Vingmed Ultrasound, Horten, Norway) became com-
mercially available allowing simultaneous acquisition of a triplane dataset and color-coded 
TDI of the left ventricle. During post-processing (Echopac), the TSI option can be applied to 
the TDI triplane dataset. The timing of the peak systolic velocities is presented as a color-
map in the apical 4-, 2- and 3-chamber views during one single heartbeat. Additionally, by 
manually tracing the endocardial borders during post-processing (surface mapping) a 3-di-
mensional volume is generated semi-automatically, portraying the area of latest activation 
allowing quick visual identiﬁcation of the delayed LV segment (Figure 7). If quantitative as-
sessment of LV dyssynchrony is preferred than the regional myocardial velocity curves can be 
derived analogously to 2-dimensional TSI analysis.
D. Strain (rate) imaging
Strain (rate) imaging (SRI) is a potentially interesting derivation from color-coded TDI. In con-
trast to TDI, which only measures myocardial velocities, SRI examines the (rate of ) myocardial 
deformation between 2 points in the region of interest. Accordingly, SRI has the potential 
advantage over TDI to diﬀerentiate between active and passive myocardial motion. Using SRI 
the extent of LV dyssynchrony can be quantiﬁed by measuring the time delays in time to peak 
systolic strain, comparable to TDI. Initial studies employing SRI to measure LV dyssynchrony 
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from the apical views (measuring longitudinal strain) reported relatively low predictive values 
for response to CRT [21]. The low predictive values were due to the relatively high angle de-
pendency of SRI which resulted in limited reproducibility of measurements. 
Dohi et al. produced more promising results when strain imaging was used to calculate LV 
dyssynchrony from the short axis views (measuring radial strain) in 38 patients undergoing 
CRT. A ≥130 ms diﬀerence in septal versus posterior wall peak strain was strongly predic-
tive of immediate improvement in stroke volume with CRT (sensitivity 95%, speciﬁcity 88%) 
(Figure 8) [24]. 
In addition, the same authors recently studied a novel echocardiographic technique, speckle 
tracking, which is able to calculate myocardial strain from conventional 2D echocardiogra-
phy. The main advantage of this technique over TDI derived strain is its lack of angle de-
pendency (Figure 9). In 48 patients undergoing CRT, a sensitivity of 91% with a speciﬁcity 
of 75% to predict acute response to CRT were obtained using a cut-oﬀ value ≥130 ms for LV 
dyssynchrony [25].
Figure 6: Tissue synchronization imaging: the colors represent time to peak systolic velocity. Green corresponds to early mechanical activation; 
yellow/orange/red indictes a delayed peak systolic velocity. Panel A shows a patient with a synchronous LV contraction (the entire left ventricle is 
colored green), Panel B shows delayed activation (indicated in orange/red) of the lateral wall.
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E. 3D echocardiography 
The main advantage of real-time 3D echocardiography (RT3DE, Philips Medical Systems, 
Andover, Massachusetts, USA) for the quantiﬁ cation of LV dyssynchrony compared to 2D 
echocardiographic techniques is that it provides simultaneous information on the timing of 
contraction of a large number of LV segments (Figure 10). With an excellent spatial resolution 
Figure 7: Example of tissue synchronization imaging applied to a triplane dataset. The areas of latest mechanical activation are indicated in 
orange/red in the apical 4-, 2- and 3-chamber views. The lower right panel shows a semi-automatically generated 3-dimensional LV volume 
portraying the area of latest mechanical activation.
��
Figure 8: Example of tissue Doppler-derived radial strain imaging in the parasternal short axis view at the mid-LV level in a patient with severe 
LV dyssynchrony (160 ms). LV dyssynchrony is deﬁ ned as the diﬀ erence in peak strain between the antero-septum (yellow curve) and the posterior 
wall (green curve). (Arrows indicate peak strain)
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RT3DE is able to provide detailed information on both global and regional LV function. Using 
this technique regional volume-time curves can be derived for each of the LV segments; LV 
dyssynchrony is assessed by comparing the times to reach minimal regional volume for each 
LV segment. The systolic dyssynchrony index is used as a marker of global LV dyssynchrony 
and is deﬁned as the standard deviation of the time taken to reach minimal regional volume 
for each of the LV segments. In addition, the regional time diﬀerences between diﬀerent seg-
ments allow the identiﬁcation of the area of latest LV activation, even when these areas are 
located in the most distal LV regions and/or the apex.
�
�
�
�
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Figure 9: Panel A: Speckle tracking derived radial strain imaging in the parasternal short-axis view at the mid LV level. In this example peak 
radial strain (arrow) occurs simultaneously in all 6 segments, indicating a synchronous LV contraction (the curves are color-coded in accordance 
with the segments on the short-axis view). Panel B: Example of radial time-strain curves from speckle tracking in a heart failure patient with LV 
dyssynchrony. The septal regions reach peak strain early in systole (blue/yellow curves), whereas the lateral segments reach peak strain late in 
systole (red/green curves, arrows indicate peak systolic strain). 
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Recently, Kapetanakis at al. demonstrated the feasibility of RT3DE to assess LV dyssynchrony 
in 174 unselected patients referred for routine echocardiography and concluded that RT3DE 
can rapidly quantify global LV dyssynchrony. 
In addition, the authors used RT3DE to calculate global LV dyssynchrony in 26 additional 
patients undergoing CRT and demonstrated a signiﬁcant diﬀerence in the systolic dyssyn-
chrony index between responders and non-responders (16.6±1.1% vs 7.1±2%, P<0.001) [26]. 
An optimal cut-oﬀ value for prediction of response however was not reported and remains 
to be deﬁned in future studies. 
F. Which echo technique?
As discussed above, a large number of diﬀerent echocardiographic techniques have been 
tested recently for quantiﬁcation of the extent of (pre-implantation) LV dyssynchrony in 
heart failure patients, to select the patients with a high likelihood of response to CRT. The 
Global LV Volume
Regional LV Volume
ESV 65 mls
EDV 132 mls
EF 48%
Figure 10: Global (top) and regional (bottom) LV volume curves derived from a 3D data set. The regional volume curves for each segment 
allow the calculation of the systolic dyssynchrony index which is deﬁned as the standard deviation of the time taken to reach minimum regional 
volume for each segment.
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echocardiographic techniques ranged from simple M-mode echocardiography (4 studies, 
257 patients) [16-19], pulsed-wave TDI (4 studies , 123 patients) [8,22,27,28], to more sophis-
ticated techniques including color-coded TDI (8 studies, 290 patients) [4,5,12,20,21,29-31], 
SRI (7 studies, 206 patients) [21,24,30-34], TSI (4 studies, 177 patients) [23,24,35,36] and 3D 
echocardiography studies, (2 studied, 39 patients) [26,37]. At present, no consensus exists 
on which technique is optimal to predict response to CRT, and the large number of diﬀerent 
echocardiographic techniques that have been published (without direct comparisons be-
tween techniques) further contribute to the confusion on the optimal technique. Moreover, 
the diﬀerent techniques employ varying numbers of segments to determine LV dyssynchrony 
(ranging from 2 to 16 segments) and diﬀerent cut-oﬀ values to deﬁne substantial LV dyssyn-
chrony (ranging from 65 ms to 130 ms). Consequently, larger multi-center studies, directly 
comparing diﬀerent echocardiographic techniques, are needed to identify the optimal tech-
nique, with the optimal number of segments and the optimal extent of LV dyssynchrony to 
predict response to CRT. The prospective, multi-center PROSPECT trial is speciﬁcally designed 
to answer these questions. The study will include approximately 300 patients with a clinical 
follow-up of 6 months and the results are expected in 2007 [38]. 
II. IMMEDIATE FOLLOW-UP
Echocardiography can be used to assess the immediate beneﬁts from CRT. In the acute set-
ting, echocardiographic studies have demonstrated that CRT immediately improved LV sys-
tolic function (LV ejection fraction), with direct disappearance of this eﬀect when CRT was 
switched oﬀ. The acute improvement in LV systolic function was reﬂected in a reduction in 
LV end-systolic volume, whereas LV end-diastolic volume remained unchanged (resulting in 
an increased LV ejection fraction [39]. In addition, echocardiographic studies demonstrated 
that some patients exhibit an immediate reduction in mitral regurgitation after CRT. Kanzaki 
et al. studied 26 patients and reported an acute reduction in regurgitant volume from 40±20 
ml to 24±17 ml (P<0.001) acutely after CRT. The mechanism underlying the reduction in mi-
tral regurgitation was evaluated using strain imaging. A signiﬁcant mechanical delay was 
demonstrated between the posteromedial and anterolateral papillary muscles at baseline 
(106±74 ms) which was reduced immediately after CRT implantation (12±8 ms, P<0.001) 
[40,41], indicating that resynchronization of the dyssynchronous papillary muscles acutely 
restored valvular competency. 
Thus, the beneﬁcial eﬀects of CRT appear related to an acute resynchronization of the left 
ventricle and papillary muscles. Echocardiography can be used to assess the LV resynchro-
nization immediately after CRT. In Figure 11 an example of a patient without resynchroniza-
tion after CRT is demonstrated. Indeed, recent data suggest that CRT may not always result 
in resynchronization (despite the presence of pre-implantation LV dyssynchrony) [42]. The 
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mechanisms underlying failure to restore LV synchrony are not entirely clear, but recent data 
demonstrated that patients with scar tissue in the postero-lateral LV segments (usually the 
area where the LV lead is located) failed to resynchronize after CRT, associated with clinical 
and echocardiographic non-response (Figure 12). In particular, the response rate to CRT was 
excellent (95%) in patients with severe baseline LV dyssynchrony without postero-lateral scar 
tissue; in patients with postero-lateral scar tissue however, the response rate was low (11%) 
[42]. Not only the location but also the extent of scar tissue is important for the response to 
Figure 11: Example of a patient without LV resynchronization. Despite the presence of severe baseline LV dyssynchrony (120 ms) between the 
basal septum (yellow curve) and the basal lateral wall (green curve), CRT was unable to reduce LV dyssynchrony (post-implantation 110 ms). As 
a result, no LV reverse remodeling was observed at 6 months follow-up (LV end-systolic volume from 245 ml to 250 ml) and LV ejection fraction 
remained unchanged (from 23% to 20%). In addition, the patient showed no change in clinical parameters.
�
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Postero-lateral scar
P=NS
LV dyssynchrony (ms)
No postero-lateral scar
P<0.05
Figure 12: In patients with postero-lateral scar tissue (usually the location of the LV pacing lead), CRT is unable to restore LV synchrony. In 
patients without scar tissue, LV dyssynchrony reduced from 93±41 ms to 31±27 ms (P<0.05) whereas in patients with scar tissue LV dyssynchrony 
remained unchanged (84±46 ms at baseline versus 78±41 ms after CRT, P=NS, Adapted from reference 33).
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CRT. Hummel et al. showed that the extent of scar tissue was inversely related to the response 
to CRT [43].
Failure to resynchronize can also be located to a mismatch between the site of latest activa-
tion and the position of the LV lead. Using color-coded TDI, Ansalone et al. demonstrated that 
the response to CRT was minimal when the LV lead was not located near the area of latest 
activation [27]. Similarly, Suﬀoletto et al. recently reported that patients with the LV lead po-
sitioned outside the area of latest activation had a signiﬁcantly lesser response to CRT [25]. 
TSI may be the ideal technique to visualize the area of latest activation and thus guide LV lead 
positioning. This principle was applied recently by Murphy et al. who used TSI to evaluate the 
interaction between the LV lead position and the area of latest activation on the one hand, 
and LV reverse remodeling after CRT on the other hand [36]. The authors observed a larger 
reduction in LV end-systolic volume in patients with the LV lead positioned in the area of 
latest activation (23% reduction in LV end-systolic volume) as compared to patients with the 
lead positioned in an adjacent (15% reduction) or a remote region (9% increase). Although 
the area of latest activation is most often located in the postero-lateral LV segments, a wide 
variation between individuals has been reported [44]. Accordingly, echocardiography (in 
particular TSI) may provide a patient tailored approach for LV lead positioning, which targets 
the area of latest LV activation. In the past this approach has been hampered by the lack of 
(echocardiographic) techniques that were able to provide an accurate 3D representation of 
regional LV dyssynchrony. 
One needs to realize however that not all areas of the left ventricle are suitable for endo-
cardial (via the coronary sinus) LV lead placement due to the absence of suitable veins in 
the targeted area. It has recently been shown that multi-slice CT scanning can be helpful in 
assessing the venous anatomy before CRT implantation [45]. Information about the venous 
anatomy can then be combined with information about the area of latest LV activation and 
if suitable branches of the coronary sinus are absent, epicardial (surgical) LV lead placement 
should be considered. 
III. LATE FOLLOW-UP
Echocardiography is the technique of choice to evaluate improvement in LV ejection fraction 
after CRT. In 125 heart failure patients, a signiﬁcant improvement in LV ejection fraction from 
23±8% to 32±9% was demonstrated after 6 months of CRT [46]. 
Yu et al. demonstrated that the improvement in LV ejection fraction is a gradual process 
with further improvements occurring over time (Figure 13) [4]. St John Sutton et al. recently 
evaluated a cohort of 228 patients included in the MIRACLE trial and demonstrated that the 
gradual improvement in LV ejection fraction was (in part) related to the etiology of heart 
failure. Patients with non-ischemic cardiomyopathy exhibit an immediate improvement in LV 
Optimal use of echocardiography in CRT 241
ejection fraction, whereas the improvement occurs more gradually in patients with ischemic 
cardiomyopathy [47]. 
In addition to improvement in LV ejection fraction, echocardiography permits measurement 
of LV reverse remodeling, with a reduction in both LV end-systolic and end-diastolic volumes. 
Reverse remodeling is clinically relevant, as reported recently by Yu et al. who demonstrated 
in 141patients that a reduction >10% in LV end-systolic volume after 3-6 months of CRT was 
the most important predictor of event-free survival at 12 months follow-up [10]. This impor-
tant observation underscores that LV reverse remodeling as measured by echocardiography 
provides the most clinically meaningful deﬁnition of response to CRT (Figure 14).
In combination with the LV reverse remodeling a reduction in mitral regurgitation may be 
observed as well (Figure 15), which can be explained by a further reduction in annular dimen-
sions resulting in a smaller regurgitant oriﬁce.
In addition to the eﬀects of CRT on the left ventricle, CRT may also aﬀect right ventricular size 
and function. Bleeker et al. demonstrated the beneﬁcial eﬀects of CRT at 6-months follow-up 
including right ventricular reverse remodeling, a reduction in tricuspid regurgitation and a 
decrease in pulmonary artery pressure [48]. 
IV. OPTIMIZATION OF PACEMAKER SETTINGS
A. AV optimization
The aim of AV optimization is to select an “optimal” AV delay that results in an increase in 
diastolic ﬁlling time and a reduction of presystolic mitral regurgitation. This may lead to an 
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*
Figure 13: Changes in LV ejection fraction following CRT in 25 patients studied by Yu et al. A gradual increase in LV ejection fraction was 
observed (*: P<0.05 versus baseline). Interestingly after cessation of CRT at 3 months follow-up a gradual decline in LV ejection fraction was 
observed (#: P<0.05 versus 3 months of CRT , Adapted form reference 4). 
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improvement of stroke volume, symptoms and LV reverse remodeling. Several acute invasive 
studies have shown that LV dP/dt can be increased with 13%-34% during AV optimization [49-
52]. Similar acute improvements have been documented in stroke volume during echocar-
diography-guided AV delay optimization [53]. However, the eﬀect on exercise performance 
is unclear [54] and the eﬀects on heart failure morbidity, hospitalizations and mortality have 
not been studied.
AV delay optimization can be performed by measuring LV diastolic ﬁlling time intervals and/
or indices of LV systolic function.
The most frequently used echocardiographic method is the iterative method, which uses 
both transmitral pulsed-wave Doppler (to assess A wave truncation and the diastolic ﬁlling 
time) and aortic continuous wave Doppler (to assess the velocity time integral, VTI, as index 
of LV stroke volume). A long sensed AV delay (shorter than the intrinsic PR to ensure capture) 
is programmed (usually between 160 and 200 ms). This AV delay is shortened in steps of 20 
ms until the A wave begins to truncate (visualized on the transmitral Doppler ﬂow registra-
tion). Once A-wave truncation is noted, the AV delay is lengthened in steps of 20 ms until 
truncation no longer occurs. The optimal AV delay is characterized by the longest diastolic 
ﬁlling time or the highest aortic VTI. To obtain an optimal aortic VTI it is advised to use a fast 
sweep speed, a large velocity scale and a low ﬁlter. An example of the eﬀect of changing the 
Baseline
6 months follow-up
Figure 14: Echocardiographic demonstration of LV reverse remodeling after 6 months of CRT; the LV end-diastolic volume decreased from 
237 ml to 118 ml.
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AV delay on aortic VTI in a patient after CRT implantation is provided in (Figure 16). Since 
several measurements are needed and one has to wait at least 10 beats before recording the 
diﬀerent ﬂows during the diﬀerent programmed AV delays, this method is time consuming. 
A faster technique that only requires the mitral inﬂow has also been proposed. This mitral 
inﬂow technique was initially developed by Ritter for patients with complete heart block 
treated with dual chamber pacing [55,56]. It requires recordings of the mitral inﬂow by 
pulsed-wave Doppler at a long and a short AV delay. A long AV delay (AV long, for example 
200 ms) results in premature mitral valve closure, prior to the paced QRS. The time interval “a” 
is measured from the termination of the mitral A wave to the onset of the paced QRS. A short 
AV delay (for example 60 ms) results in closure of the mitral valve due to onset of LV systolic 
contraction. The electromechanical delay, time interval “b”, is measured from the onset of the 
paced QRS to the termination of the mitral A wave. The optimal AV delay is then calculated 
by the equation AVlong – (b-a). Although attractive, this method has to be used cautiously in 
patients treated with CRT since loading conditions may signiﬁcantly alter LV ﬁlling pressures. 
Also, in patients with elevated ﬁlling pressures (such as CRT patients), the mitral A wave may 
be severely attenuated or abbreviated which limits visualization of mitral A wave truncation. 
Baseline
6 months
follow-up
Post-implantation
Figure 15: Patient with severe mitral regurgitation before CRT implantation. No signiﬁcant change in severity of mitral regurgitation was 
observed immediately after CRT implantation. At 6 months follow-up however, a signiﬁcant reduction in mitral regurgitation was observed, 
secondary to the LV reverse remodeling
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Because of the time-eﬀorts and lack of proven clinical beneﬁt, AV optimization is not rou-
tinely performed. Instead, a short AV delay (usually in the range of 100-120 ms) is often pro-
grammed and AV optimization is only performed in patients who do not respond to CRT. 
In addition, many questions are unresolved regarding AV optimization at the present time. 
For example the eﬀect of body position (supine versus sitting) on the optimal AV delay is 
unknown. More importantly, it is largely unknown whether the AV delay should be short-
ened, kept constant or prolonged as heart rate increases during exercise in CRT patients. In 
previous multicenter trials the AV delay was programmed ﬁxed or with dynamic shortening. 
However, Scharf et al [54] reported that the relatively short baseline AV delay should be pro-
longed and not shortened at increased heart rates to maintain stroke volume in CRT patients. 
If conﬁrmed in future studies, this would imply that dynamic AV lengthening should become 
available in new CRT devices.
B. VV optimization 
The aim of VV optimization is to select an “optimal” interventricular (VV) interval that further 
improves inter- and intraventricular dyssynchrony and thus mechanical eﬃciency or stroke 
volume. Acute invasive studies have shown that VV optimization resulted in a further improve-
ment of dP/dt [51,52]. Sogaard et al. [31] showed in 20 patients that sequential VV activation 
resulted in a further reduction of delayed longitudinal contraction with a further increase of 
diastolic ﬁlling time, as compared to simultaneous biventricular activation. Accordingly Van-
derheyden et al. [57] reported in 20 patients that VV optimization resulted in prolongation 
of LV ﬁlling time, reduction of inter- and in intra LV dyssynchrony, with an increase in stroke 
volume. Although these small studies appear to support VV optimization, larger studies on 
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AV delay (ms)
 VTI (cm)
Figure 16: Example of the eﬀect of changing the AV delay on aortic VTI in a patient after CRT implantation. The optimal AV delay is derived at 
100-120 ms yielding the highest aortic VTI.
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the eﬀects on exercise performance, heart failure morbidity/hospitalizations and mortality 
are not available yet.
Currently, consensus is lacking on which echocardiographic parameters should be measured 
during VV optimization. It seems logical however that both parameters of inter- and intra LV 
dyssynchrony as well as stroke volume should be evaluated. 
Vanderheyden et al. [57] and Parreira et al. [58] used pulsed-wave TDI to assess inter- and 
intra LV dyssynchrony as well as the aortic VTI to assess stroke volume. In these studies VV op-
timization was performed by advancing the LV stimulus (left ventricle ﬁrst) or the RV stimulus 
(right ventricle ﬁrst) by 20 ms intervals up to 60 ms.
Leon et al. [59] evaluated the hemodynamic eﬀects of VV optimization in 376 patients under-
going CRT implantation by measuring the aortic VTI for each VV interval. In 81% of patients 
optimization of the VV timing interval resulted in an increase in stroke volume, with a median 
increase of 8.6%. Of interest, in the majority of patients the highest aortic VTI was derived 
when the left ventricle was paced ﬁrst [59], (Figure 17). 
As with AV optimization, many questions are unresolved regarding VV optimization. There 
are virtually no published data on the eﬀect of body position, exercise or outcome. Also, it is 
unclear whether AV optimization should proceed VV optimization or vice versa. 
SUMMARY
The role of echocardiography in patients with CRT can be deﬁned as follows.
First, echocardiography can optimize selection of CRT candidates by demonstration of LV 
dyssynchrony, and many echocardiographic techniques have been proposed. The extent of 
�
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�� ����� ������� �� �����
% patients
Figure 17: Optimal VV timing settings at pre-hospital discharge. In the majority of patients (55%) the aortic VTI was highest when the left 
ventricle was paced before the right ventricle. (Adapted from reference 59). 
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LV dyssynchrony that is mandatory for response to CRT is not yet deﬁned, but may be derived 
from the PROSPECT trial [38].
Moreover, echocardiography can be used to assess immediate response to CRT including 
detection of acute LV resynchronization. Also, echocardiography is useful to evaluate long-
term beneﬁt from CRT (i.e. LV reverse remodeling).
Finally, echocardiography is important in optimization of pacemaker settings, including AV 
and VV optimization.
Optimal use of echocardiography in CRT 247
REFERENCES 
1] Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl 
J Med 2002;346:1845-53.
2] Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization therapy with or without an 
implantable deﬁbrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
3] St John Sutton MG, Plappert T, Abraham WT, et al. Eﬀect of cardiac resynchronization therapy on 
left ventricular size and function in chronic heart failure. Circulation 2003;107:1985-90.
4] Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse re-
modeling and improved synchronicity by simultaneously delaying regional contraction after 
biventricular pacing therapy in heart failure. Circulation 2002;105:438-45. 
5] Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prog-
nosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004;44:1834-40.
6]  Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy, Issues before implantation. 
J Am Coll Cardiol 2005;46:2153-67. 
7] Auricchio A, Stellbrink C, Block M, et al. Eﬀect of pacing chamber and atrioventricular delay on 
acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-
3001.
8] Bordachar P, Laﬁtte S, Reuter S, et al. Echocardiographic parameters of ventricular dyssynchrony 
validation in patients with heart failure using sequential biventricular pacing. J Am Coll Cardiol 
2004;44:2154-65.
9] Leon AR, Abraham WT, Brozena S, et al. Cardiac resynchronization with sequential biventricular 
pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol 2005;46:2298-
304.
10] Yu CM, Bleeker GB, Fung JWH, et al. LV reverse remodeling but not clinical improvement predicts 
long-term survival after cardiac resynchronization therapy. Circulation 2005;112:1580-6.
11] St John Sutton MG, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural 
remodeling with cardiac resynchronization at one year is a function of etiology. Circulation 
2006;113:266-72.
12] Yu CM, Fung JWH, Lin H, et al. Predictors of left ventricular reverse remodeling after cardiac resyn-
chronization therapy for heart failure secondary to idiopathic dilated or ischemic cardiomyopa-
thy. Am.J Cardiol. 2003;91:684-8.
13] Yu CM, Lin H, Zhang Q, et al. High prevalence of left ventricular systolic and diastolic asynchrony 
in patients with congestive heart failure and normal QRS duration. Heart 2003;89:54-60.
14] Bleeker GB, Schalij MJ, Molhoek SG, et al. Relationship between QRS duration and left ventricular 
dyssynchrony in patients with end-stage heart failure. J Cardiovasc Electrophysiol 2004:15:544-9.
15] Ghio S, Constantin C, Klersy C, et al. Interventricular and intraventricular dyssynchrony are com-
mon in heart failure patients, regardless of QRS duration. Eur Heart J 2004;35:571-8.
16] Pitzalis MV, Iacoviello, Romito R, et al. Cardiac resynchronization therapy tailored by echocardio-
graphic evaluation of ventricular asynchrony. J Am Coll Cardiol 2002;40:1615-22.
17]  Pitzalis MV, Iacoviello, Romito R, et al. Ventricular asynchrony predicts a better outcome in pa-
tients with chronic heart failure receiving cardiac resynchronization therapy. J Am Coll Cardiol 
2005;45:65-9.
18] Marcus GM, Rose E, Viloria EM, et al. Septal to posterior wall motion delay fails to predict reverse 
remodeling or clinical improvement in patients undergoing cardiac resynchronization therapy. J 
Am Coll Cardiol 2005;46:2208-14.
19] Bleeker GB, Schalij MJ, Boersma E, et al. Relative merits of M-mode echocardiography and tissue 
Doppler imaging for prediction of response to cardiac resynchronization therapy in patients with 
heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol in press. 
20] Notabartolo D, Merlino JD, Smith AL, et al. Usefulness of the peak velocity diﬀerence by tissue 
Doppler imaging technique as an eﬀective predictor of response to cardiac resynchronization 
therapy. Am.J.Cardiol. 2004;94:817-20.
21] Yu CM, Fung JW, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and 
postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonisch-
emic heart failure after cardiac resynchronization therapy. Circulation 2004;110:66-73.
248
C
ha
pt
er
 1
6
22] Penicka M, Bartunek J, de Bruyne B, et al. Improvement of left ventricular function after cardiac 
resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 
2004;109:978-83.
23] Yu CM, Zhang Q, Fung JW, et al. A novel tool to assess systolic asynchrony and identify respond-
ers of cardiac resynchronization therapy by tissue synchronization imaging. J Am.Coll.Cardiol. 
2005;45:677-84.
24] Dohi K, Suﬀoletto MS, Schwartzman D, et al. Utility of Echocardiographic radial strain imaging to 
quantify left ventricular dyssynchrony and predict acute response to cardiac resynchronization 
therapy. Am J Cardiol 2005;96:112-6. 
25] Suﬀoletto MS, Dohi K, Cannesson M, et al. Novel speckle-tracking radial strain from routine black-
and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac 
resynchronization therapy. Circulation 2006;113:960-8.
26] Kapetanakis S, Kearney MT, Siva A, et al. Real- time Three-dimensional echocardiography. Circula-
tion 2005;112:992-1000. 
27] Ansalone G, Giannantoni P, Ricci R et al. Doppler myocardial imaging in patients with heart failure 
receiving biventricular pacing treatment. Am Heart J 2001;142:881-96
28] Garrigue S, Reuter S, Labeque JN, et al. Usefullness of biventricular pacing in patients with con-
gestive heart failure and right bundle branch block. Am J Cardiol 2001;88:1436-41.
29] Bax JJ, Marwick TH, Molhoek SG, et al. Left ventricular dyssynchrony predicts beneﬁt of cardiac 
resynchronization therapy in patients with end-stage heart failure before pacemaker implanta-
tion. Am J Cardiol 2003;92:1238-40.
30] Sogaard P, Egeblad H, Kim WY, et al. Tissue Doppler imaging predicts improved systolic perfor-
mance and reversed left ventricular remodeling during long-term cardiac resynchronization 
therapy. J.Am.Coll.Cardiol. 2002;40:723-30.
31] Sogaard P, Egeblad H, Pedersen AK, et al. Sequential versus simultaneous biventricular resynchro-
nization for severe heart failure: evaluation by tissue Doppler imaging. Circulation 2002;106:2078-
84. 
32  Breithardt OA, Stellbrink C, Herbots L, et al. Cardiac resynchronization therapy can reverse abnor-
mal myocardial strain distribution in patients with heart failure receiving cardiac resynchroniza-
tion therapy. J Am Coll Cardiol 2003;42:486-94. 
33] Sun JP, Chinchoy E, Donal E, et al. Evaluation of ventricular synchrony using novel Doppler echo-
cardiographic indices in patients with heart failure receiving cardiac resynchronization therapy. J 
Am Soc Echocardiogr 2004;17:845-50.
34] Popovic ZB, Grimm RA, Perlic G, et al. Noninvasive assessment of cardiac resynchronization 
therapy for congestive heart failure using myocardial strain and left ventricular peak power as 
parameters of myocardial synchrony and function. J Cardiovasc Electrophysiol 2002;13:1203-8. 
35] Gorcsan J, Kanzaki H, Bazaz R, et al. Usefullness of echocardiographic tissue synchronization im-
aging to predict acute response to cardiac resynchronization therapy. Am J Cardiol 2004;93:1178-
81.
36] Murphy RT, Sigurdsson G, Mulamalla S, et al. Tissue synchronization imaging and optimal left 
ventricular pacing site in cardiac resynchronization therapy. Am J Cardiol 2006;97:1615-21. 
37]  Zhang Q, Yu CM, Fung JW, et al. Assessment of the eﬀect of cardiac resynchronization therapy 
on intraventricular mechanical synchronicity by regional volumetric changes. Am J Cardiol 
2005;95:126-9.
38] Yu CM, Abraham WT, Bax JJ, et al. Predictors of response to cardiac resynchronization therapy 
(PROSPECT)-Study design. Am.Heart J. 2005;149:600-5.
39] Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute eﬀects of cardiac resynchronization 
therapy on functional mitral regurgitation in advance systolic heart failure. J Am Coll Cardiol 
2003;41:765-70. 
40] Kanzaki H, Bazaz R, Schwartzman D, et al. A mechanism for immediate reduction in mitral regur-
gitation after cardiac resynchronization therapy. J Am C]oll Cardiol 2004;44:1619-25.
41] Brandt RR, Reiner C, Arnold R, et al. Contractile response and mitral regurgitation after temporary 
interruption of long-term cardiac resynchronization therapy. Eur Heart J 2006;27:187-92.
42] Bleeker GB, Kaandorp TAM, Lamb HJ, et al. Eﬀect of posterolateral scar tissue on clinical and echo-
cardiographic improvement after cardiac resynchronization therapy. Circulation 2006;113:969-7.
Optimal use of echocardiography in CRT 249
43] Hummel JP, Lindner JR, Belcik JT, et al. Extent of myocardial viability predicts response to biven-
tricular pacing in ischemic cardiomyopathy. Heart Rhythm 2005;2:1211-7.
44] Van de Veire N, de Sutter J, van Camp G, et al. Global and regional parameters of dyssynchrony in 
ischemic and non-ischemic cardiomyopathy. Am J Cardiol 2005;95:421-3.
45] Jongbloed MR, Lamb HJ, Bax JJ, et al. Noninvasive visualization of the cardiac venous system 
using multislice computed tomography. J Am Coll Cardiol 2005;45:749-53.
46] Molhoek SG, Bax JJ, Bleeker GB, et al. Long-term follow-up of cardiac resynchronization therapy 
in patients with end-stage heart failure. J Cardiovasc Electrophysiol 2005;16:1-7.
47] St John Sutton MG, Plappert T, Hilpisch KE, et al. Sustained reverse left ventricular structural remod-
eling with cardiac resynchronization therapy is a function of etiology. Circulation 2006;113:266-
72. 
48]  Bleeker GB, Schalij MJ, Nihoyannopoulos P et al. Left ventricular dyssynchronrony predicts right 
ventricular remodeling after cardiac resynchronization therapy. J Am Coll Cardiol 2005;46:2264-
9.
49] Auricchio A, Stellbrink C, Block M, et al. Eﬀect of pacing chamber and atrioventricular delay on 
acute systolic function of paced patients with congestive heart failure. Circulation 1999;99:2993-
3001.
50] Kass DA, Chen CH, Curry C, et al. Improved left ventricular mechanics from acute VDD pacing in 
patients with dilated cardiomyopathy and ventricular conduction delay. Circulation 1999;99:1567-
73.
51] Perego GB, Chianca R, Facchini M, et al. Simultaneous versus sequential biventricular pacing in 
dilated cardiomyopathy: an acute hemodynamic study. Eur J Heart Fail 2003;5:305-13.
52] van Gelder BM, Bracke FA, Meijer A, et al. Eﬀect of optimizing the VV interval on left ventricular 
contractility in cardiac resynchronization therapy. Am J Cardiol 2004;93:1500-3.
53] Porciani MC, Dondina C, Macioce R, et al. Echocardiographic examinination of atrioventricular 
and interventricular delay optimization in cardiac resynchronization therapy. Am J Cardiol 
2005;95:1108-10.
54] Scharf C, Li P, Muntwyler J, et al. Rate-dependent AV delay optimization in cardiac resynchroniza-
tion therapy. Pacing Clin Electrophysiol 2005;28:279-84.
55] Ritter P, Dib JC, Lelievre T et al. Quick determination of the optimal AV delay at rest in patients 
paced in DDD mode for complete AV block (abstr). Eur J C P E 1994;4:A163.
56] Ritter P. Indications for permanent pacing and choice of pacemakers. In : W Fisher and P Ritter, 
Editors, Cardiac Pacing in Clinical Practice, Springer Verlag, Berlin (1998):166-202.
57] Vanderheyden M, De Backer T, Rivero-Ayzera M, et al. Tailored echocardiographic interventricular 
delay programming further optimizes left ventricular performance after cardiac resynchroniza-
tion therapy. Heart Rhythm 2005;2:1066-72.
58] Parreira L, Santos JF, Madeira J, et al. Cardiac resynchronization therapy with sequential biven-
tricular pacing: impact of echocardiography guided VV delay optimization on acute results. Rev 
Port Cardiol 2005;24:1355-65.
 59] Leon AR, Abraham WT, Brozena S, et al. Cardiac resynchronization therapy with sequential 
biventricular pacing for the treatment of moderate-to-severe heart failure. J Am Coll Cardiol 
2005;46:2298-304. 

Summary, Conclusions and 
Future perspectives

Summary, Conclusions and Future perspectives 253
SUMMARY
The general introduction (Chapter 1) of this thesis provides a description of the rationale 
behind cardiac resynchronization therapy (CRT) and a general overview of the clinical re-
sults using CRT in patients with chronic heart failure. After the initial promising results in 
patients with drug-refractory heart failure in the late 1990’s, the beneﬁcial eﬀects of CRT have 
now been clearly conﬁrmed in large randomized trials which have currently included >4000 
patients. The beneﬁcial eﬀects of CRT included an improvement in clinical symptoms (New 
York Heart Association (NYHA) class, quality-of-life and 6 minute walking distance) as well as 
an improvement in echocardiographic parameters (left ventricular (LV) ejection fraction, LV 
volumes and mitral regurgitation). In addition, the number of hospitalizations for decompen-
sated heart failure and all-cause mortality were reduced after CRT in comparison to optimal 
medical therapy.
Based on these excellent results the use of CRT in patients with chronic heart failure is now 
considered a class I indication in both the ESC and the ACC/AHA/HRS guidelines. Accord-
ing to the guidelines, CRT is recommended in patients with moderate-to severe heart failure 
(NYHA class III-IV), impaired LV ejection fraction (<35%) and a widened QRS complex (>120 
ms). However, in parallel to these impressive results, a consistent number of patients do 
not respond to CRT when the current selection criteria are applied. When response to CRT 
is deﬁned using clinical parameters (e.g. improvement in NYHA class or quality-of life) the 
prevalence of non-responders is approximately 30% and when echocardiographic param-
eters (LV reverse remodeling, improvement in LV ejection fraction) are applied, the number 
of non-responders is usually around 40%. 
The aim of the current thesis was improve the current selection criteria for CRT in order to 
reduce the number of non-responders. To achieve this goal the pathophysiological mecha-
nisms underlying (non-) response to CRT were studied (Parts I and II) in order to develop 
more optimal CRT selection criteria (Part III). In addition, introduction of new selection crite-
ria may lead to the application of CRT in patient groups that are not eligible for CRT according 
to the established selection criteria (Part IV). 
Part I: Beneﬁcial eﬀects of CRT
In Chapter 2 the response rate to CRT was evaluated in elderly patients (deﬁned as ≥70 years 
of age) and compared to the results of CRT observed in younger patients (<70 years). A total of 
170 consecutive patients was included based on established selection criteria for CRT (NYHA 
class III-IV, LV ejection fraction <35% and QRS duration >120 ms with LBBB). Mean patient 
age was 66±11 years and the study population comprised of 102 (60%) patients <70 years 
and 68 patients (40%) ≥70 years. Patients ≥70 years were more likely to have an ischemic car-
diomyopathy (48% vs. 66%, P<0.05); all other baseline characteristics were comparable. In all 
patients, clinical and echocardiographic parameters improved signiﬁcantly at 6 months fol-
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low-up (e.g. NYHA class decreased from 3.2±0.4 to 2.2±0.7, P<0.001, and LV ejection fraction 
increased from 21±8% to 28±9%, P<0.001), associated with LV reverse remodeling. Improve-
ments in clinical and echocardiographic parameters were comparable between patients <70 
years and ≥70 years. The percentage of responders was also similar in both groups (75% ver-
sus 78%, ns). In addition, survival at 1 year after implantation was comparable in the patients 
<70 years and patients ≥70 years. CRT is thus equally eﬀective in elderly patients in terms of 
improvement in clinical and echocardiographic parameters and 1-year mortality. Also, the 
percentage of individual responders to CRT is not diﬀerent in elderly patients. 
This study indicates that age does not inﬂuence response to CRT and demonstrates that CRT 
should also be considered in patients ≥70 years
The aim of Chapter 3 was to evaluate whether a gender diﬀerence exists in the response 
rate to CRT. One-hundred seventy-three patients consecutive patients (NYHA class III-IV, LV 
ejection fraction ≤35%, QRS duration >120 ms with LBBB) were included. No diﬀerences in 
baseline characteristics were observed between men (n=137) and women (n=36) except 
that non-ischemic cardiomyopathy was more frequent in women (67% vs. 38%, P<0.05). At 6 
months follow-up the magnitude of improvement in clinical and echocardiographic param-
eters was similar between women and men; e.g. the improvement in NYHA class was 0.9±0.6 
in women and 1.0±0.7 in men (P=NS) and the increase in LV ejection fraction was 8±8% in 
women as compared to 7±9% in men (P=NS). The percentage of individual responders was 
not diﬀerent between women and men (76% vs. 80%, P=NS) and 2-year survival was compa-
rable for women and men (84% vs. 80%, P=NS). 
In conclusion, no gender diﬀerences were observed in response to CRT and long-term sur-
vival after CRT.
In Chapter 4 the precise relationship between improvement in clinical and echocardiographic 
parameters was evaluated. In recent studies a clear deﬁnition of response to CRT is lacking and 
both clinical and echocardiographic end-points are currently used. It is also unclear whether 
patients with clinical response also improve in echocardiographic end-points (and vice versa). 
One hundred forty-four consecutive patients (NYHA class III/IV, LV ejection fraction ≤35% and 
QRS duration ≥120 ms with LBBB) were included. At 3-6 months after CRT implantation clinical 
response (deﬁned as improvement ≥1 NYHA class) and echocardiographic response (deﬁned 
as a decrease >15% in LV end-systolic volume) occurred in 101 (70%) and 81 (56%) patients re-
spectively. Clinical improvement without echocardiographic response was observed in 27 (19%) 
patients, whereas 7 (5%) patients showed no clinical response, in the presence of echocardio-
graphic response. Accordingly, the disagreement between the 2 end-points was mainly related 
to patients who responded clinically without showing LV reverse remodeling. This observation 
may be explained by the presence of a placebo eﬀect with respect to improvement in clinical 
symptoms following CRT, as already reported in double-blind randomized trials. 
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Thus, a good agreement (76%) between clinical and echocardiographic response from CRT 
was observed. Still, the echocardiographic response rate (56%) is somewhat lower than the 
clinical response rate (70%).
Part II: Mechanism of beneﬁt from CRT
In Chapter 5 the beneﬁcial eﬀects of CRT on the size of the right ventricle and on the severity 
of tricuspid regurgitation were evaluated. Both right ventricular (RV) size and function are 
known to be strong and independent predictors of prognosis in patients with heart failure 
and beneﬁcial eﬀects of CRT on the right ventricle may further explain the mechanism of 
beneﬁt from CRT. Fifty-six consecutive patients (NYHA class III-IV, LV ejection fraction ≤35% 
and QRS duration >120 ms with LBBB) were included. At 6 months follow-up LV ejection 
fraction improved signiﬁcantly from 19±6% to 26±8% (P<0.001) and LV end-diastolic volume 
decreased from 257±98 ml to 227±86 ml (P<0.001). In addition, RV annulus decreased signiﬁ-
cantly from 37±9 mm to 32±10 mm, RV short-axis from 29±11 mm to 26±7 mm, and RV long-
axis from 89±11 mm to 82±10 mm (all P<0.001) with the largest decrease in the patients with 
the largest right ventricles at baseline. Interestingly, LV and RV reverse remodeling were only 
observed in patients with substantial LV dyssynchrony at baseline. Finally, signiﬁcant reduc-
tions in severity of tricuspid regurgitation and pulmonary artery pressure were observed. 
Thus, CRT results in signiﬁcant reverse LV and RV remodeling after 6 months of CRT in pa-
tients with LV dyssynchrony. Moreover, CRT leads to a reduction of the severity of tricuspid 
regurgitation and a decrease in pulmonary artery pressure. Both ﬁndings may contribute to 
a better understanding of the beneﬁcial mechanism of CRT. 
In recent CRT studies a clear deﬁnition of response to CRT is lacking and both clinical and 
echocardiographic end-points (with arbitrary cut-oﬀ values) are currently used. The echocar-
diographic response rate is usually somewhat lower (60%) than the clinical response rate (70-
80%) and in 24% there is a disagreement between clinical and echocardiographic response 
rate (see chapter 4). The goal of chapter 6 was to deﬁne the most clinically relevant deﬁnition 
of response to CRT. One hundred forty-one patients (NYHA class III-IV, LV ejection fraction <40% 
and QRS duration >120 ms) who received CRT were included and were followed for a mean 
period of 695±491 days. During the follow-up period there were 22 (15.6%) deaths, mostly 
due to heart failure or sudden cardiac death. ROC curve analysis revealed that a reduction in 
LV end-systolic volume ≥9.5% has a sensitivity of 70% and speciﬁcity of 70% in predicting all-
cause mortality, and 87% and 69% respectively for cardiovascular mortality. With this cut-oﬀ 
value, there were 87 (61.7%) responders of reverse remodeling. In Kaplan-Meier survival analy-
sis, responders has signiﬁcantly lower all-cause morality (6.9% Vs 30.6%, Log-rank χ2=13.26, 
p=0.0003), cardiovascular mortality (2.3% Vs 24.1%, Log-rank χ2=17.1, p<0.0001), and heart 
failure events (11.5% Vs 33.3%, Log-rank χ2=8.71, p=0.0032) than non-responders. Interest-
ingly, improvements in clinical parameters were unable to predict any outcome event. 
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In conclusion, the strongest predictor of improved survival and reduction in heart failure 
events following CRT is a reduction of LV end-systolic volume >10% at 3-6 months follow-up 
and may thus be considered the most clinically relevant deﬁnition of response to CRT. 
In Chapter 7 a detailed invasive analysis of the hemodynamic consequences of CRT at mid-
term follow-up was performed using pressure-volume loop analysis. Twenty-two patients 
scheduled for implantation of a CRT device (NYHA class III-IV, LV ejection fraction <35% and 
QRS duration >120ms with LBBB) were included. During diagnostic catheterization prior to 
CRT and at 6 months follow-up pressure-volume loop analysis during right atrial pacing at 80, 
100, 120 and 140 beats/min was performed by conductance catheter. Using the pressure-vol-
ume loops it was demonstrated that previously reported acute improvements in LV function 
remain present at 6 months follow-up: dP/dtMAX (+18%, p<0.01), dP/dtMIN (+13%, p<0.05), SW 
(+34%, p<0.05). Eﬀects of increased pacing rate were improved towards more physiological 
responses for LV ejection fraction, cardiac output and dP/dtMAX. Moreover, the study shows 
improved ventricular-arterial coupling (+69%, p<0.01) and improved mechanical eﬃciency 
(+44%, p<0.005). Thus, acute hemodynamic improvements following CRT are maintained 
at mid-term-follow-up. In addition, ventricular-arterial coupling, mechanical eﬃciency, and 
chronotropic responses are improved after 6 months of CRT. These ﬁndings may help to ex-
plain the improved functional status and exercise tolerance in heart failure patients treated 
with CRT.
In Chapter 8 the time course and the extent of LV resynchronization after CRT implantation 
and their relation with response to CRT were evaluated in 100 consecutive patients (NYHA 
class III-IV, LV ejection fraction ≤35% and QRS duration >120 ms) with evidence of pre-implan-
tation LV dyssynchrony (≥65 ms, see chapter 12) on color-coded tissue Doppler imaging (TDI). 
Immediately after CRT implantation LV dyssynchrony was reduced from 114±36 ms to 40±33 
ms (P<0.001) which persisted at 6 months follow-up (35±31 ms (P<0.001 versus baseline and 
P=NS versus immediate post-implantation). At 6 months follow-up 85 patients were classiﬁed 
as responders to CRT (deﬁned as >10% reduction in LV end-systolic volume (see chapter 6). 
Thus, patient selection based on pre-implantation detection of LV dyssynchrony using TDI 
results in a superior echocardiographic response rate compared to selection based on the 
traditional CRT selection criteria (echocardiographic response rate around 60%). Immediately 
post-implantation the responders to CRT demonstrated a signiﬁcant reduction in LV dyssyn-
chrony from 115±37 ms to 32±23 ms (P<0.001). The non-responders, however failed to show 
a signiﬁcant reduction in LV dyssynchrony (from 106±29 ms to 79±44 ms, P=NS). If the extent 
of acute LV resynchronization was <20%, response to CRT at 6 months follow-up was never 
observed. Conversely, 93% of patients with LV resynchronization ≥20% responded to CRT. 
In conclusion, LV resynchronization following CRT is an acute phenomenon, and predicts 
response to CRT at 6 months follow-up. 
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Part III: Prediction of response to CRT
The presence of pre-implantation LV dyssynchrony seems mandatory for a positive response 
to CRT (see chapters 8,12). In the current selection criteria, QRS duration is used as a marker 
of LV dyssynchrony. However, recent studies indicate that QRS duration does not predict re-
sponse to CRT. This issue is addressed in chapter 9 in which the precise relationship between 
QRS duration and LV dyssynchrony on TDI was studied in 90 consecutive heart failure patients 
(NYHA class III-IV and LV ejection fraction <35%). Based on the QRS duration, 30 consecutive 
patients with a narrow QRS complex were included (QRS duration ≤120 ms), 30 patients with 
an intermediate QRS duration (120-150 ms), and 30 patients with a wide QRS complex (>150 
ms). Severe LV dyssynchrony (>60 ms) was observed in 27% of patients with narrow QRS com-
plex, in 60% of patients with intermediate QRS duration and in 70% of patients with wide 
QRS complex. No signiﬁcant correlation existed between QRS duration and LV dyssynchrony 
(r=0.26, P=NS). In conclusion, 30-40% of heart failure patients with QRS duration >120 ms do 
not exhibit LV dyssynchrony, which may explain non-response to CRT. Alternatively, 27% of 
patients with heart failure and a narrow QRS complex has a signiﬁcant LV dyssynchrony and 
may be candidates for CRT.
In chapter 10 the prevalence of LV dyssynchrony was studied in 64 heart failure patients 
(NYHA class III-IV, LV ejection fraction <35%) with a narrow QRS complex (≤120 ms).Substan-
tial LV dyssynchrony (deﬁned as LV dyssynchrony >60 ms) was observed in 33% of these 
patients. No signiﬁcant correlation was found between QRS duration and LV dyssynchrony 
(r=0.12, P=NS). No baseline clinical parameters were able to predict the presence of LV dys-
synchrony in this patient group. Substantial inter-ventricular (LV- RV) dyssynchrony (>50 ms) 
was present in only 5% of the patients, suggesting that QRS duration is a marker of inter-
ventricular dyssynchrony rather than LV dyssynchrony. 
In conclusion, substantial LV dyssynchrony is present in 33% of patients with heart failure and 
a narrow QRS complex which implies that CRT should also be considered in these patients.
The presence of pre-implantation LV dyssynchrony and consequent LV resynchronization 
by CRT are considered as the key mechanism of response to CRT (see chapters 8,12). Both 
M-mode echocardiography (using the septal-to-posterior wall motion delay, SPWMD) and 
color-coded TDI have been proposed for assessment of LV dyssynchrony and prediction of re-
sponse to CRT. In chapter 11 a head-to-head comparison between M-mode echocardiogra-
phy and color-coded TDI was performed for assessment of LV dyssynchrony and prediction of 
response to CRT in 98 consecutive heart failure patients (NYHA class III-IV, LV ejection fraction 
≤35% and QRS duration >120 ms) undergoing CRT implantation. Pre-implantation LV dyssyn-
chrony assessment using M-mode echocardiography was not feasible in 41% of patients due 
to akinesia of the septal and/or posterior walls or poor acoustic windows. Conversely, with 
LV dyssynchrony could be assessed in 96% of patients using TDI. At 6 months follow-up, 75 
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patients (77%) were classiﬁed as responders to CRT (deﬁned as improvement ≥1 NYHA class). 
The sensitivity and speciﬁcity of M-mode echocardiography to predict response to CRT were 
substantially lower as compared to TDI assessment of LV dyssynchrony (66% vs. 90%, P<0.05 
and 50% vs. 82%, P= NS respectively). 
Thus, LV dyssynchrony assessment was only feasible in 59% of patients with M-mode echo-
cardiography as compared to 96% (P< 0.05) when color-coded TDI was used. In addition, 
color-coded TDI was superior over M-mode echocardiography for prediction of response to 
CRT.
In chapter 12 response to CRT was predicted by the presence of LV dyssynchrony assessed by 
color-coded TDI. Moreover, the prognostic value of LV dyssynchrony in patients undergoing 
CRT was assessed. Eighty-ﬁve consecutive heart failure patients (NYHA class III-IV, LV ejection 
fraction ≤35% and QRS duration ≥120 ms with LBBB) were evaluated by TDI before CRT. None 
of the baseline characteristics (including all current selection criteria; NYHA class, LV ejection 
fraction and QRS duration) were diﬀerent between clinical responders (74%) and clinical non-
responders (26%), except for a larger LV dyssynchrony on TDI in responders (87±49 ms versus 
35±20 ms, P<0.01). Patients with no or minimal dyssynchrony (<40 ms) had a low likelihood of 
improvement in clinical parameters and reverse remodeling, whereas patients with extensive 
dyssynchrony (≥80 ms) had a high likelihood of response. Using a cutoﬀ value of 65 ms for 
LV dyssynchrony, a sensitivity of 81% and speciﬁcity of 81% to predict response to CRT, were 
obtained. Patients with dyssynchrony ≥65 ms had an excellent prognosis (6% event-rate) after 
CRT, as compared to a 50% event-rate in patients with dyssynchrony <65 ms (P<0.001). 
Thus, none of baseline characteristics (including the current selection criteria) are able to 
predict response to CRT. In contrast, LV dyssynchrony ≥65 ms on TDI is highly predictive for 
response to CRT. In addition, patients with LV dyssynchrony ≥65 ms have an excellent prog-
nosis after CRT.
In Chapter 13 the eﬀects of scar tissue in the postero-lateral LV segments (the area were 
the LV pacing lead is usually located) were evaluated in 40 consecutive heart failure patients 
(NYHA class III-IV, LV ejection fraction ≤35%, QRS duration >120 ms and LBBB) with an isch-
emic cardiomyopathy undergoing CRT implantation. The localization and transmurality of 
scar tissue was evaluated with contrast-enhanced MRI. Fourteen patients (35%) had a trans-
mural (>50% of LV wall thickness) postero-lateral scar. In contrast to patients without pos-
tero-lateral scar tissue, these patients showed a low response rate (14% vs. 81%, P<0.05) and 
did not improve in clinical or echocardiographic parameters. In addition, LV dyssynchrony 
remained unchanged after CRT implantation (84±46 ms vs. 78±41 ms, P=NS). In contrast, pa-
tients without postero-lateral scar tissue and severe baseline dyssynchrony (≥65 ms) showed 
an excellent response rate of 95%, compared to patients with a postero-lateral scar and/or 
absent LV dyssynchrony (11%). 
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In conclusion, CRT is unable to reduce LV dyssynchrony in patients with transmural scar tissue 
in the postero-lateral LV segments, resulting in clinical and echocardiographic non-response 
to CRT. 
Part IV: Emerging indications
In chapters 9 and 10 it was demonstrated that approximately one third of heart failure pa-
tients with a narrow QRS complex (who are currently not eligible for CRT) exhibits substantial 
LV dyssynchrony thereby suggesting that these patients may also beneﬁt from CRT. Accord-
ingly, in chapter 14 the eﬀects of CRT were evaluated in heart failure patients with narrow 
QRS complex (<120 ms) and evidence of left ventricular (LV) dyssynchrony on TDI. Thirty-
three consecutive patients with narrow QRS complex and 33 consecutive patients with wide 
QRS complex (control group) were prospectively included. All patients needed to have LV 
dyssynchrony ≥65 ms on TDI, New York Heart Association (NYHA) class III-IV heart failure and 
LV ejection fraction ≤35%. Baseline characteristics, particularly LV dyssynchrony, were com-
parable between patients with narrow and wide QRS complex (mean QRS duration 110±8 ms 
versus 175±22 ms). No signiﬁcant relationship was observed between baseline QRS duration 
and LV dyssynchrony in all patients (r=0.21, P=NS). The improvement in clinical symptoms 
and the extent of LV reverse remodeling was comparable between patients with narrow and 
wide QRS complex (mean NYHA class reduction 0.9±0.6 versus 1.1±0.6, P=NS and mean LV 
end-systolic volume reduction 39±34 ml versus 44±46 ml, P=NS). 
Thus, CRT appears to be beneﬁcial in patients with narrow QRS complex (<120 ms) and severe 
LV dyssynchrony on TDI, with similar improvement in symptoms and comparable LV reverse 
remodeling to patients with wide QRS complex. 
In Chapter 15 the eﬀects of CRT were evaluated in patients with mildly symptomatic heart 
failure (NYHA class II), who are also not eligible for CRT according to the current CRT selection 
criteria. Fifty consecutive patients with NYHA class II heart failure and 50 consecutive NYHA 
class III/IV patients (control group) were prospectively included. All patients had LV ejection 
fraction ≤35% and QRS duration >120 ms. The severity of baseline LV dyssynchrony was not 
diﬀerent between patients in NYHA class II as compared to NYHA class III/IV patients and CRT 
resulted in a similar degree of LV resynchronization. The magnitude of improvement in clini-
cal parameters was signiﬁcantly less in the NYHA class II patients (e.g. NYHA class improved 
by 0.3±0.6 vs. 1.0±0.8, respectively, P<0.05), however patients without change in NYHA class 
(56%) still improved signiﬁcantly in LV ejection fraction and LV volumes. The overall improve-
ment in LV ejection fraction (7±11% vs. 7±7%, respectively, P=NS) and the decrease in LV 
volumes was comparable between NYHA class II patients and the control group. 
In conclusion, CRT has comparable eﬀects in patients with NYHA class II and NYHA class III/IV 
heart failure in terms of LV resynchronization, improvement in LV ejection fraction and LV 
reverse remodeling. 
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Part V: Optimal use of echocardiography in cardiac resynchronization therapy 
Chapter 16 provides an integration of the data from Chapters 2-15 and gives an overview of 
the optimal use of echocardiography in the care of patients undergoing CRT implantation, 
both before implantation (LV dyssynchrony detection), as well as after implantation (follow-
up, optimization of pacemaker settings). A summary of chapter 16 will be given in the fol-
lowing section “conclusions and future perspectives”. 
CONCLUSIONS AND FUTURE PERSPECTIVES
Despite the impressive results of CRT in large randomized trials, a consistent number of pa-
tients fails to improve following CRT when the established selection criteria (NYHA class III-IV, 
LV ejection fraction <35% and QRS duration >120 ms) are applied. A reduction in end-systolic 
volume >10% after 3-6 months of CRT recently proved to be the best predictor of improved 
long-term survival following CRT and therefore provides the most clinical meaningful deﬁni-
tion of response to CRT. According to this deﬁnition 40% of patients do not respond to CRT. 
When response to CRT is deﬁned using clinical parameters (e.g. improvement in NYHA class 
or quality-of life) the prevalence of non-responders usually around 30%. 
Recent studies, addressing the issue of non-response to CRT have indicated that none of 
the baseline patient characteristics, (including the current selection criteria: QRS duration, 
NYHA class and LV ejection fraction) are able to predict a positive response to CRT, thereby 
highlighting the need for improvement of the current selection criteria. In the search for bet-
ter selection criteria it has now been clearly demonstrated that the key mechanism of beneﬁt 
from CRT is the presence of baseline LV dyssynchrony and its subsequent reduction following 
CRT implantation. In contrast, the presence inter-ventricular dyssynchrony appears of less 
importance. 
Detection of LV dyssynchrony
Traditionally, QRS duration has been used as an (indirect) marker of LV dyssynchrony, but this 
parameter recently proved to be a poor marker of LV dyssynchrony, thereby explaining its 
low predictive value for response to CRT. 
Since these observations, several cardiac imaging techniques have been tested for their abil-
ity to detect and quantify LV dyssynchrony. Among the diﬀerent techniques, echocardiogra-
phy proved particularly well suited for detection of LV dyssynchrony in the clinical setting. 
Most experience has been obtained with color-coded TDI, which proved highly predictive for 
both clinical response and prognosis after CRT implantation. In addition, various other echo-
cardiographic techniques have been introduced ranging from simple M-mode echocardiog-
raphy to more sophisticated echocardiographic techniques, such as strain (rate) imaging and 
recently 3D-echocardiography. At present, no consensus exists on which technique is optimal 
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for prediction of response to CRT, and the large number of diﬀerent echocardiographic tech-
niques that have been published (without direct comparisons between techniques) further 
contribute to the confusion on the optimal technique. Moreover, the diﬀerent techniques 
employ varying numbers of segments to determine LV dyssynchrony (ranging from 2 to 16 
segments) and diﬀerent cut-oﬀ values to deﬁne substantial LV dyssynchrony (ranging from 
65 ms to 130 ms). Consequently, larger multi-center studies, directly comparing diﬀerent 
echocardiographic techniques, are needed to identify the optimal technique, with the opti-
mal number of segments and the optimal extent of LV dyssynchrony to predict response to 
CRT. The prospective, multi-center PROSPECT-trial is speciﬁcally designed to answer some of 
these questions and the results are expected in 2007. However, although the relative merits 
and the precise cut-oﬀ values of all these diﬀerent techniques for prediction of response to 
CRT remain to be deﬁned, it has now been convincingly proven that patient selection based 
on echocardiographic detection of LV dyssynchrony is superior compared to patient selec-
tion based on the current selection criteria. It is therefore anticipated that echocardiographic 
detection of LV dyssynchrony will be included in future ACC/AHA/ESC guidelines.
Novel indications
Despite the fact that current guidelines only recommend the use of CRT in patients with NYHA 
class III-IV, LV ejection fraction <35% and QRS duration >120 ms it is expected that novel 
indications for CRT will be validated in the near future. In particular, recent small studies have 
demonstrated that CRT may be eﬀective in the following three patient categories that are 
outside the established selection criteria; 1] heart failure patients with narrow QRS complex 
(<120 ms) and echocardiographic evidence of LV dyssynchrony (main goal: improvement of 
clinical symptoms / LV function and LV reverse remodeling), 2] patients with mildly symptom-
atic heart failure (NYHA class I-II) and impaired LV function (main goal: improvement in LV 
function, LV reverse remodeling and prevention of heart failure progression) and 3] patients 
with RV pacing induced LV dyssynchrony and (minimally) impaired LV function (main goal: 
prevention of heart failure progression) . 
Scar tissue and LV lead positioning
Finally, recent data highlighted the importance of other issues related to response to CRT. In 
particular, the localization of the LV pacing lead in the area of latest LV activation appears to 
result in the highest beneﬁt from CRT. Various echocardiographic techniques are currently 
available to assess the area of latest LV activation (including triplane tissue synchronization 
imaging and real-time 3D echocardiography), but more evidence is needed before recom-
mendations can be made. In addition, assessment of scar tissue in the LV pacing area is 
important; large areas of scar tissue in the left ventricle appear to reduce beneﬁt of CRT. In 
addition, it was recently demonstrated that CRT is unable to reduce LV dyssynchrony in the 
presence of scar tissue in the postero-lateral LV segments, resulting in non-response to CRT. 
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It may thus be considered to include pre-implantation assessment of scar tissue by contrast-
enhanced MRI. 
Conclusion
In conclusion, in the current ﬁeld of CRT research there is clear need for large multi-center 
(randomized) trials to conﬁrm the ﬁndings of recent small single-center studies in particular 
addressing the following topics; 1] The deﬁnition of the optimal echocardiographic method 
to detect LV dyssynchrony 2] Validation of novel CRT indications (narrow QRS complex, NYHA 
class I-II and RV pacing induced LV dyssynchrony) and 3] Evaluation of the inﬂuence of LV scar 
tissue and LV lead positioning. 
Awaiting the results of these trials it is anticipated that in the near future the current patient 
selection criteria will be extended with the presence of substantial LV dyssynchrony (sponta-
neous or RV pacing induced and irrespective of QRS duration).
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SAMENVATTING
De introductie van dit proefschrift (Hoofdstuk 1) geeft een overzicht van het werkingsme-
chanisme van cardiale resynchronisatie therapie (CRT) en beschrijft de klinische resultaten 
van CRT die zijn beschreven bij patiënten met chronisch hartfalen. 
Na de veelbelovende eerste resultaten in de tweede helft van de 90’er jaren van de vorige 
eeuw, zijn de positieve eﬀecten van CRT nu ook overtuigend bewezen in grote gerandomi-
seerde studies die inmiddels meer dan 4000 patiënten hebben geïncludeerd. De positieve 
eﬀecten van CRT zijn onder meer een verbetering in klinische symptomen (zoals NYHA func-
tionele klasse, kwaliteit van leven en 6-minutenloopafstand) en een verbetering in echocar-
diographische parameters (Linker ventrikel (LV) ejectiefractie, LV volumina en mitralisklep 
insuﬃciëntie). Bovendien leidde CRT tot een afname van het aantal opnames voor gedecom-
penseerd hartfalen en een afname van de mortaliteit in vergelijking met patiënten die alleen 
werden behandeld met optimale farmacologische therapie. 
Naar aanleiding van deze indrukwekkende resultaten wordt CRT op dit moment, zowel in 
de Europese (ESC) als in Amerikaanse richtlijnen (ACC/AHA/HRS) beschouwd als een klasse I 
indicatie in patiënten met chronisch hartfalen.
In deze richtlijnen wordt CRT aanbevolen bij patiënten met (matig-) ernstig hartfalen (NYHA 
klasse III-IV), een verminderde LV ejectie fractie (<35%) en een verbreed QRS complex (>120 
ms). Echter, naast deze indrukwekkende resultaten bleek er ook een groep patiënten te zijn 
die niet verbeterde na CRT, ondanks selectie volgens de huidige richtlijnen (de zogenaamde 
non-responders). 
Wanneer non-response na CRT wordt gedeﬁnieerd als de afwezigheid van een verbetering 
in klinische symptomen (bijv. verbetering in NYHA klasse of kwaliteit van leven) dan is het 
percentage non-responders ongeveer 30% en wanneer non-response wordt gedeﬁnieerd 
met behulp van echocardiographische parameters (LV reverse remodeling of verbetering in 
LV ejectiefractie) dan ligt het percentage non-responders rond de 40%. 
Het doel van dit proefschrift was om de huidige CRT selectiecriteria zo te verbeteren dat 
het aantal non-responders na CRT vermindert. Om dit doel te bereiken werd het pathophy-
siologische mechanisme van (non-) response na CRT bestudeerd (Deel I en II) om zo meer 
optimale selectiecriteria te ontwikkelen (Deel III). Bovendien werd naar aanleiding van de 
nieuw ontwikkelde selectiecriteria het gebruik van CRT ook getest in patiënten die volgens 
de huidige criteria geen indicatie voor CRT hebben (Deel IV). 
Deel I: Positieve eﬀecten van CRT
In Hoofdstuk 2 werd het percentage responders na CRT vergeleken tussen oudere (gedeﬁ-
nieerd als ≥70 jaar) en jongere patiënten (<70 jaar). 170 opeenvolgende patiënten werden 
geïncludeerd op basis van de huidige CRT selectiecriteria (NYHA klasse III-IV, LV ejectiefractie 
<35% en een QRS duur van >120 ms (met linker bundeltakblok patroon)). De gemiddelde 
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leeftijd van de patiënten was 66±11 jaar, waarbij 102 (60%) patiënten < 70 jaar oud was. 
Patiënten ≥70 jaar hadden vaker een ischemische cardiomyopathie als oorzaak van hartfalen 
(48% vs. 66%, P<0.05); alle andere patiënten karakteristieken voor implantatie waren gelijk. 
Na 6 maanden follow-up werd er in de gehele patiëntengroep een signiﬁcante verbetering 
gezien in zowel de klinische als de echocardiographische parameters (bijv. de NYHA klasse 
nam af van 3.2±0.4 naar 2.2±0.7, P<0.001, de LV ejectiefractie nam toe van 21±8% naar 28±9%, 
P<0.001, en er was sprake van een signiﬁcante LV reverse remodeling). De mate van verbete-
ring in klinische en echocardiographische parameters was vergelijkbaar in de patiënten < 70 
jaar en ≥70 jaar. Tevens was het percentage responders gelijk in beide groepen (75% vs. 78%, 
P=NS). Verder was de 1-jaarsoverleving vergelijkbaar in de patiënten < 70 jaar en ≥70 jaar. 
CRT heeft dus vergelijkbare positieve eﬀecten in oudere patiënten en jongere patiënten wat 
betreft verbetering in klinische en echocardiographische parameters en 1-jaarsoverleving. 
Ook is het percentage responders in oudere patiënten niet verschillend van het percentage 
in jongere patiënten. 
Deze studie geeft aan dat de leeftijd van de patiënt geen invloed heeft op de mate van res-
ponse na CRT en dat CRT dus ook overwogen dient te worden in oudere patiënten.
Het doel van Hoofdstuk 3 was om het eﬀect van het geslacht van de patiënt op de mate 
van response na CRT te evalueren. 173 opeenvolgende patiënten (NYHA klasse III-IV, LV 
ejectiefractie ≤35% en een QRS duur >120 ms (met linkerbundeltakblok patroon) werden 
geïncludeerd. Er waren geen verschillen in de pre-implantatie patiënten karakteristieken 
tussen mannen (n=137) en vrouwen (n=36), behalve dat vrouwen meer frequent een non-is-
chemische oorzaak van het hartfalen hadden (67% vs. 38%, P<0.05). Na 6 maanden follow-up 
was de mate van verbetering in klinische en echocardiographische parameters vergelijkbaar 
tussen beide groepen; bijv. de verbetering in NYHA klasse was 0.9±0.6 in vrouwen en 1.0±0.7 
in mannen (P=NS) en de toename in LV ejectiefractie was 8±8% in vrouwen vergeleken met 
een toename van 7±9% in mannen (P=NS). Het percentage van individuele responders was 
niet verschillend tussen mannen en vrouwen (76% vs. 80%, P=NS) en de 2-jaars overleving 
was vergelijkbaar in beide groepen (84% vs. 80%, P=NS). 
Concluderend, laat deze studie zien dat er geen verschillen zijn in het percentage responders 
en de overleving na CRT tussen mannen en vrouwen. 
In Hoofdstuk 4 werd de precieze relatie tussen de verbetering in klinische en echocardiogra-
phische parameters onderzocht. In recente studies werd er geen vaste deﬁnitie van response 
gehanteerd en zowel klinische als echocardiographische eindpunten worden op dit moment 
gebruikt. Het is onduidelijk of patiënten met een klinische verbetering na CRT ook verbeteren 
in echocardiographische eindpunten (en vice versa). 144 opeenvolgende patiënten ( NYHA 
klasse III-IV, LV ejectie fractie ≤35% en een QRS duur van ≥120 ms (met linkerbundeltakblok 
patroon) werden geïncludeerd. 3-6 maanden na CRT implantatie werd een klinische response 
(verbetering ≥1 NYHA klasse) waargenomen in 101 (70%) patiënten en een echocardiographi-
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sche response (afname van het eind-systolische volume >15%) vond plaats in 81 (56%) patiën-
ten. Klinische response zonder echo response vond plaats in 27 (19%) patiënten, terwijl 7 (5%) 
patiënten verbeterden in echocardiographische parameters zonder verbetering in klinische 
symptomen. De afwezigheid van overeenstemming tussen beide eindpunten in 24% van de 
patiënten werd dus voornamelijk veroorzaakt door patiënten met een verbetering in klinische 
symptomen, zonder een verbetering in echocardiographische parameters. Deze observatie 
kan worden verklaard door de aanwezigheid van een placebo eﬀect in relatie tot de klinische 
verbetering na CRT, iets wat in eerdere gerandomiseerde studies reeds beschreven is. 
Samenvattend, is er een goede relatie (76%) tussen klinische en echocardiographische res-
ponse na CRT. Toch wordt echocardiographische response na CRT (56%) minder frequent 
gezien dan klinische response (70%). 
Deel II: Werkingsmechanisme van CRT
In Hoofdstuk 5 werden de eﬀecten van CRT op de grootte van de rechter ventrikel en de 
ernst van de tricuspidalisklep insuﬃciëntie bestudeerd. Het is bekend dat zowel de grootte 
als de functie van de rechter ventrikel belangrijke en onafhankelijke voorspellers zijn van 
prognose in patiënten met hartfalen. Eventuele positieve eﬀecten van CRT op de rechter-
ventrikel kunnen daarom een verdere verklaring geven van het werkingsmechanisme van 
CRT. 56 opeenvolgende patiënten (NYHA klasse III-IV, LV ejectiefractie ≤35% en een QRS duur 
> 120 ms (met linkerbundeltakblok patroon) werden geïncludeerd. Na 6 maanden van CRT 
verbeterde de LV ejectiefractie van 19±6% naar 26±8% (P<0.001) en het LV eind-diastolische 
volume nam af van 257±98 ml naar 227±86 ml (P<0.001). Verder nam de diameter van de 
tricuspidalisklep-annulus signiﬁcant af van 37±9 mm naar 32±10 mm, de korte-as diameter 
van de rechter ventrikel nam af van 29±11 mm tot 26±7 mm, en de lange-as diameter van 
de rechter ventrikel nam af van 89±11 mm naar 82±10 mm (alle metingen P<0.001), waarbij 
de grootste afname werd gezien in patiënten met de grootste rechter ventrikels voor im-
plantatie. Een interessante observatie was het feit dat de afname van de linker-en rechter 
ventrikelgrootte alleen werd gezien in patiënten met een substantiële LV dyssynchronie voor 
de implantatie. Tenslotte was er een signiﬁcante afname in de ernst van de tricuspidalisinsuf-
ﬁcentie en in de pulmonaaldrukken. 
Concluderend, leidt CRT tot een signiﬁcante afname van de linker-en rechter ventrikelgroot-
te. Bovendien leidt CRT tot een afname van de ernst van de tricuspidalisinsuﬃcentie en de 
druk in de pulmonaal arterie. Deze bevindingen kunnen een bijdrage leveren aan de verdere 
ontrafeling van het werkingsmechanisme van CRT.
In recente CRT studies ontbreekt een duidelijk omschreven deﬁnitie van response en zowel 
klinische als echocardiographische eindpunten (met arbitraire afkapwaarden) worden ge-
bruikt. Het aantal echocardiographische responders is normaalgesproken lager (rond de 60%) 
dan het aantal klinische responders (70-80%) en bij 24% van de patiënten is er geen over-
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eenstemming tussen klinische en echocardiographische response. (zie Hoofdstuk 4) Het doel 
van Hoofdstuk 6 was om de klinisch meest relevante deﬁnitie van response te deﬁniëren. 
144 patiënten (NYHA klasse III-IV, LV ejectiefractie <40% en QRS duur >120 ms) die een CRT 
implantatie ondergingen werden geïncludeerd en werden gevolgd voor een gemiddelde pe-
riode van 695±491 dagen. Gedurende deze periode overleden er 22 (15.6%) patiënten, voor-
namelijk als gevolg van progressief hartfalen en plotse hartdood. ROC curve analyse toonde 
aan dat een afname van ≥9.5% in het LV eind-systolische volume een sensitiviteit van 70% en 
een speciﬁciteit van 70% had voor het voorspellen van de totale mortaliteit, en 87% en 69% 
respectievelijk voor het voorspellen van cardiovasculaire mortaliteit. Met deze afkapwaarde 
werd response gezien in 87 (61.7%) patiënten. In de Kaplan-Meier overlevings analyse hadden 
de responders een signiﬁcant lagere totale mortaliteit (6.9% versus 30.6%, Log-rank χ2=13.26, 
p=0.0003), cardiovasculaire mortaliteit (2.3% versus 24.1%, Log-rank χ2=17.1, p<0.0001), and 
hartfalen “events” (11.5% versus 33.3%, Log-rank χ2=8.71, p=0.0032) vergeleken met de non-
responders. In tegenstelling tot verbeteringen in LV volumina waren verbeteringen in klini-
sche parameters als gevolg van CRT niet in staat om de prognose na CRT te voorspellen. 
Samenvattend, bleek een afname van 10% in het LV eind-systolische volume na 3-6 maanden 
van CRT de beste voorspeller voor een verbeterde overleving te zijn. Deze parameter kan 
daardoor als de klinisch meest relevante deﬁnitie van response na CRT worden beschouwd. 
In Hoofdstuk 7 is een gedetailleerde invasieve studie uitgevoerd naar de hemodynamische 
eﬀecten van CRT met behulp van druk-volume curve analyse. 22 patiënten (NYHA klasse III-
IV, LV ejectiefractie <35% en QRS duur >120 ms (met linkerbundeltakblok patroon) werden 
geïncludeerd. Voor CRT implantatie en na 6 maanden follow-up werd tijdens diagnostische 
hartcatherisatie een druk-volume curve analyse (d.m.v. een conductie-cathether) verricht tij-
dens rechts atriaal pacen met frequenties van 80, 100, 120 en 140 slagen/minuut. Met behulp 
van de druk-volume curves werd aangetoond dat eerder beschreven acute verbeteringen in 
LV functie ook na 6 maanden nog aanwezig zijn: dP/dtMAX (+18%, p<0.01), dP/dtMIN (+13%, 
p<0.05), SW (+34%, p<0.05). De eﬀecten van een CRT leidden tot een meer fysiologische 
reactie op de verhoging van de hartfrequentie, wat betreft LV ejectiefractie, cardiac output 
en dP/dtMAX. Bovendien liet deze studie een verbeterde ventriculaire-arteriële koppeling zien 
(+69%, p<0.01) en een verbeterde mechanische eﬃciëntie (+44%, p<0.005). 
Samenvattend, blijven de acute hemodynamische eﬀecten van CRT behouden na 6 maanden 
follow-up. Tevens is er een verbetering in de ventriculaire arteriële koppeling, mechanische 
eﬃciëntie en chronotrope response na 6 maanden van CRT. Deze bevindingen kunnen de 
positieve eﬀecten van CRT verder verklaren. 
In Hoofdstuk 8 werden het tijdsbeloop en de mate van LV resynchronisatie na CRT implan-
tatie en hun relatie met response na CRT bestudeerd in 100 opeenvolgende patiënten (NYHA 
klasse III-IV, LV ejectiefractie ≤35% QRS duur >120 ms). Alleen patiënten met echocardio-
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graphisch bewijs van LV dyssynchronie (≥65 ms, zie Hoofdstuk 12) op color-coded tissue 
Doppler imaging (TDI) werden geïncludeerd. Meteen na CRT implantatie was er een afname 
van LV dyssynchronie van 114±36 ms naar 40±33 ms (P<0.001), welke onveranderd bleef na 
6 maanden (35±31 ms (P<0.001 vs. voor implantatie en P=NS vs. meteen na implantatie). Na 
6 maanden follow-up werden 85 patiënten geclassiﬁceerd als responders (gedeﬁnieerd als 
een >10% afname in LV eind-systolisch volume (zie Hoofdstuk 6). Patiëntenselectie geba-
seerd op de aanwezigheid van echocardiographische LV dyssynchronie m.b.v. TDI voor CRT 
implantatie is dus superieur vergeleken met selectie volgens de traditionele selectie criteria 
(met een echocardiographische response rond de 60%). Meteen na implantatie vertoonden 
de responders een signiﬁcante afname van de LV dyssynchronie van 115±37 ms naar 32±23 
ms (P<0.001). De non-responders, aan de andere kant, lieten geen signiﬁcante afname van 
de LV dyssynchronie na implantatie zien (van 106±29 ms naar 79±44 ms, P=NS). Onder de 
patiënten met <20% acute reductie in LV dyssynchronie waren er geen patiënten met een 
echocardiographische response na 6 maanden. Patiënten met een ≥20% acute reductie in LV 
dyssynchronie daarentegen hadden een 93% response percentage. 
Concluderend, is LV resynchronisatie na CRT een acuut fenomeen, en de aan/afwezigheid 
van acute LV resynchronisatie is een voorspeller van response na 6 maanden van CRT. 
Deel III: Voorspellen van response na CRT
De aanwezigheid van LV dyssynchronie voor implantatie lijkt noodzakelijk voor een positief 
eﬀect van CRT (zie Hoofdstukken 8,12).
In de huidige selectiecriteria wordt de duur van het QRS complex gebruikt als maat voor 
de mate van LV dyssynchronie. Recente studies hebben echter laten zien dat de duur van 
het QRS complex niet voorspeld wie er gaat verbeteren na CRT implantatie. Dit onderwerp 
wordt behandeld in Hoofdstuk 9, waarin de relatie tussen de duur van het  QRS complex 
en de mate van LV dyssynchronie worden onderzocht in 90  opeenvolgende patiënten met 
hartfalen, (NYHA klasse III-IV en LV ejectiefractie <35%). Patiënten werden geïncludeerd in 3 
groepen gebaseerd op de duur van het QRS complex: 30 patiënten met een smal QRS com-
plex (≤120 ms), 30 patiënten met een matig-ernstige QRS complex verbreding (120-150 ms) 
en 30 patiënten met een sterk verbreed QRS complex (>150). LV dyssynchronie werd gezien 
in 27% van de patiënten met een smal QRS complex, in 60% van de patiënten met een matig-
ernstige QRS verbreding en in 70% van de patiënten met een sterk verbreed QRS complex. 
Er was geen signiﬁcante correlatie tussen de duur van het QRS complex en de mate van LV 
dyssynchronie. (r=0.26, P=NS). 
Samenvattend, was er bij 30-40% van de patiënten met hartfalen en een QRS complex van 
>120 ms geen sprake van LV dyssynchronie, hetgeen non-response na CRT in deze   patiën-
tengroep kan verklaren. Verder, vertoont 27% van de patiënten met een smal QRS  complex 
LV dyssynchronie, hetgeen aangeeft dat deze patiënten ook baat zouden kunnen hebben 
bij CRT.
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In Hoofdstuk 10 werd de prevalentie van LV dyssynchronie bestudeerd in 64 patiënten met 
hartfalen (NYHA klasse III-IV, LV ejectiefractie <35%) en een smal QRS complex (≤120 ms).
Substantiële LV dyssynchronie (gedeﬁnieerd als LV dyssynchronie >60 ms) was Aanwezig in 
33% van de patiënten. Geen signiﬁcante correlatie werd gezien tussen de duur van het QRS 
complex en de mate van LV dyssynchronie (r=0.12, P=NS). Geen van de patiënten karakteris-
tieken voor implantatie was in staat om de aanwezigheid van LV dyssynchronie te voorspel-
len. Substantiële inter-ventriculaire dyssynchronie (tussen linker-en rechter ventrikel, >50 
ms) was aanwezig in slechts 5% van de patiënten, hetgeen suggereert dat de duur van het 
QRS complex meer een afspiegeling is van inter-ventriculaire dyssynchronie dan van LV dys-
synchronie. 
Concluderend, is LV dyssynchronie aanwezig in 33% van de patiënten met hartfalen en een 
smal QRS complex. Deze bevinding geeft aan dat CRT ook zou kunnen worden overwogen in 
patiënten met een smal QRS complex. 
De aanwezigheid van LV dyssynchronie voor implantatie en de daaropvolgende afname na 
CRT implantatie wordt beschouwd als het sleutelmechanisme van verbetering na CRT (zie 
Hoofdstukken 8,12). Zowel M-mode echocardiographie ( met behulp van de septal-to-
posterior wall motion delay, SPWMD) en color-coded TDI worden op dit moment gebruikt 
voor de bepaling van LV dyssynchronie om zo patiënten met een hoge kans op response te 
selecteren. In Hoofdstuk 11 wordt een directe vergelijking uitgevoerd tussen M-mode echo-
cardiographie en color-coded TDI. Beide technieken worden vergeleken voor hun vermogen 
om LV dyssynchronie te detecteren en response na CRT te voorspellen in 98 opeenvolgende 
patiënten met hartfalen (NYHA klasse III-IV, LV ejectiefractie ≤35% en QRS duur >120 ms). Het 
bepalen van LV dyssynchronie voor implantatie met behulp van M-mode echocardiographie 
was niet mogelijk in 41% als gevolg van akinesie van het septum of de posterior wand of door 
een slecht acoustisch venster. LV dyssynchronie detectie met behulp van TDI daarentegen 
was mogelijk in 96% van de patiënten. Na 6 maanden follow-up werden 75 patienten (77%) 
geclassiﬁceerd als responders (gedeﬁnieerd als een verbetering ≥1 NYHA klasse). De sensi-
tiviteit en speciﬁciteit van M-mode echocardiographie om response na CRT te voorspellen 
waren substantieel lager vergeleken met TDI. (66% versus 90%, P<0.05 en 50% versus 82%, 
P= NS, respectievelijk). 
Samenvattend, was LV dyssynchronie detectie met behulp van M-mode echocardiographie 
slechts mogelijk in 59% van de patiënten, terwijl met TDI dit percentage 96% was (P< 0.05). 
Bovendien was de voorspellende waarde van TDI voor response na CRT superieur vergeleken 
met M-mode echocardiographie.
In Hoofdstuk 12 werd color-coded TDI gebruikt om LV dyssynchronie te detecteren met als 
doel om patiënten met een hoge kans op verbetering na CRT te identiﬁceren. Bovendien 
werd de prognostische waarde van LV dyssynchronie in patiënten die een CRT implantatie 
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ondergingen bestudeerd. 85 opeenvolgende patiënten met hartfalen (NYHA klasse III-IV, LV 
ejectiefractie ≤35% en een QRS duur ≥120 ms (met linkerbundeltakblok patroon) werden 
onderzocht met TDI voor CRT implantatie. Geen van de patiënten karakteristieken voor de 
implantatie (inclusief alle huidige CRT selectiecriteria: NYHA klasse, LV ejectiefractie en QRS 
duur) waren verschillend tussen de klinische responders (74%) en klinische non-responders 
(26%). De enige pre-implantatie parameter die de responders van de non-responders on-
derscheidde was de mate van LV dyssynchronie op TDI (87±49 ms vs. 35±20 ms, P<0.01). 
Patiënten zonder of met minimale LV dyssynchronie (<40 ms) hadden een lage kans op ver-
betering in klinische parameters en LV reverse remodeling, terwijl patiënten met een forse 
LV dyssynchronie (≥80 ms) een hoge kans op response hadden. Met een afkapwaarde van 
65 ms had de LV dyssynchronie een sensitiviteit van 81% en een speciﬁciteit of 81% om res-
ponse te voorspellen. Patiënten met een LV dyssynchronie van ≥65 ms hadden bovendien 
een uitstekende prognose (6% “events”) na CRT implantatie vergeleken met een 50% “events” 
in patiënten met een LV dyssynchronie <65 ms (P<0.001). 
Samenvattend, was geen van de pre-implantatie patiënten karakteristieken in staat om res-
ponse na CRT te voorspellen (inclusief de huidige CRT selectiecriteria). Een LV dyssynchronie 
op TDI ≥65 ms had daarentegen een goede voorspellende waarde voor response na CRT 
implantatie. Bovendien hadden patiënten met een LV dyssynchronie ≥65 ms een uitstekende 
prognose na CRT implantatie.
In Hoofdstuk 13 worden de eﬀecten van littekenweefsel in de postero-laterale LV segmenten 
(dit is de regio waar de LV pacing lead meestal ligt) bestudeerd in 40 patiënten (NYHA klasse 
III-IV, LV ejectiefractie ≤35%, en QRS duur >120 ms (met linkerbundeltakblok patroon)) met 
een ischemische cardiomyopathie die een CRT implantatie ondergingen. De localisatie en 
de transmuraliteit van het littekenweefsel werd bepaald met behulp van contrast-enhanced 
MRI. Bij 14 patiënten (35%) was er sprake van een transmuraal litteken (>50% van de wand-
dikte) in de postero-laterale LV segmenten. In tegenstelling tot patiënten zonder postero-
lateraal littekenweefsel liet deze patiëntengroep een laag percentage responders zien (14% 
versus 81%, P<0.05) en verbeterden zij niet in klinische of echocardiographische parameters. 
Bovendien, bleef de LV dyssynchronie onveranderd na CRT implantatie (84±46 ms versus 
78±41 ms, P=NS). Daarentegen hadden patiënten zonder postero-lateraal littekenweefsel in 
combinatie met pre-implantatie LV dyssynchronie ≥65 ms een hoge kans op response (95%) 
vergeleken met patiënten met postero-lateraal littekenweefsel en/of afwezigheid van pre-
implantatie LV dyssynchrony (11%).
Samenvattend, is CRT niet in staat om LV dyssynchronie te reduceren in de aanwezigheid van 
postero-lateraal littekenweefsel, hetgeen resulteert in klinische en echocardiographische 
non-response na CRT. 
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Deel IV: Nieuwe indicaties
In de Hoofdstukken 9 en 10 werd gezien dat er bij ongeveer een derde van de patiënten met 
hartfalen en een smal QRS complex (deze patiënten hebben op dit moment geen indicatie 
voor CRT) sprake is van substantiële LV dyssynchronie, wat suggereert dat deze patiënten 
ook baat kunnen hebben bij CRT. 
Naar aanleiding van deze bevindingen werden in Hoofdstuk 14 de eﬀecten van CRT in 
patiënten met hartfalen, een smal QRS complex (<120 ms) en LV dyssynchronie op TDI ge-
evalueerd. 33 patiënten met een smal QRS complex en 33 patiënten met een verbreed QRS 
complex (controlegroep) werden prospectief geïncludeerd. Patiënten werden geïncludeerd 
op basis van de volgende criteria: LV dyssynchronie ≥65 ms op TDI, NYHA klasse III-IV en LV 
ejectiefractie ≤35%. De pre-implantatie patiënten karakteristieken, in het bijzonder de mate 
van LV dyssynchronie waren vergelijkbaar tussen de patiënten met een smal en een verbreed 
QRS complex (gemiddelde QRS duur 110±8 ms vs. 175±22 ms). Geen signiﬁcante relatie was 
aanwezig tussen QRS duur en LV dyssynchronie (r=0.21, P=NS). De mate van verbetering in 
klinische symptomen en LV functie was vergelijkbaar tussen patiënten met een smal en een 
verbreed QRS complex (gemiddelde reductie in NYHA klasse 0.9±0.6 vs. 1.1±0.6, P=NS en een 
gemiddelde reductie in LV eind-systolisch volume 39±34 ml vs. 44±46 ml, P=NS). 
Concluderend, resulteert CRT in positieve eﬀecten in patiënten met een smal QRS complex 
en LV dyssynchronie op TDI, met klinische en echocardiographische verbeteringen die verge-
lijkbaar zijn met de verbeteringen in patiënten met een verbreed QRS complex.
In Hoofdstuk 15 werden de eﬀecten van CRT in patiënten met milde symptomen van hartfa-
len (NYHA klasse II) onderzocht. Deze patiënten hebben op dit moment geen indicatie voor 
CRT. Vijftig opeenvolgende patiënten met NYHA klasse II hartfalen en 50 patiënten met NYHA 
klasse III-IV hartfalen (controlegroep) werden prospectief geïncludeerd. Alle patiënten had-
den een LV ejectiefractie ≤35% en een QRS duur >120 ms. De mate van LV dyssynchronie was 
niet verschillend tussen patiënten in NYHA klasse II en de patiënten in NYHA klasse III/IV en 
CRT resulteerde in een vergelijkbare mate van LV resynchronisatie. 
De mate van verbetering in klinische parameters was signiﬁcant lager in de NYHA klasse 
II patiënten (bijv. NYHA klasse verbeterde met 0.3±0.6 vs. 1.0±0.8, respectievelijk, P<0.05), 
opvallend was echter dat de patiënten zonder verbetering in NYHA klasse (56%) wel een 
verbetering lieten zien in LV ejectiefractie en LV volumina. Bovendien was de verbetering 
in LV ejectiefractie en de afname in LV volumina niet verschillend tussen de NYHA klasse 
II en de NYHA klasse III/IV patiënten (bijv. verbetering in LV ejectiefractie 7±11% vs. 7±7%, 
respectievelijk, P=NS).
Concluderend, zijn de eﬀecten van CRT in NYHA klasse II patiënten vergelijkbaar met de ef-
fecten in NYHA klasse III-IV patiënten wat betreft de mate van LV resynchronisatie, de verbe-
tering in LV ejectiefractie en de mate van LV reverse remodeling. 
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Deel V: Optimaal gebruik van echocardiograﬁe bij cardiale resynchronisatie 
therapie. 
Hoofdstuk 16 geeft een integratie van de informatie die is beschreven in de Hoofdstukken 
2-15 en geeft een handleiding voor het optimale gebruik van echocardiographie in de zorg 
voor patiënten die een CRT implantatie ondergaan, zowel voor de implantatie (LV dyssyn-
chronie detectie), als ook na de implantatie (follow-up en optimalisatie van de pacemaker 
settings). Een samenvatting van Hoofdstuk 16 is verwerkt in de volgende sectie “conclusies 
en toekomstperspectief”.
CONCLUSIES EN TOEKOMSTPERSPECTIEF
Ondanks de indrukwekkende resultaten van CRT in grote gerandomiseerde studies, blijkt een 
consistent aantal patiënten niet te verbeteren wanneer zij volgens de huidige CRT selectiecri-
teria (NYHA klasse III-IV, LV ejectiefractie <35% en QRS duur >120 ms) worden geselecteerd. 
Recent bleek dat een afname van het eind-systolische volume van >10% na 3-6 maanden 
CRT de beste voorspeller van een verbeterde lange-termijn overleving na CRT was en dus de 
meest klinisch relevante deﬁnitie van response na CRT verschaft. Volgens deze deﬁnitie van 
response heeft ongeveer 40% van de patiënten geen verbetering na CRT. Wanneer response 
na CRT gedeﬁnieerd wordt met behulp van klinische parameters (bijv. verbetering in NYHA 
klasse of kwaliteit van leven) dan is het aantal non-responders rond de 30%. 
Recente studies hebben aangegeven dat geen van de pre-implantatie patiënten karakteris-
tieken (inclusief de huidige selectie criteria: QRS duur, NYHA klasse en LV ejectiefractie) in 
staat zijn om een positieve response na CRT te voorspellen. Deze bevindingen benadruk-
ken de noodzaak voor de verbetering van huidige selectie criteria. Tijdens de zoektocht naar 
betere selectiecriteria is het nu duidelijk aangetoond dat het sleutelmechanisme van CRT de 
reductie van pre-implantatie LV dyssynchronie is. De aanwezigheid van inter-ventriculaire 
dyssynchronie daarentegen bleek minder van belang. 
Detectie van LV dyssynchronie
Van oudsher werd de duur van het QRS complex gebruikt als een (indirecte) maat voor LV 
dyssynchronie, echter recent bleek deze parameter een slechte afspiegeling te geven van 
de mate van LV dyssynchronie, waarmee de lage voorspellende waarde van QRS duur voor 
response na CRT werd verklaard. 
Na deze observatie, zijn verschillende cardiale beeldvormingstechnieken geëvalueerd voor 
hun vermogen om LV dyssynchronie te detecteren en te kwantiﬁceren. 
Van deze technieken bleek vooral echocardiographie uitermate geschikt om LV dyssynchro-
nie te detecteren in de klinische praktijk. 
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Op dit moment is de meeste ervaring opgedaan met color-coded TDI en deze techniek bleek 
een goede voorspeller van zowel klinische response als ook van prognose na CRT implanta-
tie. Naast TDI zijn er verschillende andere echocardiographische technieken geïntroduceerd 
variërend van M-mode echocardiographie tot strain rate imaging en 3D echocardiographie. 
Op dit moment is er geen consensus over welke techniek het meest geschikt is om response 
na CRT te voorspellen en het grote aantal echocardiographische technieken dat voor dit doel 
is geïntroduceerd (zonder deze technieken onderling te vergelijken) draagt verder bij aan 
de verwarring over de optimale techniek. Bovendien maakt iedere techniek gebruik van een 
verschillend aantal cardiale segmenten (van 2 tot 16 segmenten) en worden er verschillende 
afkapwaardes gebruikt ( van 65 tot 130 ms). 
Om te komen tot de keuze voor een optimale techniek (met een optimaal aantal segmenten 
en een optimale afkapwaarde) voor de voorspelling van response na CRT is er een dringende 
behoefte aan grotere multi-center studies die de verschillende technieken vergelijken. De 
prospectieve multi-center PROSPECT-studie is speciﬁek ontworpen om een aantal van deze 
vragen te beantwoorden en de resultaten worden verwacht in 2007. 
Echter, ondanks het feit dat er op dit moment onduidelijkheid bestaat over de meest op-
timale echocardiographische techniek is in de laatste jaren overduidelijk bewezen dat pa-
tiëntenselectie gebaseerd op echocardiographische detectie van LV dyssynchronie superieur 
is vergeleken met selectie gebaseerd op de huidige criteria. Het ligt daarom in de lijn der 
verwachting dat de echocardiographische detectie van LV dyssynchronie zal worden geïn-
cludeerd in toekomstige Europese en Amerikaanse richtlijnen. 
Nieuwe indicaties
Ondanks het feit dat de huidige richtlijnen het gebruik van CRT alleen adviseren in patiënten 
met NYHA klasse III-IV hartfalen, LV ejectiefractie ≤35% en een QRS duur ≥120 ms is het te 
verwachten dat in de toekomst enkele nieuwe indicaties voor CRT zullen worden gevalideerd. 
Recente studies hebben namelijk aangetoond dat CRT ook van nut kan zijn in de volgende 
drie patiëntencategorieën (die op dit moment geen indicatie voor CRT hebben); 1] patiënten 
met hartfalen en een smal QRS complex (<120 ms) in combinatie met echocardiographische 
bewijs van LV dyssynchronie (doel: verbetering van klinische symptomen / LV functie en LV 
reverse remodeling), 2] patiënten met milde symptomen van hartfalen (NYHA klasse II) en 
verminderde LV functie (doel: verbetering van LV functie, LV reverse remodeling en preventie 
van progressie van hartfalen) en 3] patiënten met een LV dyssynchronie als gevolg van rechts 
ventriculair pacen in combinatie met een verminderde LV functie (doel: preventie van pro-
gressie van hartfalen). 
Samenvatting, Conclusies en Toekomstperspectief 275
Littekenweefsel en LV lead positie
Tenslotte, zijn er nog een aantal andere factoren die van invloed kunnen zijn op de mate van 
response na CRT. In het bijzonder de positie van de LV pacing lead in het gebied van laatste 
LV activatie lijkt te resulteren in de grootste mate van verbetering na CRT. 
Verschillende echocardiographische technieken zijn op dit moment beschikbaar om dit ge-
bied van laatste LV activatie te identiﬁceren (zoals triplane tissue synchronization imaging 
and real-time 3D echocardiographie). Echter, voordat er aanbevelingen kunnen worden ge-
daan wat betreft LV lead positie zal er meer onderzoek moeten worden gedaan. Een tweede 
factor die mogelijk is gerelateerd aan non-response is de aanwezigheid van littekenweefsel 
in de linker ventrikel; grote gebieden van littekenweefsel lijken het eﬀect van CRT te ver-
minderen. Bovendien is recent aangetoond dat CRT niet in staat is om LV dyssynchronie te 
verminderen in de aanwezigheid van littekenweefsel in de postero-laterale segmenten van 
de linker ventrikel, resulterend in non-response na CRT. Het kan daarom overwogen worden 
om littekenweefsel in de linker ventrikel te identiﬁceren voor CRT implantatie (bijv. met con-
trast enhanced MRI). 
Conclusie 
Concluderend is er op dit moment op het gebied van CRT-research een dringende behoefte 
aan multi-center studies om recente bevindingen uit kleinere single-center studies te beves-
tigen. Deze studies zouden zich op de volgende onderwerpen moeten richten: 1] Het deﬁni-
eren van de optimale echocardiographische methode om LV dyssynchronie te detecteren 2] 
Validatie van nieuwe CRT indicaties (smal QRS complex, NYHA klasse I-II en rechts ventriculair 
pacing geïnduceerde LV dyssynchronie) en 3] evaluatie van de invloed van LV littekenweefsel 
en LV lead positie 
In afwachting van deze resultaten is het te verwachten dat de huidige richtlijnen voor CRT 
patiëntenselectie in de toekomst zullen worden uitgebreid met de aanwezigheid van LV dys-
synchronie (spontaan of geïnduceerd (rechts-ventricular pacen) en onafhankelijk van QRS 
duur). 
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